<!DOCTYPE html>
<html lang="en">
  <head>
    <title>US20190292130A1 - Cationic lipids for nucleic acid delivery and preparation thereof 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US20190292130A1/en">
    <meta name="description" content="
     The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Cationic lipids for nucleic acid delivery and preparation thereof 
       ">
    <meta name="DC.date" content="2017-11-07" scheme="dateSubmitted">
    <meta name="DC.description" content="
     The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids. 
   
   ">
    <meta name="citation_patent_application_number" content="US:16/347,995">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/fe/90/62/01494a350ae5ee/US20190292130A1.pdf">
    <meta name="citation_patent_publication_number" content="US:20190292130:A1">
    <meta name="DC.date" content="2019-09-26">
    <meta name="DC.contributor" content="Dan Peer" scheme="inventor">
    <meta name="DC.contributor" content="Srinivas Ramishetti" scheme="inventor">
    <meta name="DC.contributor" content="Ramot at Tel Aviv University Ltd" scheme="assignee">
    <meta name="DC.relation" content="US:3703554" scheme="references">
    <meta name="citation_reference" content="Anonymous, database CAS Registry, compound 38456-03-0, retrieved from CAS using CAS SciFiner on 2/13/2023." scheme="references">
    <meta name="citation_reference" content="BORDENCA, CAS SciFinder n abstract of US 3,703,554 (database CAPLUS AN: 1973:93638), 1973, 2 pages." scheme="references">
    <meta name="citation_reference" content="RICE et al., Journal of the American Chemical Society (1953), 75, p. 1750." scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      
      #gb { top: 15px; left: auto; right: 0; width: auto; min-width: 135px !important; }   
      body { transition: none; }
    </style>
    <script></script>

    <script>
      window.version = 'patent-search.search_20250707_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;
      window.experiments.plogs = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.html">
  </head>
  <body unresolved>
    
    
    <script></script>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.js"></script>
    <search-app>
      
      

      <article class="result" itemscope itemtype="http://schema.org/ScholarlyArticle">
  <h1 itemprop="pageTitle">US20190292130A1 - Cationic lipids for nucleic acid delivery and preparation thereof 
        - Google Patents</h1>
  <span itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </span>

  <meta itemprop="type" content="patent">
  <a href="https://patentimages.storage.googleapis.com/fe/90/62/01494a350ae5ee/US20190292130A1.pdf" itemprop="pdfLink">Download PDF</a>
  <h2>Info</h2>

  <dl>
    <dt>Publication number</dt>
    <dd itemprop="publicationNumber">US20190292130A1</dd>
    <meta itemprop="numberWithoutCodes" content="20190292130">
    <meta itemprop="kindCode" content="A1">
    <meta itemprop="publicationDescription" content="Patent application publication">
    <span>US20190292130A1</span>
    <span>US16/347,995</span>
    <span>US201716347995A</span>
    <span>US2019292130A1</span>
    <span>US 20190292130 A1</span>
    <span>US20190292130 A1</span>
    <span>US 20190292130A1</span>
    <span>  </span>
    <span> </span>
    <span> </span>
    <span>US 201716347995 A</span>
    <span>US201716347995 A</span>
    <span>US 201716347995A</span>
    <span>US 2019292130 A1</span>
    <span>US2019292130 A1</span>
    <span>US 2019292130A1</span>

    <dt>Authority</dt>
    <dd itemprop="countryCode">US</dd>
    <dd itemprop="countryName">United States</dd>

    <dt>Prior art keywords</dt>
    <dd itemprop="priorArtKeywords" repeat>octadeca</dd>
    <dd itemprop="priorArtKeywords" repeat>dien</dd>
    <dd itemprop="priorArtKeywords" repeat>dimethylamino</dd>
    <dd itemprop="priorArtKeywords" repeat>formula</dd>
    <dd itemprop="priorArtKeywords" repeat>ethyl</dd>

    <dt>Prior art date</dt>
    <dd><time itemprop="priorArtDate" datetime="2016-11-08">2016-11-08</time></dd>

    <dt>Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)</dt>
    <dd itemprop="legalStatusIfi" itemscope>
      <span itemprop="status">Granted</span>
    </dd>
  </dl>

  <dt>Application number</dt>
  <dd itemprop="applicationNumber">US16/347,995</dd>

  

  <dt>Other versions</dt>
  <dd itemprop="directAssociations" itemscope repeat>
    <a href="/patent/US11851389B2/en">
      <span itemprop="publicationNumber">US11851389B2</span>
      (<span itemprop="primaryLanguage">en</span>
    </a>
  </dd>

  <dt>Inventor</dt>
  <dd itemprop="inventor" repeat>Dan Peer</dd>
  <dd itemprop="inventor" repeat>Srinivas Ramishetti</dd>

  <dt>Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)</dt>
  <dd itemprop="assigneeCurrent" repeat>
    Ramot at Tel Aviv University Ltd
  </dd>

  <dt>Original Assignee</dt>
  <dd itemprop="assigneeOriginal" repeat>Ramot at Tel Aviv University Ltd</dd>

  <dt>Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)</dt>
  <dd><time itemprop="priorityDate" datetime="2016-11-08">2016-11-08</time></dd>

  <dt>Filing date</dt>
  <dd><time itemprop="filingDate" datetime="2017-11-07">2017-11-07</time></dd>

  <dt>Publication date</dt>
  <dd><time itemprop="publicationDate" datetime="2019-09-26">2019-09-26</time></dd>

  
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-11-07">2017-11-07</time>
    <span itemprop="title">Application filed by Ramot at Tel Aviv University Ltd</span>
    <span itemprop="type">filed</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    <span itemprop="assigneeSearch">Ramot at Tel Aviv University Ltd</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-11-07">2017-11-07</time>
    <span itemprop="title">Priority to US16/347,995</span>
    <span itemprop="type">priority</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US11851389B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2019-05-07">2019-05-07</time>
    <span itemprop="title">Assigned to RAMOT AT TEL-AVIV UNIVERSITY LTD.</span>
    <span itemprop="type">reassignment</span>
    
    
    
    
    <span itemprop="assigneeSearch">RAMOT AT TEL-AVIV UNIVERSITY LTD.</span>
    <span itemprop="description" repeat>ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).</span>
    <span itemprop="description" repeat>Assignors: PEER, DAN, RAMISHETTI, Srinivas</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2019-09-26">2019-09-26</time>
    <span itemprop="title">Publication of US20190292130A1</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US20190292130A1/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2023-12-26">2023-12-26</time>
    <span itemprop="title">Application granted</span>
    <span itemprop="type">granted</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2023-12-26">2023-12-26</time>
    <span itemprop="title">Publication of US11851389B2</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US11851389B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date">Status</time>
    <span itemprop="title">Active</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    <span itemprop="current" content="true" bool>Current</span>
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2039-11-18">2039-11-18</time>
    <span itemprop="title">Adjusted expiration</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>

  <h2>Links</h2>
  <ul>
    <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoLink">
          <a href="https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&d=PG01&s1=20190292130.PGNR." itemprop="url" target="_blank"><span itemprop="text">USPTO</span></a>
        </li>
        
        <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoPatentCenterLink">
          <a href="https://patentcenter.uspto.gov/applications/16347995" itemprop="url" target="_blank"><span itemprop="text">USPTO PatentCenter</span></a>
        </li>
        <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoAssignmentLink">
          <a href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=20190292130" itemprop="url" target="_blank"><span itemprop="text">USPTO Assignment</span></a>
        </li>

    <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="espacenetLink">
        <a href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=2019292130A1&amp;KC=A1&amp;FT=D" itemprop="url" target="_blank"><span itemprop="text">Espacenet</span></a>
      </li>
      

    

    <li itemprop="links" itemscope repeat>
      <meta itemprop="id" content="globalDossierLink">
      <a href="https://globaldossier.uspto.gov/result/application/US/16347995/1" itemprop="url" target="_blank"><span itemprop="text">Global Dossier</span></a>
    </li>

    

      

      

      <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="stackexchangeLink">
        <a href="https://patents.stackexchange.com/questions/tagged/US20190292130" itemprop="url"><span itemprop="text">Discuss</span></a>
      </li>
      
  </ul>

  <ul itemprop="concept" itemscope>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">0</span>
      <span itemprop="name">[1*]CC(N)[W][3H](=O)N([2*])C[Y][3*]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[1*]CC(N)[W][3H](=O)N([2*])C[Y][3*]</span>
      <span itemprop="inchi_key"></span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">117</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KYDOTURNYHBXPQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">KYDOTURNYHBXPQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">3</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JSZKFIQSNGXADN-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCN1CCN(C)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCN1CCN(C)CC1</span>
      <span itemprop="inchi_key">JSZKFIQSNGXADN-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QAUGDBGCCGNQEL-ILFLBGHUSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)[C@@H](N)CC1=CNC=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)[C@@H](N)CC1=CNC=N1</span>
      <span itemprop="inchi_key">QAUGDBGCCGNQEL-ILFLBGHUSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CMZVMMOUEVEBNB-DNSMMJTHSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@@H](N)CCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@@H](N)CCCCN(C)C</span>
      <span itemprop="inchi_key">CMZVMMOUEVEBNB-DNSMMJTHSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KEJCBBGPFXFEGL-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OCCCCN(C)C</span>
      <span itemprop="inchi_key">KEJCBBGPFXFEGL-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ICPXYZBYAQSPIR-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCON(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCON(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCN(C)C</span>
      <span itemprop="inchi_key">ICPXYZBYAQSPIR-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PMSKGQAKRLJMAD-BOYKQRMESA-N</span>
      <span itemprop="name">CCCCC/C=C\CC(=O)OCCCCCCCCON(CCCCCCCCOC(=O)C/C=C\CCCCC)C(=O)SCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CC(=O)OCCCCCCCCON(CCCCCCCCOC(=O)C/C=C\CCCCC)C(=O)SCCN(C)C</span>
      <span itemprop="inchi_key">PMSKGQAKRLJMAD-BOYKQRMESA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NGPVGQQNFAQCMC-PUHRYQSPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(C/C=C\CCCCC)CCCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(C/C=C\CCCCC)CCCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">NGPVGQQNFAQCMC-PUHRYQSPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HILLHYDWLMDYMW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCNN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCNN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCN(C)C</span>
      <span itemprop="inchi_key">HILLHYDWLMDYMW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AJKQAJLUIAQDKU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCCN(C)C</span>
      <span itemprop="inchi_key">AJKQAJLUIAQDKU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CMDXEEWRGHELQB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCOC(=O)CCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCOC(=O)CCCCCCCCC</span>
      <span itemprop="inchi_key">CMDXEEWRGHELQB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CVWMRTXGORHWRR-IODKGUOHSA-N</span>
      <span itemprop="name">B.CC.CC(C)(C)OC(=O)NN.CCCCC/C=C\C/C=C\CCCCCCCC=O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)CCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)OC(C)(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NCCCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(N)CCCCCCCC/C=C\C/C=C\CCCCC.CCCCC/C=C\C/C=C\CCCCCCCCO.CN(C)CCCC(=O)O.CPC.C[Na].O=C=O.O=C=O.O=C=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">B.CC.CC(C)(C)OC(=O)NN.CCCCC/C=C\C/C=C\CCCCCCCC=O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)CCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)OC(C)(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NCCCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(N)CCCCCCCC/C=C\C/C=C\CCCCC.CCCCC/C=C\C/C=C\CCCCCCCCO.CN(C)CCCC(=O)O.CPC.C[Na].O=C=O.O=C=O.O=C=O</span>
      <span itemprop="inchi_key">CVWMRTXGORHWRR-IODKGUOHSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RZAVMYGOJPLHSU-NRAFMHCYSA-N</span>
      <span itemprop="name">B.CC.CCCCC/C=C\C/C=C\CCCCCCCC=O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC/C=C\C/C=C\CCCCC.CN(C)CCCC(=O)O.C[Na].NCCO.O=C=O.O=C=O.O=C=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">B.CC.CCCCC/C=C\C/C=C\CCCCCCCC=O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC/C=C\C/C=C\CCCCC.CN(C)CCCC(=O)O.C[Na].NCCO.O=C=O.O=C=O.O=C=O</span>
      <span itemprop="inchi_key">RZAVMYGOJPLHSU-NRAFMHCYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OQPHPNPJVZOWOY-UHFFFAOYSA-N</span>
      <span itemprop="name">C#CC#CC#CC#CC#CC#CC#CN(C#CC#CC#CC#CC#CC#CC#C)CC(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C#CC#CC#CC#CC#CC#CC#CN(C#CC#CC#CC#CC#CC#CC#C)CC(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="inchi_key">OQPHPNPJVZOWOY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CVVWORJBEJPHTG-UHFFFAOYSA-N</span>
      <span itemprop="name">C#CC#CC#CC#CC#CC#CC#CN(C#CC#CC#CC#CC#CC#CC#C)CCOC(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C#CC#CC#CC#CC#CC#CC#CN(C#CC#CC#CC#CC#CC#CC#C)CCOC(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="inchi_key">CVVWORJBEJPHTG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VYRHIWQGSRUVIY-UHFFFAOYSA-N</span>
      <span itemprop="name">C#CC#CC#CC#CC#CC#CC#CN(C#CC#CC#CC#CC#CC#CC#C)OC(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C#CC#CC#CC#CC#CC#CC#CN(C#CC#CC#CC#CC#CC#CC#C)OC(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="inchi_key">VYRHIWQGSRUVIY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IQTXRJKIHWVKKZ-UHFFFAOYSA-N</span>
      <span itemprop="name">C#CC#CC#CC#CC#CC#CC#CN(C)CC(=O)COCCOC.C#CC#CC#CC#CC#CC#CC#CN(C)CCOC(=O)COCCOC.C#CC#CC#CC#CC#CC#CC#CN(C)OC(=O)COCCOC.C#CC#CC#CC#CC#CC#CC#CNN(C)C(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C#CC#CC#CC#CC#CC#CC#CN(C)CC(=O)COCCOC.C#CC#CC#CC#CC#CC#CC#CN(C)CCOC(=O)COCCOC.C#CC#CC#CC#CC#CC#CC#CN(C)OC(=O)COCCOC.C#CC#CC#CC#CC#CC#CC#CNN(C)C(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="inchi_key">IQTXRJKIHWVKKZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JNMZCYIEZWMZBR-UHFFFAOYSA-N</span>
      <span itemprop="name">C#CC#CC#CC#CC#CC#CC#CNN(C#CC#CC#CC#CC#CC#CC#C)C(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C#CC#CC#CC#CC#CC#CC#CNN(C#CC#CC#CC#CC#CC#CC#C)C(=O)COCCOC.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]</span>
      <span itemprop="inchi_key">JNMZCYIEZWMZBR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HRURFFOUCQIXMA-UHFFFAOYSA-N</span>
      <span itemprop="name">C.CC(=O)OB[Na].CC(=O)OOC(C)=O.CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCCN(C)C.CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCOC(=O)CCCN(C)C.CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCOC(=O)CCCCCCCCC.CN(C)CCCN.CPC.NCCO.O=CCCCCCCO.OCCCCCCCO.[H]C(=O)CCCCCCOC(=O)CC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.CC(=O)OB[Na].CC(=O)OOC(C)=O.CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCCN(C)C.CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCOC(=O)CCCN(C)C.CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCOC(=O)CCCCCCCCC.CN(C)CCCN.CPC.NCCO.O=CCCCCCCO.OCCCCCCCO.[H]C(=O)CCCCCCOC(=O)CC</span>
      <span itemprop="inchi_key">HRURFFOUCQIXMA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GHTPCASQRLQJLG-UHFFFAOYSA-N</span>
      <span itemprop="name">C.CCN.CN(C)CC=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.CCN.CN(C)CC=O</span>
      <span itemprop="inchi_key">GHTPCASQRLQJLG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JXMRRUPPKGAKAJ-UHFFFAOYSA-N</span>
      <span itemprop="name">C.NCC=O.NCNP</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.NCC=O.NCNP</span>
      <span itemprop="inchi_key">JXMRRUPPKGAKAJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NJJZQLWRQLVDAA-UHFFFAOYSA-N</span>
      <span itemprop="name">C.NCN</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.NCN</span>
      <span itemprop="inchi_key">NJJZQLWRQLVDAA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OBVCHQZKWMXMOX-UHFFFAOYSA-N</span>
      <span itemprop="name">CB(O)NCN.O=CCN1CCCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CB(O)NCN.O=CCN1CCCC1</span>
      <span itemprop="inchi_key">OBVCHQZKWMXMOX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IIDACAGJUFYEMA-RRBLESCISA-N</span>
      <span itemprop="name">CB(O)N[C@@H](CCCCN(C)C)C(=O)O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@@H](N)CCCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@H](CCCCN(C)C)NB(C)O.CCCCC/C=C\C/C=C\CCCCCCCCN(N)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CB(O)N[C@@H](CCCCN(C)C)C(=O)O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@@H](N)CCCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@H](CCCCN(C)C)NB(C)O.CCCCC/C=C\C/C=C\CCCCCCCCN(N)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">IIDACAGJUFYEMA-RRBLESCISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UONMCLJHPGSUAC-XUNPLWNBSA-N</span>
      <span itemprop="name">CC(C)(C)OC(=O)NN.CCCCCC/C=C\COC(=O)CCCCCN(CCCCCC(=O)OC/C=C\CCCCCC)CC(=O)CCCN(C)C.CCCCCC/C=C\COC(=O)CCCCCN(N)CCCCCC(=O)OC/C=C\CCCCCC.CCCCCC/C=C\COC(=O)CCCCOC.CN(C)CCCC(=O)O.N=NN(O)[Na].O=C(O)CCCCCO.O=C1CCCCCO1.O=CCCCCC(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)OC(=O)NN.CCCCCC/C=C\COC(=O)CCCCCN(CCCCCC(=O)OC/C=C\CCCCCC)CC(=O)CCCN(C)C.CCCCCC/C=C\COC(=O)CCCCCN(N)CCCCCC(=O)OC/C=C\CCCCCC.CCCCCC/C=C\COC(=O)CCCCOC.CN(C)CCCC(=O)O.N=NN(O)[Na].O=C(O)CCCCCO.O=C1CCCCCO1.O=CCCCCC(=O)O</span>
      <span itemprop="inchi_key">UONMCLJHPGSUAC-XUNPLWNBSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IXDOJZRYVUPKSL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCC(CC)C(=O)O.CCCC(=O)O.CCCCCCCCC(CCCCCC)C(=O)OCCCCCCNN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCN(C)C.CN(C)CCCN.CN(C)CCN(CCCCCCO)NCCCCCCO.COC(=O)CCCCC(=O)NN(CCN(C)C)C(=O)CCCCC(=O)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCC(CC)C(=O)O.CCCC(=O)O.CCCCCCCCC(CCCCCC)C(=O)OCCCCCCNN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCN(C)C.CN(C)CCCN.CN(C)CCN(CCCCCCO)NCCCCCCO.COC(=O)CCCCC(=O)NN(CCN(C)C)C(=O)CCCCC(=O)OC</span>
      <span itemprop="inchi_key">IXDOJZRYVUPKSL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MEUWLKKIBXJJNL-DFIVFKFMSA-N</span>
      <span itemprop="name">CCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCC)NCCCC(=N)N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCC)NCCCC(=N)N</span>
      <span itemprop="inchi_key">MEUWLKKIBXJJNL-DFIVFKFMSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XUEQEPJGVKNRTP-IRDHSGILSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)NN(CCN(C)C)C(=O)CCCCCCC/C=C\C/C=C\CCCCC.CCCCC/C=C\C/C=C\CCCCCCCC(=O)O.CCCCC/C=C\C/C=C\CCCCCCCCNN(CCCCCCCC/C=C\C/C=C\CCCCC)CCN(C)C.CN(C)CCNN.[AlH3].[LiH]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)NN(CCN(C)C)C(=O)CCCCCCC/C=C\C/C=C\CCCCC.CCCCC/C=C\C/C=C\CCCCCCCC(=O)O.CCCCC/C=C\C/C=C\CCCCCCCCNN(CCCCCCCC/C=C\C/C=C\CCCCC)CCN(C)C.CN(C)CCNN.[AlH3].[LiH]</span>
      <span itemprop="inchi_key">XUEQEPJGVKNRTP-IRDHSGILSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FUGTTXKTCVBXQA-VUCXGXJLSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC=O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NCCN(C)C.CN(C)CCCN.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC=O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NCCN(C)C.CN(C)CCCN.[Cl-]</span>
      <span itemprop="inchi_key">FUGTTXKTCVBXQA-VUCXGXJLSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BZMPLTCMZBNIBN-GONAPNCESA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC=O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(O)CCCCCCCC/C=C\C/C=C\CCCCC.CN(C)CCCC(=O)O.NO.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC=O.CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN(C)C.CCCCC/C=C\C/C=C\CCCCCCCCN(O)CCCCCCCC/C=C\C/C=C\CCCCC.CN(C)CCCC(=O)O.NO.[Cl-]</span>
      <span itemprop="inchi_key">BZMPLTCMZBNIBN-GONAPNCESA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VHJBVQFNRNYMQB-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)NOCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)NOCCCCN(C)C</span>
      <span itemprop="inchi_key">VHJBVQFNRNYMQB-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QVJLCZGBRCZXCL-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CC1=CNC=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CC1=CNC=N1</span>
      <span itemprop="inchi_key">QVJLCZGBRCZXCL-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BMFOKZIELNBBNJ-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">BMFOKZIELNBBNJ-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GWMZBIFKWAMXGV-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CCCN1CCCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CCCN1CCCC1</span>
      <span itemprop="inchi_key">GWMZBIFKWAMXGV-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CVUTZVDMKCREJW-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CCCN1CCN(C)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CCCN1CCN(C)CC1</span>
      <span itemprop="inchi_key">CVUTZVDMKCREJW-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OPNMSAAGMJDUBW-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCN(C)C</span>
      <span itemprop="inchi_key">OPNMSAAGMJDUBW-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">POPDJKYTLXESCZ-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCN1CCCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCN1CCCC1</span>
      <span itemprop="inchi_key">POPDJKYTLXESCZ-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZHPPKUKKSZATHF-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCN(C)C</span>
      <span itemprop="inchi_key">ZHPPKUKKSZATHF-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CZZDRCAOWVCXSX-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CC1=CNC=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CC1=CNC=N1</span>
      <span itemprop="inchi_key">CZZDRCAOWVCXSX-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XBAWKYUGYYSWGZ-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCC(=N)N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCC(=N)N</span>
      <span itemprop="inchi_key">XBAWKYUGYYSWGZ-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VXHLVEWQGUIWMM-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">VXHLVEWQGUIWMM-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DEGBVFIWHCIWRB-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCN1CCCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCN1CCCC1</span>
      <span itemprop="inchi_key">DEGBVFIWHCIWRB-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CHSQRJDITOKBJX-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CN(C)C</span>
      <span itemprop="inchi_key">CHSQRJDITOKBJX-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PCLHLDAOQIGKRY-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)CCOCCCCN(C)C</span>
      <span itemprop="inchi_key">PCLHLDAOQIGKRY-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PITBYSVUWVIAFD-KFOZCGKISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@@H](N)CC1=CNC=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@@H](N)CC1=CNC=N1</span>
      <span itemprop="inchi_key">PITBYSVUWVIAFD-KFOZCGKISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KMZBQHTXZUTRNF-XUGPUNSISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@@H](N)CCCNC(=N)N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)[C@@H](N)CCCNC(=N)N</span>
      <span itemprop="inchi_key">KMZBQHTXZUTRNF-XUGPUNSISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NYLILAFLPNVBFR-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC1=CNC=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC1=CNC=N1</span>
      <span itemprop="inchi_key">NYLILAFLPNVBFR-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SSOLEUDIBWCYLR-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC(=N)N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC(=N)N</span>
      <span itemprop="inchi_key">SSOLEUDIBWCYLR-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GINJSCGTIDOCCQ-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">GINJSCGTIDOCCQ-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ADLXHLDQFCVXEC-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN1CCN(C)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN1CCN(C)CC1</span>
      <span itemprop="inchi_key">ADLXHLDQFCVXEC-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UCCLJGYQQHYZJX-ZBQRHYSVSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCN1CCN(C)CC1.CCCCC/C=C\C/C=C\CCCCCCCCN(O)CCCCCCCC/C=C\C/C=C\CCCCC.CN1CCN(CCC(=O)OO)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCN1CCN(C)CC1.CCCCC/C=C\C/C=C\CCCCCCCCN(O)CCCCCCCC/C=C\C/C=C\CCCCC.CN1CCN(CCC(=O)OO)CC1</span>
      <span itemprop="inchi_key">UCCLJGYQQHYZJX-ZBQRHYSVSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DNSVCGRKYJTVEB-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CN(C)C</span>
      <span itemprop="inchi_key">DNSVCGRKYJTVEB-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ICNJQBZENQJFRL-ZFUXOTDWSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCN(C)C)NCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCN(C)C)NCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">ICNJQBZENQJFRL-ZFUXOTDWSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZYDBEJOSIYIIFH-DYMXKLMASA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCN(C)C)NCCCCCCCCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCN(C)C)NCCCCCCCCCCCCCCCCCC</span>
      <span itemprop="inchi_key">ZYDBEJOSIYIIFH-DYMXKLMASA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VHFVFEIQUCUIOM-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">VHFVFEIQUCUIOM-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PZDPBQMZPZSYEY-ZFUXOTDWSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(NCCCCCCCC/C=C\CCCCCCCC)C(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(NCCCCCCCC/C=C\CCCCCCCC)C(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">PZDPBQMZPZSYEY-ZFUXOTDWSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UAADMOJRWLQUQA-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCN(C)C</span>
      <span itemprop="inchi_key">UAADMOJRWLQUQA-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YXRNXZUIQNFQAF-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCN1CCCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNN(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCN1CCCC1</span>
      <span itemprop="inchi_key">YXRNXZUIQNFQAF-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CRXZKQSXIBSCFF-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNN(CCCCCCCC/C=C\C/C=C\CCCCC)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNN(CCCCCCCC/C=C\C/C=C\CCCCC)CCN(C)C</span>
      <span itemprop="inchi_key">CRXZKQSXIBSCFF-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YAYVXTAGQNVHTK-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCON(CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCON(CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">YAYVXTAGQNVHTK-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZLZXKDNJRZOOJE-BOYKQRMESA-N</span>
      <span itemprop="name">CCCCC/C=C\CC(=O)OCCCCCCCCN(CCCCCCCCOC(=O)C/C=C\CCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CC(=O)OCCCCCCCCN(CCCCCCCCOC(=O)C/C=C\CCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">ZLZXKDNJRZOOJE-BOYKQRMESA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PUXCDKMHAPKCGE-BOYKQRMESA-N</span>
      <span itemprop="name">CCCCC/C=C\CC(=O)OCCCCCCCCNN(CCCCCCCCOC(=O)C/C=C\CCCCC)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CC(=O)OCCCCCCCCNN(CCCCCCCCOC(=O)C/C=C\CCCCC)CCN(C)C</span>
      <span itemprop="inchi_key">PUXCDKMHAPKCGE-BOYKQRMESA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MOQAZEMZCTWXAP-LYWFMZLMSA-N</span>
      <span itemprop="name">CCCCC/C=C\CC(CCCCCC)C(=O)OCCCCCCCCNN(CCCCCCCCOC(=O)C(C/C=C\CCCCC)CCCCCC)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CC(CCCCCC)C(=O)OCCCCCCCCNN(CCCCCCCCOC(=O)C(C/C=C\CCCCC)CCCCCC)CCN(C)C</span>
      <span itemprop="inchi_key">MOQAZEMZCTWXAP-LYWFMZLMSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YBQGROFWHBZGFJ-PUHRYQSPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(C/C=C\CCCCC)CCCCCC)CC(=O)SCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(C/C=C\CCCCC)CCCCCC)CC(=O)SCCN(C)C</span>
      <span itemprop="inchi_key">YBQGROFWHBZGFJ-PUHRYQSPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FZJYXQSXRXVRTQ-PUHRYQSPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(C/C=C\CCCCC)CCCCCC)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(C/C=C\CCCCC)CCCCCC)CCCN(C)C</span>
      <span itemprop="inchi_key">FZJYXQSXRXVRTQ-PUHRYQSPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZKGXXFPLFILGAL-PUHRYQSPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(C/C=C\CCCCC)CCCCCC)CCOC(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(C/C=C\CCCCC)CCCCCC)CCOC(=O)CN(C)C</span>
      <span itemprop="inchi_key">ZKGXXFPLFILGAL-PUHRYQSPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WAGRJIKZVCGROC-JZTLMNBPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCC/C=C\CCCCC)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCC/C=C\CCCCC)CCCN(C)C</span>
      <span itemprop="inchi_key">WAGRJIKZVCGROC-JZTLMNBPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JSVDFFPINHLJLU-JZTLMNBPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCC/C=C\CCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCC/C=C\CCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">JSVDFFPINHLJLU-JZTLMNBPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AAEGWELIRYJVSR-YZLQMOBTSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCC/C=C\CCCCC)CCOC(=O)CNC(=N)N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCC/C=C\CCCCC)CCOC(=O)CNC(=N)N</span>
      <span itemprop="inchi_key">AAEGWELIRYJVSR-YZLQMOBTSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CZHNKYLRVUZNEA-JZTLMNBPSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCC/C=C\CCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOC(=O)CCCCCCCN(CCCCCCCC(=O)OCC/C=C\CCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">CZHNKYLRVUZNEA-JZTLMNBPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KBWALMHVXQJZLK-VMNXYWKNSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOC(=O)CCCCCN(CCCCCC(=O)OCC/C=C\CCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOC(=O)CCCCCN(CCCCCC(=O)OCC/C=C\CCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">KBWALMHVXQJZLK-VMNXYWKNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JZJIZYMLVKMENI-VMNXYWKNSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOC(=O)CCCCCN(CCCCCC(=O)OCC/C=C\CCCCC)CCOCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOC(=O)CCCCCN(CCCCCC(=O)OCC/C=C\CCCCC)CCOCCCCN(C)C</span>
      <span itemprop="inchi_key">JZJIZYMLVKMENI-VMNXYWKNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KEXHHLVKWMCJJF-XSYHWHKQSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOC(=O)CCCCCN(CCO)CCCCCC(=O)OCC/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOC(=O)CCCCCN(CCO)CCCCCC(=O)OCC/C=C\CCCCC</span>
      <span itemprop="inchi_key">KEXHHLVKWMCJJF-XSYHWHKQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IQESYZKBHOJKHW-JTFWXBGUSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOCCCCCCN(CCCCCCOCC/C=C\CCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOCCCCCCN(CCCCCCOCC/C=C\CCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">IQESYZKBHOJKHW-JTFWXBGUSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YLKIRDQNVRTBIB-JTFWXBGUSA-N</span>
      <span itemprop="name">CCCCC/C=C\CCOCCCCCCN(CCCCCCOCC/C=C\CCCCC)CCOCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\CCOCCCCCCN(CCCCCCOCC/C=C\CCCCC)CCOCCCCN(C)C</span>
      <span itemprop="inchi_key">YLKIRDQNVRTBIB-JTFWXBGUSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GAIURVHSHSXTQA-MPKYGIEOSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCN(CCCCCC(=O)OC/C=C\CCCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCN(CCCCCC(=O)OC/C=C\CCCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">GAIURVHSHSXTQA-MPKYGIEOSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NFTKTSOHOKOJDC-YFJQDTPYSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCN(CCCCCC(=O)OC/C=C\CCCCCC)CC(=O)OC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCN(CCCCCC(=O)OC/C=C\CCCCCC)CC(=O)OC(C)(C)C</span>
      <span itemprop="inchi_key">NFTKTSOHOKOJDC-YFJQDTPYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">USASYPMFYRABGL-JZTLMNBPSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCN(N)CCCCCC(=O)OC/C=C\CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCN(N)CCCCCC(=O)OC/C=C\CCCCCC</span>
      <span itemprop="inchi_key">USASYPMFYRABGL-JZTLMNBPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZZYHVGBLUZBRJS-NTMALXAHSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCOC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCOC</span>
      <span itemprop="inchi_key">ZZYHVGBLUZBRJS-NTMALXAHSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NVGXQXSLMNKAKI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCC(CCCCCC)OC(=O)CCCCCCCCCNN(CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCC(CCCCCC)OC(=O)CCCCCCCCCNN(CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC)CCN(C)C</span>
      <span itemprop="inchi_key">NVGXQXSLMNKAKI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DXCTZRZIJLPDSK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCC)CCCCCC)CC(=O)SCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCC)CCCCCC)CC(=O)SCCN(C)C</span>
      <span itemprop="inchi_key">DXCTZRZIJLPDSK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LRLHZJLGCNGQJT-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCC)CCCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCC(CCCCCC)OC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCC)CCCCCC)CCOC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">LRLHZJLGCNGQJT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JMOLZNNXZPAGBH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)O</span>
      <span itemprop="inchi_key">JMOLZNNXZPAGBH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YUGNGGOGSZJTCK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCN(CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCN(CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCCN(C)C</span>
      <span itemprop="inchi_key">YUGNGGOGSZJTCK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HCRPVQUQTBJXRD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCN(CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC)OCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCN(CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC)OCCCCN(C)C</span>
      <span itemprop="inchi_key">HCRPVQUQTBJXRD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BQDGDAQRFLCDFS-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCNN(CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCNN(CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCN(C)C</span>
      <span itemprop="inchi_key">BQDGDAQRFLCDFS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XWVAWOGQNQTMMD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">XWVAWOGQNQTMMD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UPCSORCKGOFMBD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)CCCCCN(C)C</span>
      <span itemprop="inchi_key">UPCSORCKGOFMBD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VSVIRADLCYRXFI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)OCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCCCOC(=O)C(CCCCCC)CCCCCCCC)OCCCCN(C)C</span>
      <span itemprop="inchi_key">VSVIRADLCYRXFI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LDHCLPVVLHYNBL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCOCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OCCCCCCCN(CCCCCCCOC(=O)CCCCCCCCC)CCOCCCCN(C)C</span>
      <span itemprop="inchi_key">LDHCLPVVLHYNBL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FXCVXIKATCCBLO-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OCCCCCCOC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OCCCCCCOC</span>
      <span itemprop="inchi_key">FXCVXIKATCCBLO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XNARCZFCHXCASO-UHFFFAOYSA-N</span>
      <span itemprop="name">CN(C)CCN(CCCCCCO)NCCCCCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CN(C)CCN(CCCCCCO)NCCCCCCO</span>
      <span itemprop="inchi_key">XNARCZFCHXCASO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OZYMCTCMBDTGFC-UHFFFAOYSA-N</span>
      <span itemprop="name">CN(C)OC(COCCOC)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CN(C)OC(COCCOC)=O</span>
      <span itemprop="inchi_key">OZYMCTCMBDTGFC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QPEBHUHCHQHZGX-UHFFFAOYSA-N</span>
      <span itemprop="name">COC(=O)CCCCC(=O)NN(CCN(C)C)C(=O)CCCCC(=O)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COC(=O)CCCCC(=O)NN(CCN(C)C)C(=O)CCCCC(=O)OC</span>
      <span itemprop="inchi_key">QPEBHUHCHQHZGX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WUZBGMQIKXKYMX-UHFFFAOYSA-N</span>
      <span itemprop="name">COCCCCCC(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COCCCCCC(=O)O</span>
      <span itemprop="inchi_key">WUZBGMQIKXKYMX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IWHLYPDWHHPVAA-UHFFFAOYSA-N</span>
      <span itemprop="name">O=C(O)CCCCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">O=C(O)CCCCCO</span>
      <span itemprop="inchi_key">IWHLYPDWHHPVAA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
  </ul>

  <section>
    <h2>Images</h2>
    <ul>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/6a/c9/66/b7199519da4d01/US20190292130A1-20190926-D00000.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/98/db/2e/8babc14489246d/US20190292130A1-20190926-D00000.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="270">
              <meta itemprop="top" content="1072">
              <meta itemprop="right" content="305">
              <meta itemprop="bottom" content="1098">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="486">
              <meta itemprop="top" content="1073">
              <meta itemprop="right" content="519">
              <meta itemprop="bottom" content="1099">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="715">
              <meta itemprop="top" content="1073">
              <meta itemprop="right" content="753">
              <meta itemprop="bottom" content="1097">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="945">
              <meta itemprop="top" content="1074">
              <meta itemprop="right" content="978">
              <meta itemprop="bottom" content="1097">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1125">
              <meta itemprop="top" content="1071">
              <meta itemprop="right" content="1162">
              <meta itemprop="bottom" content="1097">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1948">
              <meta itemprop="top" content="1074">
              <meta itemprop="right" content="1983">
              <meta itemprop="bottom" content="1101">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="2162">
              <meta itemprop="top" content="1074">
              <meta itemprop="right" content="2196">
              <meta itemprop="bottom" content="1100">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="2802">
              <meta itemprop="top" content="1074">
              <meta itemprop="right" content="2838">
              <meta itemprop="bottom" content="1099">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/e5/09/90/e315f91885ce3b/US20190292130A1-20190926-D00001.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/bb/32/35/54aa2635a715b5/US20190292130A1-20190926-D00001.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="269">
              <meta itemprop="top" content="1099">
              <meta itemprop="right" content="309">
              <meta itemprop="bottom" content="1124">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="485">
              <meta itemprop="top" content="1098">
              <meta itemprop="right" content="518">
              <meta itemprop="bottom" content="1123">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="944">
              <meta itemprop="top" content="1100">
              <meta itemprop="right" content="982">
              <meta itemprop="bottom" content="1124">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/61/64/dd/f309ad1bd3176f/US20190292130A1-20190926-D00002.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/c9/c4/a7/5dc847bfa563e7/US20190292130A1-20190926-D00002.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="302">
              <meta itemprop="top" content="1076">
              <meta itemprop="right" content="334">
              <meta itemprop="bottom" content="1102">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="513">
              <meta itemprop="top" content="1077">
              <meta itemprop="right" content="549">
              <meta itemprop="bottom" content="1102">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="746">
              <meta itemprop="top" content="1072">
              <meta itemprop="right" content="778">
              <meta itemprop="bottom" content="1103">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1155">
              <meta itemprop="top" content="1076">
              <meta itemprop="right" content="1190">
              <meta itemprop="bottom" content="1103">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/58/7f/ff/cdd7edb174bd78/US20190292130A1-20190926-D00003.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/ac/1e/a7/d1d16faf756860/US20190292130A1-20190926-D00003.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="3">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1312">
              <meta itemprop="top" content="1693">
              <meta itemprop="right" content="1358">
              <meta itemprop="bottom" content="1740">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="3">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1345">
              <meta itemprop="top" content="713">
              <meta itemprop="right" content="1392">
              <meta itemprop="bottom" content="760">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="3">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1367">
              <meta itemprop="top" content="483">
              <meta itemprop="right" content="1413">
              <meta itemprop="bottom" content="530">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/c7/ee/e5/b2e223df0734d9/US20190292130A1-20190926-D00004.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/b0/63/13/dcc0fdd0dafe28/US20190292130A1-20190926-D00004.png">
        <ul>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/4d/b7/a1/27ed24ac4d484e/US20190292130A1-20190926-D00005.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/34/08/8b/a477248f0122cf/US20190292130A1-20190926-D00005.png">
        <ul>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/7b/90/fa/b33741d82bbaee/US20190292130A1-20190926-D00006.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/61/f3/28/fee5e6b22a13a7/US20190292130A1-20190926-D00006.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="6">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="509">
              <meta itemprop="top" content="749">
              <meta itemprop="right" content="550">
              <meta itemprop="bottom" content="783">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/af/47/a1/ec002087fdf845/US20190292130A1-20190926-D00007.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/a5/13/75/3c31b2982416cd/US20190292130A1-20190926-D00007.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1170">
              <meta itemprop="top" content="1641">
              <meta itemprop="right" content="1219">
              <meta itemprop="bottom" content="1691">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1193">
              <meta itemprop="top" content="1412">
              <meta itemprop="right" content="1238">
              <meta itemprop="bottom" content="1457">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1202">
              <meta itemprop="top" content="664">
              <meta itemprop="right" content="1249">
              <meta itemprop="bottom" content="711">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1226">
              <meta itemprop="top" content="436">
              <meta itemprop="right" content="1268">
              <meta itemprop="bottom" content="479">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1219">
              <meta itemprop="top" content="929">
              <meta itemprop="right" content="1291">
              <meta itemprop="bottom" content="1001">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="9">
            <meta itemprop="label" content="Lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1045">
              <meta itemprop="top" content="1518">
              <meta itemprop="right" content="1099">
              <meta itemprop="bottom" content="1572">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/9d/19/5e/356619c46621f8/US20190292130A1-20190926-D00008.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/81/4c/93/7979048b55d229/US20190292130A1-20190926-D00008.png">
        <ul>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/c6/45/22/784f0552f68dcd/US20190292130A1-20190926-D00009.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/9c/98/4c/2d530c7e81a0ca/US20190292130A1-20190926-D00009.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="15">
            <meta itemprop="label" content="Lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="971">
              <meta itemprop="top" content="841">
              <meta itemprop="right" content="1033">
              <meta itemprop="bottom" content="876">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/43/2f/0e/304289b3ffd7c2/US20190292130A1-20190926-D00010.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/be/0a/d9/3b7f0b8a313b44/US20190292130A1-20190926-D00010.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="10">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="266">
              <meta itemprop="top" content="909">
              <meta itemprop="right" content="314">
              <meta itemprop="bottom" content="942">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="10">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1493">
              <meta itemprop="top" content="180">
              <meta itemprop="right" content="1539">
              <meta itemprop="bottom" content="220">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/16/6d/ba/8ba850a6eabf31/US20190292130A1-20190926-D00011.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/95/41/ee/8ca2d70138c2be/US20190292130A1-20190926-D00011.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="11">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="162">
              <meta itemprop="top" content="942">
              <meta itemprop="right" content="201">
              <meta itemprop="bottom" content="967">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="11">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="Chapters">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="159">
              <meta itemprop="top" content="433">
              <meta itemprop="right" content="197">
              <meta itemprop="bottom" content="469">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/1c/cb/03/5ea599e30eb76b/US20190292130A1-20190926-D00012.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/a1/3b/2d/a6c7d7e8d5da38/US20190292130A1-20190926-D00012.png">
        <ul>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/b1/a3/2c/75a5287db6a061/US20190292130A1-20190926-D00013.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/ff/66/22/a903bd2f9781dd/US20190292130A1-20190926-D00013.png">
        <ul>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/34/5e/9a/f61d9c25468fc9/US20190292130A1-20190926-D00014.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/b0/b5/11/ccce22df8433d8/US20190292130A1-20190926-D00014.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="14">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="783">
              <meta itemprop="top" content="1239">
              <meta itemprop="right" content="829">
              <meta itemprop="bottom" content="1270">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="14">
            <meta itemprop="id" content="2000">
            <meta itemprop="label" content="positive control lipo">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1586">
              <meta itemprop="top" content="1185">
              <meta itemprop="right" content="1672">
              <meta itemprop="bottom" content="1228">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="14">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="567">
              <meta itemprop="top" content="1183">
              <meta itemprop="right" content="611">
              <meta itemprop="bottom" content="1226">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="14">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="920">
              <meta itemprop="top" content="1187">
              <meta itemprop="right" content="960">
              <meta itemprop="bottom" content="1228">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="14">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1270">
              <meta itemprop="top" content="1188">
              <meta itemprop="right" content="1313">
              <meta itemprop="bottom" content="1227">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="14">
            <meta itemprop="id" content="5">
            <meta itemprop="label" content="SCHEME">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="437">
              <meta itemprop="top" content="1240">
              <meta itemprop="right" content="465">
              <meta itemprop="bottom" content="1268">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/a2/b0/47/7c131923d89294/US20190292130A1-20190926-D00015.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/a6/26/4c/9099bf14cbe467/US20190292130A1-20190926-D00015.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="15">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="251">
              <meta itemprop="top" content="311">
              <meta itemprop="right" content="274">
              <meta itemprop="bottom" content="347">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="15">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1143">
              <meta itemprop="top" content="658">
              <meta itemprop="right" content="1168">
              <meta itemprop="bottom" content="726">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="15">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1227">
              <meta itemprop="top" content="1107">
              <meta itemprop="right" content="1303">
              <meta itemprop="bottom" content="1175">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/d4/6c/f7/6551993383d649/US20190292130A1-20190926-D00016.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/5a/d6/da/ba5ea4819ea5f4/US20190292130A1-20190926-D00016.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="16">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="613">
              <meta itemprop="top" content="145">
              <meta itemprop="right" content="636">
              <meta itemprop="bottom" content="187">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/1f/1f/47/6aeb9bc7819cec/US20190292130A1-20190926-D00017.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/5c/63/45/0e2b984513bf1b/US20190292130A1-20190926-D00017.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="17">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="Chapters">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1271">
              <meta itemprop="top" content="204">
              <meta itemprop="right" content="1297">
              <meta itemprop="bottom" content="234">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="17">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="724">
              <meta itemprop="top" content="1032">
              <meta itemprop="right" content="774">
              <meta itemprop="bottom" content="1074">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="17">
            <meta itemprop="id" content="54">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1389">
              <meta itemprop="top" content="1032">
              <meta itemprop="right" content="1437">
              <meta itemprop="bottom" content="1076">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/50/98/20/4897288399f3ee/US20190292130A1-20190926-D00018.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/f1/0b/a1/81bca41cd9f099/US20190292130A1-20190926-D00018.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="18">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1633">
              <meta itemprop="top" content="409">
              <meta itemprop="right" content="1691">
              <meta itemprop="bottom" content="449">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="18">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1631">
              <meta itemprop="top" content="1410">
              <meta itemprop="right" content="1663">
              <meta itemprop="bottom" content="1445">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="18">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="945">
              <meta itemprop="top" content="313">
              <meta itemprop="right" content="1005">
              <meta itemprop="bottom" content="367">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="18">
            <meta itemprop="id" content="4">
            <meta itemprop="label" content="Chapters">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1629">
              <meta itemprop="top" content="1156">
              <meta itemprop="right" content="1661">
              <meta itemprop="bottom" content="1191">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="18">
            <meta itemprop="id" content="54">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="692">
              <meta itemprop="top" content="321">
              <meta itemprop="right" content="747">
              <meta itemprop="bottom" content="370">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="18">
            <meta itemprop="id" content="6">
            <meta itemprop="label" content="Dimethyl">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1630">
              <meta itemprop="top" content="908">
              <meta itemprop="right" content="1659">
              <meta itemprop="bottom" content="947">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/bc/bb/ab/08137bb71cd812/US20190292130A1-20190926-D00019.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/f9/44/6f/16dad762940a47/US20190292130A1-20190926-D00019.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="19">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1636">
              <meta itemprop="top" content="1221">
              <meta itemprop="right" content="1656">
              <meta itemprop="bottom" content="1255">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="19">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="Chapters">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1631">
              <meta itemprop="top" content="696">
              <meta itemprop="right" content="1661">
              <meta itemprop="bottom" content="732">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="19">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="845">
              <meta itemprop="top" content="236">
              <meta itemprop="right" content="903">
              <meta itemprop="bottom" content="286">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="19">
            <meta itemprop="id" content="4">
            <meta itemprop="label" content="Chapters">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1629">
              <meta itemprop="top" content="436">
              <meta itemprop="right" content="1662">
              <meta itemprop="bottom" content="472">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="19">
            <meta itemprop="id" content="5">
            <meta itemprop="label" content="SCHEME">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1633">
              <meta itemprop="top" content="172">
              <meta itemprop="right" content="1661">
              <meta itemprop="bottom" content="209">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="19">
            <meta itemprop="id" content="54">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="589">
              <meta itemprop="top" content="236">
              <meta itemprop="right" content="650">
              <meta itemprop="bottom" content="286">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/45/f9/ae/82537fe8d28ce9/US20190292130A1-20190926-D00020.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/e7/c7/d7/f3fb13682ba6e2/US20190292130A1-20190926-D00020.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="20">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1458">
              <meta itemprop="top" content="837">
              <meta itemprop="right" content="1518">
              <meta itemprop="bottom" content="877">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="20">
            <meta itemprop="id" content="15">
            <meta itemprop="label" content="Lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1460">
              <meta itemprop="top" content="370">
              <meta itemprop="right" content="1520">
              <meta itemprop="bottom" content="406">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="20">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="635">
              <meta itemprop="top" content="160">
              <meta itemprop="right" content="693">
              <meta itemprop="bottom" content="211">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="20">
            <meta itemprop="id" content="5">
            <meta itemprop="label" content="SCHEME">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1457">
              <meta itemprop="top" content="1304">
              <meta itemprop="right" content="1487">
              <meta itemprop="bottom" content="1342">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="20">
            <meta itemprop="id" content="54">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="302">
              <meta itemprop="top" content="154">
              <meta itemprop="right" content="364">
              <meta itemprop="bottom" content="210">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/4a/60/8f/4ac0340f7e07f9/US20190292130A1-20190926-D00021.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/74/c8/fd/4fe274f9482c84/US20190292130A1-20190926-D00021.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="21">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="lipid">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1464">
              <meta itemprop="top" content="1317">
              <meta itemprop="right" content="1487">
              <meta itemprop="bottom" content="1351">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="21">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1462">
              <meta itemprop="top" content="1066">
              <meta itemprop="right" content="1494">
              <meta itemprop="bottom" content="1100">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="21">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="Chapters">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1462">
              <meta itemprop="top" content="818">
              <meta itemprop="right" content="1491">
              <meta itemprop="bottom" content="855">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="21">
            <meta itemprop="id" content="4">
            <meta itemprop="label" content="Chapters">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1461">
              <meta itemprop="top" content="569">
              <meta itemprop="right" content="1491">
              <meta itemprop="bottom" content="604">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="21">
            <meta itemprop="id" content="5">
            <meta itemprop="label" content="SCHEME">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1464">
              <meta itemprop="top" content="314">
              <meta itemprop="right" content="1490">
              <meta itemprop="bottom" content="349">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/74/b3/c8/0b61005fe10f42/US20190292130A1-20190926-D00022.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/11/7d/a1/7a0483f1d0a780/US20190292130A1-20190926-D00022.png">
        <ul>
        </ul>
      </li>
    </ul>
  </section>

  <section>
    <h2>Classifications</h2>
    <ul>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P35/00</span>&mdash;<span itemprop="Description">Antineoplastic agents</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C211/00</span>&mdash;<span itemprop="Description">Compounds containing amino groups bound to a carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C211/01</span>&mdash;<span itemprop="Description">Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C211/20</span>&mdash;<span itemprop="Description">Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C211/22</span>&mdash;<span itemprop="Description">Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton containing at least two amino groups bound to the carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/06</span>&mdash;<span itemprop="Description">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/16</span>&mdash;<span itemprop="Description">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/18</span>&mdash;<span itemprop="Description">Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P29/00</span>&mdash;<span itemprop="Description">Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/00</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/02</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/04</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/06</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/08</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/00</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/02</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/04</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/00</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/02</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/00</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/02</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/04</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/06</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/10</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/00</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/02</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/04</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/06</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/10</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/12</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/00</span>&mdash;<span itemprop="Description">Carboxylic acid amides</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/00</span>&mdash;<span itemprop="Description">Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/00</span>&mdash;<span itemprop="Description">Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/10</span>&mdash;<span itemprop="Description">Hydrazines</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/00</span>&mdash;<span itemprop="Description">Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/10</span>&mdash;<span itemprop="Description">Hydrazines</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/12</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/14</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/00</span>&mdash;<span itemprop="Description">Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/10</span>&mdash;<span itemprop="Description">Hydrazines</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/12</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/16</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of an unsaturated carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/00</span>&mdash;<span itemprop="Description">Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/24</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/26</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/00</span>&mdash;<span itemprop="Description">Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/24</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/26</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C243/28</span>&mdash;<span itemprop="Description">Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/00</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/04</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C333/00</span>&mdash;<span itemprop="Description">Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C333/02</span>&mdash;<span itemprop="Description">Monothiocarbamic acids; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C333/10</span>&mdash;<span itemprop="Description">Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups being part of any of the groups, X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C59/00</span>&mdash;<span itemprop="Description">Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, Ometal, CHO, keto, ether, groups, groups, or groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C59/01</span>&mdash;<span itemprop="Description">Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D233/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D233/54</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D233/64</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/12</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/125</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/13</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/14</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/145</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/15</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/00</span>&mdash;<span itemprop="Description">Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/09</span>&mdash;<span itemprop="Description">Recombinant DNA-technology</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/11</span>&mdash;<span itemprop="Description">DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/113</span>&mdash;<span itemprop="Description">Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/00</span>&mdash;<span itemprop="Description">Structure or type of the nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/10</span>&mdash;<span itemprop="Description">Type of nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/14</span>&mdash;<span itemprop="Description">Type of nucleic acid interfering nucleic acids [NA]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
    </ul>
  </section>

  

  

  <section>
    <h2>Definitions</h2>
    <ul>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for in vivo therapeutic applications.</span>
        <meta itemprop="num_attr" content="0001">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.</span>
        <meta itemprop="num_attr" content="0001">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Therapeutic nucleic acids</span>
        <span itemprop="definition">including small interfering RNA (siRNA), micro RNA (miRNA), antisense oligo nucleotides, messenger RNA (mRNA), ribozymes, pDNA and immune stimulating nucleic acids are act via a variety of mechanisms. Specific proteins can be downregulated by siRNA or miRNA through RNA interference (RNAi). Hematopoietic cells, such as leukocytes in general, and primary T lymphocytes and B-cells in particular, are notoriously hard to transfect with small interfering RNAs (siRNAs).</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA interference</span>
        <span itemprop="definition">RNA interference</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA and miRNA constructs</span>
        <span itemprop="definition">can be synthesized with any nucleotide sequence directed against a target protein.</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA constructs</span>
        <span itemprop="definition">have shown the ability to specially silence target proteins in both in vitro and in vivo models. These are currently being evaluated in clinical studies.</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA</span>
        <span itemprop="definition">messenger RNA</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA</span>
        <span itemprop="definition">is the family of large RNA molecules which transport the genetic information from DNA to ribosome.</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some nucleic acids</span>
        <span itemprop="definition">such as mRNA or plasmids, can be used to effect expression of specific cellular products. Such nucleic acids would be useful in the treatment of diseases related deficiency of a protein or enzyme.</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">problems associated with nucleic acids in therapeutic contexts</span>
        <span itemprop="definition">One of the major problems with therapeutic nucleic acids is the stability of the phosphodiester inter nucleotide link and its susceptibility to nucleases. Apart from that these nucleic acids have limited ability to cross the cell membrane.</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cationic lipids</span>
        <span itemprop="definition">have proved to be excellent carriers of nucleic acids to treat varies diseases in gene therapy applications.</span>
        <meta itemprop="num_attr" content="0004">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid nanoparticles formed from cationic lipids and other co-lipids</span>
        <span itemprop="definition">such as cholesterol, DSPC and PEGylated lipids encapsulated oligonucleotides which protect them from degradation and facilitate the cellular uptake. Nevertheless, there remains a need in the art for suitable and efficient delivery platforms for delivery of oligonucleotides.</span>
        <meta itemprop="num_attr" content="0004">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to novel cationic lipids which can be used in lipid nanoparticle preparation. These lipid nanoparticles protect nucleic acids from degradation, clearance from circulation and intracellular release.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid encapsulated lipid nanoparticles</span>
        <span itemprop="definition">advantageously are well-tolerated and provide an adequate therapeutic index, such that patient treatment at an effective dose of the nucleic acid is not associated with unacceptable toxicity and/or risk to the patient.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">also provides the methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulations with nucleic acids.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to novel cationic lipids, and formulations of such lipids with siRNA and pDNA.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs</span>
        <span itemprop="definition">lipid nanoparticles</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipids structures</span>
        <span itemprop="definition">are based on functional groups such as hydrazine, hydrazide or hydroxylamine linked, directly or through a linker to a fatty acid residue RC(  O), RC(  O)O or R wherein RCOOH is the corresponding fatty acid which may be saturated or unsaturated.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipids</span>
        <span itemprop="definition">also contain a functional head group, for example an amine, an N-containing heterocycle or heteroaryl, or an amino acid side chain (e.g., histidine or arginine side chains), which is linked through a linker, e.g., an alkylene chain.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipids</span>
        <span itemprop="definition">feature an asymmetrical structure and enhanced charge, hence it is hypothesized that such lipids will display improved binding and improve endosomal escape (i.e., enhanced stability) due to structural imbalance.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Other lipids according to the invention</span>
        <span itemprop="definition">have symmetrical structures as further described herein.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a cationic lipid comprising a functional group represented by the structure:</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently O, N or NH, wherein X and Y cannot both simultaneously be O;</span>
        <meta itemprop="num_attr" content="0009">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S</span>
        <meta itemprop="num_attr" content="0010">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="0011">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0 or 1</span>
        <meta itemprop="num_attr" content="0012">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">z</span>
        <span itemprop="definition">is 0 or 2;</span>
        <meta itemprop="num_attr" content="0013">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises two fatty acid residues symmetrically or asymmetrically linked to the aforementioned functional group.</span>
        <meta itemprop="num_attr" content="0014">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (I):</span>
        <meta itemprop="num_attr" content="0015">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="0017">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S</span>
        <meta itemprop="num_attr" content="0018">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0019">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0023">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z</span>
        <span itemprop="definition">is OC(  O), C(  O)O or O;</span>
        <meta itemprop="num_attr" content="0029">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, 4, 5 or 6;</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0 or 1</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p</span>
        <span itemprop="definition">is 0 or 1</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">z</span>
        <span itemprop="definition">is 0 or 2;</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of formula (I)</span>
        <span itemprop="definition">comprises a functional group selected from hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine.</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a functional group</span>
        <span itemprop="definition">selected from hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine.</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 0. In other embodiments of formula (I), m is 1. In other embodiments of formula (I), p is 0. In other embodiments of formula (I), p is 1. In other embodiments of formula (I), m is 0 and p is 0. In other embodiments of formula (I), m is 1 and p is 0. In other embodiments of formula (I), z is 0. In other embodiments of formula (I), z is 2. In other embodiments of formula (I), T C. In other embodiments of formula (I), W is a bond. In other embodiments of formula (I), R 1 is NR 4 R 5 .</span>
        <meta itemprop="num_attr" content="0035">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (II):</span>
        <meta itemprop="num_attr" content="0037">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="0039">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="0040">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S</span>
        <meta itemprop="num_attr" content="0043">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0044">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0048">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z</span>
        <span itemprop="definition">is OC(  O), C(  O)O or O;</span>
        <meta itemprop="num_attr" content="0054">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, 4, 5 or 6;</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0 or 1</span>
        <meta itemprop="num_attr" content="0056">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p</span>
        <span itemprop="definition">is 0 or 1</span>
        <meta itemprop="num_attr" content="0057">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">z</span>
        <span itemprop="definition">is 0 or 2;</span>
        <meta itemprop="num_attr" content="0058">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of formula (II)</span>
        <span itemprop="definition">comprises a functional group selected from hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine.</span>
        <meta itemprop="num_attr" content="0060">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a functional group</span>
        <span itemprop="definition">selected from hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine.</span>
        <meta itemprop="num_attr" content="0060">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 0. In other embodiments of formula (II), m is 1. In other embodiments of formula (II), m is 1. In other embodiments of formula (II), m is 1 and p is 0. In other embodiments of formula (II), z is 0. In other embodiments of formula (II), z is 2. In other embodiments of formula (II), T is C. In other embodiments of formula (II), W is a bond. In some embodiments of formula (II), m is 0 and W is O.</span>
        <meta itemprop="num_attr" content="0061">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (IIa). In some representative embodiments of formula (IIa), the cationic lipid is represented by the structure of formula (IIa-1). In other representative embodiments of formula (IIa), the cationic lipid is represented by the structure of formula (IIa-2). In other representative embodiments of formula (IIa), the cationic lipid is represented by the structure of formula (IIa-3). In other representative embodiments of formula (IIa), the cationic lipid is represented by the structure of formula (IIa-4). In other representative embodiments of formula (II), the cationic lipid is represented by the structure of formula (IIb). In some representative embodiments of formula (IIb), the cationic lipid is represented by the structure of formula (IIb-11).</span>
        <meta itemprop="num_attr" content="0062">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of the present invention</span>
        <span itemprop="definition">is represented by the structure of formula (III):</span>
        <meta itemprop="num_attr" content="0066">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently O, N or NH, wherein X and Y cannot both simultaneously be O;</span>
        <meta itemprop="num_attr" content="0067">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of R 1 , R 2 and R 3</span>
        <span itemprop="definition">is independently absent or a C 10 -C 22 alkyl, a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl;</span>
        <meta itemprop="num_attr" content="0068">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is an integer between 1 and 30; including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of the present invention</span>
        <span itemprop="definition">is represented by the structure of formula (IIIA):</span>
        <meta itemprop="num_attr" content="0069">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently O, N or NH, wherein X and Y cannot both simultaneously be O; each of R 1 , R 2 and R 3 is independently absent or a C 10 -C 22 alkyl, a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl; n is an integer between 1 and 30; and x is 0 or 2; including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a composition</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a composition</span>
        <span itemprop="definition">comprising the cationic lipid of any one of formulae (I), (Ia), (Ia-1), (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb), (IIb-1) and (III), and further comprising at least one additional neutral or PEG-modified lipid.</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the composition</span>
        <span itemprop="definition">may further comprise a nucleic acid.</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">examples include, but are not limited to, small interfering RNA (siRNA), micro RNA (miRNA), antisense oligo nucleotides, messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA and immune stimulating nucleic acids.</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">small interfering RNA</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">miRNA</span>
        <span itemprop="definition">micro RNA</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">antisense oligo nucleotides</span>
        <span itemprop="definition">messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA and immune stimulating nucleic acids.</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA</span>
        <span itemprop="definition">messenger RNA</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ribozymes</span>
        <span itemprop="definition">pDNA</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CRISPR mRNA</span>
        <span itemprop="definition">CRISPR mRNA</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">gRNA</span>
        <span itemprop="definition">immune stimulating nucleic acids</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a method of gene silencing, comprising the step of contacting a cell with a composition according to the present invention.</span>
        <meta itemprop="num_attr" content="0072">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cell</span>
        <span itemprop="definition">is a cancer cell.</span>
        <meta itemprop="num_attr" content="0072">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions of the present invention</span>
        <span itemprop="definition">may be used as a delivery system to administer a therapeutic agent to its target location in the body.</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a method for administering a therapeutic agent, by preparing a composition comprising a cationic lipid as described herein and a therapeutic agent, and administering the combination to a subject in need thereof.</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids of the present invention</span>
        <span itemprop="definition">can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids (including, for example, sterols) and/or their analogs, and/or polymer conjugated lipids to form lipid nanoparticles for the delivery of therapeutic agents.</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">are used to deliver nucleic acids for the treatment of various diseases or conditions, in particular leukocyte associated conditions such as inflammation and/or lack of sufficient protein.</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a method of treating a leukocyte associated condition, the method comprising the step of administering to a subject in need thereof a composition according to the present invention.</span>
        <meta itemprop="num_attr" content="0075">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the leukocyte associated condition</span>
        <span itemprop="definition">may be selected from the group consisting of cancer, infection, autoimmune diseases, neurodegenerative diseases and inflammation.</span>
        <meta itemprop="num_attr" content="0075">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 1</span>
        <span itemprop="definition">In vitro gene silencing effect lipid 1: Human T cells SupT1 were treated with lipid nanoparticle (LNP) comprising of cationic lipid 1 encapsulated siCD45 for 48 hrs (A) or 72 hrs (B) at different siRNA doses (0.4   M, 0.2   M, 0.1   M).</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP</span>
        <span itemprop="definition">lipid nanoparticle</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 2</span>
        <span itemprop="definition">Drug resistant human ovarian carcinoma cells (NAR) were treated with either LNP-siPLK-1 or LNP-siLuc nanoparticles for 72 hr and PLK-1 expression was measured by qPCR.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 3</span>
        <span itemprop="definition">In vitro gene silencing effect of lipid 1 in NAR cells: Human ovarian cancer cells (NAR cells) were treated with lipid1/siPLK1 nanoparticles for 48 hr at different siRNA concentrations (0.2   M and 0.1   M). Apoptotic cells were analyzed by FACS using PI/Annexin.</span>
        <meta itemprop="num_attr" content="0079">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 4</span>
        <span itemprop="definition">In vitro gene silencing effect of lipid 10 and 11 in NAR cells: Human ovarian cancer cells (NAR cells) were treated with lipid1/siPLK1 nanoparticles for 48 hr at different siRNA concentrations (0.1   M and 0.05   M). Apoptotic cells were analyzed by FACS using PI/Annexin.</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 5</span>
        <span itemprop="definition">Human ovarian carcinoma cells (OVCAR 8) were treated with either LNP-siPLK-1 or LNP-siLuc nanoparticles for 72 hr and PLK-1 expression was measured by qPCR.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 6</span>
        <span itemprop="definition">Spheroids of drug resistant human ovarian carcinoma cells (NAR) were treated with either LNP-siPLK-1 or LNP-siLuc nanoparticles for 72 hr and PLK-1 expression was measured by qPCR.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 7</span>
        <span itemprop="definition">Human colon carcinoma cells (HCT116) were incubated with LNPs (comprising MC3, Lipids 38 or Lipid 55) with ctl siRNA for 72 hrs. Cell viability was measured by XTT assay.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 10</span>
        <span itemprop="definition">shows cell proliferation (% of untreated cells) vs. concentration of siPLK1.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 8</span>
        <span itemprop="definition">In vitro gene silencing effects of Lipids 38 or 55.</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Human multiple myeloma suspension cells</span>
        <span itemprop="definition">(U266) were incubated with LNPs containing siPLK1 at different concentrations for 48 hrs.</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PLK1 expression</span>
        <span itemprop="definition">was measured by qPCR.</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PLK1-mRNA levels</span>
        <span itemprop="definition">were normalized to LNPs-ctl siRNA treated cells.</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 9</span>
        <span itemprop="definition">Effect of PLK1 silencing on cell viability.</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Human multiple myeloma suspension cells</span>
        <span itemprop="definition">(U266) were incubated with LNPs comprising cationic lipids 38 or 55 and siPLK1 or ctl-siRNA at different concentrations for 48 hrs.</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cell viability induced by PLK1 down regulation</span>
        <span itemprop="definition">was measured by XTT assay.</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 10</span>
        <span itemprop="definition">Effect of PLK1 silencing on cell viability; Human B-cell lymphoma suspension cells (RPMI-8226) were incubated with LNPs comprising cationic lipids 38 or 55 and siPLK1 or ctl-siRNA at different concentrations for 48 hrs. Cell viability induced by PLK1 down regulation was measured by XTT assay.</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 11</span>
        <span itemprop="definition">Effect of PLK1 silencing on cell viability.</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Human multiple myeloma suspension cells (MM1)</span>
        <span itemprop="definition">were incubated with LNPs comprising cationic lipids 38 or 55 and siPLK1 or ctl-siRNA at different concentrations for 48 hrs.</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cell viability induced by PLK1 down regulation</span>
        <span itemprop="definition">was measured by XTT assay.</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 12</span>
        <span itemprop="definition">In vitro expression of pDNA.</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Human colon carcinoma cells</span>
        <span itemprop="definition">HCT 116 were incubated with LNPs-LUC pDNA at different concentrations for 48 hrs. Luciferase expression was measured by luminometer.</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipofectamine 2000</span>
        <span itemprop="definition">Lipo 2000 was used as positive control.</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs</span>
        <span itemprop="definition">were formulated with lipid 38 and different amounts of DOPE, along with other co-lipids Chol, and PEG-DMG.</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 13</span>
        <span itemprop="definition">HEK 293 cells were treated with LNP-DNA nanoparticles (10:1 N/P ratio, 0.6 nM DNA) for 72 hr and mKATE expression was analyzed by flow cytometry.</span>
        <meta itemprop="num_attr" content="0089">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 14</span>
        <span itemprop="definition">HEK 293 cells were treated with LNP-DNA nanoparticles (10:1 N/P ratio) at different DNA for 72 hr and mKATE expression was analyzed by flow cytometry.</span>
        <meta itemprop="num_attr" content="0090">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 14A</span>
        <span itemprop="definition">Lipid 1.</span>
        <meta itemprop="num_attr" content="0090">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 14B</span>
        <span itemprop="definition">Lipid 10.</span>
        <meta itemprop="num_attr" content="0090">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 15</span>
        <span itemprop="definition">In vitro delivery of mRNA. Hard to transfect murine macrophage cells (RAW 264.7) were treated with LNPs containing cationic lipids 38 or 54 and luciferase mRNA for 18 hrs at different mRNA concentrations. Luciferase expression was measured by luminometer.</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 16</span>
        <span itemprop="definition">In vivo delivery of mRNA.</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs containing cationic lipids 38 or 54 luciferase mRNA</span>
        <span itemprop="definition">was administered intramuscularly to C57BL6/j mice at 1 mg/kg body weight. Luciferase expression was measured by bioluminescence imaging system Biospace: (A) after 8 hrs of i.m. administration; and (B) after 24 hrs.</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 17</span>
        <span itemprop="definition">LNPs composed of either lipid 54 or lipid 38 formulated with luciferase mRNA were administered intravenously into C57BL6/j mice at 1 mg/kg body weight. After 8 hrs, luciferase expression was measured by bioluminescence imaging system Biospace.</span>
        <meta itemprop="num_attr" content="0093">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 18</span>
        <span itemprop="definition">In vivo delivery of mRNA to liver.</span>
        <meta itemprop="num_attr" content="0094">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs composed of lipid 38 formulated with luciferase mRNA</span>
        <span itemprop="definition">were administered intravenously into C57BL6/j mice at 1 mg/kg body weight. After 8 hrs and 24 hrs of administration, luciferase expression was measured by bioluminescence imaging system Biospace.</span>
        <meta itemprop="num_attr" content="0094">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 19</span>
        <span itemprop="definition">No liver toxicity in Non-human primate compared with MC3.</span>
        <meta itemprop="num_attr" content="0095">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">serum</span>
        <span itemprop="definition">was collected at and analyzed for ALT, AST. Each data point is an average of 2 animals  SEM.</span>
        <meta itemprop="num_attr" content="0095">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">based on the discovery of cationic lipids useful in preparing lipid nanoparticles to deliver active agents in vitro and in vivo.</span>
        <meta itemprop="num_attr" content="0096">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipids of the present invention</span>
        <span itemprop="definition">are useful in delivery of nucleic acids such as siRNA, miRNA and mRNA etc.</span>
        <meta itemprop="num_attr" content="0096">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a cationic lipid comprising a hydrazine, hydrazine, hydroxylamine, ethanolamine or diethylene diamine moiety linked to at least one saturated or unsaturated fatty acid residue.</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises two fatty acid residues asymmetrically linked to the hydrazine, hydrazine, hydroxylamine, ethanolamine or diethylene diamine moiety.</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a cationic lipid comprising a functional group represented by the structure:</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently O, N or NH, wherein X and Y cannot both be O;</span>
        <meta itemprop="num_attr" content="0100">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0 or 1</span>
        <meta itemprop="num_attr" content="0103">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">z</span>
        <span itemprop="definition">is 0 or 2;</span>
        <meta itemprop="num_attr" content="0104">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently O or N, wherein X and Y cannot both be O.</span>
        <meta itemprop="num_attr" content="0106">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises two fatty acid residues symmetrically or asymmetrically linked to the aforementioned functional group.</span>
        <meta itemprop="num_attr" content="0107">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is N</span>
        <meta itemprop="num_attr" content="0108">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (I):</span>
        <meta itemprop="num_attr" content="0108">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S;</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">NR 4 R 5</span>
        <span itemprop="definition">wherein R 4 and R 5 are each independently a C 1 -C 4 alkyl; or R 4 and R 5 together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR 4 R 5 represent a guanidine group (NHC(  NH)NH 2 );</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z</span>
        <span itemprop="definition">is OC(  O), C(  O)O or O;</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are selected from the group consisting of: (a) a C 10 -C 22 alkyl, a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl; and (b) C 4 -C 10 alkylene-ZC 4 -C 22 alkyl wherein Z is OC(  O), C(  O)O or O.</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a C 10 -C 22 alkyl</span>
        <span itemprop="definition">a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 4 -C 10 alkylene-ZC 4 -C 22 alkyl</span>
        <span itemprop="definition">wherein Z is OC(  O), C(  O)O or O.</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is NR 4 R 5 . In some embodiments of formula (I), R 1 is the side chain of a natural or unnatural amino acid. In some embodiments of formula (I), R 1 is a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from the group consisting of O, N and S.</span>
        <meta itemprop="num_attr" content="0120">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of formula (I)</span>
        <span itemprop="definition">comprises a functional group selected from the group consisting of hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine.</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a functional group</span>
        <span itemprop="definition">selected from the group consisting of hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine.</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 0. In other embodiments of formula (I), m is 1. In other embodiments of formula (I), p is 0. In other embodiments of formula (I), p is 1. In other embodiments of formula (I), m is 0 and p is 0. In other embodiments of formula (I), m is 1 and p is 0. In other embodiments of formula (I), z is 0. In other embodiments of formula (I), z is 2. In other embodiments of formula (I), T is C. In other embodiments of formula (I), W is a bond.</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , R 3 , Y, m, n and z</span>
        <span itemprop="definition">are as defined in formula (I).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 0. In other embodiments of formula (Ia), m is 1. In other embodiments of formula (I), z is 0. In other embodiments of formula (Ia), R 2 and R 3 are each independently a C 14 -C 20 alkyl or a C 14 -C 20 alkenyl. In other embodiments of formula (Ia), R 2 and R 3 are each independently a C 4 -C 10 alkylene-ZC 4 -C 22 alkyl wherein Z is OC(  O), C(  O)O or O.</span>
        <meta itemprop="num_attr" content="0124">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are each independently a C 4 -C 10 alkylene-ZC 4 -C 22 alkenyl wherein Z is OC(  O), C(  O)O or O.</span>
        <meta itemprop="num_attr" content="0124">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is O.</span>
        <meta itemprop="num_attr" content="0124">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is NH</span>
        <meta itemprop="num_attr" content="0125">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is NR 4 R 5 , and the compound is represented by the structure of formula (Ia-1):</span>
        <meta itemprop="num_attr" content="0126">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 , R 3 , R 4 , R 5 , Y, m, n and z</span>
        <span itemprop="definition">are as defined in formula (I).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are each CH 3 .</span>
        <meta itemprop="num_attr" content="0127">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5 together with the nitrogen to which they are attached</span>
        <span itemprop="definition">form a heterocyclic ring selected from the group consisting of pyrrolidinyl piperidininyl and piperazinyl, each of which is optionally substituted with an alkyl.</span>
        <meta itemprop="num_attr" content="0127">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a heterocyclic ring</span>
        <span itemprop="definition">selected from the group consisting of pyrrolidinyl piperidininyl and piperazinyl, each of which is optionally substituted with an alkyl.</span>
        <meta itemprop="num_attr" content="0127">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (II):</span>
        <meta itemprop="num_attr" content="0128">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S;</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">NR 4 R 5</span>
        <span itemprop="definition">wherein R 4 and R 5 are each independently a C 1 -C 4 alkyl; or R 4 and R 5 together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR 4 R 5 represent a guanidine group (NHC(  NH)NH 2 );</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z</span>
        <span itemprop="definition">is OC(  O), C(  O)O or O;</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are selected from the group consisting of: (a) a C 10 -C 22 alkyl, a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl; and (b) C 4 -C 10 alkylene-ZC 4 -C 22 alkyl wherein Z is OC(  O), C(  O)O or O.</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a C 10 -C 22 alkyl</span>
        <span itemprop="definition">a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 4 -C 10 alkylene-ZC 4 -C 22 alkyl</span>
        <span itemprop="definition">wherein Z is OC(  O), C(  O)O or O.</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 0. In other embodiments of formula (II), m is 1. In other embodiments of formula (II), m is 1. In other embodiments of formula (II), m is 1 and p is 0. In other embodiments of formula (II), z is 0. In other embodiments of formula (II), z is 2. In other embodiments of formula (II), T is C. In other embodiments of formula (II), W is a bond. In some embodiments of formula (II), m is 0 and W is O.</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (IIa):</span>
        <meta itemprop="num_attr" content="0143">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , R 3 , X, T, W, n, m, p and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , R 3 , X, n, m and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is NR 4 R 5 , and the compound is represented by the structure of formula (IIa-2):</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 , R 3 , R 4 , R 5 , X, n, m and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is the side chain of a natural or unnatural amino acid</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 , R 3 , X, n and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compounds of formula (IIa-5)</span>
        <span itemprop="definition">can be used as intermediates for preparing compounds of formula (IIa-4):</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are as defined in formula (IIa-4).</span>
        <meta itemprop="num_attr" content="0149">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (IIb):</span>
        <meta itemprop="num_attr" content="0150">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R, R 2 , R 3 , T, W, X, Y n, m, p and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 , R 3 , R 4 , R 5 , X, Y, n, m and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are each independently a C 14 -C 20 alkyl or a C 14 -C 20 alkenyl.</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are each independently a C 4 -C 10 alkylene-ZC 4 -C 22 alkyl wherein Z is OC(  O), C(  O)O or O.</span>
        <meta itemprop="num_attr" content="0153">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are each independently a C 4 -C 10 alkylene-ZC 4 -C 22 alkenyl wherein Z is OC(  O), C(  O)O or O.</span>
        <meta itemprop="num_attr" content="0154">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is O.</span>
        <meta itemprop="num_attr" content="0155">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is NH</span>
        <meta itemprop="num_attr" content="0156">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is NH</span>
        <meta itemprop="num_attr" content="0157">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are each CH 3 , or wherein R 4 and R 5 together with the nitrogen to which they are attached form a heterocyclic ring selected from the group consisting of pyrrolidinyl piperidinyl and piperazinyl, each of which is optionally substituted with an alkyl.</span>
        <meta itemprop="num_attr" content="0158">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of the present invention</span>
        <span itemprop="definition">is represented by the structure of formula (III):</span>
        <meta itemprop="num_attr" content="0160">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently O, N or NH, wherein X and Y cannot both be O; each of R 1 , R 2 and R 3 is independently absent or a C 10 -C 22 alkyl, a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl; and n is an integer between 1 and 30; including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of the present invention</span>
        <span itemprop="definition">is represented by the structure of formula (IIIA):</span>
        <meta itemprop="num_attr" content="0161">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently O, N or NH, wherein X and Y cannot both be O; each of R 1 , R 2 and R 3 is independently absent or a C 10 -C 22 alkyl, a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl; n is an integer between 1 and 30; and x is 0 or 2; including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently selected from the group consisting of O and N. In other embodiments of formula (III), X and Y are each independently selected from the group consisting of O, N and NH.</span>
        <meta itemprop="num_attr" content="0162">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a cationic lipid comprising a functional group represented by the structure:</span>
        <meta itemprop="num_attr" content="0164">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently O or N, wherein X and Y cannot both be O;</span>
        <meta itemprop="num_attr" content="0165">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S</span>
        <meta itemprop="num_attr" content="0166">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="0167">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0 or 1</span>
        <meta itemprop="num_attr" content="0168">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">z</span>
        <span itemprop="definition">is 0 or 2;</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">comprises two fatty acid residues symmetrically or asymmetrically linked to the aforementioned functional group.</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (I):</span>
        <meta itemprop="num_attr" content="0171">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="0173">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S</span>
        <meta itemprop="num_attr" content="0174">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0175">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0179">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, 4, 5 or 6;</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0 or 1</span>
        <meta itemprop="num_attr" content="0183">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p</span>
        <span itemprop="definition">is 0 or 1</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">z</span>
        <span itemprop="definition">is 0 or 2;</span>
        <meta itemprop="num_attr" content="0185">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of formula (I)</span>
        <span itemprop="definition">comprises a functional group selected from hydrazine, hydroxylamine and hydrazide.</span>
        <meta itemprop="num_attr" content="0186">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a functional group</span>
        <span itemprop="definition">selected from hydrazine, hydroxylamine and hydrazide.</span>
        <meta itemprop="num_attr" content="0186">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 0. In other embodiments of formula (I), m is 1. In other embodiments of formula (I), p is 0. In other embodiments of formula (I), p is 1. In other embodiments of formula (I), m is 0 and p is 0. In other embodiments of formula (I), m is 1 and p is 0. In other embodiments of formula (I), z is 0. In other embodiments of formula (I), z is 2. In other embodiments of formula (I), T is C. In other embodiments of formula (I), W is a bond. In other embodiments of formula (I), R 1 is NR 4 R 5 .</span>
        <meta itemprop="num_attr" content="0187">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , R 3 , Y, m, n and z</span>
        <span itemprop="definition">are as defined in formula (I).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 0.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 1.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">z</span>
        <span itemprop="definition">is 0.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are each independently a C 14 -C 20 alkyl or a C 14 -C 20 alkenyl.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are each independently a C 4 -C 10 alkylene-ZC 4 -C 22 alkyl wherein Z is OC(  O) or C(  O)O.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is O.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is NH.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is NR 4 R 5 , and the compound is represented by the structure of formula (Ia-1):</span>
        <meta itemprop="num_attr" content="0189">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 , R 3 , R 4 , R 5 , Y, m, n and z</span>
        <span itemprop="definition">are as defined in formula (I).</span>
        <meta itemprop="num_attr" content="0190">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are each CH 3 .</span>
        <meta itemprop="num_attr" content="0190">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5 together with the nitrogen to which they are attached</span>
        <span itemprop="definition">form a heterocyclic ring selected from pyrrolidinyl piperidininyl and piperazinyl, each of which is optionally substituted with an alkyl.</span>
        <meta itemprop="num_attr" content="0190">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a heterocyclic ring</span>
        <span itemprop="definition">selected from pyrrolidinyl piperidininyl and piperazinyl, each of which is optionally substituted with an alkyl.</span>
        <meta itemprop="num_attr" content="0190">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (II):</span>
        <meta itemprop="num_attr" content="0190">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="0192">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is O or NH</span>
        <meta itemprop="num_attr" content="0193">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T</span>
        <span itemprop="definition">is C or S</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">W</span>
        <span itemprop="definition">is a bond, O, NH or S</span>
        <meta itemprop="num_attr" content="0196">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0201">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0, 1, 2, 3, 4, 5 or 6;</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">0 or 1</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p</span>
        <span itemprop="definition">is 0 or 1</span>
        <meta itemprop="num_attr" content="0206">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">z</span>
        <span itemprop="definition">is 0 or 2;</span>
        <meta itemprop="num_attr" content="0207">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of formula (II)</span>
        <span itemprop="definition">comprises a functional group selected from hydrazine, hydroxylamine and hydrazide.</span>
        <meta itemprop="num_attr" content="0209">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a functional group</span>
        <span itemprop="definition">selected from hydrazine, hydroxylamine and hydrazide.</span>
        <meta itemprop="num_attr" content="0209">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 0. In other embodiments of formula (I), m is 1. In other embodiments of formula (II), m is 1. In other embodiments of formula (I), m is 1 and p is 0. In other embodiments of formula (II), z is 0. In other embodiments of formula (II), z is 2. In other embodiments of formula (II), T is C. In other embodiments of formula (II), W is a bond.</span>
        <meta itemprop="num_attr" content="0210">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (IIa):</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , R 3 , X, T, W, n, m, p and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , R 3 , X, n, m and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is NR 4 R 5</span>
        <meta itemprop="num_attr" content="0213">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound</span>
        <span itemprop="definition">is represented by the structure of formula (IIa-2):</span>
        <meta itemprop="num_attr" content="0213">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 , R 3 , R 4 , R 5 , X, n, m and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is the side chain of a natural or unnatural amino acid; and R 1 , R 2 , R 3 , X, n and z are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is represented by the structure of formula (IIb):</span>
        <meta itemprop="num_attr" content="0215">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 , R 2 , R 3 , T, W, X, Y n, m, p and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 , R 3 , R 4 , R 5 , X, Y, n, m and z</span>
        <span itemprop="definition">are as defined in formula (II).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are each independently a C 14 -C 20 alkyl or a C 14 -C 20 alkenyl.</span>
        <meta itemprop="num_attr" content="0217">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are each independently a C 4 -C 10 alkylene-ZC 4 -C 22 alkyl wherein Z is OC(  O) or C(  O)O.</span>
        <meta itemprop="num_attr" content="0218">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is O.</span>
        <meta itemprop="num_attr" content="0219">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">is NH</span>
        <meta itemprop="num_attr" content="0220">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is NH</span>
        <meta itemprop="num_attr" content="0221">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 and R 5</span>
        <span itemprop="definition">are each CH 3 , or wherein R 4 and R 5 together with the nitrogen to which they are attached form a heterocyclic ring selected from pyrrolidinyl piperidinyl, piperazinyl, each of which is optionally substituted with an alkyl.</span>
        <meta itemprop="num_attr" content="0222">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid of the present invention</span>
        <span itemprop="definition">is represented by the structure of formula (III):</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X and Y</span>
        <span itemprop="definition">are each independently is O or N;</span>
        <meta itemprop="num_attr" content="0224">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of R 1 , R 2 and R 3</span>
        <span itemprop="definition">is independently absent or a C 10 -C 22 alkyl, a C 10 -C 22 alkenyl or a C 10 -C 22 alkynyl;</span>
        <meta itemprop="num_attr" content="0225">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">1 to 30; including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl group</span>
        <span itemprop="definition">refers to any saturated aliphatic hydrocarbon, including straight-chain and branched-chain alkyl groups.</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl group</span>
        <span itemprop="definition">has 1-4 carbons designated here as C 1 -C 4 -alkyl.</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl group</span>
        <span itemprop="definition">has 10-22 carbons designated here as C 10 -C 22 -alkyl.</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl group</span>
        <span itemprop="definition">has 4-10 carbons designated here as C 4 -C 10 -alkyl.</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl group</span>
        <span itemprop="definition">has 4-22 carbons designated here as C 4 -C 22 -alkyl.</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl group</span>
        <span itemprop="definition">may be unsubstituted or substituted by one or more groups selected from halogen, hydroxy, alkoxy carbonyl, amido, alkylamido, dialkylamido, nitro, amino, alkylamino, dialkylamino, carboxyl, thio and thioalkyl.</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkenyl</span>
        <span itemprop="definition">refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond including straight-chain, branched-chain and cyclic alkenyl groups.</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkenyl group</span>
        <span itemprop="definition">has 10-22 carbons designated here as C 10 -C 22 -alkenyl.</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkenyl group</span>
        <span itemprop="definition">has 4-10 carbons designated here as C 4 -C 10 -alkenyl.</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkenyl group</span>
        <span itemprop="definition">has 4-22 carbons designated here as C 4 -C 22 -alkenyl.</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkenyl groups</span>
        <span itemprop="definition">include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexyl-butenyl and decenyl.</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkenyl group</span>
        <span itemprop="definition">can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkynyl</span>
        <span itemprop="definition">refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond including straight-chain and branched-chain.</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkynyl group</span>
        <span itemprop="definition">has 10-22 carbons designated here as C 10 -C 22 -alkynyl.</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkynyl group</span>
        <span itemprop="definition">has 4-10 carbons designated here as C 4 -C 10 -alkynyl.</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkynyl group</span>
        <span itemprop="definition">has 4-22 carbons designated here as C 4 -C 22 -alkynyl.</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkynyl groups</span>
        <span itemprop="definition">include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl, heptynyl, octynyl and decynyl.</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkynyl group</span>
        <span itemprop="definition">can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heteroaryl</span>
        <span itemprop="definition">used herein alone or as part of another group refers to a heteroaromatic system containing at least one heteroatom ring wherein the atom is selected from nitrogen, sulfur and oxygen.</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heteroaryl</span>
        <span itemprop="definition">contains 5 or more ring atoms.</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heteroaryl group</span>
        <span itemprop="definition">can be monocyclic, bicyclic, tricyclic and the like. Also included in this definition are the benzoheterocyclic rings. If nitrogen is a ring atom, the present invention also contemplates the N-oxides of the nitrogen containing heteroaryls.</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heteroaryl moieities</span>
        <span itemprop="definition">include thienyl, benzothienyl, 1-naphthothienyl, thianthrenyl, furyl, benzofuryl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, indazolyl, purinyl, isoquinolyl, quinolyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, carbolinyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl and the like.</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heteroaryl group</span>
        <span itemprop="definition">can be unsubstituted or substituted through available atoms with one or more groups defined hereinabove for alkyl.</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heterocyclic ring</span>
        <span itemprop="definition">or heterocyclyl used herein alone or as part of another group refers to a five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heteroatoms</span>
        <span itemprop="definition">such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These five-membered to eight-membered rings</span>
        <span itemprop="definition">can be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred.</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Preferred heterocyclic ring moieties</span>
        <span itemprop="definition">include piperidinyl, pyrrolidinyl piperazinyl, pyrrolinyl, pyrazolinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, indolinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, dihydropyranyl, tetrahydropyranyl, dihydrothiazolyl, and the like.</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cyclic group</span>
        <span itemprop="definition">is pyrrolidinyl.</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heteroaryl or heterocyclyl group</span>
        <span itemprop="definition">is piperidinyl. In other embodiments, the heterocyclyl group is piperidine.</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heterocyclyl group</span>
        <span itemprop="definition">can be unsubstituted or substituted through available atoms with one or more groups defined hereinabove for alkyl.</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amino acid</span>
        <span itemprop="definition">or amino acids is understood to include the 20 naturally occurring amino acids, i.e., alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.</span>
        <meta itemprop="num_attr" content="0231">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amino acids</span>
        <span itemprop="definition">refers to non-natural amino acids or synthetic amino acids.</span>
        <meta itemprop="num_attr" content="0231">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amino acid</span>
        <span itemprop="definition">includes both D- and L-amino acids.</span>
        <meta itemprop="num_attr" content="0232">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amino acid side chain</span>
        <span itemprop="definition">refers to a group R of an amino acid of the formula H 2 NC(R)COOH.</span>
        <meta itemprop="num_attr" content="0232">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydroxylamine</span>
        <span itemprop="definition">moiety as used herein refers to the group NHO</span>
        <meta itemprop="num_attr" content="0234">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydrozide</span>
        <span itemprop="definition">moiety as used herein refers to the group C(  O)NN</span>
        <meta itemprop="num_attr" content="0235">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydroxylamine</span>
        <span itemprop="definition">moiety as used herein refers to the group OCH 2 CH 2 N or NCH 2 CH 2 O</span>
        <meta itemprop="num_attr" content="0236">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ethylenediamine</span>
        <span itemprop="definition">moiety as used herein refers to the group NCH 2 CH 2 N or NCH 2 CH 2 N</span>
        <meta itemprop="num_attr" content="0237">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">guanidine</span>
        <span itemprop="definition">refers to the group NHC(  NH)NH 2 .</span>
        <meta itemprop="num_attr" content="0238">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term leaving group as used herein</span>
        <span itemprop="definition">refers to any labile leaving group with is readily replaced by another moiety.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the leaving group</span>
        <span itemprop="definition">is selected from the group consisting of halogen, sulfonyloxy and OC(O)R wherein R is an alkyl, aryl or alkylaryl.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the leaving group</span>
        <span itemprop="definition">is selected from the group consisting of Cl, Br, I, mesylate (OMs), triflate (OTr) and tosylate (OTs).</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the leaving group X</span>
        <span itemprop="definition">is Br.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">protecting group</span>
        <span itemprop="definition">refers to chemical residues used to block reactive sites during chemical synthesis, that enable chemical reaction to be carried out selectively at one reaction site in a multifunctional compound, other reactive sites must be temporarily blocked. The residues used to block these reactive sites called protecting groups.</span>
        <meta itemprop="num_attr" content="0240">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nitrogen protecting group</span>
        <span itemprop="definition">or N protecting group or amino protecting group as used herein interchangeably refers to refers to a readily cleavable group bonded to amino groups.</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amino-protecting groups</span>
        <span itemprop="definition">include t-butoxycarbonyl (BOC), benzyloxycarbonyl, acetyl, phenylcarbonyl, or a silyl group, which can be substituted with alkyl (trialkylsilyl), with an aryl (triarylsilyl) or a combination thereof (e.g., dialkylphenylsilyl), e.g., trimethylsilyl (TMS) or t-butyldimethyl silyl (TBDMS).</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">BOC</span>
        <span itemprop="definition">t-butoxycarbonyl</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">benzyloxycarbonyl</span>
        <span itemprop="definition">acetyl</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phenylcarbonyl</span>
        <span itemprop="definition">or a silyl group, which can be substituted with alkyl (trialkylsilyl), with an aryl (triarylsilyl</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydroxy protecting groups</span>
        <span itemprop="definition">include, for example, C 1 -C 4 alkyl (e.g., methyl, ethyl, propyl, butyl and the like), CH 2 Ph (benzyl or bzl), allyl (All), (allyl)-CO(C 1 -C 6 alkyl), SO 2 (C 1 -C 6 alkyl), SO 2 -aryl, COAr in which Ar is an aryl group as defined above, and CO(C 1 -C 6 alkyl)Ar (e.g., a carboxybenzyl (Bz) group).</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 1 -C 4 alkyl</span>
        <span itemprop="definition">e.g., methyl, ethyl, propyl, butyl and the like</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CH 2 Ph</span>
        <span itemprop="definition">benzyl or bzl</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">allyl (All)</span>
        <span itemprop="definition">(allyl)-CO(C 1 -C 6 alkyl), SO 2 (C 1 -</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydroxy protecting groups</span>
        <span itemprop="definition">include acid sensitive protecting groups such as tetrahydropyranyl (THP), methoxymethyl (MOM), triphenylmethyl (Trityl) and dimethoxy trityl (DMT).</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">THP</span>
        <span itemprop="definition">tetrahydropyranyl</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MOM</span>
        <span itemprop="definition">methoxymethyl</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Trityl</span>
        <span itemprop="definition">triphenylmethyl</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DMT</span>
        <span itemprop="definition">dimethoxy trityl</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pharmaceutically acceptable salts</span>
        <span itemprop="definition">includes both acid and base addition salts, which retain the biologically effectiveness of the acid or base.</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">salt</span>
        <span itemprop="definition">encompasses both basic and acid addition salts, including but not limited to, carboxylate salts or salts with amine nitrogens, and include salts formed with the organic and inorganic anions and cations discussed below. Furthermore, the term includes salts that form by standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids.</span>
        <meta itemprop="num_attr" content="0242">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such acids</span>
        <span itemprop="definition">include hydrochloric, hydrofluoric, trifluoroacetic, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, phthalic, tartaric, lauric, stearic, salicylic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic, and like acids.</span>
        <meta itemprop="num_attr" content="0242">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each possibility</span>
        <span itemprop="definition">represents a separate embodiment of the invention.</span>
        <meta itemprop="num_attr" content="0242">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">organic or inorganic cation</span>
        <span itemprop="definition">refers to counter-ions for the anion of a salt.</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the counter-ions</span>
        <span itemprop="definition">include, but are not limited to, alkali and alkaline earth metals (such as lithium, sodium, potassium, barium, aluminum and calcium); ammonium and mono-, di- and tri-alkyl amines such as trimethylamine, cyclohexylamine; and the organic cations, such as dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylammonium, dibenzylethylenediammonium, and like cations. See, for example, Berge et al., J. Pharm. Sci . (1977), 66:1-19, which is incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions and Therapeutic Uses</span>
        <span itemprop="definition">are Compositions and Therapeutic Uses</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a composition comprising a cationic lipid according to any one of formulae (I), (Ia), (Ia-1), (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), e.g., any one of compounds 1 to 66, and a pharmaceutically acceptable excipient.</span>
        <meta itemprop="num_attr" content="0244">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the composition</span>
        <span itemprop="definition">may further comprise comprising at least one additional neutral or PEG-modified lipid.</span>
        <meta itemprop="num_attr" content="0244">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the composition</span>
        <span itemprop="definition">may further comprise a nucleic acid.</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">include small interfering RNA (siRNA), micro RNA (miRNA), antisense oligo nucleotides, messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA and immune stimulating nucleic acids.</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">small interfering RNA</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">miRNA</span>
        <span itemprop="definition">micro RNA</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA</span>
        <span itemprop="definition">messenger RNA</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ribozymes</span>
        <span itemprop="definition">pDNA</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CRISPR mRNA</span>
        <span itemprop="definition">CRISPR mRNA</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">gRNA</span>
        <span itemprop="definition">immune stimulating nucleic acids.</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provides a method of gene silencing, comprising the step of contacting a cell with a composition comprising a cationic lipid of the present invention.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cell</span>
        <span itemprop="definition">is a cancer cell.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the composition</span>
        <span itemprop="definition">further comprises one or more components selected from the group consisting of a neutral lipid, a charged lipid, a steroid, and a polymer-conjugated lipid.</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a neutral lipid</span>
        <span itemprop="definition">a charged lipid</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a steroid</span>
        <span itemprop="definition">a polymer-conjugated lipid</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions of the present invention</span>
        <span itemprop="definition">may be used as a delivery system to administer a therapeutic agent to its target location in the body.</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a method for administering a therapeutic agent, by preparing a composition comprising a cationic lipid as described herein and a therapeutic agent, and administering the combination to a subject in need thereof.</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">provide novel cationic lipids that enable the formulation of improved compositions for the in vitro and in vivo delivery of IVT-mRNA and/or other oligonucleotides.</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">these lipid nanoparticle compositions</span>
        <span itemprop="definition">are useful for expression of protein encoded by mRNA.</span>
        <meta itemprop="num_attr" content="0250">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">these improved lipid nanoparticles compositions</span>
        <span itemprop="definition">are useful for upregulation of endogenous protein expression by delivering miRNA inhibitors targeting one specific miRNA or a group of miRNA regulating one target mRNA or several mRNA.</span>
        <meta itemprop="num_attr" content="0251">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">these improved lipid nanoparticle compositions</span>
        <span itemprop="definition">are useful for down-regulating (e.g., silencing) the protein levels and/or mRNA levels of target genes.</span>
        <meta itemprop="num_attr" content="0252">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">are also useful for delivery of mRNA and plasmids for expression of transgenes.</span>
        <meta itemprop="num_attr" content="0253">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle compositions</span>
        <span itemprop="definition">are useful for inducing a pharmacological effect resulting from expression of a protein, e.g., increased production of red blood cells through the delivery of a suitable erythropoietin mRNA, or protection against infection through delivery of mRNA encoding for a suitable antibody.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">may be in the form of nanoparticles and administered as is.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticles</span>
        <span itemprop="definition">may be administered in a solution.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticles</span>
        <span itemprop="definition">may be formulated to a suitable pharmaceutical composition to be administered by any desired route of administration.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">routes of administration</span>
        <span itemprop="definition">include such routes as, but not limited to: topical, oral or parenteral.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compositions used</span>
        <span itemprop="definition">may be in the form of solid, semi-solid or liquid dosage forms, such, as for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions</span>
        <span itemprop="definition">may include the cationic particles, a pharmaceutical acceptable excipient, and, optionally, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, and the like. It is preferred that the pharmaceutically acceptable carrier be one which is inert to the nucleic acid encapsulated within the particles and which has no detrimental side effects or toxicity under the conditions of use.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the administration</span>
        <span itemprop="definition">is localized. In some embodiments, the administration is systemic.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">injectable formulations for parenteral administration</span>
        <span itemprop="definition">can be prepared as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable excipients</span>
        <span itemprop="definition">are, for example, water, saline, dextrose, glycerol, ethanol or the like.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions to be administered</span>
        <span itemprop="definition">may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, and the like.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Aqueous injection suspensions</span>
        <span itemprop="definition">may also contain substances that increase the viscosity of the suspension, including, for example, sodium carboxymethylcellulose, sorbitol, and/or dextran.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the suspension</span>
        <span itemprop="definition">may also contain stabilizers.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the parenteral formulations</span>
        <span itemprop="definition">can be present in unit dose or multiple dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, such as, for example, water, for injections immediately prior to use.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">parenteral administration</span>
        <span itemprop="definition">includes intravenous administration.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutically acceptable, non-toxic composition</span>
        <span itemprop="definition">may be formed by the incorporation of any of the normally employed excipients, such as, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">excipients</span>
        <span itemprop="definition">such as, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such compositions</span>
        <span itemprop="definition">include solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations and the like.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations suitable for oral administration</span>
        <span itemprop="definition">can consist of liquid solutions such as effective amounts of the compound(s) dissolved in diluents such as water, saline, or orange juice; sachets, lozenges, and troches, each containing a predetermined amount of the active ingredient as solids or granules; powders, suspensions in an appropriate liquid; and suitable emulsions.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Liquid formulations</span>
        <span itemprop="definition">may include diluents such as water and alcohols, (such as, for example ethanol, benzyl alcohol, and the polyethylene alcohols), either with or without the addition of a pharmaceutically acceptable surfactant, suspending agents, or emulsifying agents.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the dosage and frequency of administration</span>
        <span itemprop="definition">may be selected in relation to the pharmacological properties of the specific nucleic acids encapsulated within the particles.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a particle comprising a nucleic acid</span>
        <span itemprop="definition">such as, for example, siRNA, miRNA, shRNA, anti-sense RNA, and the like, may be used in the treatment of various leukocyte-associated conditions, depending on the identity of the nucleic acid, the specific target leukocyte, and the like.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid encapsulated within the particles</span>
        <span itemprop="definition">may be a nucleic acid capable of inducing silencing of a target gene.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target gene</span>
        <span itemprop="definition">may be any gene, the expression of which is related to the condition to be treated.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target gene</span>
        <span itemprop="definition">may be a gene selected from, but not limited to: growth factors (such as EGFR, PDGFR), genes related to angiogenesis pathways (such as VEGF, Integrins), genes involved in intracellular signaling pathways and cell cycle regulation (such as PI3K/AKT/mTOR, Ras/Raf/MAPK, PDK1, CHK1, PLK1, Cyclins).</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">growth factors</span>
        <span itemprop="definition">such as EGFR, PDGFR</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">genes related to angiogenesis pathways</span>
        <span itemprop="definition">such as VEGF, Integrins</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">genes involved in intracellular signaling pathways and cell cycle regulation</span>
        <span itemprop="definition">such as PI3K/AKT/mTOR, Ras/Raf/MAPK, PDK1, CHK1, PLK1, Cyclins.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a combination of nucleic acids, each having one or more targets</span>
        <span itemprop="definition">may be encapsulated within the particles.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">exemplary leukocyte-associated conditions that may be treated by the targeted particles</span>
        <span itemprop="definition">may be selected from, but not limited to: various types of cancer, various infections (such as, for example, viral infection, bacterial infection, fungal infection, and the like), autoimmune diseases, neurodegenerative diseases, inflammations, and the like.</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">various infections</span>
        <span itemprop="definition">such as, for example, viral infection, bacterial infection, fungal infection, and the like</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">autoimmune diseases</span>
        <span itemprop="definition">such as, for example, neurodegenerative diseases, inflammations, and the like.</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the targeted particles comprising a nucleic acid</span>
        <span itemprop="definition">may be used for the treatment of cancer.</span>
        <meta itemprop="num_attr" content="0261">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cancer</span>
        <span itemprop="definition">is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms that normally govern proliferation and differentiation.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cancer</span>
        <span itemprop="definition">is a blood cancer.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">blood cancers</span>
        <span itemprop="definition">are lymphoma, leukemia and myeloma. Lymphomas may be divided into two categories: Hodgkin lymphoma and non-Hodgkin lymphoma. Most non-Hodgkin lymphomas are B-cell lymphomas, that grow quickly (high-grade) or slowly (low-grade). There are 14 types of B-cell non-Hodgkin lymphomas. The others are T-cell lymphomas.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid that may be used for the treatment of cancer</span>
        <span itemprop="definition">is directed against a target gene, which is involved in the regulation of cell cycle.</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the target gene</span>
        <span itemprop="definition">may be Polo-like Kinase 1 (PLK), Cyclin D1, CHK1, Notch pathway genes.</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the plurality of lipids of the lipid particles</span>
        <span itemprop="definition">may be of natural or synthetic source and may be selected from, but not limited to: cationic lipids, phosphatidylethanolamines, ionized lipids, membrane stabilizing lipids, phospholipids, and the like, or combinations thereof. Each possibility represents a separate embodiment of the present invention.</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the membrane stabilizing lipids</span>
        <span itemprop="definition">may be selected from, but not limited to: cholesterol, phospholipids (such as, for example, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, diphosphatidylglycerols), cephalins, sphingolipids (sphingomyelins and glycosphingolipids), glycoglycerolipids, and combinations thereof.</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phospholipids</span>
        <span itemprop="definition">such as, for example, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, diphosphatidylglycerols</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cephalins</span>
        <span itemprop="definition">such as, for example, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidy</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phosphatidylethanolamines</span>
        <span itemprop="definition">may be selected from, but not limited to: 1,2-dilauroyl-L-phosphatidyl-ethanolamine (DLPE), 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhPE) 1,3-Dipalmitoyl-sn-glycero-2-phosphoethanolamine (1,3-DPPE), 1-Palmitoyl-3-oleoyl-sn-glycero-2-phosphoethanolamine (1,3-POPE), Biotin-Phosphatidylethanolamine, 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), Dipalmitoylphosphatidylethanolamine (DPPE), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) or combinations thereof.</span>
        <meta itemprop="num_attr" content="0266">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DLPE</span>
        <span itemprop="definition">1,2-d</span>
        <meta itemprop="num_attr" content="0266">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">neutral lipid</span>
        <span itemprop="definition">refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at physiological pH</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">such lipids</span>
        <span itemprop="definition">include, but are not limited to, phosphotidylcholines such as 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Dipalmitoyl-sn-glyccro-3-phosphocholine (DPPC), 1,2-Dimyristoyl-sn-glyccro-3-phosphocholine (DMPC), 1-Palmitoyl-2-olcoyl-sn-glyccro-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), phophatidyl ethanolamines such as 1,2-Diolcoyl-sn-glyccro-3-phosphoethanolamine (DOPE), sphingomyelins (SM), ceramide</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DOPE</span>
        <span itemprop="definition">1,2-D</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">may further include one or more PEG derivatives.</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG derivatives</span>
        <span itemprop="definition">may be conjugated to one or more additional molecules, such as, a lipid.</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG derivative</span>
        <span itemprop="definition">is selected from, but not limited to: PEG-DMG 3-N-(-methoxy poly(ethylene glycol)2000)carbamoyl-1,2-dimyrisyl glycerol, PEG-cDMA 3-N-(-methoxy poly(ethylene glycol)2000)carbamoyl-1,2-dimyristyloxy-propylamine; PEG-cDSA, 3-N-(-methoxy poly(ethylene glycol)2000)carbamoyl-1,2-distearyloxy-propylamine, DSPE-PEG, PEG-maleimide, DSPE-PEG-maleimide, or combinations thereof.</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-maleimide</span>
        <span itemprop="definition">DSPE-PEG-maleimide</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPE-PEG-maleimide</span>
        <span itemprop="definition">or combinations thereof.</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the maleimide derivative/moiety</span>
        <span itemprop="definition">may be conjugated, attached or linked to a PEG-derivative, which may be by itself conjugated, linked and/or attached to a lipid.</span>
        <meta itemprop="num_attr" content="0269">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ratio between the various lipids in the particle</span>
        <span itemprop="definition">may vary. In some embodiments, the ratio is a molar ratio. In some embodiments, the ratio is a weight ratio. In some embodiments, each of the lipid groups may be at molar ratio/a weight ratio of about 1%-99%.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the weight ratio between the nucleic acid and the lipid mixture</span>
        <span itemprop="definition">may be adjusted so as to achieve maximal biological effect by the nucleic acid on the target site.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ratio between the nucleic acid and the lipid phase</span>
        <span itemprop="definition">may be 1:1.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the weight ratio between the nucleic acid and the lipid phase</span>
        <span itemprop="definition">may be 1:2.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the weight ratio between the nucleic acid and the lipid phase</span>
        <span itemprop="definition">may be 1:5.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the weight ratio between the nucleic acid and the lipid phase</span>
        <span itemprop="definition">may be 1:10.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the weight ratio between the nucleic acid and the lipids phase</span>
        <span itemprop="definition">may be 1:16.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the weight ratio between the nucleic acid and the lipid phase</span>
        <span itemprop="definition">may be 1:20.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the weight ratio between the nucleic acid and the lipid phase</span>
        <span itemprop="definition">is about 1:1 to 1:20 (w:w).</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">are nanoparticles.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles (including the nucleic acid encapsulated within) and the targeting moiety on the surface particles</span>
        <span itemprop="definition">have a particle size (diameter) in the range of about 10 to about 500 nm.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">have a particle size (diameter) in the range of about 10 to about 350 nm.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">have a particle size (diameter) in the range of about 50 to about 250 nm.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">have a particle size (diameter) in the range of about 10 to about 200 nm.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">have a particle size (diameter) in the range of about 20 to about 200 nm.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">have a particle size (diameter) in the range of about 50 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 75 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 90 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 100 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 120 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 150 to about 200.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">have a particle size (diameter) in the range of about 50 to about 150 nm. In some embodiments, the particles have a particle size (diameter) in the range of over about 10 nm. In some embodiments, the particles have a particle size (diameter) of over about 20 nm. In some embodiments, the particles have a particle size (diameter) of over about 30 nm. In some embodiments, the particles have a particle size (diameter) of over about 40 nm. In some embodiments, the particles have a particle size (diameter) of over about 50 nm. In some embodiments, the particles have a particle size (diameter) of over about 60 nm.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">have a particle size (diameter) of over about 70 nm. In some embodiments, the particles have a particle size (diameter) of over about 80 nm. In some embodiments, the particles have a particle size (diameter) of over about 90 nm. In some embodiments, the particles have a particle size (diameter) of over about 100 nm. In some embodiments, the particles have a particle size (diameter) of over about 200 nm. In some embodiments, the particles have a particle size (diameter) of not more than about 500 nm.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles (including the nucleic acid encapsulated within)</span>
        <span itemprop="definition">have a particle size (diameter) in the range of about 5 to about 200 nm. In some embodiments, the particles (including the nucleic acid encapsulated within) have a particle size (diameter) in the range of about 50 to about 60 nm. In some embodiments, the particles (including the nucleic acid encapsulated within) have a particle size (diameter) in the range of about 55 to about 58 nm. In some embodiments, the size is a hydrodynamic diameter.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particles</span>
        <span itemprop="definition">may be comprised of a cationic lipid (such as compound shown in Table 1 or 2), cholesterol, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), PEG derivative (such as DMG-PEG) and PEG-maleimide conjugated to a lipid (such as DSPE-PEG-maleimide); at various mol:mol ratios, and further conjugated to a targeting moiety, wherein the targeting moiety is conjugated, linked, attached to the maleimide moiety.</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic lipid</span>
        <span itemprop="definition">such as compound shown in Table 1 or 2</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPC</span>
        <span itemprop="definition">1,2-Distearoyl-sn-glycero-3-phosphocholine</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG derivative</span>
        <span itemprop="definition">such as DMG-PEG</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG-maleimide conjugated to a lipid</span>
        <span itemprop="definition">such as DSPE-PEG-maleimide</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid phase</span>
        <span itemprop="definition">may be comprised of: cationic lipid (DLinMC3)/DSPC/cholesterol/DMG-PEG/DSPE-PEG-Maleimide (mol/mol 50:10:38:1.5:0.5).</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid phase</span>
        <span itemprop="definition">may be comprised of: DLinMC3-DMA/Chol/DSPC/DMG-PEG/DSPE-PEG-maleimide (mol/mol 50:38:10:1.95:0.05).</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid phase</span>
        <span itemprop="definition">may comprise about 30-60% (mol) cationic lipids.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid(s)</span>
        <span itemprop="definition">may comprise about 40-50% (mol) of the lipid phase.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid phase</span>
        <span itemprop="definition">may comprise about 20-70% (mol) membrane stabilizing lipids.</span>
        <meta itemprop="num_attr" content="0275">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the membrane stabilizing lipids</span>
        <span itemprop="definition">may comprise about 40-60% of the lipid phase.</span>
        <meta itemprop="num_attr" content="0275">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">more than one type of membrane stabilizing lipid</span>
        <span itemprop="definition">may be used in the lipid phase.</span>
        <meta itemprop="num_attr" content="0275">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the membrane stabilizing lipid</span>
        <span itemprop="definition">may include cholesterol (being about 30-50% (mol) of the lipid phase), and a phospholipid (such as, for example, DSPC), that may be about 5-15% (mol) of the lipid phase.</span>
        <meta itemprop="num_attr" content="0275">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid phase</span>
        <span itemprop="definition">may comprise about 0.01-3% (mol:mol) of PEG-maleimide (optionally conjugated to a lipid).</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-maleimide</span>
        <span itemprop="definition">may comprise about 0.05-0.6% of the lipid mixture.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an additional PEG-derivative</span>
        <span itemprop="definition">(conjugated to a lipid) may comprise about 0.5-10% of the lipid phase composition.</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method for the preparation of targeted particles for delivery of a nucleic acid to leukocytes</span>
        <span itemprop="definition">comprising one or more of the steps of:</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipids</span>
        <span itemprop="definition">are suspended in an acidic aqueous buffer, such as, ethanol.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">is in an acetate buffer solution.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">may be mixed with the lipid mixture in a microfluidizer mixer to form particles encapsulating/carrying the nucleic acid.</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid</span>
        <span itemprop="definition">As referred to herein, the terms nucleic acid, nucleic acid molecules oligonucleotide, polynucleotide, and nucleotide may interchangeably be used herein.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the terms</span>
        <span itemprop="definition">are directed to polymers of deoxy ribonucleotides (DNA), ribonucleotides (RNA), and modified forms thereof in the form of a separate fragment or as a component of a larger construct, linear or branched, single stranded, double stranded, triple stranded, or hybrids thereof.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term</span>
        <span itemprop="definition">also encompasses RNA/DNA hybrids.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides</span>
        <span itemprop="definition">may include sense and antisense oligonucleotide or polynucleotide sequences of DNA or RNA.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the DNA or RNA molecules</span>
        <span itemprop="definition">may be, for example, but not limited to: complementary DNA (cDNA), genomic DNA, synthesized DNA, recombinant DNA, or a hybrid thereof or an RNA molecule such as, for example, mRNA, shRNA, siRNA, miRNA, Antisense RNA, and the like. Each possibility represents a separate embodiment of the present invention.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the terms</span>
        <span itemprop="definition">further include oligonucleotides composed of naturally occurring bases, sugars, and covalent inter nucleoside linkages, as well as oligonucleotides having non-naturally occurring portions, which function similarly to respective naturally occurring portions.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polypeptide</span>
        <span itemprop="definition">peptide and protein are used interchangeably herein to refer to a polymer of amino acid residues.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the terms</span>
        <span itemprop="definition">apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">construct</span>
        <span itemprop="definition">refers to an artificially assembled or isolated nucleic acid molecule which may include one or more nucleic acid sequences, wherein the nucleic acid sequences may include coding sequences (that is, sequence which encodes an end product), regulatory sequences, non-coding sequences, or any combination thereof.</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">construct</span>
        <span itemprop="definition">includes, for example, vector but should not be seen as being limited thereto.</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Expression vector</span>
        <span itemprop="definition">refers to constructs that have the ability to incorporate and express heterologous nucleic acid fragments (such as, for example, DNA), in a foreign cell.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an expression vector</span>
        <span itemprop="definition">comprises nucleic acid sequences/fragments (such as DNA, mRNA, tRNA, rRNA), capable of being transcribed.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid sequences/fragments</span>
        <span itemprop="definition">such as DNA, mRNA, tRNA, rRNA</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Many prokaryotic and eukaryotic expression vectors</span>
        <span itemprop="definition">are known and/or commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the expression vector</span>
        <span itemprop="definition">may encode for a double stranded RNA molecule in the target site.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term expression, as used herein,</span>
        <span itemprop="definition">refers to the production of a desired end-product molecule in a target cell.</span>
        <meta itemprop="num_attr" content="0293">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the end-product molecule</span>
        <span itemprop="definition">may include, for example an RNA molecule; a peptide or a protein; and the like; or combinations thereof.</span>
        <meta itemprop="num_attr" content="0293">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">introducing</span>
        <span itemprop="definition">and transfection may interchangeably be used and refer to the transfer of molecules, such as, for example, nucleic acids, polynucleotide molecules, vectors, and the like into a target cell(s), and more specifically into the interior of a membrane-enclosed space of a target cell(s).</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the molecules</span>
        <span itemprop="definition">can be introduced into the target cell(s) by any means known to those of skill in the art, for example as taught by Sambrook et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York (2001), the contents of which are incorporated by reference herein.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Means of introducing molecules into a cell</span>
        <span itemprop="definition">include, for example, but are not limited to: heat shock, calcium phosphate transfection, PEI transfection, electroporation, lipofection, transfection reagent(s), viral-mediated transfer, and the like, or combinations thereof.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the transfection of the cell</span>
        <span itemprop="definition">may be performed on any type of cell, of any origin, such as, for example, human cells, animal cells, plant cells, virus cell, and the like.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cells</span>
        <span itemprop="definition">may be selected from isolated cells, tissue cultured cells, cell lines, cells present within an organism body, and the like.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">treating</span>
        <span itemprop="definition">and treatment as used herein refers to abrogating, inhibiting, slowing or reversing the progression of a disease or condition, ameliorating clinical symptoms of a disease or condition or preventing the appearance of clinical symptoms of a disease or condition.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">preventing</span>
        <span itemprop="definition">is defined herein as barring a subject from acquiring a disorder or disease or condition.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">treatment of cancer</span>
        <span itemprop="definition">is directed to include one or more of the following: a decrease in the rate of growth of the cancer (i.e. the cancer still grows but at a slower rate); cessation of growth of the cancerous growth, i.e., stasis of the tumor growth, and, the tumor diminishes or is reduced in size.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term</span>
        <span itemprop="definition">also includes reduction in the number of metastases, reduction in the number of new metastases formed, slowing of the progression of cancer from one stage to the other and a decrease in the angiogenesis induced by the cancer. In most preferred cases, the tumor is totally eliminated. Additionally included in this term is lengthening of the survival period of the subject undergoing treatment, lengthening the time of diseases progression, tumor regression, and the like.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cancer</span>
        <span itemprop="definition">is a blood cancer.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term Leukocytes</span>
        <span itemprop="definition">is directed to white blood cells (WBCs), produced and derived from a multipotent, hematopoietic stem cell in the bone marrow.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the white blood cells</span>
        <span itemprop="definition">have nuclei, and types of white blood cells can be classified in into five main types, including, neutrophils, eosinophils, basophils, lymphocytes, and monocytes, based on functional or physical characteristics.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the main types</span>
        <span itemprop="definition">may be classified into subtypes.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lymphocytes</span>
        <span itemprop="definition">include B cells, T cells, and NK cells.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B-cells</span>
        <span itemprop="definition">for example, release antibodies and assist activation of T cells.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T cells</span>
        <span itemprop="definition">for example, can be classified to several subtypes, including: T-helper cells (CD4&#43; Th) which activate and regulate T and B cells; cytotoxic T cells (CD8&#43;) that can target and kill virus-infected cells and tumor cells; Gamma-delta T cells (   T cells) which can bridge between innate and adaptive immune responses and be involved in phagocytosis; and Regulatory (suppressor) T cells which modulate the immune system, maintain tolerance to self-antigens, and abrogate autoimmune conditions.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T-helper cells</span>
        <span itemprop="definition">CD4&#43; Th</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cytotoxic T cells</span>
        <span itemprop="definition">CD8&#43;</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">  T cells</span>
        <span itemprop="definition">Gamma-delta T cells</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Regulatory (suppressor) T cells</span>
        <span itemprop="definition">which modulate the immune system, maintain tolerance to self-antigens, and abrogate autoimmune conditions.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compounds of the present invention</span>
        <span itemprop="definition">can be prepared in accordance the following general synthetic methods:</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids used for LNPs production</span>
        <span itemprop="definition">were purchased from Avanti Polar lipids (USA).</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Monoclonal antibodies</span>
        <span itemprop="definition">anti-CD45 AF647, Annexin-647 was purchased from BioLegend.</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Propodeum Iodide</span>
        <span itemprop="definition">was purchased from Sigma-Aldrich.</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA molecules</span>
        <span itemprop="definition">were designed and screened by Alnylam Pharmaceuticals (USA). Chemically modified siRNAs sequences:</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CD45 siRNA</span>
        <span itemprop="definition">(SEQ ID NO: 1) Sense strand: cuGGcuGAAuuucAGAGcAdTsdT (SEQ ID NO: 2) Anti-Sense strand: UGCUCUGAAAUUcAGCcAGdTsdT NC5 siRNA (siNC5 or ctl siRNA): Sense strand: CAUAUUGCGCGUAUAGUCGCGUUAG Anti-Sense strand: UGGUAUAACGCGCAUAUCAGCGCAAUC Luc siRNA (siLuc): (SEQ ID NO: 3) Sense strand: cuuAcGcuGAGuAcuucGAdTsdT (SEQ ID NO: 4) Anti-Sense strand: UCGAAGuACUcAGCGuAAGdTsdT Alexa-647-labeled siRNA possessed the same sequence as siLuc. 2-OMe modified nucleotides are in lower case, and phosphorothioate linkages are represented by s.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PLK 1 siRNA</span>
        <span itemprop="definition">(PLK 1) Sense strand GCUUAAUGACGAGUUCUUUACUUCT Anti-Sense strand: GACGAAUUACUGCUCAAGAAAUGAAGA</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs</span>
        <span itemprop="definition">Lipid-Based Nanoparticles</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs</span>
        <span itemprop="definition">were prepared by using microfluidic micro mixture (Precision NanoSystems, Vancouver, BC, Canada) as described by Cohen et. al.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One volume of lipid mixtures</span>
        <span itemprop="definition">cationic lipid, DSPC, Chol, DMG-PEG and DSPE-PEG Mal at 50:10:38:1.5:0.5 mole ratio, 9.64 nM total lipid concentration</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">three volumes of siRNA (1:16 w/w siRNA to lipid) containing acetate buffer solutions</span>
        <span itemprop="definition">were injected through the micro mixer at a combined flow rate of 2 mL/minute (0.5 mL/min for ethanol and 1.5 mL/min for aqueous buffer).</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">For labeled LNPs</span>
        <span itemprop="definition">10% of Alexa-647 labeled siRNA were incorporated.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cy5 labeled particles</span>
        <span itemprop="definition">10% Cy5 labeled non-targeted siRNA was used. The resultant mixture was dialyzed against PBS (pH 7.4) for 16 h to remove ethanol.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs size distribution and    potential</span>
        <span itemprop="definition">were determined by dynamic light scattering using a Malvern nano ZS   -sizer (Malvern instruments, UK). For size measurements, LNPs were diluted 1:20 in PBS. All utilized samples showed a polydispersity index (PDI) lower than 0.2. For    potential measurements, LNPs were diluted 1:200 in DDW. In some cases, as indicated, size and zeta potential measurements were performed in water.</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PDI</span>
        <span itemprop="definition">polydispersity index</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA levels of pololike kinase 1 (PLK1 gene) in cells</span>
        <span itemprop="definition">was quantified by real-time PCR, forty eight or Seventy-two hours post-transfection.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Total RNA</span>
        <span itemprop="definition">was isolated using the E-Z RNA purification kit (Biological industries, Beit Haemek, Israel), and 1   g of RNA from each sample was reverse transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif.), Quantification of cDNA (5 ng total) was performed on the step one Sequence Detection System (Applied Biosystems, Foster City, Calif.) using syber green (Applied Biosystems). GAPDH was chosen as a housekeeping gene.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Supt1 or NAR or OVCAR cells</span>
        <span itemprop="definition">were placed in tissue culture 12-wells plates at a density of 1  10 5 cells with 1 mL of full medium.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs containing different siRNAs</span>
        <span itemprop="definition">siPLK1 or siCD45 or siLUC</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cells</span>
        <span itemprop="definition">were isolated at different time intervals mentioned in the figures and analyzed by either flow cytometry (for siCD45 knockdown), or qPCR for analysis of PLK1 silencing.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Apoptosis assay using PI/Annexin</span>
        <span itemprop="definition">was analyzed by flow cytometry in case of siPLK1 induced cell death.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the transfected cells</span>
        <span itemprop="definition">were washed with ice-cold PBS, and fixed with 70% ethanol for 1 h. Then, the cells were washed twice with cold PBS and incubated for 10 min at 37 C. in 250   L PBS with 10   g/mL propidium iodide (PI), 2.5   g/mL DNase-free RNase A (Sigma, USA) and 0.01% Triton-X. PI fluorescence was assessed by flow cytometry. Analyzes by FlowJoTM were performed on at least 9000 cells per samples after gating out debris and cell duplets based on the FL2-Area/FL2-Width channels. Cell cycle distributions were obtained via the application of the Dean-Jett-Fox model on gated cells with RMS scores ranging between 1.5 and 2.5.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Linoleic acid</span>
        <span itemprop="definition">(0.88 mg, 3.14 mmol) and EDCI (0.9 mg, 4.71 mmol) were taken in a 100 mL flask and dissolved in dry DCM followed by addition of dimethylaminoethyl hydrazine hydrochloride (0.2 mg, 1.25 mmol) and tri ethylamine (0.1 ml). The reaction mixture was stirred for 24 hr, washed with water and brine solution.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Linoleic alcohol</span>
        <span itemprop="definition">(1.7 g, 6.3 mmol) was dissolved in dry DCM under argon and molecular sieves were added to the reaction mixture.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PCC</span>
        <span itemprop="definition">(2 g, 9.5 mmol) was added by fractions to the reaction mixture over a period of 10 min. The reaction mixture was stirred for 1 hr and filtered through silica pad to remove PCC followed by evaporating the solvent to yield 1.5 g of crude linoleic aldehyde.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N, N-dilinoleyl-boc hydrazide</span>
        <span itemprop="definition">(1.3 g, 2.07 mmol) was dissolved in dry DCM under argon atmosphere.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction mixture</span>
        <span itemprop="definition">was cooled to 0 C. and trifluoroacetic acid (TFA) (2 mL) was added drop wise and stirred for 3 hr.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TFA</span>
        <span itemprop="definition">trifluoroacetic acid</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction mixture</span>
        <span itemprop="definition">was washed with sodium bicarbonate followed by brine solution.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the solvent</span>
        <span itemprop="definition">was evaporated and the crude reaction mixture (0.4 g, 0.76 mmol), N, N-dimethyl aminobutyric acid (0.19 g, 1.3 mmol) and EDCI (0.43 g, 2.26 mmol) were dissolved in dry DCM under argon atmosphere.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Triethylamine</span>
        <span itemprop="definition">was added and the reaction stirred for 24 hr.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction mixture</span>
        <span itemprop="definition">was washed with water followed by sodium bicarbonate and brine solution.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the solvent</span>
        <span itemprop="definition">was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl 3 (2:98) to yield 0.3 g of pure lipid 10 as colorless liquid.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound 2</span>
        <span itemprop="definition">was dissolved in dry THF and 1M LAH in THF solution was added to the reaction mixture and refluxed for 12 h. The reaction was quenched with ammonium chloride solution followed by solvent evaporation and silica gel column chromatography purification yielded pure lipid 12.</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N,N-dilinoleyl hydrazine</span>
        <span itemprop="definition">300 mg, 0.56 mmol</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N    ,N    dimethyl-N    boc L-lysine</span>
        <span itemprop="definition">180 mg, 1.13 mmol</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EDCI</span>
        <span itemprop="definition">320 mg, 1.68 mmol</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction mixture</span>
        <span itemprop="definition">was stirred for 24 h, and then the reaction mixture was washed with water followed by sodium bicarbonate and brine solution.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the crude product</span>
        <span itemprop="definition">was purified by silica gel column chromatography (MeOH:CHCl 3 ; 3:97) to yield 200 mg of pure compound.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">reaction mixture</span>
        <span itemprop="definition">was purified by silica gel column chromatography using chloroform and methanol solvent system (95:5) to yield 120 mg of pure compound 11 (2-amino-6-(dimethylamino)-N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hexanehydrazide) as semi solid.</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Linoleyl aldehyde (2.64 g, 10.0 mmol, 2 equiv.) and hydroxylamine hydrochloride (0.34 g, 5.0 mmol, 1.0 equiv.)</span>
        <span itemprop="definition">were dissolved in dry DCM under argon atmosphere then trimethylamine (0.7 ml, 5.0 mmol, 1.0 equiv.) was added. After dissolving the compounds, sodium triacetoxyborohydride (3.1 g, 15.0 mmol, 3 equiv.) was added to the reaction mixture and stirred for 24 hr at room temperature. The reaction was quenched with sodium hydroxide solution followed by washing with water and brine solution. The solvent was evaporated and the residue was purified by silica column chromatography (EtOAc:Hexane (5:95) to yield 1.5 g (55%) of pure white color compound N,N-dilinoleyl-hydroxylamine.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N,N-dilinoleyl-hydroxylamine</span>
        <span itemprop="definition">(0.48 g, 0.90 mmol, 1 equiv.)</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N, N-dimethyl aminobutyric acid hydrochloride</span>
        <span itemprop="definition">(0.30 g, 1.8 mmol, 2 equiv.)</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EDCI</span>
        <span itemprop="definition">(0.34 g, 1.8 mmol, 2 equiv.</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DMAP</span>
        <span itemprop="definition">(0.01 g, 0.09 mmol, 0.1 equiv.) were dissolved in dry DCM under argon atmosphere.</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">trimethylamine</span>
        <span itemprop="definition">(0.25 ml, 1.8 mmol, 2 equiv.) was added and the reaction was stirred for 24 hr.</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction mixture</span>
        <span itemprop="definition">was washed with water, followed by sodium bicarbonate and brine solution.</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the solvent</span>
        <span itemprop="definition">was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl3 (3:97) to yield 0.6 g (85%) of pure lipid 14 as colorless liquid.</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Linoleyl aldehyde</span>
        <span itemprop="definition">(1.7 g, 6.06 mmol, 2 equiv.), N,N-dimethylaminoethyl hydrazine hydrochloride (0.53 g, 3.03 mmol, 1 equiv.) and trimethylamine (0.84 ml, 6.06 mmol, 2 equiv.) were dissolved in dry DCM under argon atmosphere, then sodium tri acetoxyborohydride (1.91 g, 9.09 mmol, 3 equiv.) was added and the reaction mixture was stirred for 24 hr at room temperature. The reaction was quenched with sodium hydroxide solution followed by washing with water and brine solution. The solvent was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl 3 (3:97) yielded 1.08 g (60%) of pure lipid 15 as colorless liquid.</span>
        <meta itemprop="num_attr" content="0346">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N,N-dilinoleyl-hydroxylamine</span>
        <span itemprop="definition">(0.20 g, 0.37 mmol, 1 equiv.)</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N-methyl piperazine propanoic acid</span>
        <span itemprop="definition">(0.12 g, 0.74 mmol, 2 equiv.)</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EDCI</span>
        <span itemprop="definition">(0.13 g, 0.74 mmol, 2 equiv.</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DMAP</span>
        <span itemprop="definition">5 mg, 0.03 mmol, 0.1 equiv.</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">trimethylamine</span>
        <span itemprop="definition">0.1 ml, 0.74 mmol, 2 equiv.</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction mixture</span>
        <span itemprop="definition">was washed with water, followed by sodium bicarbonate and brine solution.</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the solvent</span>
        <span itemprop="definition">was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl 3 (5:95) to yield 0.21 g (76%) of pure lipid as colorless liquid.</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Linoleyl aldehyde (2.64 g, 10.0 mmol, 2 equiv.) and ethanolamine (0.30 g, 5.0 mmol, 1 equiv.)</span>
        <span itemprop="definition">were dissolved in dry DCM under argon atmosphere, then sodium tri acetoxyborohydride (3.1 g, 15.0 mmol, 3 equiv.) was added, and the reaction mixture was stirred for 24 hr at room temperature. The reaction was quenched with sodium hydroxide solution followed by washing with water and brine solution. The solvent was evaporated and the residue was purified by column chromatography (MeOH:CHCl 3 (2:98) to yield 2.3 g (85%) of pure yellowish color compound N,N-dilinoleyl-aminoethanol.</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N, N-dilinoleyl-aminoethanol</span>
        <span itemprop="definition">(0.55 g, 1.0 mmol, 1 equiv.), N,N-dimethyl aminobutyric acid (0.33 g, 2.0 mmol, 2 equiv.), EDCI (0.38 g, 2.0 mmol, 2 equiv.) and DMAP (0.01 g, 0.01 mmol, 0.1 equiv.) were dissolved in dry DCM under argon atmosphere.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Trimethylamine</span>
        <span itemprop="definition">(0.28 ml, 2.00 mmol, 2 equiv.) was added and the reaction mixture was stirred for 24 hr. The reaction mixture was washed with water, followed by sodium bicarbonate and brine solution. The solvent was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl 3 (3:97) to yield 0.46 g (70%) of pure lipid 38 as colorless liquid.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">1,7-heptanediol</span>
        <span itemprop="definition">(5 g, 37 mmol) was taken in a 100 mL flask and dissolved in dry DCM followed by portion-wise slow addition of PCC (8.9 g, 41.6 mmol) for 15 min. Then, the reaction mixture was stirred at room temperature for 2 h. The crude reaction mixture was filtered through a silica gel pad and washed with DCM (2  50 mL). The organic solvent was dried over with Na 2 SO 4 and the solvent was removed under reduced pressure. The obtained crude hydroxyl aldehyde was used directly without any further purification.</span>
        <meta itemprop="num_attr" content="0362">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methyl adipate</span>
        <span itemprop="definition">(1.6 g, 10.0 mmol), dimethylaminoethyl hydrazine (0.88 g, 5. 0 mmol) and EDC (2.8 g, 15.0 mmol) were dissolved in dry DCM followed by addition of triethyl amine. The reaction mixture was stirred for overnight. The reaction mixture was washed with water followed by brine solution and dried over sodium sulphate. The crude mixture was purified by column chromatography (MeOH:CHCl 3 (5:95) to give pale yellow liquid.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject"> -caprolactone</span>
        <span itemprop="definition">(2.2 g, 20.0 mmol) was dissolved in dioxane 6 mL, and 50 ml of a 3M NaOH solution was added. The mixture was stirred at room temperature overnight. The solution was washed with ethyl acetate to remove some organic impurities. The aqueous layer was acidified to pH 3-4 with concentrated HCl 37% and then extracted with ethyl acetate (2  50 mL). The organic layer was washed with saturated NaCl (2  50 mL), dried with Na 2 SO 4 , and filtered. The organic layer was concentrated in vacuo to yield&gt;90% (2.0 g) as colorless oil.</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">reaction mixture</span>
        <span itemprop="definition">was added sodium bicarbonate and the mixture was washed with water, followed by and brine solution and drying over Na 2 SO 4 .</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the solvent</span>
        <span itemprop="definition">was evaporated and the reaction mixture was purified by silica column chromatography (MeOH:CHCl 3 (5:95) to yield 85% (0.20 g) of pure lipid as pale yellow liquid.</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP-siRNA formulations</span>
        <span itemprop="definition">Size (d    nm) PDI Zeta-potential (mV) Dlin-MC3-DMA 44.5 0.18   1 Lipid 1 45.1 0.14 18.5 Lipid 2 56.3 0.06 13.9 Lipid 9 75.1 0.04   13.6 Lipid 10 50.5 0.08 18.5 Lipid 11 108.5 0.10 20.4 Lipid 14 44.3 0.09   3.6 Lipid 15 52.5 0.11 10.1 Lipid 33 46.0 0.15   10.8 Lipid 21 67.7 0.16   2.8 Lipid 38 59.0 0.08 6.7 Lipid 55 97.0 0.17   1.28 Lipid 54 138.6 0.06   1.82</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 1</span>
        <span itemprop="definition">depicts in vitro gene silencing effect lipid 1: Human T cells SupT1 were treated with lipid nanoparticle (LNP) comprising of cationic lipid 1 encapsulated siCD45 for 48 hrs (A) or 72 hrs (B) at different siRNA doses (0.4   M, 0.2   M, 0.1   M). The results demonstrate the efficiency of the lipid 1 to down-regulate CD45 gene in hard to transfect T cells.</span>
        <meta itemprop="num_attr" content="0420">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP</span>
        <span itemprop="definition">lipid nanoparticle</span>
        <meta itemprop="num_attr" content="0420">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">NAR</span>
        <span itemprop="definition">Drug resistant human ovarian carcinoma cells</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP-siPLK-1 or LNP-siLuc nanoparticles Lipid 1 LNPs</span>
        <span itemprop="definition">A</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid 10&amp;11 LNPs</span>
        <span itemprop="definition">B</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PLK-1 expression</span>
        <span itemprop="definition">was measured by qPCR as described in Example 1.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid1 containing LNPs</span>
        <span itemprop="definition">downregulating the proto-oncogene PLK1 efficiently, this can induce the apoptosis in cancer cells.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs with lipid 1</span>
        <span itemprop="definition">did not affect plk1 expression.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid 10&amp;11 containing LNPs-siPLK1</span>
        <span itemprop="definition">also down regulating plk1 gene efficiently at different doses whereas siLUC LNPs has no effect on plk1 expression.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">NAR cells</span>
        <span itemprop="definition">Human ovarian cancer cells</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid1/siPLK1 nanoparticles</span>
        <span itemprop="definition">for 48 hr at different siRNA concentrations (0.2   M and 0.1   M).</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Apoptotic cells</span>
        <span itemprop="definition">were analyzed by FACS using PI/Annexin.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siPLK1-LNPs</span>
        <span itemprop="definition">with lipid1 inducing apoptosis in cancer cell due to downregulation of proto-oncogene plk1.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Percentage of early apoptotic cells</span>
        <span itemprop="definition">was higher in cells treated with siPLK1-LNPs at 0.2 uM dose of siPLK1.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siLUC-LNPs</span>
        <span itemprop="definition">There was no effect on cell cycle in cells treated with siLUC-LNPs indicating the efficient delivery of siPLK1 to NAR cells.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">NAR cells</span>
        <span itemprop="definition">Human ovarian cancer cells (NAR cells) were treated with either lipid10 or lipid 11/siPLK1 nanoparticles for 48 hr at different siRNA concentrations (0.1   M and 0.05   M).</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siLUC-LNPs</span>
        <span itemprop="definition">used as a negative control.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Apoptotic cells</span>
        <span itemprop="definition">were analyzed by FACS using PI/Annexin.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siPLK1-LNPs</span>
        <span itemprop="definition">composed of either lipid10 or lipid 11 efficiently downregulating PLK1 gene followed by inducing apoptosis in NAR cells.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid 1 containing LNPs</span>
        <span itemprop="definition">efficiently downregulating PLK1 gene compared to dlin-mc3-dma containing LNPs.</span>
        <meta itemprop="num_attr" content="0424">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Spheroids of drug resistant human ovarian carcinoma cells</span>
        <span itemprop="definition">were treated with LNPs composed of lipid1 and with either siPLK-1 or siLuc s for 72 hr and PLK-1 expression was measured by qPCR.</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Spheroids</span>
        <span itemprop="definition">are 3D cultures of tumor cells mimicking in vivo tumors.</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid1 containing siPLK1-LNPs</span>
        <span itemprop="definition">significantly downregulating PLK1 gene compared to siLUC-LNPs indicating the efficiency of lipid1 to deliver siRNA in to NAR spheroids.</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs composed of either lipid 38 or lipid 55</span>
        <span itemprop="definition">were incubated with LNPs with ctl siRNA (see methods) for 72 hrs. The cell viability was measured by XTT assay. Toxicity of LNPs composed of either lipid 38 or lipid 55 is compared with gold standard LNPs composed of Dlin-MC3-DMA. As shown in FIG. 7 , LNPs composed of either lipid 38 or lipid 55 are less toxic than LNPs composed of Dlin-MC3-DMA in a dose dependent manner.</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siPLK1-LNPs or siCtl-LNPs</span>
        <span itemprop="definition">composed of either lipid 38 or 55 at different concentrations for 48 hrs.</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cell viability affected by PLK1 down regulation</span>
        <span itemprop="definition">was measured by XTT assay.</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siPLK1-LNPs composed of either lipid 38 or lipid 55</span>
        <span itemprop="definition">has more effect on cell viability compared to Dlin-MC3-DMA LNPs due to efficient downregulation of PLK1 gene, whereas siCtl-LNPs has no effect on the cell viability indicating the safe use of new lipids.</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siPLK1-LNPs or siCtl-LNPs</span>
        <span itemprop="definition">composed of either lipid 38 or 55 at different concentrations for 48 hrs.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cell viability affected by PLK1 down regulation</span>
        <span itemprop="definition">was measured by XTT assay.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siPLK1-LNPs composed of either lipid 38 or lipid 55</span>
        <span itemprop="definition">exhibiting a dose dependent effect on B-cell lymphoma cancer cell viability due to efficient downregulation of PLK1 gene, whereas siCtl-LNPs has no effect on the cell viability.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siPLK1-LNPs or siCtl-LNPs</span>
        <span itemprop="definition">composed of either lipid 38 or 55 at different concentrations for 48 hrs.</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cell viability affected by PLK1 down regulation</span>
        <span itemprop="definition">was measured by XTT assay.</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siPLK1-LNPs composed of either lipid 38 or lipid 55</span>
        <span itemprop="definition">exhibiting a dose dependent effect on multiple myeloma cancer cell viability due to PLK1 downregulation, whereas siCtl-LNPs has no effect on the cell viability.</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs-LUC pDNA</span>
        <span itemprop="definition">Human colon carcinoma cells (HCT 116) were incubated with LNPs-LUC pDNA at different concentrations for 48 hrs. Luciferase expression was measured by luminometer. Lipofectamine 2000 (Lipo 2000) was used as positive control. LNPs were composed of lipid 38 and different amounts of co-lipid DOPE, along with other co-lipids such as Chol, PEG-DMG. As shown in FIG. 12 , LNPs-pDNA composed of lipid 38 efficiently delivering pDNA to the nucleus. The amount of luciferase expression was similar to positive control lipo 2000.</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HEK cells</span>
        <span itemprop="definition">were treated with LNPs composed of either lipid1 or lipid 10 encapsulated with mKATE-pDNA at the concentration of 0.6 nM pDNA. After 72 hr, mKATE expression was analyzed by flow cytometry. As shown in FIG. 13 , LNPs composed of either lipid1 or lipid 10 efficiently delivering the pDNA to the nucleus and mKATE expression was observed, whereas Dlin-MC3-DMA LNPs did not show any effect on mKATE expression.</span>
        <meta itemprop="num_attr" content="0432">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HEK cells</span>
        <span itemprop="definition">were treated with LNPs composed of either lipid1 or lipid 10 encapsulated with mKATE-pDNA at different amount pDNA. After 72 hr, mKATE expression was analyzed by flow cytometry. As shown in FIG. 14A , LNPs-pDNA composed of lipid 1 did not show any dose dependent expression, but as shown in FIG. 14B , lipid 10 containing LNPs exhibiting a dose dependent expression of mKATE.</span>
        <meta itemprop="num_attr" content="0433">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hard to transfect murine macrophage cells</span>
        <span itemprop="definition">(RAW 264.7) were treated with LNPs composed of either Lipid38 or Lipid 54 and formulated with luciferase mRNA at different amounts of mRNA. After 18 hrs luciferase expression was measured by luminometer. As shown in FIG. 15 , luciferase expression was observed in cells treated with lipid 38-LNPs efficiently compared to lipid 54-LNPs, further a dose dependent expression was observed in lipid 38 containing LNPs.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs composed of either lipid 54 or lipid 38 formulated with luciferase mRNA</span>
        <span itemprop="definition">were administered intramuscularly in to C57BL6/j mice at 1 mg/kg body weight. Luciferase expression was measured by bioluminescence imaging system Biospace: (a) after 8 hrs of i.m. administration; and (b) after 24 hrs. As shown in FIG. 16 , significant amounts of luciferase were observed after 8 hrs of administration for both LNPs composed of either lipid 38 or lipid 54. The expression was still high 24 hrs after the administration of LNPs indicating the efficiency of these lipids in delivering mRNA in vivo.</span>
        <meta itemprop="num_attr" content="0435">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs composed of either lipid 54 or lipid 38 formulated with luciferase mRNA</span>
        <span itemprop="definition">were administered intravenously into C57BL6/j mice at 1 mg/kg body weight. After 8 hrs, luciferase expression was measured by bioluminescence imaging system Biospace. As shown in FIG. 17 , mice treated with LNPs composed of lipid 38 and mRNA showing significant amount of luciferase in mouse liver compared to LNPs composed of lipid 54.</span>
        <meta itemprop="num_attr" content="0436">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs composed of lipid 38 formulated with luciferase mRNA</span>
        <span itemprop="definition">were administered intravenously into C57BL6/j mice at 1 mg/kg body weight. After 8 hrs and 24 hrs of administration, luciferase expression was measured by bioluminescence imaging system Biospace. As shown in FIG. 18 , significant amount of luciferase expression was observed in liver. Moreover the luciferase expression was high after 8 hrs compared to after 24 hrs.</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 19</span>
        <span itemprop="definition">demonstrates that there is no liver toxicity in Non-human primate compared with MC3.</span>
        <meta itemprop="num_attr" content="0438">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">I.v. administration</span>
        <span itemprop="definition">(1 ml/kg) of (0.5 mg/kg) of MC3 particles with siNC5 and lipid 38-based particles with siNC5 (0.5 mg/Kg).</span>
        <meta itemprop="num_attr" content="0438">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">serum</span>
        <span itemprop="definition">was collected at and analyzed for ALT, AST (by Roch Cobra Auto analyzer). Each data point is an average of 2 animals  SEM.</span>
        <meta itemprop="num_attr" content="0438">
      </li>
    </ul>
  </section>

  <section>
    <h2>Landscapes</h2>
    <ul>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Organic Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Life Sciences &amp; Earth Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Veterinary Medicine</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Public Health</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Animal Behavior &amp; Ethology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmacology &amp; Pharmacy</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Genetics &amp; Genomics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical Kinetics &amp; Catalysis</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Molecular Biology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nuclear Medicine, Radiotherapy &amp; Molecular Imaging</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biomedical Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Epidemiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Zoology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Bioinformatics &amp; Cheminformatics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Wood Science &amp; Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pain &amp; Pain Management</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Rheumatology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Plant Pathology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Physics &amp; Mathematics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biophysics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biochemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Microbiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Proteomics, Peptides &amp; Aminoacids</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Oil, Petroleum &amp; Natural Gas</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmaceuticals Containing Other Organic And Inorganic Compounds</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Organic Low-Molecular-Weight Compounds And Preparation Thereof</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Preparation</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicines That Contain Protein Lipid Enzymes And Other Medicines</span>
        (<span itemprop="type">AREA</span>)
      </li>
    </ul>
  </section>


  <section itemprop="abstract" itemscope>
    <h2>Abstract</h2>
    
    <div itemprop="content" html><abstract mxw-id="PA325850519" lang="EN" source="national office" load-source="docdb">
    <div class="abstract">The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.</div>
  </abstract>
  </div>
  </section>

  <section itemprop="description" itemscope>
    <h2>Description</h2>
    
    <div itemprop="content" html><ul mxw-id="PDES208170458" lang="EN" load-source="patent-office" class="description">
    
    <heading id="h-0001">FIELD OF THE INVENTION</heading>
    <li> <para-num num="[0001]"> </para-num> <div id="p-0002" num="0001" class="description-line">The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for in vivo therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.</div>
    </li> <heading id="h-0002">BACKGROUND OF THE INVENTION</heading>
    <li> <para-num num="[0002]"> </para-num> <div id="p-0003" num="0002" class="description-line">Therapeutic nucleic acids including small interfering RNA (siRNA), micro RNA (miRNA), antisense oligo nucleotides, messenger RNA (mRNA), ribozymes, pDNA and immune stimulating nucleic acids are act via a variety of mechanisms. Specific proteins can be downregulated by siRNA or miRNA through RNA interference (RNAi). Hematopoietic cells, such as leukocytes in general, and primary T lymphocytes and B-cells in particular, are notoriously hard to transfect with small interfering RNAs (siRNAs). Modulating immune cells function, such as T cells and B-cells, by downregulating specific genes using RNA interference (RNAi) holds tremendous potential in advancing targeted therapies in many immune related disorders including cancer, inflammation, autoimmunity and viral infections. The therapeutic applications of RNAi are extremely broad, since siRNA and miRNA constructs can be synthesized with any nucleotide sequence directed against a target protein. To date, siRNA constructs have shown the ability to specially silence target proteins in both in vitro and in vivo models. These are currently being evaluated in clinical studies.</div>
    </li> <li> <para-num num="[0003]"> </para-num> <div id="p-0004" num="0003" class="description-line">Messenger RNA (mRNA) is the family of large RNA molecules which transport the genetic information from DNA to ribosome. Some nucleic acids, such as mRNA or plasmids, can be used to effect expression of specific cellular products. Such nucleic acids would be useful in the treatment of diseases related deficiency of a protein or enzyme. However many problems associated with nucleic acids in therapeutic contexts. One of the major problems with therapeutic nucleic acids is the stability of the phosphodiester inter nucleotide link and its susceptibility to nucleases. Apart from that these nucleic acids have limited ability to cross the cell membrane.</div>
    </li> <li> <para-num num="[0004]"> </para-num> <div id="p-0005" num="0004" class="description-line">Cationic lipids have proved to be excellent carriers of nucleic acids to treat varies diseases in gene therapy applications. Lipid nanoparticles formed from cationic lipids and other co-lipids such as cholesterol, DSPC and PEGylated lipids encapsulated oligonucleotides which protect them from degradation and facilitate the cellular uptake. Nevertheless, there remains a need in the art for suitable and efficient delivery platforms for delivery of oligonucleotides.</div>
    </li> <heading id="h-0003">SUMMARY OF THE INVENTION</heading>
    <li> <para-num num="[0005]"> </para-num> <div id="p-0006" num="0005" class="description-line">The present invention relates to novel cationic lipids which can be used in lipid nanoparticle preparation. These lipid nanoparticles protect nucleic acids from degradation, clearance from circulation and intracellular release. In addition, the nucleic acid encapsulated lipid nanoparticles advantageously are well-tolerated and provide an adequate therapeutic index, such that patient treatment at an effective dose of the nucleic acid is not associated with unacceptable toxicity and/or risk to the patient. The present invention also provides the methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulations with nucleic acids.</div>
    </li> <li> <para-num num="[0006]"> </para-num> <div id="p-0007" num="0006" class="description-line">In some embodiments, the present invention relates to novel cationic lipids, and formulations of such lipids with siRNA and pDNA. These lipid nanoparticles (LNPs) were further characterized by DLS and assessed for their in vitro activity in various cancer cell lines.</div>
    </li> <li> <para-num num="[0007]"> </para-num> <div id="p-0008" num="0007" class="description-line">According to the principles of the present invention, the lipids structures are based on functional groups such as hydrazine, hydrazide or hydroxylamine linked, directly or through a linker to a fatty acid residue RC(O), RC(O)O or R wherein RCOOH is the corresponding fatty acid which may be saturated or unsaturated. The lipids also contain a functional head group, for example an amine, an N-containing heterocycle or heteroaryl, or an amino acid side chain (e.g., histidine or arginine side chains), which is linked through a linker, e.g., an alkylene chain. In some embodiments, the lipids feature an asymmetrical structure and enhanced charge, hence it is hypothesized that such lipids will display improved binding and improve endosomal escape (i.e., enhanced stability) due to structural imbalance. Other lipids according to the invention have symmetrical structures as further described herein.</div>
    </li> <li> <para-num num="[0008]"> </para-num> <div id="p-0009" num="0008" class="description-line">Thus, in one embodiment, the present invention relates to a cationic lipid comprising a functional group represented by the structure:</div>
    </li> <li> <div id="p-0010" num="0000" class="description-line"> <br/>W-(T=O)<sub>m</sub>X(CH<sub>2</sub>)<sub>z</sub>Y
</div>
    </li> <li> <div id="p-0011" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0009]"> </para-num> <div id="p-0012" num="0009" class="description-line">X and Y are each independently O, N or NH, wherein X and Y cannot both simultaneously be O;</div>
    </li> <li> <para-num num="[0010]"> </para-num> <div id="p-0013" num="0010" class="description-line">W is a bond, O, NH or S;</div>
    </li> <li> <para-num num="[0011]"> </para-num> <div id="p-0014" num="0011" class="description-line">T is C or S;</div>
    </li> <li> <para-num num="[0012]"> </para-num> <div id="p-0015" num="0012" class="description-line">m is 0 or 1; and</div>
    </li> <li> <para-num num="[0013]"> </para-num> <div id="p-0016" num="0013" class="description-line">z is 0 or 2;</div>
    </li> <li> <div id="p-0017" num="0000" class="description-line">wherein the functional group is linked to at least one saturated or unsaturated fatty acid residue.</div>
    </li> <li> <para-num num="[0014]"> </para-num> <div id="p-0018" num="0014" class="description-line">In some embodiments, the cationic lipid comprises two fatty acid residues symmetrically or asymmetrically linked to the aforementioned functional group.</div>
    </li> <li> <para-num num="[0015]"> </para-num> <div id="p-0019" num="0015" class="description-line">In one aspect of the present invention, the cationic lipid is represented by the structure of formula (I):</div>
    </li> <li> <div id="p-0020" num="0000" class="description-line">
      <chemistry id="CHEM-US-00001" num="00001">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3e/6c/f9/a5b58d061c9320/US20190292130A1-20190926-C00001.png"><img id="EMI-C00001" he="22.35mm" wi="69.93mm" file="US20190292130A1-20190926-C00001.TIF" alt="Figure US20190292130A1-20190926-C00001" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="89" alt="Figure US20190292130A1-20190926-C00001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3e/6c/f9/a5b58d061c9320/US20190292130A1-20190926-C00001.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US20190292130A1-20190926-C00001.CDX"> </attachment>
          <attachment idref="CHEM-US-00001" attachment-type="mol" file="US20190292130A1-20190926-C00001.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0021" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0016]"> </para-num> <div id="p-0022" num="0016" class="description-line">Y is O or NH;</div>
    </li> <li> <para-num num="[0017]"> </para-num> <div id="p-0023" num="0017" class="description-line">T is C or S;</div>
    </li> <li> <para-num num="[0018]"> </para-num> <div id="p-0024" num="0018" class="description-line">W is a bond, O, NH or S;</div>
    </li> <li> <para-num num="[0019]"> </para-num> <div id="p-0025" num="0019" class="description-line">R<sup>1 </sup>is selected from the group consisting of:
</div> </li> <ul> <li id="ul0001-0001" num="0000"> <ul> <li id="ul0002-0001" num="0020">(a) NR<sup>4</sup>R<sup>5 </sup>wherein R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</li> <li id="ul0002-0002" num="0021">(b) the side chain of a natural or unnatural amino acid; and</li> <li id="ul0002-0003" num="0022">(c) a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from the group consisting of O, N and S;</li> </ul> </li> </ul>

    <li> <para-num num="[0023]"> </para-num> <div id="p-0026" num="0023" class="description-line">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
</div> </li> <ul> <li id="ul0003-0001" num="0000"> <ul> <li id="ul0004-0001" num="0024">(a) C<sub>10</sub>-C<sub>22 </sub>alkyl;</li> <li id="ul0004-0002" num="0025">(b) C<sub>10</sub>-C<sub>22 </sub>alkenyl;</li> <li id="ul0004-0003" num="0026">(c) C<sub>10</sub>-C<sub>22 </sub>alkynyl;</li> <li id="ul0004-0004" num="0027">(d) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl; and</li> <li id="ul0004-0005" num="0028">(e) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkenyl;</li> </ul> </li> </ul>

    <li> <para-num num="[0029]"> </para-num> <div id="p-0027" num="0029" class="description-line">Z is OC(O), C(O)O or O;</div>
    </li> <li> <para-num num="[0030]"> </para-num> <div id="p-0028" num="0030" class="description-line">n is 0, 1, 2, 3, 4, 5 or 6;</div>
    </li> <li> <para-num num="[0031]"> </para-num> <div id="p-0029" num="0031" class="description-line">m is 0 or 1;</div>
    </li> <li> <para-num num="[0032]"> </para-num> <div id="p-0030" num="0032" class="description-line">p is 0 or 1; and</div>
    </li> <li> <para-num num="[0033]"> </para-num> <div id="p-0031" num="0033" class="description-line">z is 0 or 2;</div>
    </li> <li> <div id="p-0032" num="0000" class="description-line">including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</div>
    </li> <li> <para-num num="[0034]"> </para-num> <div id="p-0033" num="0034" class="description-line">In some embodiments, the compound of formula (I) comprises a functional group selected from hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0035]"> </para-num> <div id="p-0034" num="0035" class="description-line">In some embodiments of formula (I), m is 0. In other embodiments of formula (I), m is 1. In other embodiments of formula (I), p is 0. In other embodiments of formula (I), p is 1. In other embodiments of formula (I), m is 0 and p is 0. In other embodiments of formula (I), m is 1 and p is 0. In other embodiments of formula (I), z is 0. In other embodiments of formula (I), z is 2. In other embodiments of formula (I), T C. In other embodiments of formula (I), W is a bond. In other embodiments of formula (I), R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>.</div>
    </li> <li> <para-num num="[0036]"> </para-num> <div id="p-0035" num="0036" class="description-line">In some representative embodiments of formula (I), p is 0, W is a bond and T is C, and the compound is represented by the structure of formula (Ia). In some representative embodiments of formula (Ia), R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (Ia-1). The structures of formulae (Ia) and (Ia-1) are depicted in the detailed description hereinbelow.</div>
    </li> <li> <para-num num="[0037]"> </para-num> <div id="p-0036" num="0037" class="description-line">In another aspect of the present invention, the cationic lipid is represented by the structure of formula (II):</div>
    </li> <li> <div id="p-0037" num="0000" class="description-line">
      <chemistry id="CHEM-US-00002" num="00002">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/89/77/3d/adab061c6e5ae6/US20190292130A1-20190926-C00002.png"><img id="EMI-C00002" he="22.35mm" wi="69.93mm" file="US20190292130A1-20190926-C00002.TIF" alt="Figure US20190292130A1-20190926-C00002" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="89" alt="Figure US20190292130A1-20190926-C00002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/89/77/3d/adab061c6e5ae6/US20190292130A1-20190926-C00002.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00002" attachment-type="cdx" file="US20190292130A1-20190926-C00002.CDX"> </attachment>
          <attachment idref="CHEM-US-00002" attachment-type="mol" file="US20190292130A1-20190926-C00002.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0038" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0038]"> </para-num> <div id="p-0039" num="0038" class="description-line">A is</div>
    </li> <li> <div id="p-0040" num="0000" class="description-line">
      <chemistry id="CHEM-US-00003" num="00003">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/4d/00/3c3877ccd78c8b/US20190292130A1-20190926-C00003.png"><img id="EMI-C00003" he="12.11mm" wi="46.14mm" file="US20190292130A1-20190926-C00003.TIF" alt="Figure US20190292130A1-20190926-C00003" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="185" height="48" alt="Figure US20190292130A1-20190926-C00003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/4d/00/3c3877ccd78c8b/US20190292130A1-20190926-C00003.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00003" attachment-type="cdx" file="US20190292130A1-20190926-C00003.CDX"> </attachment>
          <attachment idref="CHEM-US-00003" attachment-type="mol" file="US20190292130A1-20190926-C00003.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0039]"> </para-num> <div id="p-0041" num="0039" class="description-line">X is O or NH;</div>
    </li> <li> <para-num num="[0040]"> </para-num> <div id="p-0042" num="0040" class="description-line">Y is O or NH;</div>
    </li> <li> <para-num num="[0041]"> </para-num> <div id="p-0043" num="0041" class="description-line">provided that when A is</div>
    </li> <li> <div id="p-0044" num="0000" class="description-line">
      <chemistry id="CHEM-US-00004" num="00004">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bc/9e/47/2b8949d68ab733/US20190292130A1-20190926-C00004.png"><img id="EMI-C00004" he="12.45mm" wi="23.45mm" file="US20190292130A1-20190926-C00004.TIF" alt="Figure US20190292130A1-20190926-C00004" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="94" height="50" alt="Figure US20190292130A1-20190926-C00004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bc/9e/47/2b8949d68ab733/US20190292130A1-20190926-C00004.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00004" attachment-type="cdx" file="US20190292130A1-20190926-C00004.CDX"> </attachment>
          <attachment idref="CHEM-US-00004" attachment-type="mol" file="US20190292130A1-20190926-C00004.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0045" num="0000" class="description-line">X and Y cannot both simultaneously be O;</div>
    </li> <li> <para-num num="[0042]"> </para-num> <div id="p-0046" num="0042" class="description-line">T is C or S;</div>
    </li> <li> <para-num num="[0043]"> </para-num> <div id="p-0047" num="0043" class="description-line">W is a bond, O, NH or S;</div>
    </li> <li> <para-num num="[0044]"> </para-num> <div id="p-0048" num="0044" class="description-line">R<sup>1 </sup>is selected from the group consisting of:
</div> </li> <ul> <li id="ul0005-0001" num="0000"> <ul> <li id="ul0006-0001" num="0045">(a) NR<sup>4</sup>R<sup>5 </sup>wherein R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</li> <li id="ul0006-0002" num="0046">(b) the side chain of a natural or unnatural amino acid; and</li> <li id="ul0006-0003" num="0047">(c) a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from the group consisting of O, N and S;</li> </ul> </li> </ul>

    <li> <para-num num="[0048]"> </para-num> <div id="p-0049" num="0048" class="description-line">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
</div> </li> <ul> <li id="ul0007-0001" num="0000"> <ul> <li id="ul0008-0001" num="0049">(a) C<sub>10</sub>-C<sub>22 </sub>alkyl;</li> <li id="ul0008-0002" num="0050">(b) C<sub>10</sub>-C<sub>22 </sub>alkenyl;</li> <li id="ul0008-0003" num="0051">(c) C<sub>10</sub>-C<sub>22 </sub>alkynyl;</li> <li id="ul0008-0004" num="0052">(d) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl; and</li> <li id="ul0008-0005" num="0053">(e) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkenyl;</li> </ul> </li> </ul>

    <li> <para-num num="[0054]"> </para-num> <div id="p-0050" num="0054" class="description-line">Z is OC(O), C(O)O or O;</div>
    </li> <li> <para-num num="[0055]"> </para-num> <div id="p-0051" num="0055" class="description-line">n is 0, 1, 2, 3, 4, 5 or 6;</div>
    </li> <li> <para-num num="[0056]"> </para-num> <div id="p-0052" num="0056" class="description-line">m is 0 or 1;</div>
    </li> <li> <para-num num="[0057]"> </para-num> <div id="p-0053" num="0057" class="description-line">p is 0 or 1; and</div>
    </li> <li> <para-num num="[0058]"> </para-num> <div id="p-0054" num="0058" class="description-line">z is 0 or 2;</div>
    </li> <li> <para-num num="[0059]"> </para-num> <div id="p-0055" num="0059" class="description-line">including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</div>
    </li> <li> <para-num num="[0060]"> </para-num> <div id="p-0056" num="0060" class="description-line">In some embodiments, the compound of formula (II) comprises a functional group selected from hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0061]"> </para-num> <div id="p-0057" num="0061" class="description-line">In some embodiments of formula (II), m is 0. In other embodiments of formula (II), m is 1. In other embodiments of formula (II), m is 1. In other embodiments of formula (II), m is 1 and p is 0. In other embodiments of formula (II), z is 0. In other embodiments of formula (II), z is 2. In other embodiments of formula (II), T is C. In other embodiments of formula (II), W is a bond. In some embodiments of formula (II), m is 0 and W is O.</div>
    </li> <li> <para-num num="[0062]"> </para-num> <div id="p-0058" num="0062" class="description-line">In some representative embodiments of formula (II), the cationic lipid is represented by the structure of formula (IIa). In some representative embodiments of formula (IIa), the cationic lipid is represented by the structure of formula (IIa-1). In other representative embodiments of formula (IIa), the cationic lipid is represented by the structure of formula (IIa-2). In other representative embodiments of formula (IIa), the cationic lipid is represented by the structure of formula (IIa-3). In other representative embodiments of formula (IIa), the cationic lipid is represented by the structure of formula (IIa-4). In other representative embodiments of formula (II), the cationic lipid is represented by the structure of formula (IIb). In some representative embodiments of formula (IIb), the cationic lipid is represented by the structure of formula (IIb-1).</div>
    </li> <li> <para-num num="[0063]"> </para-num> <div id="p-0059" num="0063" class="description-line">The structures of formulae (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1) are depicted in the detailed description hereinbelow.</div>
    </li> <li> <para-num num="[0064]"> </para-num> <div id="p-0060" num="0064" class="description-line">Specific examples of the compounds of formula (I), (Ia), (Ia-1), (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1) are compounds 1-66, the structures of which are depicted in Table 1 in the Detailed Description. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0065]"> </para-num> <div id="p-0061" num="0065" class="description-line">An intermediate of formula (IIa-5), which can be used to prepare a compound of formula (IIa-4), represents a separate embodiment of the invention.</div>
    </li> <li> <para-num num="[0066]"> </para-num> <div id="p-0062" num="0066" class="description-line">In another aspect, the cationic lipid of the present invention is represented by the structure of formula (III):</div>
    </li> <li> <div id="p-0063" num="0000" class="description-line">
      <chemistry id="CHEM-US-00005" num="00005">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/51/d1/67/5146ea6d1de54a/US20190292130A1-20190926-C00005.png"><img id="EMI-C00005" he="19.30mm" wi="69.93mm" file="US20190292130A1-20190926-C00005.TIF" alt="Figure US20190292130A1-20190926-C00005" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="77" alt="Figure US20190292130A1-20190926-C00005" class="patent-full-image" src="https://patentimages.storage.googleapis.com/51/d1/67/5146ea6d1de54a/US20190292130A1-20190926-C00005.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00005" attachment-type="cdx" file="US20190292130A1-20190926-C00005.CDX"> </attachment>
          <attachment idref="CHEM-US-00005" attachment-type="mol" file="US20190292130A1-20190926-C00005.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0064" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0067]"> </para-num> <div id="p-0065" num="0067" class="description-line">X and Y are each independently O, N or NH, wherein X and Y cannot both simultaneously be O;</div>
    </li> <li> <para-num num="[0068]"> </para-num> <div id="p-0066" num="0068" class="description-line">each of R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is independently absent or a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl; and</div>
    </li> <li> <div id="p-0067" num="0000" class="description-line">n is an integer between 1 and 30;
<br/>
including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.
</div>
    </li> <li> <para-num num="[0069]"> </para-num> <div id="p-0068" num="0069" class="description-line">In another aspect, the cationic lipid of the present invention is represented by the structure of formula (IIIA):</div>
    </li> <li> <div id="p-0069" num="0000" class="description-line">
      <chemistry id="CHEM-US-00006" num="00006">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/38/e0/83c05c613e53df/US20190292130A1-20190926-C00006.png"><img id="EMI-C00006" he="19.39mm" wi="69.93mm" file="US20190292130A1-20190926-C00006.TIF" alt="Figure US20190292130A1-20190926-C00006" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="78" alt="Figure US20190292130A1-20190926-C00006" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/38/e0/83c05c613e53df/US20190292130A1-20190926-C00006.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00006" attachment-type="cdx" file="US20190292130A1-20190926-C00006.CDX"> </attachment>
          <attachment idref="CHEM-US-00006" attachment-type="mol" file="US20190292130A1-20190926-C00006.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0070" num="0000" class="description-line">wherein
<br/>
X and Y are each independently O, N or NH, wherein X and Y cannot both simultaneously be O;
<br/>
each of R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is independently absent or a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl;
<br/>
n is an integer between 1 and 30; and
<br/>
x is 0 or 2;
<br/>
including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.
</div>
    </li> <li> <para-num num="[0070]"> </para-num> <div id="p-0071" num="0070" class="description-line">Specific examples of the compounds of formula (III) are compounds 67-70, the structures of which are depicted in Table 2 in the Detailed Description. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0071]"> </para-num> <div id="p-0072" num="0071" class="description-line">In another aspect, the present invention relates to a composition comprising the cationic lipid of any one of formulae (I), (Ia), (Ia-1), (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb), (IIb-1) and (III), and further comprising at least one additional neutral or PEG-modified lipid. In some embodiments, the composition may further comprise a nucleic acid. Examples of nucleic acids include, but are not limited to, small interfering RNA (siRNA), micro RNA (miRNA), antisense oligo nucleotides, messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA and immune stimulating nucleic acids. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0072]"> </para-num> <div id="p-0073" num="0072" class="description-line">In another aspect, the present invention relates to a method of gene silencing, comprising the step of contacting a cell with a composition according to the present invention. In some embodiments, the cell is a cancer cell.</div>
    </li> <li> <para-num num="[0073]"> </para-num> <div id="p-0074" num="0073" class="description-line">In other embodiments, the compositions of the present invention may be used as a delivery system to administer a therapeutic agent to its target location in the body. Thus, in some embodiments, the present invention relates to a method for administering a therapeutic agent, by preparing a composition comprising a cationic lipid as described herein and a therapeutic agent, and administering the combination to a subject in need thereof.</div>
    </li> <li> <para-num num="[0074]"> </para-num> <div id="p-0075" num="0074" class="description-line">The cationic lipids of the present invention can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids (including, for example, sterols) and/or their analogs, and/or polymer conjugated lipids to form lipid nanoparticles for the delivery of therapeutic agents. In some instances the lipid nanoparticles are used to deliver nucleic acids for the treatment of various diseases or conditions, in particular leukocyte associated conditions such as inflammation and/or lack of sufficient protein.</div>
    </li> <li> <para-num num="[0075]"> </para-num> <div id="p-0076" num="0075" class="description-line">Thus, in some embodiments, the present invention relates to a method of treating a leukocyte associated condition, the method comprising the step of administering to a subject in need thereof a composition according to the present invention. The leukocyte associated condition may be selected from the group consisting of cancer, infection, autoimmune diseases, neurodegenerative diseases and inflammation.</div>
    </li> <li> <para-num num="[0076]"> </para-num> <div id="p-0077" num="0076" class="description-line">Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.</div>
    
    
    </li> <description-of-drawings>
      <heading id="h-0004">BRIEF DESCRIPTION OF THE DRAWINGS</heading>
      <li> <para-num num="[0077]"> </para-num> <div id="p-0078" num="0077" class="description-line"> <figref idrefs="DRAWINGS">FIG. 1</figref>: In vitro gene silencing effect lipid 1: Human T cells SupT1 were treated with lipid nanoparticle (LNP) comprising of <figure-callout id="1" label="cationic lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">cationic lipid</figure-callout> 1 encapsulated siCD45 for 48 hrs (A) or 72 hrs (B) at different siRNA doses (0.4 M, 0.2 M, 0.1 M).</div>
      </li> <li> <para-num num="[0078]"> </para-num> <div id="p-0079" num="0078" class="description-line"> <figref idrefs="DRAWINGS">FIG. 2</figref>: Drug resistant human ovarian carcinoma cells (NAR) were treated with either LNP-siPLK-1 or LNP-siLuc nanoparticles for 72 hr and PLK-1 expression was measured by qPCR.</div>
      </li> <li> <para-num num="[0079]"> </para-num> <div id="p-0080" num="0079" class="description-line"> <figref idrefs="DRAWINGS">FIG. 3</figref>: In vitro gene silencing effect of <figure-callout id="1" label="lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">lipid</figure-callout> 1 in NAR cells: Human ovarian cancer cells (NAR cells) were treated with lipid1/siPLK1 nanoparticles for 48 hr at different siRNA concentrations (0.2 M and 0.1 M). Apoptotic cells were analyzed by FACS using PI/Annexin.</div>
      </li> <li> <para-num num="[0080]"> </para-num> <div id="p-0081" num="0080" class="description-line"> <figref idrefs="DRAWINGS">FIG. 4</figref>: In vitro gene silencing effect of <figure-callout id="10" label="lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">lipid</figure-callout> 10 and 11 in NAR cells: Human ovarian cancer cells (NAR cells) were treated with lipid1/siPLK1 nanoparticles for 48 hr at different siRNA concentrations (0.1 M and 0.05 M). Apoptotic cells were analyzed by FACS using PI/Annexin.</div>
      </li> <li> <para-num num="[0081]"> </para-num> <div id="p-0082" num="0081" class="description-line"> <figref idrefs="DRAWINGS">FIG. 5</figref>: Human ovarian carcinoma cells (OVCAR 8) were treated with either LNP-siPLK-1 or LNP-siLuc nanoparticles for 72 hr and PLK-1 expression was measured by qPCR.</div>
      </li> <li> <para-num num="[0082]"> </para-num> <div id="p-0083" num="0082" class="description-line"> <figref idrefs="DRAWINGS">FIG. 6</figref>: Spheroids of drug resistant human ovarian carcinoma cells (NAR) were treated with either LNP-siPLK-1 or LNP-siLuc nanoparticles for 72 hr and PLK-1 expression was measured by qPCR.</div>
      </li> <li> <para-num num="[0083]"> </para-num> <div id="p-0084" num="0083" class="description-line"> <figref idrefs="DRAWINGS">FIG. 7</figref>: Human colon carcinoma cells (HCT116) were incubated with LNPs (comprising MC3, <figure-callout id="38" label="Lipids" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">Lipids</figure-callout> 38 or Lipid 55) with ctl siRNA for 72 hrs. Cell viability was measured by XTT assay. <figref idrefs="DRAWINGS">FIG. 10</figref> shows cell proliferation (% of untreated cells) vs. concentration of siPLK1.</div>
      </li> <li> <para-num num="[0084]"> </para-num> <div id="p-0085" num="0084" class="description-line"> <figref idrefs="DRAWINGS">FIG. 8</figref>: In vitro gene silencing effects of <figure-callout id="38" label="Lipids" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">Lipids</figure-callout> 38 or 55. Human multiple myeloma suspension cells (U266) were incubated with LNPs containing siPLK1 at different concentrations for 48 hrs. PLK1 expression was measured by qPCR. PLK1-mRNA levels were normalized to LNPs-ctl siRNA treated cells.</div>
      </li> <li> <para-num num="[0085]"> </para-num> <div id="p-0086" num="0085" class="description-line"> <figref idrefs="DRAWINGS">FIG. 9</figref>: Effect of PLK1 silencing on cell viability. Human multiple myeloma suspension cells (U266) were incubated with LNPs comprising <figure-callout id="38" label="cationic lipids" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">cationic lipids</figure-callout> 38 or 55 and siPLK1 or ctl-siRNA at different concentrations for 48 hrs. Cell viability induced by PLK1 down regulation was measured by XTT assay.</div>
      </li> <li> <para-num num="[0086]"> </para-num> <div id="p-0087" num="0086" class="description-line"> <figref idrefs="DRAWINGS">FIG. 10</figref>: Effect of PLK1 silencing on cell viability; Human B-cell lymphoma suspension cells (RPMI-8226) were incubated with LNPs comprising <figure-callout id="38" label="cationic lipids" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">cationic lipids</figure-callout> 38 or 55 and siPLK1 or ctl-siRNA at different concentrations for 48 hrs. Cell viability induced by PLK1 down regulation was measured by XTT assay.</div>
      </li> <li> <para-num num="[0087]"> </para-num> <div id="p-0088" num="0087" class="description-line"> <figref idrefs="DRAWINGS">FIG. 11</figref>: Effect of PLK1 silencing on cell viability. Human multiple myeloma suspension cells (MM1) were incubated with LNPs comprising <figure-callout id="38" label="cationic lipids" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">cationic lipids</figure-callout> 38 or 55 and siPLK1 or ctl-siRNA at different concentrations for 48 hrs. Cell viability induced by PLK1 down regulation was measured by XTT assay.</div>
      </li> <li> <para-num num="[0088]"> </para-num> <div id="p-0089" num="0088" class="description-line"> <figref idrefs="DRAWINGS">FIG. 12</figref>: In vitro expression of pDNA. Human colon carcinoma cells (HCT 116) were incubated with LNPs-LUC pDNA at different concentrations for 48 hrs. Luciferase expression was measured by luminometer. Lipofectamine 2000 (Lipo 2000) was used as positive control. LNPs were formulated with <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 and different amounts of DOPE, along with other co-lipids Chol, and PEG-DMG.</div>
      </li> <li> <para-num num="[0089]"> </para-num> <div id="p-0090" num="0089" class="description-line"> <figref idrefs="DRAWINGS">FIG. 13</figref>: HEK 293 cells were treated with LNP-DNA nanoparticles (10:1 N/P ratio, 0.6 nM DNA) for 72 hr and mKATE expression was analyzed by flow cytometry.</div>
      </li> <li> <para-num num="[0090]"> </para-num> <div id="p-0091" num="0090" class="description-line"> <figref idrefs="DRAWINGS">FIG. 14</figref>: HEK 293 cells were treated with LNP-DNA nanoparticles (10:1 N/P ratio) at different DNA for 72 hr and mKATE expression was analyzed by flow cytometry. <figref idrefs="DRAWINGS">FIG. 14A</figref>: <figure-callout id="1" label="Lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">Lipid</figure-callout> 1. <figref idrefs="DRAWINGS">FIG. 14B</figref>: <figure-callout id="10" label="Lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">Lipid</figure-callout> 10.</div>
      </li> <li> <para-num num="[0091]"> </para-num> <div id="p-0092" num="0091" class="description-line"> <figref idrefs="DRAWINGS">FIG. 15</figref>: In vitro delivery of mRNA. Hard to transfect murine macrophage cells (RAW 264.7) were treated with LNPs containing <figure-callout id="38" label="cationic lipids" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}"> <figure-callout id="54" label="cationic lipids" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">cationic lipids</figure-callout> </figure-callout> 38 or 54 and luciferase mRNA for 18 hrs at different mRNA concentrations. Luciferase expression was measured by luminometer.</div>
      </li> <li> <para-num num="[0092]"> </para-num> <div id="p-0093" num="0092" class="description-line"> <figref idrefs="DRAWINGS">FIG. 16</figref>: In vivo delivery of mRNA. LNPs containing <figure-callout id="38" label="cationic lipids" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}"> <figure-callout id="54" label="cationic lipids" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">cationic lipids</figure-callout> </figure-callout> 38 or 54 luciferase mRNA was administered intramuscularly to C57BL6/j mice at 1 mg/kg body weight. Luciferase expression was measured by bioluminescence imaging system Biospace: (A) after 8 hrs of i.m. administration; and (B) after 24 hrs.</div>
      </li> <li> <para-num num="[0093]"> </para-num> <div id="p-0094" num="0093" class="description-line"> <figref idrefs="DRAWINGS">FIG. 17</figref>: LNPs composed of either <figure-callout id="54" label="lipid" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">lipid</figure-callout> 54 or <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 formulated with luciferase mRNA were administered intravenously into C57BL6/j mice at 1 mg/kg body weight. After 8 hrs, luciferase expression was measured by bioluminescence imaging system Biospace.</div>
      </li> <li> <para-num num="[0094]"> </para-num> <div id="p-0095" num="0094" class="description-line"> <figref idrefs="DRAWINGS">FIG. 18</figref>: In vivo delivery of mRNA to liver. LNPs composed of <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 formulated with luciferase mRNA were administered intravenously into C57BL6/j mice at 1 mg/kg body weight. After 8 hrs and 24 hrs of administration, luciferase expression was measured by bioluminescence imaging system Biospace.</div>
      </li> <li> <para-num num="[0095]"> </para-num> <div id="p-0096" num="0095" class="description-line"> <figref idrefs="DRAWINGS">FIG. 19</figref>: No liver toxicity in Non-human primate compared with MC3. Cynomolgus monkeys (n=2 per group, males) received a single i.v. administration (1 ml/kg) of (0.5 mg/kg) of MC3 particles with siNC5 and lipid 38-based particles with siNC5 (0.5 mg/Kg). At 1 and 24 h post administration serum was collected at and analyzed for ALT, AST. Each data point is an average of 2 animalsSEM.</div>
    </li> </description-of-drawings>
    
    
    <heading id="h-0005">DETAILED DESCRIPTION OF THE PRESENT INVENTION</heading>
    <li> <para-num num="[0096]"> </para-num> <div id="p-0097" num="0096" class="description-line">The present invention based on the discovery of cationic lipids useful in preparing lipid nanoparticles to deliver active agents in vitro and in vivo. The cationic lipids of the present invention are useful in delivery of nucleic acids such as siRNA, miRNA and mRNA etc.</div>
    </li> <heading id="h-0006">Cationic Lipids</heading>
    <li> <para-num num="[0097]"> </para-num> <div id="p-0098" num="0097" class="description-line">In some embodiment, the present invention relates to a cationic lipid comprising a hydrazine, hydrazine, hydroxylamine, ethanolamine or diethylene diamine moiety linked to at least one saturated or unsaturated fatty acid residue. In some embodiments, the cationic lipid comprises two fatty acid residues asymmetrically linked to the hydrazine, hydrazine, hydroxylamine, ethanolamine or diethylene diamine moiety.</div>
    </li> <li> <para-num num="[0098]"> </para-num> <div id="p-0099" num="0098" class="description-line">As contemplated herein, the present invention relates to a cationic lipid comprising a functional group represented by the structure:</div>
    </li> <li> <div id="p-0100" num="0000" class="description-line"> <br/>W-(T=O)<sub>m</sub>X(CH<sub>2</sub>)<sub>z</sub>Y;
</div>
    </li> <li> <para-num num="[0099]"> </para-num> <div id="p-0101" num="0099" class="description-line">wherein</div>
    </li> <li> <para-num num="[0100]"> </para-num> <div id="p-0102" num="0100" class="description-line">X and Y are each independently O, N or NH, wherein X and Y cannot both be O;</div>
    </li> <li> <para-num num="[0101]"> </para-num> <div id="p-0103" num="0101" class="description-line">W is a bond, O, NH or S;</div>
    </li> <li> <para-num num="[0102]"> </para-num> <div id="p-0104" num="0102" class="description-line">T is C or S;</div>
    </li> <li> <para-num num="[0103]"> </para-num> <div id="p-0105" num="0103" class="description-line">m is 0 or 1; and</div>
    </li> <li> <para-num num="[0104]"> </para-num> <div id="p-0106" num="0104" class="description-line">z is 0 or 2;
</div> </li> <ul> <li id="ul0009-0001" num="0000"> <ul> <li id="ul0010-0001" num="0105">wherein the functional group is linked to at least one saturated or unsaturated fatty acid residue.</li> </ul> </li> </ul>

    <li> <para-num num="[0106]"> </para-num> <div id="p-0107" num="0106" class="description-line">In some embodiments, X and Y are each independently O or N, wherein X and Y cannot both be O.</div>
    </li> <li> <para-num num="[0107]"> </para-num> <div id="p-0108" num="0107" class="description-line">In some embodiments, the cationic lipid comprises two fatty acid residues symmetrically or asymmetrically linked to the aforementioned functional group.</div>
    </li> <li> <para-num num="[0108]"> </para-num> <div id="p-0109" num="0108" class="description-line">In one aspect of the present invention, X is N, and the cationic lipid is represented by the structure of formula (I):</div>
    </li> <li> <div id="p-0110" num="0000" class="description-line">
      <chemistry id="CHEM-US-00007" num="00007">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f3/70/2b/77f200fda025e5/US20190292130A1-20190926-C00007.png"><img id="EMI-C00007" he="22.94mm" wi="69.93mm" file="US20190292130A1-20190926-C00007.TIF" alt="Figure US20190292130A1-20190926-C00007" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="92" alt="Figure US20190292130A1-20190926-C00007" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f3/70/2b/77f200fda025e5/US20190292130A1-20190926-C00007.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00007" attachment-type="cdx" file="US20190292130A1-20190926-C00007.CDX"> </attachment>
          <attachment idref="CHEM-US-00007" attachment-type="mol" file="US20190292130A1-20190926-C00007.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0111" num="0000" class="description-line">wherein</div>
    </li> <heading id="h-0007">Y is O or NH;</heading>
    <heading id="h-0008">T is C or S;</heading>
    <li> <para-num num="[0109]"> </para-num> <div id="p-0112" num="0109" class="description-line">W is a bond, O, NH or S;
<br/>
R<sup>1 </sup>is selected from the group consisting of:
</div>
    </li> <li> <para-num num="[0110]"> </para-num> <div id="p-0113" num="0110" class="description-line">(a) NR<sup>4</sup>R<sup>5 </sup>wherein R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</div>
    </li> <li> <para-num num="[0111]"> </para-num> <div id="p-0114" num="0111" class="description-line">(b) the side chain of a natural or unnatural amino acid; and</div>
    </li> <li> <para-num num="[0112]"> </para-num> <div id="p-0115" num="0112" class="description-line">(c) a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from the group consisting of O, N and S;</div>
    </li> <li> <div id="p-0116" num="0000" class="description-line">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
</div> </li> <ul> <li id="ul0011-0001" num="0000"> <ul> <li id="ul0012-0001" num="0113">(a) C<sub>10</sub>-C<sub>22 </sub>alkyl;</li> <li id="ul0012-0002" num="0114">(b) C<sub>10</sub>-C<sub>22 </sub>alkenyl;</li> <li id="ul0012-0003" num="0115">(c) C<sub>10</sub>-C<sub>22 </sub>alkynyl;</li> <li id="ul0012-0004" num="0116">(d) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl; and</li> <li id="ul0012-0005" num="0117">(e) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkenyl;</li> </ul> </li> </ul>

    <heading id="h-0009">Z is OC(O), C(O)O or O;</heading>
    <li> <para-num num="[0118]"> </para-num> <div id="p-0117" num="0118" class="description-line">n is 0, 1, 2, 3, 4, 5 or 6;
<br/>
m is 0 or 1;
<br/>
p is 0 or 1; and
<br/>
z is 0 or 2;
<br/>
including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.
</div>
    </li> <li> <para-num num="[0119]"> </para-num> <div id="p-0118" num="0119" class="description-line">In some embodiments of formula (I), R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of: (a) a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl; and (b) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl wherein Z is OC(O), C(O)O or O. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0120]"> </para-num> <div id="p-0119" num="0120" class="description-line">In some embodiments of formula (I), R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>. In some embodiments of formula (I), R<sup>1 </sup>is the side chain of a natural or unnatural amino acid. In some embodiments of formula (I), R<sup>1 </sup>is a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from the group consisting of O, N and S.</div>
    </li> <li> <para-num num="[0121]"> </para-num> <div id="p-0120" num="0121" class="description-line">In some embodiments, the compound of formula (I) comprises a functional group selected from the group consisting of hydrazine, hydroxylamine, hydrazide, ethanolamine and ethylenediamine. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0122]"> </para-num> <div id="p-0121" num="0122" class="description-line">In some embodiments of formula (I), m is 0. In other embodiments of formula (I), m is 1. In other embodiments of formula (I), p is 0. In other embodiments of formula (I), p is 1. In other embodiments of formula (I), m is 0 and p is 0. In other embodiments of formula (I), m is 1 and p is 0. In other embodiments of formula (I), z is 0. In other embodiments of formula (I), z is 2. In other embodiments of formula (I), T is C. In other embodiments of formula (I), W is a bond.</div>
    </li> <li> <para-num num="[0123]"> </para-num> <div id="p-0122" num="0123" class="description-line">In some representative embodiments of formula (I), p is 0, W is a bond and T is C, and the compound is represented by the structure of formula (Ia):</div>
    </li> <li> <div id="p-0123" num="0000" class="description-line">
      <chemistry id="CHEM-US-00008" num="00008">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a2/9e/17/afadc5d123687c/US20190292130A1-20190926-C00008.png"><img id="EMI-C00008" he="22.35mm" wi="69.93mm" file="US20190292130A1-20190926-C00008.TIF" alt="Figure US20190292130A1-20190926-C00008" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="89" alt="Figure US20190292130A1-20190926-C00008" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a2/9e/17/afadc5d123687c/US20190292130A1-20190926-C00008.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00008" attachment-type="cdx" file="US20190292130A1-20190926-C00008.CDX"> </attachment>
          <attachment idref="CHEM-US-00008" attachment-type="mol" file="US20190292130A1-20190926-C00008.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0124" num="0000" class="description-line">wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, Y, m, n and z are as defined in formula (I).</div>
    </li> <li> <para-num num="[0124]"> </para-num> <div id="p-0125" num="0124" class="description-line">In some embodiments of formula (Ia), m is 0. In other embodiments of formula (Ia), m is 1. In other embodiments of formula (I), z is 0. In other embodiments of formula (Ia), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>14</sub>-C<sub>20 </sub>alkyl or a C<sub>14</sub>-C<sub>20 </sub>alkenyl. In other embodiments of formula (Ia), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl wherein Z is OC(O), C(O)O or O. In other embodiments, of formula (a), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkenyl wherein Z is OC(O), C(O)O or O. In other embodiments of formula (Ia), Y is O.</div>
    </li> <li> <para-num num="[0125]"> </para-num> <div id="p-0126" num="0125" class="description-line">In other embodiments of formula (Ia), Y is NH.</div>
    </li> <li> <para-num num="[0126]"> </para-num> <div id="p-0127" num="0126" class="description-line">In other representative embodiments of formula (I), R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (Ia-1):</div>
    </li> <li> <div id="p-0128" num="0000" class="description-line">
      <chemistry id="CHEM-US-00009" num="00009">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/76/0b/be/7fe5ae8d3866d5/US20190292130A1-20190926-C00009.png"><img id="EMI-C00009" he="22.35mm" wi="69.93mm" file="US20190292130A1-20190926-C00009.TIF" alt="Figure US20190292130A1-20190926-C00009" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="89" alt="Figure US20190292130A1-20190926-C00009" class="patent-full-image" src="https://patentimages.storage.googleapis.com/76/0b/be/7fe5ae8d3866d5/US20190292130A1-20190926-C00009.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00009" attachment-type="cdx" file="US20190292130A1-20190926-C00009.CDX"> </attachment>
          <attachment idref="CHEM-US-00009" attachment-type="mol" file="US20190292130A1-20190926-C00009.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0129" num="0000" class="description-line">wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, Y, m, n and z are as defined in formula (I).</div>
    </li> <li> <para-num num="[0127]"> </para-num> <div id="p-0130" num="0127" class="description-line">In some embodiments of formula (Ia-1), R<sup>4 </sup>and R<sup>5 </sup>are each CH<sub>3</sub>. In other embodiments of formula (Ia-1), R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a heterocyclic ring selected from the group consisting of pyrrolidinyl piperidininyl and piperazinyl, each of which is optionally substituted with an alkyl. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0128]"> </para-num> <div id="p-0131" num="0128" class="description-line">In another aspect of the present invention, the cationic lipid is represented by the structure of formula (II):</div>
    </li> <li> <div id="p-0132" num="0000" class="description-line">
      <chemistry id="CHEM-US-00010" num="00010">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d5/eb/7d/014b8cd21c751d/US20190292130A1-20190926-C00010.png"><img id="EMI-C00010" he="22.94mm" wi="69.93mm" file="US20190292130A1-20190926-C00010.TIF" alt="Figure US20190292130A1-20190926-C00010" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="92" alt="Figure US20190292130A1-20190926-C00010" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d5/eb/7d/014b8cd21c751d/US20190292130A1-20190926-C00010.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00010" attachment-type="cdx" file="US20190292130A1-20190926-C00010.CDX"> </attachment>
          <attachment idref="CHEM-US-00010" attachment-type="mol" file="US20190292130A1-20190926-C00010.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0133" num="0000" class="description-line">wherein</div>
    </li> <heading id="h-0010">A is</heading>
    <li> <para-num num="[0129]"> </para-num> <div id="p-0134" num="0129" class="description-line">
      <chemistry id="CHEM-US-00011" num="00011">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/e2/a4/b5da2c2bf07548/US20190292130A1-20190926-C00011.png"><img id="EMI-C00011" he="12.45mm" wi="46.65mm" file="US20190292130A1-20190926-C00011.TIF" alt="Figure US20190292130A1-20190926-C00011" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="187" height="50" alt="Figure US20190292130A1-20190926-C00011" class="patent-full-image" src="https://patentimages.storage.googleapis.com/da/e2/a4/b5da2c2bf07548/US20190292130A1-20190926-C00011.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00011" attachment-type="cdx" file="US20190292130A1-20190926-C00011.CDX"> </attachment>
          <attachment idref="CHEM-US-00011" attachment-type="mol" file="US20190292130A1-20190926-C00011.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0011">X is O or NH;</heading>
    <heading id="h-0012">Y is O or NH;</heading>
    <li> <para-num num="[0130]"> </para-num> <div id="p-0135" num="0130" class="description-line">provided that when A is</div>
    </li> <li> <div id="p-0136" num="0000" class="description-line">
      <chemistry id="CHEM-US-00012" num="00012">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c6/96/60/bae9dd5066006c/US20190292130A1-20190926-C00012.png"><img id="EMI-C00012" he="12.45mm" wi="22.44mm" file="US20190292130A1-20190926-C00012.TIF" alt="Figure US20190292130A1-20190926-C00012" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="90" height="50" alt="Figure US20190292130A1-20190926-C00012" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c6/96/60/bae9dd5066006c/US20190292130A1-20190926-C00012.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00012" attachment-type="cdx" file="US20190292130A1-20190926-C00012.CDX"> </attachment>
          <attachment idref="CHEM-US-00012" attachment-type="mol" file="US20190292130A1-20190926-C00012.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0137" num="0000" class="description-line">X and Y cannot both be O;</div>
    </li> <heading id="h-0013">T is C or S;</heading>
    <li> <para-num num="[0131]"> </para-num> <div id="p-0138" num="0131" class="description-line">W is a bond, O, NH or S;
<br/>
R<sup>1 </sup>is selected from the group consisting of:
</div>
    </li> <li> <para-num num="[0132]"> </para-num> <div id="p-0139" num="0132" class="description-line">(a) NR<sup>4</sup>R<sup>5 </sup>wherein R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</div>
    </li> <li> <para-num num="[0133]"> </para-num> <div id="p-0140" num="0133" class="description-line">(b) the side chain of a natural or unnatural amino acid; and</div>
    </li> <li> <para-num num="[0134]"> </para-num> <div id="p-0141" num="0134" class="description-line">(c) a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from the group consisting of O, N and S;</div>
    </li> <li> <div id="p-0142" num="0000" class="description-line">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:</div>
    </li> <li> <para-num num="[0135]"> </para-num> <div id="p-0143" num="0135" class="description-line">(a) C<sub>10</sub>-C<sub>22 </sub>alkyl;</div>
    </li> <li> <para-num num="[0136]"> </para-num> <div id="p-0144" num="0136" class="description-line">(b) C<sub>10</sub>-C<sub>22 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0137]"> </para-num> <div id="p-0145" num="0137" class="description-line">(c) C<sub>10</sub>-C<sub>22 </sub>alkynyl;</div>
    </li> <li> <para-num num="[0138]"> </para-num> <div id="p-0146" num="0138" class="description-line">(d) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl; and</div>
    </li> <li> <para-num num="[0139]"> </para-num> <div id="p-0147" num="0139" class="description-line">(e) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkenyl;</div>
    </li> <heading id="h-0014">Z is OC(O), C(O)O or O;</heading>
    <li> <para-num num="[0140]"> </para-num> <div id="p-0148" num="0140" class="description-line">n is 0, 1, 2, 3, 4, 5 or 6;
<br/>
m is 0 or 1;
<br/>
p is 0 or 1; and
<br/>
z is 0 or 2;
<br/>
including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.
</div>
    </li> <li> <para-num num="[0141]"> </para-num> <div id="p-0149" num="0141" class="description-line">In some embodiments of formula (II), R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of: (a) a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl; and (b) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl wherein Z is OC(O), C(O)O or O. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0142]"> </para-num> <div id="p-0150" num="0142" class="description-line">In some embodiments of formula (II), m is 0. In other embodiments of formula (II), m is 1. In other embodiments of formula (II), m is 1. In other embodiments of formula (II), m is 1 and p is 0. In other embodiments of formula (II), z is 0. In other embodiments of formula (II), z is 2. In other embodiments of formula (II), T is C. In other embodiments of formula (II), W is a bond. In some embodiments of formula (II), m is 0 and W is O.</div>
    </li> <li> <para-num num="[0143]"> </para-num> <div id="p-0151" num="0143" class="description-line">In some representative embodiments of formula (II), the cationic lipid is represented by the structure of formula (IIa):</div>
    </li> <li> <div id="p-0152" num="0000" class="description-line">
      <chemistry id="CHEM-US-00013" num="00013">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e7/20/3e/4cec874e9de9e6/US20190292130A1-20190926-C00013.png"><img id="EMI-C00013" he="22.94mm" wi="69.93mm" file="US20190292130A1-20190926-C00013.TIF" alt="Figure US20190292130A1-20190926-C00013" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="92" alt="Figure US20190292130A1-20190926-C00013" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e7/20/3e/4cec874e9de9e6/US20190292130A1-20190926-C00013.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00013" attachment-type="cdx" file="US20190292130A1-20190926-C00013.CDX"> </attachment>
          <attachment idref="CHEM-US-00013" attachment-type="mol" file="US20190292130A1-20190926-C00013.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0153" num="0000" class="description-line">wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X, T, W, n, m, p and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0144]"> </para-num> <div id="p-0154" num="0144" class="description-line">In some embodiments of formula (IIa) p is 0, W is a bond and T is C, and the compound is represented by the structure of formula (IIa-1):</div>
    </li> <li> <div id="p-0155" num="0000" class="description-line">
      <chemistry id="CHEM-US-00014" num="00014">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/13/f8/0138c8b63a8455/US20190292130A1-20190926-C00014.png"><img id="EMI-C00014" he="18.80mm" wi="69.93mm" file="US20190292130A1-20190926-C00014.TIF" alt="Figure US20190292130A1-20190926-C00014" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="75" alt="Figure US20190292130A1-20190926-C00014" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d9/13/f8/0138c8b63a8455/US20190292130A1-20190926-C00014.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00014" attachment-type="cdx" file="US20190292130A1-20190926-C00014.CDX"> </attachment>
          <attachment idref="CHEM-US-00014" attachment-type="mol" file="US20190292130A1-20190926-C00014.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0156" num="0000" class="description-line">wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X, n, m and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0145]"> </para-num> <div id="p-0157" num="0145" class="description-line">In other embodiments of formula (IIa), R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (IIa-2):</div>
    </li> <li> <div id="p-0158" num="0000" class="description-line">
      <chemistry id="CHEM-US-00015" num="00015">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f3/9f/8d/a6ed281a345ac6/US20190292130A1-20190926-C00015.png"><img id="EMI-C00015" he="18.80mm" wi="69.93mm" file="US20190292130A1-20190926-C00015.TIF" alt="Figure US20190292130A1-20190926-C00015" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="75" alt="Figure US20190292130A1-20190926-C00015" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f3/9f/8d/a6ed281a345ac6/US20190292130A1-20190926-C00015.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00015" attachment-type="cdx" file="US20190292130A1-20190926-C00015.CDX"> </attachment>
          <attachment idref="CHEM-US-00015" attachment-type="mol" file="US20190292130A1-20190926-C00015.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0159" num="0000" class="description-line">wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, n, m and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0146]"> </para-num> <div id="p-0160" num="0146" class="description-line">In yet other embodiments of formula (IIa), p is 1, m is 1, W is a bond and T is C, and the compound is represented by the structure of formula (IIa-3):</div>
    </li> <li> <div id="p-0161" num="0000" class="description-line">
      <chemistry id="CHEM-US-00016" num="00016">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/42/28/c0/fbf91db67c5a5a/US20190292130A1-20190926-C00016.png"><img id="EMI-C00016" he="19.39mm" wi="69.93mm" file="US20190292130A1-20190926-C00016.TIF" alt="Figure US20190292130A1-20190926-C00016" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="78" alt="Figure US20190292130A1-20190926-C00016" class="patent-full-image" src="https://patentimages.storage.googleapis.com/42/28/c0/fbf91db67c5a5a/US20190292130A1-20190926-C00016.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00016" attachment-type="cdx" file="US20190292130A1-20190926-C00016.CDX"> </attachment>
          <attachment idref="CHEM-US-00016" attachment-type="mol" file="US20190292130A1-20190926-C00016.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0162" num="0000" class="description-line">wherein R<sup>1 </sup>is the side chain of a natural or unnatural amino acid; and R<sup>2</sup>, R<sup>3</sup>, X, n and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0147]"> </para-num> <div id="p-0163" num="0147" class="description-line">In some embodiments of formula (IIa), p is 0, R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, W is a bond, m is 0, X is O and the compound is represented by the structure of formula (IIa-4):</div>
    </li> <li> <div id="p-0164" num="0000" class="description-line">
      <chemistry id="CHEM-US-00017" num="00017">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/80/30/15/304c80716efdbd/US20190292130A1-20190926-C00017.png"><img id="EMI-C00017" he="13.63mm" wi="69.93mm" file="US20190292130A1-20190926-C00017.TIF" alt="Figure US20190292130A1-20190926-C00017" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="55" alt="Figure US20190292130A1-20190926-C00017" class="patent-full-image" src="https://patentimages.storage.googleapis.com/80/30/15/304c80716efdbd/US20190292130A1-20190926-C00017.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00017" attachment-type="cdx" file="US20190292130A1-20190926-C00017.CDX"> </attachment>
          <attachment idref="CHEM-US-00017" attachment-type="mol" file="US20190292130A1-20190926-C00017.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0148]"> </para-num> <div id="p-0165" num="0148" class="description-line">In some embodiments, compounds of formula (IIa-5) can be used as intermediates for preparing compounds of formula (IIa-4):</div>
    </li> <li> <div id="p-0166" num="0000" class="description-line">
      <chemistry id="CHEM-US-00018" num="00018">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1f/2d/60/6af3b3fed439c9/US20190292130A1-20190926-C00018.png"><img id="EMI-C00018" he="12.87mm" wi="69.93mm" file="US20190292130A1-20190926-C00018.TIF" alt="Figure US20190292130A1-20190926-C00018" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="51" alt="Figure US20190292130A1-20190926-C00018" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1f/2d/60/6af3b3fed439c9/US20190292130A1-20190926-C00018.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00018" attachment-type="cdx" file="US20190292130A1-20190926-C00018.CDX"> </attachment>
          <attachment idref="CHEM-US-00018" attachment-type="mol" file="US20190292130A1-20190926-C00018.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0149]"> </para-num> <div id="p-0167" num="0149" class="description-line">wherein R<sup>2 </sup>and R<sup>3 </sup>are as defined in formula (IIa-4).</div>
    </li> <li> <para-num num="[0150]"> </para-num> <div id="p-0168" num="0150" class="description-line">In other representative embodiments of formula (II), the cationic lipid is represented by the structure of formula (IIb):</div>
    </li> <li> <div id="p-0169" num="0000" class="description-line">
      <chemistry id="CHEM-US-00019" num="00019">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/77/97/3a/965ccdc20767ea/US20190292130A1-20190926-C00019.png"><img id="EMI-C00019" he="22.94mm" wi="69.93mm" file="US20190292130A1-20190926-C00019.TIF" alt="Figure US20190292130A1-20190926-C00019" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="92" alt="Figure US20190292130A1-20190926-C00019" class="patent-full-image" src="https://patentimages.storage.googleapis.com/77/97/3a/965ccdc20767ea/US20190292130A1-20190926-C00019.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00019" attachment-type="cdx" file="US20190292130A1-20190926-C00019.CDX"> </attachment>
          <attachment idref="CHEM-US-00019" attachment-type="mol" file="US20190292130A1-20190926-C00019.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0170" num="0000" class="description-line">wherein R, R<sup>2</sup>, R<sup>3</sup>, T, W, X, Y n, m, p and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0151]"> </para-num> <div id="p-0171" num="0151" class="description-line">In some representative embodiments of formula (IIb), p is 0, W is a bond, T is C, and R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (IIb-1):</div>
    </li> <li> <div id="p-0172" num="0000" class="description-line">
      <chemistry id="CHEM-US-00020" num="00020">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/28/02/ab/b0cdef8d0bef8b/US20190292130A1-20190926-C00020.png"><img id="EMI-C00020" he="18.80mm" wi="69.93mm" file="US20190292130A1-20190926-C00020.TIF" alt="Figure US20190292130A1-20190926-C00020" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="75" alt="Figure US20190292130A1-20190926-C00020" class="patent-full-image" src="https://patentimages.storage.googleapis.com/28/02/ab/b0cdef8d0bef8b/US20190292130A1-20190926-C00020.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00020" attachment-type="cdx" file="US20190292130A1-20190926-C00020.CDX"> </attachment>
          <attachment idref="CHEM-US-00020" attachment-type="mol" file="US20190292130A1-20190926-C00020.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0173" num="0000" class="description-line">wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, Y, n, m and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0152]"> </para-num> <div id="p-0174" num="0152" class="description-line">In some embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>14</sub>-C<sub>20 </sub>alkyl or a C<sub>14</sub>-C<sub>20 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0153]"> </para-num> <div id="p-0175" num="0153" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl wherein Z is OC(O), C(O)O or O.</div>
    </li> <li> <para-num num="[0154]"> </para-num> <div id="p-0176" num="0154" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkenyl wherein Z is OC(O), C(O)O or O.</div>
    </li> <li> <para-num num="[0155]"> </para-num> <div id="p-0177" num="0155" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), X is O.</div>
    </li> <li> <para-num num="[0156]"> </para-num> <div id="p-0178" num="0156" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), X is NH.</div>
    </li> <li> <para-num num="[0157]"> </para-num> <div id="p-0179" num="0157" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), Y is NH.</div>
    </li> <li> <para-num num="[0158]"> </para-num> <div id="p-0180" num="0158" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), R<sup>4 </sup>and R<sup>5 </sup>are each CH<sub>3</sub>, or wherein R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a heterocyclic ring selected from the group consisting of pyrrolidinyl piperidinyl and piperazinyl, each of which is optionally substituted with an alkyl.</div>
    </li> <li> <para-num num="[0159]"> </para-num> <div id="p-0181" num="0159" class="description-line">Specific examples of the compounds of formula (I), (Ia), (la-1), (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIa-5), (IIb) and (IIb-1) are compounds 1-66, the structures of which are depicted in Table 1 hereinbelow. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <div id="p-0182" num="0000" class="description-line">
      <tables id="TABLE-US-00001" num="00001">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 1</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">No.</td>
                <td class="description-td">Chemical structure/<figure-callout id="1" label="Chemical name" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">Chemical name</figure-callout> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00021" num="00021">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9a/21/e8/e6ddb2d631c4e4/US20190292130A1-20190926-C00021.png"><img id="EMI-C00021" he="25.32mm" wi="109.22mm" file="US20190292130A1-20190926-C00021.TIF" alt="Figure US20190292130A1-20190926-C00021" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="101" alt="Figure US20190292130A1-20190926-C00021" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9a/21/e8/e6ddb2d631c4e4/US20190292130A1-20190926-C00021.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00021" attachment-type="cdx" file="US20190292130A1-20190926-C00021.CDX"> </attachment>
                      <attachment idref="CHEM-US-00021" attachment-type="mol" file="US20190292130A1-20190926-C00021.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00022" num="00022">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/81/a3/1fa45b972db08d/US20190292130A1-20190926-C00022.png"><img id="EMI-C00022" he="25.32mm" wi="118.96mm" file="US20190292130A1-20190926-C00022.TIF" alt="Figure US20190292130A1-20190926-C00022" img-content="table" img-format="tif" orientation="portrait" inline="no" width="476" height="101" alt="Figure US20190292130A1-20190926-C00022" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/81/a3/1fa45b972db08d/US20190292130A1-20190926-C00022.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00022" attachment-type="cdx" file="US20190292130A1-20190926-C00022.CDX"> </attachment>
                      <attachment idref="CHEM-US-00022" attachment-type="mol" file="US20190292130A1-20190926-C00022.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00023" num="00023">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/b3/ff/f9bf331f47d035/US20190292130A1-20190926-C00023.png"><img id="EMI-C00023" he="22.27mm" wi="123.27mm" file="US20190292130A1-20190926-C00023.TIF" alt="Figure US20190292130A1-20190926-C00023" img-content="table" img-format="tif" orientation="portrait" inline="no" width="493" height="89" alt="Figure US20190292130A1-20190926-C00023" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/b3/ff/f9bf331f47d035/US20190292130A1-20190926-C00023.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00023" attachment-type="cdx" file="US20190292130A1-20190926-C00023.CDX"> </attachment>
                      <attachment idref="CHEM-US-00023" attachment-type="mol" file="US20190292130A1-20190926-C00023.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00024" num="00024">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f4/5a/17/8280d0bc153ee4/US20190292130A1-20190926-C00024.png"><img id="EMI-C00024" he="25.32mm" wi="118.96mm" file="US20190292130A1-20190926-C00024.TIF" alt="Figure US20190292130A1-20190926-C00024" img-content="table" img-format="tif" orientation="portrait" inline="no" width="476" height="101" alt="Figure US20190292130A1-20190926-C00024" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f4/5a/17/8280d0bc153ee4/US20190292130A1-20190926-C00024.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00024" attachment-type="cdx" file="US20190292130A1-20190926-C00024.CDX"> </attachment>
                      <attachment idref="CHEM-US-00024" attachment-type="mol" file="US20190292130A1-20190926-C00024.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00025" num="00025">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ed/c1/b9/ef2fbf6ff0894f/US20190292130A1-20190926-C00025.png"><img id="EMI-C00025" he="26.16mm" wi="118.96mm" file="US20190292130A1-20190926-C00025.TIF" alt="Figure US20190292130A1-20190926-C00025" img-content="table" img-format="tif" orientation="portrait" inline="no" width="476" height="105" alt="Figure US20190292130A1-20190926-C00025" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ed/c1/b9/ef2fbf6ff0894f/US20190292130A1-20190926-C00025.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00025" attachment-type="cdx" file="US20190292130A1-20190926-C00025.CDX"> </attachment>
                      <attachment idref="CHEM-US-00025" attachment-type="mol" file="US20190292130A1-20190926-C00025.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00026" num="00026">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/de/73/06/a129dc51223d93/US20190292130A1-20190926-C00026.png"><img id="EMI-C00026" he="22.61mm" wi="125.14mm" file="US20190292130A1-20190926-C00026.TIF" alt="Figure US20190292130A1-20190926-C00026" img-content="table" img-format="tif" orientation="portrait" inline="no" width="501" height="90" alt="Figure US20190292130A1-20190926-C00026" class="patent-full-image" src="https://patentimages.storage.googleapis.com/de/73/06/a129dc51223d93/US20190292130A1-20190926-C00026.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00026" attachment-type="cdx" file="US20190292130A1-20190926-C00026.CDX"> </attachment>
                      <attachment idref="CHEM-US-00026" attachment-type="mol" file="US20190292130A1-20190926-C00026.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">7</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00027" num="00027">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a6/f0/46/8aa2bef2951a8e/US20190292130A1-20190926-C00027.png"><img id="EMI-C00027" he="19.73mm" wi="128.95mm" file="US20190292130A1-20190926-C00027.TIF" alt="Figure US20190292130A1-20190926-C00027" img-content="table" img-format="tif" orientation="portrait" inline="no" width="516" height="79" alt="Figure US20190292130A1-20190926-C00027" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a6/f0/46/8aa2bef2951a8e/US20190292130A1-20190926-C00027.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00027" attachment-type="cdx" file="US20190292130A1-20190926-C00027.CDX"> </attachment>
                      <attachment idref="CHEM-US-00027" attachment-type="mol" file="US20190292130A1-20190926-C00027.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00028" num="00028">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/40/4b/d3/c1358b37432381/US20190292130A1-20190926-C00028.png"><img id="EMI-C00028" he="22.61mm" wi="130.73mm" file="US20190292130A1-20190926-C00028.TIF" alt="Figure US20190292130A1-20190926-C00028" img-content="table" img-format="tif" orientation="portrait" inline="no" width="523" height="90" alt="Figure US20190292130A1-20190926-C00028" class="patent-full-image" src="https://patentimages.storage.googleapis.com/40/4b/d3/c1358b37432381/US20190292130A1-20190926-C00028.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00028" attachment-type="cdx" file="US20190292130A1-20190926-C00028.CDX"> </attachment>
                      <attachment idref="CHEM-US-00028" attachment-type="mol" file="US20190292130A1-20190926-C00028.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">9</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00029" num="00029">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/50/c4/2f/7f96fa96ca7746/US20190292130A1-20190926-C00029.png"><img id="EMI-C00029" he="23.45mm" wi="115.32mm" file="US20190292130A1-20190926-C00029.TIF" alt="Figure US20190292130A1-20190926-C00029" img-content="table" img-format="tif" orientation="portrait" inline="no" width="461" height="94" alt="Figure US20190292130A1-20190926-C00029" class="patent-full-image" src="https://patentimages.storage.googleapis.com/50/c4/2f/7f96fa96ca7746/US20190292130A1-20190926-C00029.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00029" attachment-type="cdx" file="US20190292130A1-20190926-C00029.CDX"> </attachment>
                      <attachment idref="CHEM-US-00029" attachment-type="mol" file="US20190292130A1-20190926-C00029.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">10</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00030" num="00030">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f3/88/a0/74cafa53f2a63f/US20190292130A1-20190926-C00030.png"><img id="EMI-C00030" he="23.45mm" wi="125.14mm" file="US20190292130A1-20190926-C00030.TIF" alt="Figure US20190292130A1-20190926-C00030" img-content="table" img-format="tif" orientation="portrait" inline="no" width="501" height="94" alt="Figure US20190292130A1-20190926-C00030" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f3/88/a0/74cafa53f2a63f/US20190292130A1-20190926-C00030.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00030" attachment-type="cdx" file="US20190292130A1-20190926-C00030.CDX"> </attachment>
                      <attachment idref="CHEM-US-00030" attachment-type="mol" file="US20190292130A1-20190926-C00030.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">11</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00031" num="00031">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4c/d0/de/7f3727c27630ff/US20190292130A1-20190926-C00031.png"><img id="EMI-C00031" he="26.08mm" wi="134.87mm" file="US20190292130A1-20190926-C00031.TIF" alt="Figure US20190292130A1-20190926-C00031" img-content="table" img-format="tif" orientation="portrait" inline="no" width="539" height="104" alt="Figure US20190292130A1-20190926-C00031" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4c/d0/de/7f3727c27630ff/US20190292130A1-20190926-C00031.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00031" attachment-type="cdx" file="US20190292130A1-20190926-C00031.CDX"> </attachment>
                      <attachment idref="CHEM-US-00031" attachment-type="mol" file="US20190292130A1-20190926-C00031.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">12</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00032" num="00032">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8c/58/81/83c4269907b7ae/US20190292130A1-20190926-C00032.png"><img id="EMI-C00032" he="22.61mm" wi="125.14mm" file="US20190292130A1-20190926-C00032.TIF" alt="Figure US20190292130A1-20190926-C00032" img-content="table" img-format="tif" orientation="portrait" inline="no" width="501" height="90" alt="Figure US20190292130A1-20190926-C00032" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8c/58/81/83c4269907b7ae/US20190292130A1-20190926-C00032.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00032" attachment-type="cdx" file="US20190292130A1-20190926-C00032.CDX"> </attachment>
                      <attachment idref="CHEM-US-00032" attachment-type="mol" file="US20190292130A1-20190926-C00032.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">13</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00033" num="00033">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/51/e3/19/2f47c56d4bc2c8/US20190292130A1-20190926-C00033.png"><img id="EMI-C00033" he="24.21mm" wi="134.11mm" file="US20190292130A1-20190926-C00033.TIF" alt="Figure US20190292130A1-20190926-C00033" img-content="table" img-format="tif" orientation="portrait" inline="no" width="536" height="97" alt="Figure US20190292130A1-20190926-C00033" class="patent-full-image" src="https://patentimages.storage.googleapis.com/51/e3/19/2f47c56d4bc2c8/US20190292130A1-20190926-C00033.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00033" attachment-type="cdx" file="US20190292130A1-20190926-C00033.CDX"> </attachment>
                      <attachment idref="CHEM-US-00033" attachment-type="mol" file="US20190292130A1-20190926-C00033.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">14</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00034" num="00034">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f7/da/c2/1c41b8b9a17f92/US20190292130A1-20190926-C00034.png"><img id="EMI-C00034" he="23.45mm" wi="125.14mm" file="US20190292130A1-20190926-C00034.TIF" alt="Figure US20190292130A1-20190926-C00034" img-content="table" img-format="tif" orientation="portrait" inline="no" width="501" height="94" alt="Figure US20190292130A1-20190926-C00034" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f7/da/c2/1c41b8b9a17f92/US20190292130A1-20190926-C00034.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00034" attachment-type="cdx" file="US20190292130A1-20190926-C00034.CDX"> </attachment>
                      <attachment idref="CHEM-US-00034" attachment-type="mol" file="US20190292130A1-20190926-C00034.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">15</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00035" num="00035">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/86/25/58/535fcba1db1cf4/US20190292130A1-20190926-C00035.png"><img id="EMI-C00035" he="22.61mm" wi="115.32mm" file="US20190292130A1-20190926-C00035.TIF" alt="Figure US20190292130A1-20190926-C00035" img-content="table" img-format="tif" orientation="portrait" inline="no" width="461" height="90" alt="Figure US20190292130A1-20190926-C00035" class="patent-full-image" src="https://patentimages.storage.googleapis.com/86/25/58/535fcba1db1cf4/US20190292130A1-20190926-C00035.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00035" attachment-type="cdx" file="US20190292130A1-20190926-C00035.CDX"> </attachment>
                      <attachment idref="CHEM-US-00035" attachment-type="mol" file="US20190292130A1-20190926-C00035.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">16</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00036" num="00036">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ee/13/43/aef502cd36a897/US20190292130A1-20190926-C00036.png"><img id="EMI-C00036" he="26.16mm" wi="118.96mm" file="US20190292130A1-20190926-C00036.TIF" alt="Figure US20190292130A1-20190926-C00036" img-content="table" img-format="tif" orientation="portrait" inline="no" width="476" height="105" alt="Figure US20190292130A1-20190926-C00036" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ee/13/43/aef502cd36a897/US20190292130A1-20190926-C00036.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00036" attachment-type="cdx" file="US20190292130A1-20190926-C00036.CDX"> </attachment>
                      <attachment idref="CHEM-US-00036" attachment-type="mol" file="US20190292130A1-20190926-C00036.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">17</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00037" num="00037">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a4/a5/64/991fe1dca81ce6/US20190292130A1-20190926-C00037.png"><img id="EMI-C00037" he="23.37mm" wi="128.95mm" file="US20190292130A1-20190926-C00037.TIF" alt="Figure US20190292130A1-20190926-C00037" img-content="table" img-format="tif" orientation="portrait" inline="no" width="516" height="93" alt="Figure US20190292130A1-20190926-C00037" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a4/a5/64/991fe1dca81ce6/US20190292130A1-20190926-C00037.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00037" attachment-type="cdx" file="US20190292130A1-20190926-C00037.CDX"> </attachment>
                      <attachment idref="CHEM-US-00037" attachment-type="mol" file="US20190292130A1-20190926-C00037.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00038" num="00038">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8c/eb/06/814a6e998fbfc2/US20190292130A1-20190926-C00038.png"><img id="EMI-C00038" he="25.91mm" wi="124.04mm" file="US20190292130A1-20190926-C00038.TIF" alt="Figure US20190292130A1-20190926-C00038" img-content="table" img-format="tif" orientation="portrait" inline="no" width="496" height="104" alt="Figure US20190292130A1-20190926-C00038" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8c/eb/06/814a6e998fbfc2/US20190292130A1-20190926-C00038.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00038" attachment-type="cdx" file="US20190292130A1-20190926-C00038.CDX"> </attachment>
                      <attachment idref="CHEM-US-00038" attachment-type="mol" file="US20190292130A1-20190926-C00038.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">19</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00039" num="00039">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4d/2b/49/e86d8e96564cdf/US20190292130A1-20190926-C00039.png"><img id="EMI-C00039" he="25.32mm" wi="109.22mm" file="US20190292130A1-20190926-C00039.TIF" alt="Figure US20190292130A1-20190926-C00039" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="101" alt="Figure US20190292130A1-20190926-C00039" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4d/2b/49/e86d8e96564cdf/US20190292130A1-20190926-C00039.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00039" attachment-type="cdx" file="US20190292130A1-20190926-C00039.CDX"> </attachment>
                      <attachment idref="CHEM-US-00039" attachment-type="mol" file="US20190292130A1-20190926-C00039.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">20</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00040" num="00040">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/95/a3/2d4208ba935a49/US20190292130A1-20190926-C00040.png"><img id="EMI-C00040" he="25.32mm" wi="109.22mm" file="US20190292130A1-20190926-C00040.TIF" alt="Figure US20190292130A1-20190926-C00040" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="101" alt="Figure US20190292130A1-20190926-C00040" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d9/95/a3/2d4208ba935a49/US20190292130A1-20190926-C00040.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00040" attachment-type="cdx" file="US20190292130A1-20190926-C00040.CDX"> </attachment>
                      <attachment idref="CHEM-US-00040" attachment-type="mol" file="US20190292130A1-20190926-C00040.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">21</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00041" num="00041">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/02/bf/d5/0e540eaf3c0e79/US20190292130A1-20190926-C00041.png"><img id="EMI-C00041" he="23.45mm" wi="137.08mm" file="US20190292130A1-20190926-C00041.TIF" alt="Figure US20190292130A1-20190926-C00041" img-content="table" img-format="tif" orientation="portrait" inline="no" width="548" height="94" alt="Figure US20190292130A1-20190926-C00041" class="patent-full-image" src="https://patentimages.storage.googleapis.com/02/bf/d5/0e540eaf3c0e79/US20190292130A1-20190926-C00041.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00041" attachment-type="cdx" file="US20190292130A1-20190926-C00041.CDX"> </attachment>
                      <attachment idref="CHEM-US-00041" attachment-type="mol" file="US20190292130A1-20190926-C00041.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">22</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00042" num="00042">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c7/39/5e/97a26131a1277d/US20190292130A1-20190926-C00042.png"><img id="EMI-C00042" he="23.45mm" wi="137.08mm" file="US20190292130A1-20190926-C00042.TIF" alt="Figure US20190292130A1-20190926-C00042" img-content="table" img-format="tif" orientation="portrait" inline="no" width="548" height="94" alt="Figure US20190292130A1-20190926-C00042" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c7/39/5e/97a26131a1277d/US20190292130A1-20190926-C00042.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00042" attachment-type="cdx" file="US20190292130A1-20190926-C00042.CDX"> </attachment>
                      <attachment idref="CHEM-US-00042" attachment-type="mol" file="US20190292130A1-20190926-C00042.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">23</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00043" num="00043">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6d/23/14/4699868f3df8be/US20190292130A1-20190926-C00043.png"><img id="EMI-C00043" he="51.65mm" wi="113.28mm" file="US20190292130A1-20190926-C00043.TIF" alt="Figure US20190292130A1-20190926-C00043" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="207" alt="Figure US20190292130A1-20190926-C00043" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6d/23/14/4699868f3df8be/US20190292130A1-20190926-C00043.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00043" attachment-type="cdx" file="US20190292130A1-20190926-C00043.CDX"> </attachment>
                      <attachment idref="CHEM-US-00043" attachment-type="mol" file="US20190292130A1-20190926-C00043.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00044" num="00044">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fb/44/78/adb15ec26442db/US20190292130A1-20190926-C00044.png"><img id="EMI-C00044" he="53.59mm" wi="97.87mm" file="US20190292130A1-20190926-C00044.TIF" alt="Figure US20190292130A1-20190926-C00044" img-content="table" img-format="tif" orientation="portrait" inline="no" width="391" height="214" alt="Figure US20190292130A1-20190926-C00044" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fb/44/78/adb15ec26442db/US20190292130A1-20190926-C00044.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00044" attachment-type="cdx" file="US20190292130A1-20190926-C00044.CDX"> </attachment>
                      <attachment idref="CHEM-US-00044" attachment-type="mol" file="US20190292130A1-20190926-C00044.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00045" num="00045">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c4/50/db/ccd87cda1d52c4/US20190292130A1-20190926-C00045.png"><img id="EMI-C00045" he="49.36mm" wi="112.61mm" file="US20190292130A1-20190926-C00045.TIF" alt="Figure US20190292130A1-20190926-C00045" img-content="table" img-format="tif" orientation="portrait" inline="no" width="450" height="197" alt="Figure US20190292130A1-20190926-C00045" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c4/50/db/ccd87cda1d52c4/US20190292130A1-20190926-C00045.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00045" attachment-type="cdx" file="US20190292130A1-20190926-C00045.CDX"> </attachment>
                      <attachment idref="CHEM-US-00045" attachment-type="mol" file="US20190292130A1-20190926-C00045.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00046" num="00046">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3a/6a/8b/7b77e209704a7d/US20190292130A1-20190926-C00046.png"><img id="EMI-C00046" he="38.02mm" wi="102.79mm" file="US20190292130A1-20190926-C00046.TIF" alt="Figure US20190292130A1-20190926-C00046" img-content="table" img-format="tif" orientation="portrait" inline="no" width="411" height="152" alt="Figure US20190292130A1-20190926-C00046" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3a/6a/8b/7b77e209704a7d/US20190292130A1-20190926-C00046.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00046" attachment-type="cdx" file="US20190292130A1-20190926-C00046.CDX"> </attachment>
                      <attachment idref="CHEM-US-00046" attachment-type="mol" file="US20190292130A1-20190926-C00046.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">27</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00047" num="00047">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/6d/07/74a7bd1118b8ec/US20190292130A1-20190926-C00047.png"><img id="EMI-C00047" he="51.73mm" wi="113.28mm" file="US20190292130A1-20190926-C00047.TIF" alt="Figure US20190292130A1-20190926-C00047" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="207" alt="Figure US20190292130A1-20190926-C00047" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/6d/07/74a7bd1118b8ec/US20190292130A1-20190926-C00047.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00047" attachment-type="cdx" file="US20190292130A1-20190926-C00047.CDX"> </attachment>
                      <attachment idref="CHEM-US-00047" attachment-type="mol" file="US20190292130A1-20190926-C00047.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00048" num="00048">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/4b/27/9bbd0470fe704f/US20190292130A1-20190926-C00048.png"><img id="EMI-C00048" he="49.53mm" wi="128.44mm" file="US20190292130A1-20190926-C00048.TIF" alt="Figure US20190292130A1-20190926-C00048" img-content="table" img-format="tif" orientation="portrait" inline="no" width="514" height="198" alt="Figure US20190292130A1-20190926-C00048" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/4b/27/9bbd0470fe704f/US20190292130A1-20190926-C00048.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00048" attachment-type="cdx" file="US20190292130A1-20190926-C00048.CDX"> </attachment>
                      <attachment idref="CHEM-US-00048" attachment-type="mol" file="US20190292130A1-20190926-C00048.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">29</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00049" num="00049">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/87/6b/35/896ede79683d3c/US20190292130A1-20190926-C00049.png"><img id="EMI-C00049" he="51.73mm" wi="113.28mm" file="US20190292130A1-20190926-C00049.TIF" alt="Figure US20190292130A1-20190926-C00049" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="207" alt="Figure US20190292130A1-20190926-C00049" class="patent-full-image" src="https://patentimages.storage.googleapis.com/87/6b/35/896ede79683d3c/US20190292130A1-20190926-C00049.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00049" attachment-type="cdx" file="US20190292130A1-20190926-C00049.CDX"> </attachment>
                      <attachment idref="CHEM-US-00049" attachment-type="mol" file="US20190292130A1-20190926-C00049.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00050" num="00050">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/09/8a/b9/f2eaecbf0f0a33/US20190292130A1-20190926-C00050.png"><img id="EMI-C00050" he="49.53mm" wi="128.44mm" file="US20190292130A1-20190926-C00050.TIF" alt="Figure US20190292130A1-20190926-C00050" img-content="table" img-format="tif" orientation="portrait" inline="no" width="514" height="198" alt="Figure US20190292130A1-20190926-C00050" class="patent-full-image" src="https://patentimages.storage.googleapis.com/09/8a/b9/f2eaecbf0f0a33/US20190292130A1-20190926-C00050.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00050" attachment-type="cdx" file="US20190292130A1-20190926-C00050.CDX"> </attachment>
                      <attachment idref="CHEM-US-00050" attachment-type="mol" file="US20190292130A1-20190926-C00050.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">31</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00051" num="00051">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c9/1f/da/e1519b06e7c0a3/US20190292130A1-20190926-C00051.png"><img id="EMI-C00051" he="27.09mm" wi="119.21mm" file="US20190292130A1-20190926-C00051.TIF" alt="Figure US20190292130A1-20190926-C00051" img-content="table" img-format="tif" orientation="portrait" inline="no" width="477" height="108" alt="Figure US20190292130A1-20190926-C00051" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c9/1f/da/e1519b06e7c0a3/US20190292130A1-20190926-C00051.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00051" attachment-type="cdx" file="US20190292130A1-20190926-C00051.CDX"> </attachment>
                      <attachment idref="CHEM-US-00051" attachment-type="mol" file="US20190292130A1-20190926-C00051.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">32</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00052" num="00052">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9f/6e/f1/41f456b7f8d85a/US20190292130A1-20190926-C00052.png"><img id="EMI-C00052" he="17.70mm" wi="118.79mm" file="US20190292130A1-20190926-C00052.TIF" alt="Figure US20190292130A1-20190926-C00052" img-content="table" img-format="tif" orientation="portrait" inline="no" width="475" height="71" alt="Figure US20190292130A1-20190926-C00052" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9f/6e/f1/41f456b7f8d85a/US20190292130A1-20190926-C00052.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00052" attachment-type="cdx" file="US20190292130A1-20190926-C00052.CDX"> </attachment>
                      <attachment idref="CHEM-US-00052" attachment-type="mol" file="US20190292130A1-20190926-C00052.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">33</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00053" num="00053">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b6/ad/1a/fca3cd3b00c939/US20190292130A1-20190926-C00053.png"><img id="EMI-C00053" he="27.09mm" wi="119.21mm" file="US20190292130A1-20190926-C00053.TIF" alt="Figure US20190292130A1-20190926-C00053" img-content="table" img-format="tif" orientation="portrait" inline="no" width="477" height="108" alt="Figure US20190292130A1-20190926-C00053" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b6/ad/1a/fca3cd3b00c939/US20190292130A1-20190926-C00053.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00053" attachment-type="cdx" file="US20190292130A1-20190926-C00053.CDX"> </attachment>
                      <attachment idref="CHEM-US-00053" attachment-type="mol" file="US20190292130A1-20190926-C00053.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">34</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00054" num="00054">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/16/1f/1a/7ff96dde71ad15/US20190292130A1-20190926-C00054.png"><img id="EMI-C00054" he="20.66mm" wi="123.70mm" file="US20190292130A1-20190926-C00054.TIF" alt="Figure US20190292130A1-20190926-C00054" img-content="table" img-format="tif" orientation="portrait" inline="no" width="495" height="83" alt="Figure US20190292130A1-20190926-C00054" class="patent-full-image" src="https://patentimages.storage.googleapis.com/16/1f/1a/7ff96dde71ad15/US20190292130A1-20190926-C00054.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00054" attachment-type="cdx" file="US20190292130A1-20190926-C00054.CDX"> </attachment>
                      <attachment idref="CHEM-US-00054" attachment-type="mol" file="US20190292130A1-20190926-C00054.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">35</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00055" num="00055">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ac/39/ae/af71d9a81d1cd6/US20190292130A1-20190926-C00055.png"><img id="EMI-C00055" he="24.21mm" wi="128.19mm" file="US20190292130A1-20190926-C00055.TIF" alt="Figure US20190292130A1-20190926-C00055" img-content="table" img-format="tif" orientation="portrait" inline="no" width="513" height="97" alt="Figure US20190292130A1-20190926-C00055" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ac/39/ae/af71d9a81d1cd6/US20190292130A1-20190926-C00055.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00055" attachment-type="cdx" file="US20190292130A1-20190926-C00055.CDX"> </attachment>
                      <attachment idref="CHEM-US-00055" attachment-type="mol" file="US20190292130A1-20190926-C00055.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">36</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00056" num="00056">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/54/20/e8/228217c1c34041/US20190292130A1-20190926-C00056.png"><img id="EMI-C00056" he="20.49mm" wi="132.76mm" file="US20190292130A1-20190926-C00056.TIF" alt="Figure US20190292130A1-20190926-C00056" img-content="table" img-format="tif" orientation="portrait" inline="no" width="531" height="82" alt="Figure US20190292130A1-20190926-C00056" class="patent-full-image" src="https://patentimages.storage.googleapis.com/54/20/e8/228217c1c34041/US20190292130A1-20190926-C00056.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00056" attachment-type="cdx" file="US20190292130A1-20190926-C00056.CDX"> </attachment>
                      <attachment idref="CHEM-US-00056" attachment-type="mol" file="US20190292130A1-20190926-C00056.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">37</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00057" num="00057">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/45/39/bf/12ccc31cc7fe6f/US20190292130A1-20190926-C00057.png"><img id="EMI-C00057" he="20.49mm" wi="124.38mm" file="US20190292130A1-20190926-C00057.TIF" alt="Figure US20190292130A1-20190926-C00057" img-content="table" img-format="tif" orientation="portrait" inline="no" width="498" height="82" alt="Figure US20190292130A1-20190926-C00057" class="patent-full-image" src="https://patentimages.storage.googleapis.com/45/39/bf/12ccc31cc7fe6f/US20190292130A1-20190926-C00057.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00057" attachment-type="cdx" file="US20190292130A1-20190926-C00057.CDX"> </attachment>
                      <attachment idref="CHEM-US-00057" attachment-type="mol" file="US20190292130A1-20190926-C00057.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">38</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00058" num="00058">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5a/2d/2e/2b973d59e32455/US20190292130A1-20190926-C00058.png"><img id="EMI-C00058" he="20.40mm" wi="134.11mm" file="US20190292130A1-20190926-C00058.TIF" alt="Figure US20190292130A1-20190926-C00058" img-content="table" img-format="tif" orientation="portrait" inline="no" width="536" height="82" alt="Figure US20190292130A1-20190926-C00058" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5a/2d/2e/2b973d59e32455/US20190292130A1-20190926-C00058.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00058" attachment-type="cdx" file="US20190292130A1-20190926-C00058.CDX"> </attachment>
                      <attachment idref="CHEM-US-00058" attachment-type="mol" file="US20190292130A1-20190926-C00058.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">39</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00059" num="00059">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/99/46/1a209845ae3673/US20190292130A1-20190926-C00059.png"><img id="EMI-C00059" he="22.86mm" wi="133.10mm" file="US20190292130A1-20190926-C00059.TIF" alt="Figure US20190292130A1-20190926-C00059" img-content="table" img-format="tif" orientation="portrait" inline="no" width="532" height="91" alt="Figure US20190292130A1-20190926-C00059" class="patent-full-image" src="https://patentimages.storage.googleapis.com/da/99/46/1a209845ae3673/US20190292130A1-20190926-C00059.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00059" attachment-type="cdx" file="US20190292130A1-20190926-C00059.CDX"> </attachment>
                      <attachment idref="CHEM-US-00059" attachment-type="mol" file="US20190292130A1-20190926-C00059.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">40</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00060" num="00060">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/eb/44/01/f72d7ff6f7944c/US20190292130A1-20190926-C00060.png"><img id="EMI-C00060" he="53.26mm" wi="108.46mm" file="US20190292130A1-20190926-C00060.TIF" alt="Figure US20190292130A1-20190926-C00060" img-content="table" img-format="tif" orientation="portrait" inline="no" width="434" height="213" alt="Figure US20190292130A1-20190926-C00060" class="patent-full-image" src="https://patentimages.storage.googleapis.com/eb/44/01/f72d7ff6f7944c/US20190292130A1-20190926-C00060.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00060" attachment-type="cdx" file="US20190292130A1-20190926-C00060.CDX"> </attachment>
                      <attachment idref="CHEM-US-00060" attachment-type="mol" file="US20190292130A1-20190926-C00060.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">41</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00061" num="00061">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/89/85/dd/6408ef431be35e/US20190292130A1-20190926-C00061.png"><img id="EMI-C00061" he="38.35mm" wi="103.55mm" file="US20190292130A1-20190926-C00061.TIF" alt="Figure US20190292130A1-20190926-C00061" img-content="table" img-format="tif" orientation="portrait" inline="no" width="414" height="153" alt="Figure US20190292130A1-20190926-C00061" class="patent-full-image" src="https://patentimages.storage.googleapis.com/89/85/dd/6408ef431be35e/US20190292130A1-20190926-C00061.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00061" attachment-type="cdx" file="US20190292130A1-20190926-C00061.CDX"> </attachment>
                      <attachment idref="CHEM-US-00061" attachment-type="mol" file="US20190292130A1-20190926-C00061.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">42</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00062" num="00062">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/88/dd/c31b7c0cde4af5/US20190292130A1-20190926-C00062.png"><img id="EMI-C00062" he="43.94mm" wi="109.22mm" file="US20190292130A1-20190926-C00062.TIF" alt="Figure US20190292130A1-20190926-C00062" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="176" alt="Figure US20190292130A1-20190926-C00062" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/88/dd/c31b7c0cde4af5/US20190292130A1-20190926-C00062.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00062" attachment-type="cdx" file="US20190292130A1-20190926-C00062.CDX"> </attachment>
                      <attachment idref="CHEM-US-00062" attachment-type="mol" file="US20190292130A1-20190926-C00062.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">43</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00063" num="00063">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/77/f9/5f4e5bf553455a/US20190292130A1-20190926-C00063.png"><img id="EMI-C00063" he="46.14mm" wi="109.22mm" file="US20190292130A1-20190926-C00063.TIF" alt="Figure US20190292130A1-20190926-C00063" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="185" alt="Figure US20190292130A1-20190926-C00063" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/77/f9/5f4e5bf553455a/US20190292130A1-20190926-C00063.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00063" attachment-type="cdx" file="US20190292130A1-20190926-C00063.CDX"> </attachment>
                      <attachment idref="CHEM-US-00063" attachment-type="mol" file="US20190292130A1-20190926-C00063.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">44</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00064" num="00064">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/41/3b/6b/fbd15c89da1061/US20190292130A1-20190926-C00064.png"><img id="EMI-C00064" he="46.14mm" wi="118.96mm" file="US20190292130A1-20190926-C00064.TIF" alt="Figure US20190292130A1-20190926-C00064" img-content="table" img-format="tif" orientation="portrait" inline="no" width="476" height="185" alt="Figure US20190292130A1-20190926-C00064" class="patent-full-image" src="https://patentimages.storage.googleapis.com/41/3b/6b/fbd15c89da1061/US20190292130A1-20190926-C00064.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00064" attachment-type="cdx" file="US20190292130A1-20190926-C00064.CDX"> </attachment>
                      <attachment idref="CHEM-US-00064" attachment-type="mol" file="US20190292130A1-20190926-C00064.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">45</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00065" num="00065">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/54/26/00/87a009205ac270/US20190292130A1-20190926-C00065.png"><img id="EMI-C00065" he="44.11mm" wi="118.96mm" file="US20190292130A1-20190926-C00065.TIF" alt="Figure US20190292130A1-20190926-C00065" img-content="table" img-format="tif" orientation="portrait" inline="no" width="476" height="176" alt="Figure US20190292130A1-20190926-C00065" class="patent-full-image" src="https://patentimages.storage.googleapis.com/54/26/00/87a009205ac270/US20190292130A1-20190926-C00065.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00065" attachment-type="cdx" file="US20190292130A1-20190926-C00065.CDX"> </attachment>
                      <attachment idref="CHEM-US-00065" attachment-type="mol" file="US20190292130A1-20190926-C00065.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">46</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00066" num="00066">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/1e/a2/c269a172e7ea2b/US20190292130A1-20190926-C00066.png"><img id="EMI-C00066" he="41.57mm" wi="119.46mm" file="US20190292130A1-20190926-C00066.TIF" alt="Figure US20190292130A1-20190926-C00066" img-content="table" img-format="tif" orientation="portrait" inline="no" width="478" height="166" alt="Figure US20190292130A1-20190926-C00066" class="patent-full-image" src="https://patentimages.storage.googleapis.com/aa/1e/a2/c269a172e7ea2b/US20190292130A1-20190926-C00066.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00066" attachment-type="cdx" file="US20190292130A1-20190926-C00066.CDX"> </attachment>
                      <attachment idref="CHEM-US-00066" attachment-type="mol" file="US20190292130A1-20190926-C00066.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">47</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00067" num="00067">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/09/db/011afed4c96190/US20190292130A1-20190926-C00067.png"><img id="EMI-C00067" he="38.52mm" wi="108.88mm" file="US20190292130A1-20190926-C00067.TIF" alt="Figure US20190292130A1-20190926-C00067" img-content="table" img-format="tif" orientation="portrait" inline="no" width="436" height="154" alt="Figure US20190292130A1-20190926-C00067" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/09/db/011afed4c96190/US20190292130A1-20190926-C00067.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00067" attachment-type="cdx" file="US20190292130A1-20190926-C00067.CDX"> </attachment>
                      <attachment idref="CHEM-US-00067" attachment-type="mol" file="US20190292130A1-20190926-C00067.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00068" num="00068">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/f9/d3/8857facf6d19d7/US20190292130A1-20190926-C00068.png"><img id="EMI-C00068" he="38.35mm" wi="113.28mm" file="US20190292130A1-20190926-C00068.TIF" alt="Figure US20190292130A1-20190926-C00068" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="153" alt="Figure US20190292130A1-20190926-C00068" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/f9/d3/8857facf6d19d7/US20190292130A1-20190926-C00068.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00068" attachment-type="cdx" file="US20190292130A1-20190926-C00068.CDX"> </attachment>
                      <attachment idref="CHEM-US-00068" attachment-type="mol" file="US20190292130A1-20190926-C00068.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">49</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00069" num="00069">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/56/fa/88/0041e6e5b574ad/US20190292130A1-20190926-C00069.png"><img id="EMI-C00069" he="38.52mm" wi="118.70mm" file="US20190292130A1-20190926-C00069.TIF" alt="Figure US20190292130A1-20190926-C00069" img-content="table" img-format="tif" orientation="portrait" inline="no" width="475" height="154" alt="Figure US20190292130A1-20190926-C00069" class="patent-full-image" src="https://patentimages.storage.googleapis.com/56/fa/88/0041e6e5b574ad/US20190292130A1-20190926-C00069.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00069" attachment-type="cdx" file="US20190292130A1-20190926-C00069.CDX"> </attachment>
                      <attachment idref="CHEM-US-00069" attachment-type="mol" file="US20190292130A1-20190926-C00069.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">50</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00070" num="00070">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/28/47/4a/5ae4794c51c0e2/US20190292130A1-20190926-C00070.png"><img id="EMI-C00070" he="44.11mm" wi="128.02mm" file="US20190292130A1-20190926-C00070.TIF" alt="Figure US20190292130A1-20190926-C00070" img-content="table" img-format="tif" orientation="portrait" inline="no" width="512" height="176" alt="Figure US20190292130A1-20190926-C00070" class="patent-full-image" src="https://patentimages.storage.googleapis.com/28/47/4a/5ae4794c51c0e2/US20190292130A1-20190926-C00070.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00070" attachment-type="cdx" file="US20190292130A1-20190926-C00070.CDX"> </attachment>
                      <attachment idref="CHEM-US-00070" attachment-type="mol" file="US20190292130A1-20190926-C00070.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">51</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00071" num="00071">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8d/9c/38/8b761eb277cc5c/US20190292130A1-20190926-C00071.png"><img id="EMI-C00071" he="41.06mm" wi="126.58mm" file="US20190292130A1-20190926-C00071.TIF" alt="Figure US20190292130A1-20190926-C00071" img-content="table" img-format="tif" orientation="portrait" inline="no" width="506" height="164" alt="Figure US20190292130A1-20190926-C00071" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8d/9c/38/8b761eb277cc5c/US20190292130A1-20190926-C00071.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00071" attachment-type="cdx" file="US20190292130A1-20190926-C00071.CDX"> </attachment>
                      <attachment idref="CHEM-US-00071" attachment-type="mol" file="US20190292130A1-20190926-C00071.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">52</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00072" num="00072">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bb/c2/9b/a7ad65a856b157/US20190292130A1-20190926-C00072.png"><img id="EMI-C00072" he="35.48mm" wi="117.94mm" file="US20190292130A1-20190926-C00072.TIF" alt="Figure US20190292130A1-20190926-C00072" img-content="table" img-format="tif" orientation="portrait" inline="no" width="472" height="142" alt="Figure US20190292130A1-20190926-C00072" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bb/c2/9b/a7ad65a856b157/US20190292130A1-20190926-C00072.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00072" attachment-type="cdx" file="US20190292130A1-20190926-C00072.CDX"> </attachment>
                      <attachment idref="CHEM-US-00072" attachment-type="mol" file="US20190292130A1-20190926-C00072.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00073" num="00073">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/9d/a2/bef37072729636/US20190292130A1-20190926-C00073.png"><img id="EMI-C00073" he="38.52mm" wi="128.44mm" file="US20190292130A1-20190926-C00073.TIF" alt="Figure US20190292130A1-20190926-C00073" img-content="table" img-format="tif" orientation="portrait" inline="no" width="514" height="154" alt="Figure US20190292130A1-20190926-C00073" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/9d/a2/bef37072729636/US20190292130A1-20190926-C00073.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00073" attachment-type="cdx" file="US20190292130A1-20190926-C00073.CDX"> </attachment>
                      <attachment idref="CHEM-US-00073" attachment-type="mol" file="US20190292130A1-20190926-C00073.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00074" num="00074">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e3/46/89/8bb30493ec10e6/US20190292130A1-20190926-C00074.png"><img id="EMI-C00074" he="49.19mm" wi="127.68mm" file="US20190292130A1-20190926-C00074.TIF" alt="Figure US20190292130A1-20190926-C00074" img-content="table" img-format="tif" orientation="portrait" inline="no" width="511" height="197" alt="Figure US20190292130A1-20190926-C00074" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e3/46/89/8bb30493ec10e6/US20190292130A1-20190926-C00074.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00074" attachment-type="cdx" file="US20190292130A1-20190926-C00074.CDX"> </attachment>
                      <attachment idref="CHEM-US-00074" attachment-type="mol" file="US20190292130A1-20190926-C00074.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">55</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00075" num="00075">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a3/27/73/46a20696ba42a3/US20190292130A1-20190926-C00075.png"><img id="EMI-C00075" he="25.23mm" wi="134.70mm" file="US20190292130A1-20190926-C00075.TIF" alt="Figure US20190292130A1-20190926-C00075" img-content="table" img-format="tif" orientation="portrait" inline="no" width="539" height="101" alt="Figure US20190292130A1-20190926-C00075" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a3/27/73/46a20696ba42a3/US20190292130A1-20190926-C00075.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00075" attachment-type="cdx" file="US20190292130A1-20190926-C00075.CDX"> </attachment>
                      <attachment idref="CHEM-US-00075" attachment-type="mol" file="US20190292130A1-20190926-C00075.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">56</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00076" num="00076">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/53/fc/65/c1f7e833a78a7c/US20190292130A1-20190926-C00076.png"><img id="EMI-C00076" he="44.11mm" wi="109.22mm" file="US20190292130A1-20190926-C00076.TIF" alt="Figure US20190292130A1-20190926-C00076" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="176" alt="Figure US20190292130A1-20190926-C00076" class="patent-full-image" src="https://patentimages.storage.googleapis.com/53/fc/65/c1f7e833a78a7c/US20190292130A1-20190926-C00076.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00076" attachment-type="cdx" file="US20190292130A1-20190926-C00076.CDX"> </attachment>
                      <attachment idref="CHEM-US-00076" attachment-type="mol" file="US20190292130A1-20190926-C00076.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">57</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00077" num="00077">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/42/97/ae/fd4ec767093c39/US20190292130A1-20190926-C00077.png"><img id="EMI-C00077" he="49.19mm" wi="108.88mm" file="US20190292130A1-20190926-C00077.TIF" alt="Figure US20190292130A1-20190926-C00077" img-content="table" img-format="tif" orientation="portrait" inline="no" width="436" height="197" alt="Figure US20190292130A1-20190926-C00077" class="patent-full-image" src="https://patentimages.storage.googleapis.com/42/97/ae/fd4ec767093c39/US20190292130A1-20190926-C00077.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00077" attachment-type="cdx" file="US20190292130A1-20190926-C00077.CDX"> </attachment>
                      <attachment idref="CHEM-US-00077" attachment-type="mol" file="US20190292130A1-20190926-C00077.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">58</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00078" num="00078">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b1/b6/a6/fd5245b5223137/US20190292130A1-20190926-C00078.png"><img id="EMI-C00078" he="19.47mm" wi="134.11mm" file="US20190292130A1-20190926-C00078.TIF" alt="Figure US20190292130A1-20190926-C00078" img-content="table" img-format="tif" orientation="portrait" inline="no" width="536" height="78" alt="Figure US20190292130A1-20190926-C00078" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b1/b6/a6/fd5245b5223137/US20190292130A1-20190926-C00078.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00078" attachment-type="cdx" file="US20190292130A1-20190926-C00078.CDX"> </attachment>
                      <attachment idref="CHEM-US-00078" attachment-type="mol" file="US20190292130A1-20190926-C00078.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">59</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00079" num="00079">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0f/a9/5e/de74fdc4fae7a6/US20190292130A1-20190926-C00079.png"><img id="EMI-C00079" he="37.00mm" wi="109.22mm" file="US20190292130A1-20190926-C00079.TIF" alt="Figure US20190292130A1-20190926-C00079" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="148" alt="Figure US20190292130A1-20190926-C00079" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0f/a9/5e/de74fdc4fae7a6/US20190292130A1-20190926-C00079.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00079" attachment-type="cdx" file="US20190292130A1-20190926-C00079.CDX"> </attachment>
                      <attachment idref="CHEM-US-00079" attachment-type="mol" file="US20190292130A1-20190926-C00079.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">60</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00080" num="00080">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1d/03/19/bacf2c4852f808/US20190292130A1-20190926-C00080.png"><img id="EMI-C00080" he="26.50mm" wi="137.92mm" file="US20190292130A1-20190926-C00080.TIF" alt="Figure US20190292130A1-20190926-C00080" img-content="table" img-format="tif" orientation="portrait" inline="no" width="552" height="106" alt="Figure US20190292130A1-20190926-C00080" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1d/03/19/bacf2c4852f808/US20190292130A1-20190926-C00080.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00080" attachment-type="cdx" file="US20190292130A1-20190926-C00080.CDX"> </attachment>
                      <attachment idref="CHEM-US-00080" attachment-type="mol" file="US20190292130A1-20190926-C00080.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">61</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00081" num="00081">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/67/9f/14/779a3b7afac69a/US20190292130A1-20190926-C00081.png"><img id="EMI-C00081" he="37.59mm" wi="118.19mm" file="US20190292130A1-20190926-C00081.TIF" alt="Figure US20190292130A1-20190926-C00081" img-content="table" img-format="tif" orientation="portrait" inline="no" width="473" height="150" alt="Figure US20190292130A1-20190926-C00081" class="patent-full-image" src="https://patentimages.storage.googleapis.com/67/9f/14/779a3b7afac69a/US20190292130A1-20190926-C00081.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00081" attachment-type="cdx" file="US20190292130A1-20190926-C00081.CDX"> </attachment>
                      <attachment idref="CHEM-US-00081" attachment-type="mol" file="US20190292130A1-20190926-C00081.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">62</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00082" num="00082">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5c/91/cc/21c8a1faf8ae63/US20190292130A1-20190926-C00082.png"><img id="EMI-C00082" he="49.11mm" wi="127.68mm" file="US20190292130A1-20190926-C00082.TIF" alt="Figure US20190292130A1-20190926-C00082" img-content="table" img-format="tif" orientation="portrait" inline="no" width="511" height="196" alt="Figure US20190292130A1-20190926-C00082" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5c/91/cc/21c8a1faf8ae63/US20190292130A1-20190926-C00082.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00082" attachment-type="cdx" file="US20190292130A1-20190926-C00082.CDX"> </attachment>
                      <attachment idref="CHEM-US-00082" attachment-type="mol" file="US20190292130A1-20190926-C00082.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">63</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00083" num="00083">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/24/83/47/94437d8f24f5d6/US20190292130A1-20190926-C00083.png"><img id="EMI-C00083" he="43.52mm" wi="118.19mm" file="US20190292130A1-20190926-C00083.TIF" alt="Figure US20190292130A1-20190926-C00083" img-content="table" img-format="tif" orientation="portrait" inline="no" width="473" height="174" alt="Figure US20190292130A1-20190926-C00083" class="patent-full-image" src="https://patentimages.storage.googleapis.com/24/83/47/94437d8f24f5d6/US20190292130A1-20190926-C00083.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00083" attachment-type="cdx" file="US20190292130A1-20190926-C00083.CDX"> </attachment>
                      <attachment idref="CHEM-US-00083" attachment-type="mol" file="US20190292130A1-20190926-C00083.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">64 (intermediate)</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00084" num="00084">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3f/30/ff/8465fe63ce0412/US20190292130A1-20190926-C00084.png"><img id="EMI-C00084" he="16.51mm" wi="107.44mm" file="US20190292130A1-20190926-C00084.TIF" alt="Figure US20190292130A1-20190926-C00084" img-content="table" img-format="tif" orientation="portrait" inline="no" width="430" height="66" alt="Figure US20190292130A1-20190926-C00084" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3f/30/ff/8465fe63ce0412/US20190292130A1-20190926-C00084.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00084" attachment-type="cdx" file="US20190292130A1-20190926-C00084.CDX"> </attachment>
                      <attachment idref="CHEM-US-00084" attachment-type="mol" file="US20190292130A1-20190926-C00084.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">65 (intermediate)</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00085" num="00085">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bb/74/8a/c0e6169d812448/US20190292130A1-20190926-C00085.png"><img id="EMI-C00085" he="40.89mm" wi="91.52mm" file="US20190292130A1-20190926-C00085.TIF" alt="Figure US20190292130A1-20190926-C00085" img-content="table" img-format="tif" orientation="portrait" inline="no" width="366" height="164" alt="Figure US20190292130A1-20190926-C00085" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bb/74/8a/c0e6169d812448/US20190292130A1-20190926-C00085.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00085" attachment-type="cdx" file="US20190292130A1-20190926-C00085.CDX"> </attachment>
                      <attachment idref="CHEM-US-00085" attachment-type="mol" file="US20190292130A1-20190926-C00085.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">66 (intermediate)</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00086" num="00086">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/df/25/5f/9ae85d0970982d/US20190292130A1-20190926-C00086.png"><img id="EMI-C00086" he="46.23mm" wi="101.01mm" file="US20190292130A1-20190926-C00086.TIF" alt="Figure US20190292130A1-20190926-C00086" img-content="table" img-format="tif" orientation="portrait" inline="no" width="404" height="185" alt="Figure US20190292130A1-20190926-C00086" class="patent-full-image" src="https://patentimages.storage.googleapis.com/df/25/5f/9ae85d0970982d/US20190292130A1-20190926-C00086.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00086" attachment-type="cdx" file="US20190292130A1-20190926-C00086.CDX"> </attachment>
                      <attachment idref="CHEM-US-00086" attachment-type="mol" file="US20190292130A1-20190926-C00086.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0160]"> </para-num> <div id="p-0183" num="0160" class="description-line">In another aspect, the cationic lipid of the present invention is represented by the structure of formula (III):</div>
    </li> <li> <div id="p-0184" num="0000" class="description-line">
      <chemistry id="CHEM-US-00087" num="00087">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e4/42/eb/3618d4f66e2a0d/US20190292130A1-20190926-C00087.png"><img id="EMI-C00087" he="19.39mm" wi="69.93mm" file="US20190292130A1-20190926-C00087.TIF" alt="Figure US20190292130A1-20190926-C00087" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="78" alt="Figure US20190292130A1-20190926-C00087" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e4/42/eb/3618d4f66e2a0d/US20190292130A1-20190926-C00087.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00087" attachment-type="cdx" file="US20190292130A1-20190926-C00087.CDX"> </attachment>
          <attachment idref="CHEM-US-00087" attachment-type="mol" file="US20190292130A1-20190926-C00087.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0185" num="0000" class="description-line">wherein
<br/>
X and Y are each independently O, N or NH, wherein X and Y cannot both be O;
<br/>
each of R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is independently absent or a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl; and
<br/>
n is an integer between 1 and 30;
<br/>
including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.
</div>
    </li> <li> <para-num num="[0161]"> </para-num> <div id="p-0186" num="0161" class="description-line">In another aspect, the cationic lipid of the present invention is represented by the structure of formula (IIIA):</div>
    </li> <li> <div id="p-0187" num="0000" class="description-line">
      <chemistry id="CHEM-US-00088" num="00088">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ec/5f/6f/f0e814fde28386/US20190292130A1-20190926-C00088.png"><img id="EMI-C00088" he="19.30mm" wi="69.93mm" file="US20190292130A1-20190926-C00088.TIF" alt="Figure US20190292130A1-20190926-C00088" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="77" alt="Figure US20190292130A1-20190926-C00088" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ec/5f/6f/f0e814fde28386/US20190292130A1-20190926-C00088.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00088" attachment-type="cdx" file="US20190292130A1-20190926-C00088.CDX"> </attachment>
          <attachment idref="CHEM-US-00088" attachment-type="mol" file="US20190292130A1-20190926-C00088.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0188" num="0000" class="description-line">wherein
<br/>
X and Y are each independently O, N or NH, wherein X and Y cannot both be O;
<br/>
each of R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is independently absent or a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl;
<br/>
n is an integer between 1 and 30; and
<br/>
x is 0 or 2;
<br/>
including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.
</div>
    </li> <li> <para-num num="[0162]"> </para-num> <div id="p-0189" num="0162" class="description-line">In some embodiments of formula (III) or (IIIA), X and Y are each independently selected from the group consisting of O and N. In other embodiments of formula (III), X and Y are each independently selected from the group consisting of O, N and NH.</div>
    </li> <li> <para-num num="[0163]"> </para-num> <div id="p-0190" num="0163" class="description-line">Specific examples of the compounds of formula (III) are compounds 67-70, the structures of which are depicted in Table 2.</div>
    </li> <li> <div id="p-0191" num="0000" class="description-line"> <tables id="TABLE-US-00002" num="00002"> <patent-tables frame="none" colsep="0" rowsep="0"> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%"> <thead> <tr class="description-tr"> <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 2</td> </tr> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td> </tr> <tr class="description-tr"> <td class="description-td">Compound </td> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">No.</td> <td class="description-td">Chemical structure/Chemical name</td> </tr> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td> </tr> </thead>  <tbody><tr class="description-tr"> <td class="description-td">67</td> <td class="description-td"> <chemistry id="CHEM-US-00089" num="00089"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/21/9e/14/870eaf972dc511/US20190292130A1-20190926-C00089.png"><img id="EMI-C00089" he="15.16mm" wi="49.19mm" file="US20190292130A1-20190926-C00089.TIF" alt="Figure US20190292130A1-20190926-C00089" img-content="table" img-format="tif" orientation="portrait" inline="no" width="197" height="61" alt="Figure US20190292130A1-20190926-C00089" class="patent-full-image" src="https://patentimages.storage.googleapis.com/21/9e/14/870eaf972dc511/US20190292130A1-20190926-C00089.png"/></a></div> <attachments> <attachment idref="CHEM-US-00089" attachment-type="cdx" file="US20190292130A1-20190926-C00089.CDX"> </attachment> <attachment idref="CHEM-US-00089" attachment-type="mol" file="US20190292130A1-20190926-C00089.MOL"> </attachment> </attachments> </chemistry> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">68</td> <td class="description-td"> <chemistry id="CHEM-US-00090" num="00090"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6a/67/23/252b46d78aa704/US20190292130A1-20190926-C00090.png"><img id="EMI-C00090" he="18.80mm" wi="45.55mm" file="US20190292130A1-20190926-C00090.TIF" alt="Figure US20190292130A1-20190926-C00090" img-content="table" img-format="tif" orientation="portrait" inline="no" width="182" height="75" alt="Figure US20190292130A1-20190926-C00090" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6a/67/23/252b46d78aa704/US20190292130A1-20190926-C00090.png"/></a></div> <attachments> <attachment idref="CHEM-US-00090" attachment-type="cdx" file="US20190292130A1-20190926-C00090.CDX"> </attachment> <attachment idref="CHEM-US-00090" attachment-type="mol" file="US20190292130A1-20190926-C00090.MOL"> </attachment> </attachments> </chemistry> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">69</td> <td class="description-td"> <chemistry id="CHEM-US-00091" num="00091"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d2/fa/b9/0bc467e9046aee/US20190292130A1-20190926-C00091.png"><img id="EMI-C00091" he="15.16mm" wi="49.19mm" file="US20190292130A1-20190926-C00091.TIF" alt="Figure US20190292130A1-20190926-C00091" img-content="table" img-format="tif" orientation="portrait" inline="no" width="197" height="61" alt="Figure US20190292130A1-20190926-C00091" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d2/fa/b9/0bc467e9046aee/US20190292130A1-20190926-C00091.png"/></a></div> <attachments> <attachment idref="CHEM-US-00091" attachment-type="cdx" file="US20190292130A1-20190926-C00091.CDX"> </attachment> <attachment idref="CHEM-US-00091" attachment-type="mol" file="US20190292130A1-20190926-C00091.MOL"> </attachment> </attachments> </chemistry> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">70</td> <td class="description-td"> <chemistry id="CHEM-US-00092" num="00092"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/55/13/78/480159108c9b4b/US20190292130A1-20190926-C00092.png"><img id="EMI-C00092" he="10.24mm" wi="60.28mm" file="US20190292130A1-20190926-C00092.TIF" alt="Figure US20190292130A1-20190926-C00092" img-content="table" img-format="tif" orientation="portrait" inline="no" width="241" height="41" alt="Figure US20190292130A1-20190926-C00092" class="patent-full-image" src="https://patentimages.storage.googleapis.com/55/13/78/480159108c9b4b/US20190292130A1-20190926-C00092.png"/></a></div> <attachments> <attachment idref="CHEM-US-00092" attachment-type="cdx" file="US20190292130A1-20190926-C00092.CDX"> </attachment> <attachment idref="CHEM-US-00092" attachment-type="mol" file="US20190292130A1-20190926-C00092.MOL"> </attachment> </attachments> </chemistry> </td> </tr> <tr class="description-tr"> <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td> </tr>  </tbody></table> </patent-tables> </tables> <br/>
where n is as defined above for formula (III) or (IIIA).
</div>
    </li> <heading id="h-0015">Additional Embodiments of the Present Invention</heading>
    <li> <para-num num="[0164]"> </para-num> <div id="p-0192" num="0164" class="description-line">In further embodiments, the present invention relates to a cationic lipid comprising a functional group represented by the structure:</div>
    </li> <li> <div id="p-0193" num="0000" class="description-line"> <br/>W-(T=O)<sub>m</sub>X(CH<sub>2</sub>)<sub>z</sub>Y
</div>
    </li> <li> <div id="p-0194" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0165]"> </para-num> <div id="p-0195" num="0165" class="description-line">X and Y are each independently O or N, wherein X and Y cannot both be O;</div>
    </li> <li> <para-num num="[0166]"> </para-num> <div id="p-0196" num="0166" class="description-line">W is a bond, O, NH or S;</div>
    </li> <li> <para-num num="[0167]"> </para-num> <div id="p-0197" num="0167" class="description-line">T is C or S;</div>
    </li> <li> <para-num num="[0168]"> </para-num> <div id="p-0198" num="0168" class="description-line">m is 0 or 1; and</div>
    </li> <li> <para-num num="[0169]"> </para-num> <div id="p-0199" num="0169" class="description-line">z is 0 or 2;</div>
    </li> <li> <div id="p-0200" num="0000" class="description-line">wherein the functional group is linked to at least one saturated or unsaturated fatty acid residue.</div>
    </li> <li> <para-num num="[0170]"> </para-num> <div id="p-0201" num="0170" class="description-line">In some embodiments, the cationic lipid comprises two fatty acid residues symmetrically or asymmetrically linked to the aforementioned functional group.</div>
    </li> <li> <para-num num="[0171]"> </para-num> <div id="p-0202" num="0171" class="description-line">In one aspect of the present invention, the cationic lipid is represented by the structure of formula (I):</div>
    </li> <li> <div id="p-0203" num="0000" class="description-line">
      <chemistry id="CHEM-US-00093" num="00093">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4f/a5/4a/b45e469badfbc9/US20190292130A1-20190926-C00093.png"><img id="EMI-C00093" he="22.86mm" wi="69.93mm" file="US20190292130A1-20190926-C00093.TIF" alt="Figure US20190292130A1-20190926-C00093" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="91" alt="Figure US20190292130A1-20190926-C00093" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4f/a5/4a/b45e469badfbc9/US20190292130A1-20190926-C00093.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00093" attachment-type="cdx" file="US20190292130A1-20190926-C00093.CDX"> </attachment>
          <attachment idref="CHEM-US-00093" attachment-type="mol" file="US20190292130A1-20190926-C00093.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0204" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0172]"> </para-num> <div id="p-0205" num="0172" class="description-line">Y is O or NH;</div>
    </li> <li> <para-num num="[0173]"> </para-num> <div id="p-0206" num="0173" class="description-line">T is C or S;</div>
    </li> <li> <para-num num="[0174]"> </para-num> <div id="p-0207" num="0174" class="description-line">W is a bond, O, NH or S;</div>
    </li> <li> <para-num num="[0175]"> </para-num> <div id="p-0208" num="0175" class="description-line">R<sup>1 </sup>is selected from the group consisting of:
</div> </li> <ul> <li id="ul0013-0001" num="0000"> <ul> <li id="ul0014-0001" num="0176">(a) NR<sup>4</sup>R<sup>5 </sup>wherein R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more heteroatoms selected from O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</li> <li id="ul0014-0002" num="0177">(b) the side chain of a natural or unnatural amino acid; and</li> <li id="ul0014-0003" num="0178">(c) a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from O, N and S;</li> </ul> </li> </ul>

    <li> <para-num num="[0179]"> </para-num> <div id="p-0209" num="0179" class="description-line">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
</div> </li> <ul> <li id="ul0015-0001" num="0000"> <ul> <li id="ul0016-0001" num="0180">(a) a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl; and</li> <li id="ul0016-0002" num="0181">(b) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl wherein Z is OC(O) or C(O)O;</li> </ul> </li> </ul>

    <li> <para-num num="[0182]"> </para-num> <div id="p-0210" num="0182" class="description-line">n is 0, 1, 2, 3, 4, 5 or 6;</div>
    </li> <li> <para-num num="[0183]"> </para-num> <div id="p-0211" num="0183" class="description-line">m is 0 or 1;</div>
    </li> <li> <para-num num="[0184]"> </para-num> <div id="p-0212" num="0184" class="description-line">p is 0 or 1; and</div>
    </li> <li> <para-num num="[0185]"> </para-num> <div id="p-0213" num="0185" class="description-line">z is 0 or 2;</div>
    </li> <li> <div id="p-0214" num="0000" class="description-line">including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</div>
    </li> <li> <para-num num="[0186]"> </para-num> <div id="p-0215" num="0186" class="description-line">In some embodiments, the compound of formula (I) comprises a functional group selected from hydrazine, hydroxylamine and hydrazide. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0187]"> </para-num> <div id="p-0216" num="0187" class="description-line">In some embodiments of formula (I), m is 0. In other embodiments of formula (I), m is 1. In other embodiments of formula (I), p is 0. In other embodiments of formula (I), p is 1. In other embodiments of formula (I), m is 0 and p is 0. In other embodiments of formula (I), m is 1 and p is 0. In other embodiments of formula (I), z is 0. In other embodiments of formula (I), z is 2. In other embodiments of formula (I), T is C. In other embodiments of formula (I), W is a bond. In other embodiments of formula (I), R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>.</div>
    </li> <li> <para-num num="[0188]"> </para-num> <div id="p-0217" num="0188" class="description-line">In some representative embodiments of formula (I), p is 0, W is a bond and T is C, and the compound is represented by the structure of formula (Ia):</div>
    </li> <li> <div id="p-0218" num="0000" class="description-line">
      <chemistry id="CHEM-US-00094" num="00094">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/c5/19/3466d29fb66de6/US20190292130A1-20190926-C00094.png"><img id="EMI-C00094" he="22.27mm" wi="69.93mm" file="US20190292130A1-20190926-C00094.TIF" alt="Figure US20190292130A1-20190926-C00094" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="89" alt="Figure US20190292130A1-20190926-C00094" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/c5/19/3466d29fb66de6/US20190292130A1-20190926-C00094.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00094" attachment-type="cdx" file="US20190292130A1-20190926-C00094.CDX"> </attachment>
          <attachment idref="CHEM-US-00094" attachment-type="mol" file="US20190292130A1-20190926-C00094.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0219" num="0000" class="description-line">wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, Y, m, n and z are as defined in formula (I). In some embodiments of formula (Ia), m is 0. In other embodiments of formula (Ia), m is 1. In other embodiments of formula (Ia), z is 0. In other embodiments of formula (Ia), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>14</sub>-C<sub>20 </sub>alkyl or a C<sub>14</sub>-C<sub>20 </sub>alkenyl. In other embodiments of formula (Ia), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl wherein Z is OC(O) or C(O)O. In other embodiments of formula (Ia), Y is O. In other embodiments of formula (Ia), Y is NH.</div>
    </li> <li> <para-num num="[0189]"> </para-num> <div id="p-0220" num="0189" class="description-line">In other representative embodiments of formula (I), R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (Ia-1):</div>
    </li> <li> <div id="p-0221" num="0000" class="description-line">
      <chemistry id="CHEM-US-00095" num="00095">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/49/8c/13/f7ab95e502e24f/US20190292130A1-20190926-C00095.png"><img id="EMI-C00095" he="22.27mm" wi="69.93mm" file="US20190292130A1-20190926-C00095.TIF" alt="Figure US20190292130A1-20190926-C00095" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="89" alt="Figure US20190292130A1-20190926-C00095" class="patent-full-image" src="https://patentimages.storage.googleapis.com/49/8c/13/f7ab95e502e24f/US20190292130A1-20190926-C00095.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00095" attachment-type="cdx" file="US20190292130A1-20190926-C00095.CDX"> </attachment>
          <attachment idref="CHEM-US-00095" attachment-type="mol" file="US20190292130A1-20190926-C00095.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0190]"> </para-num> <div id="p-0222" num="0190" class="description-line">wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, Y, m, n and z are as defined in formula (I). In some embodiments of formula (Ia-1), R<sup>4 </sup>and R<sup>5 </sup>are each CH<sub>3</sub>. In other embodiments of formula (Ia-1), R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a heterocyclic ring selected from pyrrolidinyl piperidininyl and piperazinyl, each of which is optionally substituted with an alkyl. Each possibility represents a separate embodiment of the present invention. In another aspect of the present invention, the cationic lipid is represented by the structure of formula (II):</div>
    </li> <li> <div id="p-0223" num="0000" class="description-line">
      <chemistry id="CHEM-US-00096" num="00096">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e0/73/06/26d595d7415cc7/US20190292130A1-20190926-C00096.png"><img id="EMI-C00096" he="22.86mm" wi="69.93mm" file="US20190292130A1-20190926-C00096.TIF" alt="Figure US20190292130A1-20190926-C00096" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="91" alt="Figure US20190292130A1-20190926-C00096" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e0/73/06/26d595d7415cc7/US20190292130A1-20190926-C00096.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00096" attachment-type="cdx" file="US20190292130A1-20190926-C00096.CDX"> </attachment>
          <attachment idref="CHEM-US-00096" attachment-type="mol" file="US20190292130A1-20190926-C00096.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0224" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0191]"> </para-num> <div id="p-0225" num="0191" class="description-line">A is</div>
    </li> <li> <div id="p-0226" num="0000" class="description-line">
      <chemistry id="CHEM-US-00097" num="00097">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2c/5c/83/bde1998e4a051f/US20190292130A1-20190926-C00097.png"><img id="EMI-C00097" he="12.02mm" wi="46.14mm" file="US20190292130A1-20190926-C00097.TIF" alt="Figure US20190292130A1-20190926-C00097" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="185" height="48" alt="Figure US20190292130A1-20190926-C00097" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2c/5c/83/bde1998e4a051f/US20190292130A1-20190926-C00097.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00097" attachment-type="cdx" file="US20190292130A1-20190926-C00097.CDX"> </attachment>
          <attachment idref="CHEM-US-00097" attachment-type="mol" file="US20190292130A1-20190926-C00097.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0192]"> </para-num> <div id="p-0227" num="0192" class="description-line">X is O or NH;</div>
    </li> <li> <para-num num="[0193]"> </para-num> <div id="p-0228" num="0193" class="description-line">Y is O or NH;</div>
    </li> <li> <para-num num="[0194]"> </para-num> <div id="p-0229" num="0194" class="description-line">provided that when A is</div>
    </li> <li> <div id="p-0230" num="0000" class="description-line">
      <chemistry id="CHEM-US-00098" num="00098">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e0/13/b1/ebc71a80908859/US20190292130A1-20190926-C00098.png"><img id="EMI-C00098" he="12.45mm" wi="23.45mm" file="US20190292130A1-20190926-C00098.TIF" alt="Figure US20190292130A1-20190926-C00098" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="94" height="50" alt="Figure US20190292130A1-20190926-C00098" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e0/13/b1/ebc71a80908859/US20190292130A1-20190926-C00098.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00098" attachment-type="cdx" file="US20190292130A1-20190926-C00098.CDX"> </attachment>
          <attachment idref="CHEM-US-00098" attachment-type="mol" file="US20190292130A1-20190926-C00098.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0231" num="0000" class="description-line">X and Y cannot both be O;</div>
    </li> <li> <para-num num="[0195]"> </para-num> <div id="p-0232" num="0195" class="description-line">T is C or S;</div>
    </li> <li> <para-num num="[0196]"> </para-num> <div id="p-0233" num="0196" class="description-line">W is a bond, O, NH or S;</div>
    </li> <li> <para-num num="[0197]"> </para-num> <div id="p-0234" num="0197" class="description-line">R<sup>1 </sup>is selected from the group consisting of:
</div> </li> <ul> <li id="ul0017-0001" num="0000"> <ul> <li id="ul0018-0001" num="0198">(a) NR<sup>4</sup>R<sup>5 </sup>wherein R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more heteroatoms selected from O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</li> <li id="ul0018-0002" num="0199">(b) the side chain of a natural or unnatural amino acid; and</li> <li id="ul0018-0003" num="0200">(c) a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from O, N and S;</li> </ul> </li> </ul>

    <li> <para-num num="[0201]"> </para-num> <div id="p-0235" num="0201" class="description-line">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
</div> </li> <ul> <li id="ul0019-0001" num="0000"> <ul> <li id="ul0020-0001" num="0202">(a) a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl; and</li> <li id="ul0020-0002" num="0203">(b) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl wherein Z is OC(O) or C(O)O;</li> </ul> </li> </ul>

    <li> <para-num num="[0204]"> </para-num> <div id="p-0236" num="0204" class="description-line">n is 0, 1, 2, 3, 4, 5 or 6;</div>
    </li> <li> <para-num num="[0205]"> </para-num> <div id="p-0237" num="0205" class="description-line">m is 0 or 1;</div>
    </li> <li> <para-num num="[0206]"> </para-num> <div id="p-0238" num="0206" class="description-line">p is 0 or 1; and</div>
    </li> <li> <para-num num="[0207]"> </para-num> <div id="p-0239" num="0207" class="description-line">z is 0 or 2;</div>
    </li> <li> <para-num num="[0208]"> </para-num> <div id="p-0240" num="0208" class="description-line">including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</div>
    </li> <li> <para-num num="[0209]"> </para-num> <div id="p-0241" num="0209" class="description-line">In some embodiments, the compound of formula (II) comprises a functional group selected from hydrazine, hydroxylamine and hydrazide. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0210]"> </para-num> <div id="p-0242" num="0210" class="description-line">In some embodiments of formula (II), m is 0. In other embodiments of formula (I), m is 1. In other embodiments of formula (II), m is 1. In other embodiments of formula (I), m is 1 and p is 0. In other embodiments of formula (II), z is 0. In other embodiments of formula (II), z is 2. In other embodiments of formula (II), T is C. In other embodiments of formula (II), W is a bond.</div>
    </li> <li> <para-num num="[0211]"> </para-num> <div id="p-0243" num="0211" class="description-line">In some representative embodiments of formula (II), the cationic lipid is represented by the structure of formula (IIa):</div>
    </li> <li> <div id="p-0244" num="0000" class="description-line">
      <chemistry id="CHEM-US-00099" num="00099">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/38/3c/a0/b771dce87c0c58/US20190292130A1-20190926-C00099.png"><img id="EMI-C00099" he="22.86mm" wi="69.93mm" file="US20190292130A1-20190926-C00099.TIF" alt="Figure US20190292130A1-20190926-C00099" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="91" alt="Figure US20190292130A1-20190926-C00099" class="patent-full-image" src="https://patentimages.storage.googleapis.com/38/3c/a0/b771dce87c0c58/US20190292130A1-20190926-C00099.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00099" attachment-type="cdx" file="US20190292130A1-20190926-C00099.CDX"> </attachment>
          <attachment idref="CHEM-US-00099" attachment-type="mol" file="US20190292130A1-20190926-C00099.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0245" num="0000" class="description-line">wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X, T, W, n, m, p and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0212]"> </para-num> <div id="p-0246" num="0212" class="description-line">In some embodiments of formula (IIa) p is 0, W is a bond and T is C, and the compound is represented by the structure of formula (IIa-1):</div>
    </li> <li> <div id="p-0247" num="0000" class="description-line">
      <chemistry id="CHEM-US-00100" num="00100">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c7/db/69/55456ea496793d/US20190292130A1-20190926-C00100.png"><img id="EMI-C00100" he="16.59mm" wi="69.93mm" file="US20190292130A1-20190926-C00100.TIF" alt="Figure US20190292130A1-20190926-C00100" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="66" alt="Figure US20190292130A1-20190926-C00100" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c7/db/69/55456ea496793d/US20190292130A1-20190926-C00100.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00100" attachment-type="cdx" file="US20190292130A1-20190926-C00100.CDX"> </attachment>
          <attachment idref="CHEM-US-00100" attachment-type="mol" file="US20190292130A1-20190926-C00100.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0248" num="0000" class="description-line">wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X, n, m and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0213]"> </para-num> <div id="p-0249" num="0213" class="description-line">In other embodiments of formula (IIa), R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (IIa-2):</div>
    </li> <li> <div id="p-0250" num="0000" class="description-line">
      <chemistry id="CHEM-US-00101" num="00101">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/d8/21/d3785609e2ccca/US20190292130A1-20190926-C00101.png"><img id="EMI-C00101" he="16.59mm" wi="69.93mm" file="US20190292130A1-20190926-C00101.TIF" alt="Figure US20190292130A1-20190926-C00101" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="66" alt="Figure US20190292130A1-20190926-C00101" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/d8/21/d3785609e2ccca/US20190292130A1-20190926-C00101.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00101" attachment-type="cdx" file="US20190292130A1-20190926-C00101.CDX"> </attachment>
          <attachment idref="CHEM-US-00101" attachment-type="mol" file="US20190292130A1-20190926-C00101.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0251" num="0000" class="description-line">wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, n, m and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0214]"> </para-num> <div id="p-0252" num="0214" class="description-line">In yet other embodiments of formula (IIa), p is 1, m is 1, W is a bond and T is C, and the compound is represented by the structure of formula (IIa-3):</div>
    </li> <li> <div id="p-0253" num="0000" class="description-line">
      <chemistry id="CHEM-US-00102" num="00102">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4e/fd/8f/e02bf95da8b496/US20190292130A1-20190926-C00102.png"><img id="EMI-C00102" he="19.56mm" wi="69.93mm" file="US20190292130A1-20190926-C00102.TIF" alt="Figure US20190292130A1-20190926-C00102" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="78" alt="Figure US20190292130A1-20190926-C00102" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4e/fd/8f/e02bf95da8b496/US20190292130A1-20190926-C00102.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00102" attachment-type="cdx" file="US20190292130A1-20190926-C00102.CDX"> </attachment>
          <attachment idref="CHEM-US-00102" attachment-type="mol" file="US20190292130A1-20190926-C00102.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0254" num="0000" class="description-line">wherein R<sup>1 </sup>is the side chain of a natural or unnatural amino acid; and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, X, n and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0215]"> </para-num> <div id="p-0255" num="0215" class="description-line">In other representative embodiments of formula (II), the cationic lipid is represented by the structure of formula (IIb):</div>
    </li> <li> <div id="p-0256" num="0000" class="description-line">
      <chemistry id="CHEM-US-00103" num="00103">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0f/e6/1f/a96924617cd4a4/US20190292130A1-20190926-C00103.png"><img id="EMI-C00103" he="22.86mm" wi="69.93mm" file="US20190292130A1-20190926-C00103.TIF" alt="Figure US20190292130A1-20190926-C00103" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="91" alt="Figure US20190292130A1-20190926-C00103" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0f/e6/1f/a96924617cd4a4/US20190292130A1-20190926-C00103.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00103" attachment-type="cdx" file="US20190292130A1-20190926-C00103.CDX"> </attachment>
          <attachment idref="CHEM-US-00103" attachment-type="mol" file="US20190292130A1-20190926-C00103.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0257" num="0000" class="description-line">wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, T, W, X, Y n, m, p and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0216]"> </para-num> <div id="p-0258" num="0216" class="description-line">In some representative embodiments of formula (IIb), p is 0, W is a bond, T is C, and R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (IIb-1):</div>
    </li> <li> <div id="p-0259" num="0000" class="description-line">
      <chemistry id="CHEM-US-00104" num="00104">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/02/0c/af/9aafadf9af2019/US20190292130A1-20190926-C00104.png"><img id="EMI-C00104" he="18.71mm" wi="69.93mm" file="US20190292130A1-20190926-C00104.TIF" alt="Figure US20190292130A1-20190926-C00104" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="75" alt="Figure US20190292130A1-20190926-C00104" class="patent-full-image" src="https://patentimages.storage.googleapis.com/02/0c/af/9aafadf9af2019/US20190292130A1-20190926-C00104.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00104" attachment-type="cdx" file="US20190292130A1-20190926-C00104.CDX"> </attachment>
          <attachment idref="CHEM-US-00104" attachment-type="mol" file="US20190292130A1-20190926-C00104.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0260" num="0000" class="description-line">wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, Y, n, m and z are as defined in formula (II).</div>
    </li> <li> <para-num num="[0217]"> </para-num> <div id="p-0261" num="0217" class="description-line">In some embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIb) and (IIb-1), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>14</sub>-C<sub>20 </sub>alkyl or a C<sub>14</sub>-C<sub>20 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0218]"> </para-num> <div id="p-0262" num="0218" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIb) and (IIb-1), R<sup>2 </sup>and R<sup>3 </sup>are each independently a C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl wherein Z is OC(O) or C(O)O.</div>
    </li> <li> <para-num num="[0219]"> </para-num> <div id="p-0263" num="0219" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIb) and (IIb-1), X is O.</div>
    </li> <li> <para-num num="[0220]"> </para-num> <div id="p-0264" num="0220" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIb) and (IIb-1), X is NH.</div>
    </li> <li> <para-num num="[0221]"> </para-num> <div id="p-0265" num="0221" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIb) and (IIb-1), Y is NH.</div>
    </li> <li> <para-num num="[0222]"> </para-num> <div id="p-0266" num="0222" class="description-line">In other embodiments of the compounds of any of formulae (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIb) and (IIb-1), R<sup>4 </sup>and R<sup>5 </sup>are each CH<sub>3</sub>, or wherein R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a heterocyclic ring selected from pyrrolidinyl piperidinyl, piperazinyl, each of which is optionally substituted with an alkyl.</div>
    </li> <li> <para-num num="[0223]"> </para-num> <div id="p-0267" num="0223" class="description-line">In another aspect, the cationic lipid of the present invention is represented by the structure of formula (III):</div>
    </li> <li> <div id="p-0268" num="0000" class="description-line">
      <chemistry id="CHEM-US-00105" num="00105">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f4/a2/7f/515169f877d490/US20190292130A1-20190926-C00105.png"><img id="EMI-C00105" he="19.47mm" wi="69.93mm" file="US20190292130A1-20190926-C00105.TIF" alt="Figure US20190292130A1-20190926-C00105" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="78" alt="Figure US20190292130A1-20190926-C00105" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f4/a2/7f/515169f877d490/US20190292130A1-20190926-C00105.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00105" attachment-type="cdx" file="US20190292130A1-20190926-C00105.CDX"> </attachment>
          <attachment idref="CHEM-US-00105" attachment-type="mol" file="US20190292130A1-20190926-C00105.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0269" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0224]"> </para-num> <div id="p-0270" num="0224" class="description-line">X and Y are each independently is O or N;</div>
    </li> <li> <para-num num="[0225]"> </para-num> <div id="p-0271" num="0225" class="description-line">each of R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is independently absent or a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl; and</div>
    </li> <li> <div id="p-0272" num="0000" class="description-line">n is 1 to 30;
<br/>
including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.
</div>
    </li> <heading id="h-0016">Chemical Definitions</heading>
    <li> <para-num num="[0226]"> </para-num> <div id="p-0273" num="0226" class="description-line">An alkyl group refers to any saturated aliphatic hydrocarbon, including straight-chain and branched-chain alkyl groups. In one embodiment, the alkyl group has 1-4 carbons designated here as C<sub>1</sub>-C<sub>4</sub>-alkyl. In another embodiment, the alkyl group has 10-22 carbons designated here as C<sub>10</sub>-C<sub>22</sub>-alkyl. In another embodiment, the alkyl group has 4-10 carbons designated here as C<sub>4</sub>-C<sub>10</sub>-alkyl. In another embodiment, the alkyl group has 4-22 carbons designated here as C<sub>4</sub>-C<sub>22</sub>-alkyl. The alkyl group may be unsubstituted or substituted by one or more groups selected from halogen, hydroxy, alkoxy carbonyl, amido, alkylamido, dialkylamido, nitro, amino, alkylamino, dialkylamino, carboxyl, thio and thioalkyl.</div>
    </li> <li> <para-num num="[0227]"> </para-num> <div id="p-0274" num="0227" class="description-line">An alkenyl group refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond including straight-chain, branched-chain and cyclic alkenyl groups. In one embodiment, the alkenyl group has 10-22 carbons designated here as C<sub>10</sub>-C<sub>22</sub>-alkenyl. In another embodiment, the alkenyl group has 4-10 carbons designated here as C<sub>4</sub>-C<sub>10</sub>-alkenyl. In another embodiment, the alkenyl group has 4-22 carbons designated here as C<sub>4</sub>-C<sub>22</sub>-alkenyl. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexyl-butenyl and decenyl. The alkenyl group can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.</div>
    </li> <li> <para-num num="[0228]"> </para-num> <div id="p-0275" num="0228" class="description-line">An alkynyl group refers to an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond including straight-chain and branched-chain. In one embodiment, the alkynyl group has 10-22 carbons designated here as C<sub>10</sub>-C<sub>22</sub>-alkynyl. In another embodiment, the alkynyl group has 4-10 carbons designated here as C<sub>4</sub>-C<sub>10</sub>-alkynyl. In another embodiment, the alkynyl group has 4-22 carbons designated here as C<sub>4</sub>-C<sub>22</sub>-alkynyl. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl, heptynyl, octynyl and decynyl. The alkynyl group can be unsubstituted or substituted through available carbon atoms with one or more groups defined hereinabove for alkyl.</div>
    </li> <li> <para-num num="[0229]"> </para-num> <div id="p-0276" num="0229" class="description-line">The term heteroaryl used herein alone or as part of another group refers to a heteroaromatic system containing at least one heteroatom ring wherein the atom is selected from nitrogen, sulfur and oxygen. The heteroaryl contains 5 or more ring atoms. The heteroaryl group can be monocyclic, bicyclic, tricyclic and the like. Also included in this definition are the benzoheterocyclic rings. If nitrogen is a ring atom, the present invention also contemplates the N-oxides of the nitrogen containing heteroaryls. Non-limiting examples of heteroaryl moieities include thienyl, benzothienyl, 1-naphthothienyl, thianthrenyl, furyl, benzofuryl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, indazolyl, purinyl, isoquinolyl, quinolyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, carbolinyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl and the like. The heteroaryl group can be unsubstituted or substituted through available atoms with one or more groups defined hereinabove for alkyl.</div>
    </li> <li> <para-num num="[0230]"> </para-num> <div id="p-0277" num="0230" class="description-line">The term heterocyclic ring or heterocyclyl used herein alone or as part of another group refers to a five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered to eight-membered rings can be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Preferred heterocyclic ring moieties include piperidinyl, pyrrolidinyl piperazinyl, pyrrolinyl, pyrazolinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, indolinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, dihydropyranyl, tetrahydropyranyl, dihydrothiazolyl, and the like. In some embodiments, the cyclic group is pyrrolidinyl. In other embodiments, the heteroaryl or heterocyclyl group is piperidinyl. In other embodiments, the heterocyclyl group is piperidine. The heterocyclyl group can be unsubstituted or substituted through available atoms with one or more groups defined hereinabove for alkyl.</div>
    </li> <li> <para-num num="[0231]"> </para-num> <div id="p-0278" num="0231" class="description-line">As used herein in the specification and in the claims section below the term amino acid or amino acids is understood to include the 20 naturally occurring amino acids, i.e., alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine. Each possibility represents a separate embodiment of the invention. According to other embodiments, the term amino acids refers to non-natural amino acids or synthetic amino acids.</div>
    </li> <li> <para-num num="[0232]"> </para-num> <div id="p-0279" num="0232" class="description-line">Furthermore, the term amino acid includes both D- and L-amino acids. According to the principles of the present invention, the term amino acid side chain refers to a group R of an amino acid of the formula H<sub>2</sub>NC(R)COOH.</div>
    </li> <li> <para-num num="[0233]"> </para-num> <div id="p-0280" num="0233" class="description-line">The term hydrazine moiety refers to the group NHNH</div>
    </li> <li> <para-num num="[0234]"> </para-num> <div id="p-0281" num="0234" class="description-line">The term hydroxylamine moiety as used herein refers to the group NHO</div>
    </li> <li> <para-num num="[0235]"> </para-num> <div id="p-0282" num="0235" class="description-line">The term hydrazide moiety as used herein refers to the group C(O)NN</div>
    </li> <li> <para-num num="[0236]"> </para-num> <div id="p-0283" num="0236" class="description-line">The term hydroxylamine moiety as used herein refers to the group OCH<sub>2</sub>CH<sub>2</sub>N or NCH<sub>2</sub>CH<sub>2</sub>O</div>
    </li> <li> <para-num num="[0237]"> </para-num> <div id="p-0284" num="0237" class="description-line">The term ethylenediamine moiety as used herein refers to the group NCH<sub>2</sub>CH<sub>2</sub>N or NCH<sub>2</sub>CH<sub>2</sub>N</div>
    </li> <li> <para-num num="[0238]"> </para-num> <div id="p-0285" num="0238" class="description-line">The term guanidine as used herein refers to the group NHC(NH)NH<sub>2</sub>.</div>
    </li> <li> <para-num num="[0239]"> </para-num> <div id="p-0286" num="0239" class="description-line">The term leaving group as used herein refers to any labile leaving group with is readily replaced by another moiety. In some embodiments, the leaving group is selected from the group consisting of halogen, sulfonyloxy and OC(O)R wherein R is an alkyl, aryl or alkylaryl. In some preferred embodiments, the leaving group is selected from the group consisting of Cl, Br, I, mesylate (OMs), triflate (OTr) and tosylate (OTs). In a currently preferred embodiment, the leaving group X is Br. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0240]"> </para-num> <div id="p-0287" num="0240" class="description-line">The term protecting group refers to chemical residues used to block reactive sites during chemical synthesis, that enable chemical reaction to be carried out selectively at one reaction site in a multifunctional compound, other reactive sites must be temporarily blocked. The residues used to block these reactive sites called protecting groups.</div>
    </li> <li> <para-num num="[0241]"> </para-num> <div id="p-0288" num="0241" class="description-line">The term nitrogen protecting group or N protecting group or amino protecting group as used herein interchangeably refers to refers to a readily cleavable group bonded to amino groups. Examples of amino-protecting groups include t-butoxycarbonyl (BOC), benzyloxycarbonyl, acetyl, phenylcarbonyl, or a silyl group, which can be substituted with alkyl (trialkylsilyl), with an aryl (triarylsilyl) or a combination thereof (e.g., dialkylphenylsilyl), e.g., trimethylsilyl (TMS) or t-butyldimethyl silyl (TBDMS). Other examples of hydroxy protecting groups include, for example, C<sub>1</sub>-C<sub>4 </sub>alkyl (e.g., methyl, ethyl, propyl, butyl and the like), CH<sub>2</sub>Ph (benzyl or bzl), allyl (All), (allyl)-CO(C<sub>1</sub>-C<sub>6 </sub>alkyl), SO<sub>2</sub>(C<sub>1</sub>-C<sub>6 </sub>alkyl), SO<sub>2</sub>-aryl, COAr in which Ar is an aryl group as defined above, and CO(C<sub>1</sub>-C<sub>6 </sub>alkyl)Ar (e.g., a carboxybenzyl (Bz) group). Other examples of hydroxy protecting groups include acid sensitive protecting groups such as tetrahydropyranyl (THP), methoxymethyl (MOM), triphenylmethyl (Trityl) and dimethoxy trityl (DMT). Each possibility represents a separate embodiment of the present invention. Protecting groups can be removed by applying deprotecting agents as known in the art. Methods of incorporation and deprotection, are described by C. B. Reese and E. Haslam, Protective Groups in Organic Chemistry, J. G. W. McOmie, Ed., Plenum Press, New York, N.Y., 1973, <figure-callout id="3" label="Chapters" filenames="US20190292130A1-20190926-D00011.png,US20190292130A1-20190926-D00017.png" state="{{state}}"> <figure-callout id="4" label="Chapters" filenames="US20190292130A1-20190926-D00018.png,US20190292130A1-20190926-D00019.png" state="{{state}}">Chapters</figure-callout> </figure-callout> 3 and 4, respectively, and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2nd ed., John Wiley and Sons, New York, N.Y., 1991 and A. J. Pearson and W. R. Roush, Activating Agents and Protecting Groups, John Wiley and Sons (1999), the contents of each of which are incorporated by reference in their entirety. According some embodiments, pharmaceutically acceptable salts includes both acid and base addition salts, which retain the biologically effectiveness of the acid or base.</div>
    </li> <li> <para-num num="[0242]"> </para-num> <div id="p-0289" num="0242" class="description-line">One or more of the cationic lipids of the invention, may be present as a salt. The term salt encompasses both basic and acid addition salts, including but not limited to, carboxylate salts or salts with amine nitrogens, and include salts formed with the organic and inorganic anions and cations discussed below. Furthermore, the term includes salts that form by standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids. Such acids include hydrochloric, hydrofluoric, trifluoroacetic, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, phthalic, tartaric, lauric, stearic, salicylic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic, and like acids. Each possibility represents a separate embodiment of the invention.</div>
    </li> <li> <para-num num="[0243]"> </para-num> <div id="p-0290" num="0243" class="description-line">The term organic or inorganic cation refers to counter-ions for the anion of a salt. The counter-ions include, but are not limited to, alkali and alkaline earth metals (such as lithium, sodium, potassium, barium, aluminum and calcium); ammonium and mono-, di- and tri-alkyl amines such as trimethylamine, cyclohexylamine; and the organic cations, such as dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylammonium, dibenzylethylenediammonium, and like cations. See, for example, Berge et al., <i>J. Pharm. Sci</i>. (1977), 66:1-19, which is incorporated herein by reference.</div>
    </li> <heading id="h-0017">Compositions and Therapeutic Uses</heading>
    <li> <para-num num="[0244]"> </para-num> <div id="p-0291" num="0244" class="description-line">In some aspects, the present invention provides a composition comprising a cationic lipid according to any one of formulae (I), (Ia), (Ia-1), (II), (IIa), (IIa-1), (IIa-2), (IIa-3), (IIa-4), (IIb) and (IIb-1), e.g., any one of <figure-callout id="1" label="compounds" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">compounds</figure-callout> 1 to 66, and a pharmaceutically acceptable excipient. The composition may further comprise comprising at least one additional neutral or PEG-modified lipid.</div>
    </li> <li> <para-num num="[0245]"> </para-num> <div id="p-0292" num="0245" class="description-line">In some embodiments, the composition may further comprise a nucleic acid. Examples of nucleic acids include small interfering RNA (siRNA), micro RNA (miRNA), antisense oligo nucleotides, messenger RNA (mRNA), ribozymes, pDNA, CRISPR mRNA, gRNA and immune stimulating nucleic acids. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0246]"> </para-num> <div id="p-0293" num="0246" class="description-line">In some embodiments, the present invention provides a method of gene silencing, comprising the step of contacting a cell with a composition comprising a cationic lipid of the present invention. In some embodiments, the cell is a cancer cell.</div>
    </li> <li> <para-num num="[0247]"> </para-num> <div id="p-0294" num="0247" class="description-line">In other embodiments, the composition further comprises one or more components selected from the group consisting of a neutral lipid, a charged lipid, a steroid, and a polymer-conjugated lipid. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0248]"> </para-num> <div id="p-0295" num="0248" class="description-line">In other embodiments, the compositions of the present invention may be used as a delivery system to administer a therapeutic agent to its target location in the body. Thus, in some embodiments, the present invention relates to a method for administering a therapeutic agent, by preparing a composition comprising a cationic lipid as described herein and a therapeutic agent, and administering the combination to a subject in need thereof.</div>
    </li> <li> <para-num num="[0249]"> </para-num> <div id="p-0296" num="0249" class="description-line">In particular embodiments, the present invention provide novel cationic lipids that enable the formulation of improved compositions for the in vitro and in vivo delivery of IVT-mRNA and/or other oligonucleotides.</div>
    </li> <li> <para-num num="[0250]"> </para-num> <div id="p-0297" num="0250" class="description-line">In some embodiments, these lipid nanoparticle compositions are useful for expression of protein encoded by mRNA.</div>
    </li> <li> <para-num num="[0251]"> </para-num> <div id="p-0298" num="0251" class="description-line">In other embodiments, these improved lipid nanoparticles compositions are useful for upregulation of endogenous protein expression by delivering miRNA inhibitors targeting one specific miRNA or a group of miRNA regulating one target mRNA or several mRNA.</div>
    </li> <li> <para-num num="[0252]"> </para-num> <div id="p-0299" num="0252" class="description-line">In other embodiments, these improved lipid nanoparticle compositions are useful for down-regulating (e.g., silencing) the protein levels and/or mRNA levels of target genes.</div>
    </li> <li> <para-num num="[0253]"> </para-num> <div id="p-0300" num="0253" class="description-line">In some other embodiments, the lipid nanoparticles are also useful for delivery of mRNA and plasmids for expression of transgenes.</div>
    </li> <li> <para-num num="[0254]"> </para-num> <div id="p-0301" num="0254" class="description-line">In yet other embodiments, the lipid nanoparticle compositions are useful for inducing a pharmacological effect resulting from expression of a protein, e.g., increased production of red blood cells through the delivery of a suitable erythropoietin mRNA, or protection against infection through delivery of mRNA encoding for a suitable antibody.</div>
    </li> <li> <para-num num="[0255]"> </para-num> <div id="p-0302" num="0255" class="description-line">According to some embodiments, the cationic lipid may be in the form of nanoparticles and administered as is. In some embodiments, the nanoparticles may be administered in a solution. In some embodiments, the nanoparticles may be formulated to a suitable pharmaceutical composition to be administered by any desired route of administration. Exemplary routes of administration include such routes as, but not limited to: topical, oral or parenteral. Depending on the intended mode of administration, the compositions used may be in the form of solid, semi-solid or liquid dosage forms, such, as for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical compositions may include the cationic particles, a pharmaceutical acceptable excipient, and, optionally, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, and the like. It is preferred that the pharmaceutically acceptable carrier be one which is inert to the nucleic acid encapsulated within the particles and which has no detrimental side effects or toxicity under the conditions of use. In some embodiments, the administration is localized. In some embodiments, the administration is systemic.</div>
    </li> <li> <para-num num="[0256]"> </para-num> <div id="p-0303" num="0256" class="description-line">In some embodiments, injectable formulations for parenteral administration can be prepared as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, and the like. Aqueous injection suspensions may also contain substances that increase the viscosity of the suspension, including, for example, sodium carboxymethylcellulose, sorbitol, and/or dextran. Optionally, the suspension may also contain stabilizers. The parenteral formulations can be present in unit dose or multiple dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, such as, for example, water, for injections immediately prior to use. In some embodiments, parenteral administration includes intravenous administration.</div>
    </li> <li> <para-num num="[0257]"> </para-num> <div id="p-0304" num="0257" class="description-line">In other embodiments, for oral administration, a pharmaceutically acceptable, non-toxic composition may be formed by the incorporation of any of the normally employed excipients, such as, for example, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, sodium crosscarmellose, glucose, gelatin, sucrose, magnesium carbonate, and the like. Such compositions include solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained release formulations and the like. Formulations suitable for oral administration can consist of liquid solutions such as effective amounts of the compound(s) dissolved in diluents such as water, saline, or orange juice; sachets, lozenges, and troches, each containing a predetermined amount of the active ingredient as solids or granules; powders, suspensions in an appropriate liquid; and suitable emulsions. Liquid formulations may include diluents such as water and alcohols, (such as, for example ethanol, benzyl alcohol, and the polyethylene alcohols), either with or without the addition of a pharmaceutically acceptable surfactant, suspending agents, or emulsifying agents.</div>
    </li> <li> <para-num num="[0258]"> </para-num> <div id="p-0305" num="0258" class="description-line">In determining the dosages of the particles to be administered, the dosage and frequency of administration may be selected in relation to the pharmacological properties of the specific nucleic acids encapsulated within the particles.</div>
    </li> <li> <para-num num="[0259]"> </para-num> <div id="p-0306" num="0259" class="description-line">In some representative embodiments, a particle comprising a nucleic acid, such as, for example, siRNA, miRNA, shRNA, anti-sense RNA, and the like, may be used in the treatment of various leukocyte-associated conditions, depending on the identity of the nucleic acid, the specific target leukocyte, and the like. In some embodiments, the nucleic acid encapsulated within the particles may be a nucleic acid capable of inducing silencing of a target gene. In some embodiments, the target gene may be any gene, the expression of which is related to the condition to be treated. In some embodiments, the target gene may be a gene selected from, but not limited to: growth factors (such as EGFR, PDGFR), genes related to angiogenesis pathways (such as VEGF, Integrins), genes involved in intracellular signaling pathways and cell cycle regulation (such as PI3K/AKT/mTOR, Ras/Raf/MAPK, PDK1, CHK1, PLK1, Cyclins). In some embodiments, a combination of nucleic acids, each having one or more targets may be encapsulated within the particles.</div>
    </li> <li> <para-num num="[0260]"> </para-num> <div id="p-0307" num="0260" class="description-line">According to some embodiments, exemplary leukocyte-associated conditions that may be treated by the targeted particles may be selected from, but not limited to: various types of cancer, various infections (such as, for example, viral infection, bacterial infection, fungal infection, and the like), autoimmune diseases, neurodegenerative diseases, inflammations, and the like.</div>
    </li> <li> <para-num num="[0261]"> </para-num> <div id="p-0308" num="0261" class="description-line">In some representative embodiments, the targeted particles comprising a nucleic acid (such as, siRNA or miRNA, shRNA, anti-sense RNA, or the like), may be used for the treatment of cancer.</div>
    </li> <li> <para-num num="[0262]"> </para-num> <div id="p-0309" num="0262" class="description-line">In some embodiments, cancer is a disorder in which a population of cells has become, in varying degrees, unresponsive to the control mechanisms that normally govern proliferation and differentiation. In some embodiments, the cancer is a blood cancer. Non-limiting examples of blood cancers are lymphoma, leukemia and myeloma. Lymphomas may be divided into two categories: Hodgkin lymphoma and non-Hodgkin lymphoma. Most non-Hodgkin lymphomas are B-cell lymphomas, that grow quickly (high-grade) or slowly (low-grade). There are 14 types of B-cell non-Hodgkin lymphomas. The others are T-cell lymphomas.</div>
    </li> <li> <para-num num="[0263]"> </para-num> <div id="p-0310" num="0263" class="description-line">In some representative embodiments, the nucleic acid that may be used for the treatment of cancer is directed against a target gene, which is involved in the regulation of cell cycle. In some representative embodiments, the target gene may be Polo-like Kinase 1 (PLK), Cyclin D1, CHK1, Notch pathway genes.</div>
    </li> <li> <para-num num="[0264]"> </para-num> <div id="p-0311" num="0264" class="description-line">According to some exemplary embodiments, the plurality of lipids of the lipid particles may be of natural or synthetic source and may be selected from, but not limited to: cationic lipids, phosphatidylethanolamines, ionized lipids, membrane stabilizing lipids, phospholipids, and the like, or combinations thereof. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0265]"> </para-num> <div id="p-0312" num="0265" class="description-line">In some embodiments, the membrane stabilizing lipids may be selected from, but not limited to: cholesterol, phospholipids (such as, for example, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylserine, phosphatidylglycerol, diphosphatidylglycerols), cephalins, sphingolipids (sphingomyelins and glycosphingolipids), glycoglycerolipids, and combinations thereof. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0266]"> </para-num> <div id="p-0313" num="0266" class="description-line">In some embodiments, the phosphatidylethanolamines may be selected from, but not limited to: 1,2-dilauroyl-L-phosphatidyl-ethanolamine (DLPE), 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-Diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhPE) 1,3-Dipalmitoyl-sn-glycero-2-phosphoethanolamine (1,3-DPPE), 1-Palmitoyl-3-oleoyl-sn-glycero-2-phosphoethanolamine (1,3-POPE), Biotin-Phosphatidylethanolamine, 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), Dipalmitoylphosphatidylethanolamine (DPPE), 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) or combinations thereof. In some embodiments, the Phosphatidylethanolamines may be conjugated to a PEG-Amine derivative. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0267]"> </para-num> <div id="p-0314" num="0267" class="description-line">According to some embodiments, neutral lipid refers to any of a number of lipid species that exist either in an uncharged or neutral zwitterionic form at physiological pH, such lipids include, but are not limited to, phosphotidylcholines such as 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-Dipalmitoyl-sn-glyccro-3-phosphocholine (DPPC), 1,2-Dimyristoyl-sn-glyccro-3-phosphocholine (DMPC), 1-Palmitoyl-2-olcoyl-sn-glyccro-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), phophatidyl ethanolamines such as 1,2-Diolcoyl-sn-glyccro-3-phosphoethanolamine (DOPE), sphingomyelins (SM), ceramides, steroids such as sterols and their derivatives. Neutral lipids may be synthetic or naturally derived.</div>
    </li> <li> <para-num num="[0268]"> </para-num> <div id="p-0315" num="0268" class="description-line">According to some embodiments, the particles (lipid phase thereof), may further include one or more PEG derivatives. In some embodiments, the PEG derivatives may be conjugated to one or more additional molecules, such as, a lipid. In some embodiments, the PEG derivative is selected from, but not limited to: PEG-DMG 3-N-(-methoxy poly(ethylene glycol)2000)carbamoyl-1,2-dimyrisyl glycerol, PEG-cDMA 3-N-(-methoxy poly(ethylene glycol)2000)carbamoyl-1,2-dimyristyloxy-propylamine; PEG-cDSA, 3-N-(-methoxy poly(ethylene glycol)2000)carbamoyl-1,2-distearyloxy-propylamine, DSPE-PEG, PEG-maleimide, DSPE-PEG-maleimide, or combinations thereof. Each possibility represents a separate embodiment of the present invention.</div>
    </li> <li> <para-num num="[0269]"> </para-num> <div id="p-0316" num="0269" class="description-line">In some embodiments, the maleimide derivative/moiety may be conjugated, attached or linked to a PEG-derivative, which may be by itself conjugated, linked and/or attached to a lipid.</div>
    </li> <li> <para-num num="[0270]"> </para-num> <div id="p-0317" num="0270" class="description-line">According to some embodiments, the ratio between the various lipids in the particle may vary. In some embodiments, the ratio is a molar ratio. In some embodiments, the ratio is a weight ratio. In some embodiments, each of the lipid groups may be at molar ratio/a weight ratio of about 1%-99%.</div>
    </li> <li> <para-num num="[0271]"> </para-num> <div id="p-0318" num="0271" class="description-line">According to some embodiments, the weight ratio between the nucleic acid and the lipid mixture may be adjusted so as to achieve maximal biological effect by the nucleic acid on the target site. In some embodiments, the ratio between the nucleic acid and the lipid phase may be 1:1. For example, the weight ratio between the nucleic acid and the lipid phase may be 1:2. For example, the weight ratio between the nucleic acid and the lipid phase may be 1:5. For example, the weight ratio between the nucleic acid and the lipid phase may be 1:10. For example, the weight ratio between the nucleic acid and the lipids phase may be 1:16. For example, the weight ratio between the nucleic acid and the lipid phase may be 1:20. In some embodiments, the weight ratio between the nucleic acid and the lipid phase is about 1:1 to 1:20 (w:w).</div>
    </li> <li> <para-num num="[0272]"> </para-num> <div id="p-0319" num="0272" class="description-line">In some embodiments, the particles are nanoparticles. In some embodiments, the particles (including the nucleic acid encapsulated within) and the targeting moiety on the surface particles have a particle size (diameter) in the range of about 10 to about 500 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 10 to about 350 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 50 to about 250 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 10 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 20 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 50 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 75 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 90 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 100 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 120 to about 200 nm. In some embodiments, the particles have a particle size (diameter) in the range of about 150 to about 200. In some embodiments, the particles have a particle size (diameter) in the range of about 50 to about 150 nm. In some embodiments, the particles have a particle size (diameter) in the range of over about 10 nm. In some embodiments, the particles have a particle size (diameter) of over about 20 nm. In some embodiments, the particles have a particle size (diameter) of over about 30 nm. In some embodiments, the particles have a particle size (diameter) of over about 40 nm. In some embodiments, the particles have a particle size (diameter) of over about 50 nm. In some embodiments, the particles have a particle size (diameter) of over about 60 nm. In some embodiments, the particles have a particle size (diameter) of over about 70 nm. In some embodiments, the particles have a particle size (diameter) of over about 80 nm. In some embodiments, the particles have a particle size (diameter) of over about 90 nm. In some embodiments, the particles have a particle size (diameter) of over about 100 nm. In some embodiments, the particles have a particle size (diameter) of over about 200 nm. In some embodiments, the particles have a particle size (diameter) of not more than about 500 nm. In some embodiments, the particles (including the nucleic acid encapsulated within) have a particle size (diameter) in the range of about 5 to about 200 nm. In some embodiments, the particles (including the nucleic acid encapsulated within) have a particle size (diameter) in the range of about 50 to about 60 nm. In some embodiments, the particles (including the nucleic acid encapsulated within) have a particle size (diameter) in the range of about 55 to about 58 nm. In some embodiments, the size is a hydrodynamic diameter.</div>
    </li> <li> <para-num num="[0273]"> </para-num> <div id="p-0320" num="0273" class="description-line">According to exemplary embodiments, the particles may be comprised of a cationic lipid (such as compound shown in Table 1 or 2), cholesterol, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), PEG derivative (such as DMG-PEG) and PEG-maleimide conjugated to a lipid (such as DSPE-PEG-maleimide); at various mol:mol ratios, and further conjugated to a targeting moiety, wherein the targeting moiety is conjugated, linked, attached to the maleimide moiety. For example, the lipid phase may be comprised of: cationic lipid (DLinMC3)/DSPC/cholesterol/DMG-PEG/DSPE-PEG-Maleimide (mol/mol 50:10:38:1.5:0.5). For example, the lipid phase may be comprised of: DLinMC3-DMA/Chol/DSPC/DMG-PEG/DSPE-PEG-maleimide (mol/mol 50:38:10:1.95:0.05).</div>
    </li> <li> <para-num num="[0274]"> </para-num> <div id="p-0321" num="0274" class="description-line">According to some embodiments, the lipid phase may comprise about 30-60% (mol) cationic lipids. For example, the cationic lipid(s) may comprise about 40-50% (mol) of the lipid phase.</div>
    </li> <li> <para-num num="[0275]"> </para-num> <div id="p-0322" num="0275" class="description-line">According to some embodiments, the lipid phase may comprise about 20-70% (mol) membrane stabilizing lipids. For example, the membrane stabilizing lipids may comprise about 40-60% of the lipid phase. In some embodiments, more than one type of membrane stabilizing lipid may be used in the lipid phase. For example, the membrane stabilizing lipid may include cholesterol (being about 30-50% (mol) of the lipid phase), and a phospholipid (such as, for example, DSPC), that may be about 5-15% (mol) of the lipid phase.</div>
    </li> <li> <para-num num="[0276]"> </para-num> <div id="p-0323" num="0276" class="description-line">According to some embodiments, the lipid phase may comprise about 0.01-3% (mol:mol) of PEG-maleimide (optionally conjugated to a lipid). For example, the PEG-maleimide may comprise about 0.05-0.6% of the lipid mixture.</div>
    </li> <li> <para-num num="[0277]"> </para-num> <div id="p-0324" num="0277" class="description-line">According to some embodiments, an additional PEG-derivative (conjugated to a lipid) may comprise about 0.5-10% of the lipid phase composition.</div>
    </li> <li> <para-num num="[0278]"> </para-num> <div id="p-0325" num="0278" class="description-line">According to some exemplary embodiments, there is provided a method for the preparation of targeted particles for delivery of a nucleic acid to leukocytes, the method comprising one or more of the steps of:
</div> </li> <ul> <li id="ul0021-0001" num="0000"> <ul> <li id="ul0022-0001" num="0279">a) mixing a plurality of lipids, including, a cationic lipid according to the invention, membrane stabilizing lipid and PEG-maleimide conjugated to a phospholipid, in an organic solvent at a desired ratio;</li> <li id="ul0022-0002" num="0280">b) adding nucleic acids to the mixture in a suitable solution at a desired ratio;</li> <li id="ul0022-0003" num="0281">c) mixing the lipid mixture and the nucleic acids in a microfluidic micromixer to form particles;</li> <li id="ul0022-0004" num="0282">d) dialyzing the particles to remove undesired solvents;</li> <li id="ul0022-0005" num="0283">e) incubating the particles with reduced targeting antibodies to generate targeted particles;</li> <li id="ul0022-0006" num="0284">f) removing unconjugated antibodies, optionally by gel filtration;</li> <li id="ul0022-0007" num="0285">g) filtration of reconstituted t-conjugated particles encapsulating nucleic acid molecules;</li> </ul> </li> </ul>

    <li> <para-num num="[0286]"> </para-num> <div id="p-0326" num="0286" class="description-line">In some embodiments, the lipids are suspended in an acidic aqueous buffer, such as, ethanol. In some embodiments, the nucleic acid is in an acetate buffer solution.</div>
    </li> <li> <para-num num="[0287]"> </para-num> <div id="p-0327" num="0287" class="description-line">In some embodiments, the nucleic acid may be mixed with the lipid mixture in a microfluidizer mixer to form particles encapsulating/carrying the nucleic acid.</div>
    </li> <heading id="h-0018">Definitions</heading>
    <li> <para-num num="[0288]"> </para-num> <div id="p-0328" num="0288" class="description-line">To facilitate an understanding of the present invention, a number of terms and phrases are defined below. It is to be understood that these terms and phrases are for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.</div>
    </li> <li> <para-num num="[0289]"> </para-num> <div id="p-0329" num="0289" class="description-line">As referred to herein, the terms nucleic acid, nucleic acid molecules oligonucleotide, polynucleotide, and nucleotide may interchangeably be used herein. The terms are directed to polymers of deoxy ribonucleotides (DNA), ribonucleotides (RNA), and modified forms thereof in the form of a separate fragment or as a component of a larger construct, linear or branched, single stranded, double stranded, triple stranded, or hybrids thereof. The term also encompasses RNA/DNA hybrids. The polynucleotides may include sense and antisense oligonucleotide or polynucleotide sequences of DNA or RNA. The DNA or RNA molecules may be, for example, but not limited to: complementary DNA (cDNA), genomic DNA, synthesized DNA, recombinant DNA, or a hybrid thereof or an RNA molecule such as, for example, mRNA, shRNA, siRNA, miRNA, Antisense RNA, and the like. Each possibility represents a separate embodiment of the present invention. The terms further include oligonucleotides composed of naturally occurring bases, sugars, and covalent inter nucleoside linkages, as well as oligonucleotides having non-naturally occurring portions, which function similarly to respective naturally occurring portions.</div>
    </li> <li> <para-num num="[0290]"> </para-num> <div id="p-0330" num="0290" class="description-line">The terms polypeptide, peptide and protein are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.</div>
    </li> <li> <para-num num="[0291]"> </para-num> <div id="p-0331" num="0291" class="description-line">The term construct, as used herein, refers to an artificially assembled or isolated nucleic acid molecule which may include one or more nucleic acid sequences, wherein the nucleic acid sequences may include coding sequences (that is, sequence which encodes an end product), regulatory sequences, non-coding sequences, or any combination thereof. The term construct includes, for example, vector but should not be seen as being limited thereto.</div>
    </li> <li> <para-num num="[0292]"> </para-num> <div id="p-0332" num="0292" class="description-line">Expression vector refers to constructs that have the ability to incorporate and express heterologous nucleic acid fragments (such as, for example, DNA), in a foreign cell. In other words, an expression vector comprises nucleic acid sequences/fragments (such as DNA, mRNA, tRNA, rRNA), capable of being transcribed. Many prokaryotic and eukaryotic expression vectors are known and/or commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art. In some representative embodiments, the expression vector may encode for a double stranded RNA molecule in the target site.</div>
    </li> <li> <para-num num="[0293]"> </para-num> <div id="p-0333" num="0293" class="description-line">The term expression, as used herein, refers to the production of a desired end-product molecule in a target cell. The end-product molecule may include, for example an RNA molecule; a peptide or a protein; and the like; or combinations thereof.</div>
    </li> <li> <para-num num="[0294]"> </para-num> <div id="p-0334" num="0294" class="description-line">As used herein, the terms introducing and transfection may interchangeably be used and refer to the transfer of molecules, such as, for example, nucleic acids, polynucleotide molecules, vectors, and the like into a target cell(s), and more specifically into the interior of a membrane-enclosed space of a target cell(s). The molecules can be introduced into the target cell(s) by any means known to those of skill in the art, for example as taught by Sambrook et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York (2001), the contents of which are incorporated by reference herein. Means of introducing molecules into a cell include, for example, but are not limited to: heat shock, calcium phosphate transfection, PEI transfection, electroporation, lipofection, transfection reagent(s), viral-mediated transfer, and the like, or combinations thereof. The transfection of the cell may be performed on any type of cell, of any origin, such as, for example, human cells, animal cells, plant cells, virus cell, and the like. The cells may be selected from isolated cells, tissue cultured cells, cell lines, cells present within an organism body, and the like.</div>
    </li> <li> <para-num num="[0295]"> </para-num> <div id="p-0335" num="0295" class="description-line">The term treating and treatment as used herein refers to abrogating, inhibiting, slowing or reversing the progression of a disease or condition, ameliorating clinical symptoms of a disease or condition or preventing the appearance of clinical symptoms of a disease or condition. The term preventing is defined herein as barring a subject from acquiring a disorder or disease or condition.</div>
    </li> <li> <para-num num="[0296]"> </para-num> <div id="p-0336" num="0296" class="description-line">The term treatment of cancer is directed to include one or more of the following: a decrease in the rate of growth of the cancer (i.e. the cancer still grows but at a slower rate); cessation of growth of the cancerous growth, i.e., stasis of the tumor growth, and, the tumor diminishes or is reduced in size. The term also includes reduction in the number of metastases, reduction in the number of new metastases formed, slowing of the progression of cancer from one stage to the other and a decrease in the angiogenesis induced by the cancer. In most preferred cases, the tumor is totally eliminated. Additionally included in this term is lengthening of the survival period of the subject undergoing treatment, lengthening the time of diseases progression, tumor regression, and the like. In some embodiments, the cancer is a blood cancer.</div>
    </li> <li> <para-num num="[0297]"> </para-num> <div id="p-0337" num="0297" class="description-line">The term Leukocytes is directed to white blood cells (WBCs), produced and derived from a multipotent, hematopoietic stem cell in the bone marrow. The white blood cells have nuclei, and types of white blood cells can be classified in into five main types, including, neutrophils, eosinophils, basophils, lymphocytes, and monocytes, based on functional or physical characteristics. The main types may be classified into subtypes. For example, lymphocytes include B cells, T cells, and NK cells. B-cells, for example, release antibodies and assist activation of T cells. T cells, for example, can be classified to several subtypes, including: T-helper cells (CD4+ Th) which activate and regulate T and B cells; cytotoxic T cells (CD8+) that can target and kill virus-infected cells and tumor cells; Gamma-delta T cells ( T cells) which can bridge between innate and adaptive immune responses and be involved in phagocytosis; and Regulatory (suppressor) T cells which modulate the immune system, maintain tolerance to self-antigens, and abrogate autoimmune conditions.</div>
    </li> <li> <para-num num="[0298]"> </para-num> <div id="p-0338" num="0298" class="description-line">Synthetic Methods</div>
    </li> <li> <para-num num="[0299]"> </para-num> <div id="p-0339" num="0299" class="description-line">The compounds of the present invention can be prepared in accordance the following general synthetic methods:</div>
    </li> <li> <div id="p-0340" num="0000" class="description-line">
      <chemistry id="CHEM-US-00106" num="00106">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/61/52/b25a9c9178453a/US20190292130A1-20190926-C00106.png"><img id="EMI-C00106" he="246.21mm" wi="76.28mm" file="US20190292130A1-20190926-C00106.TIF" alt="Figure US20190292130A1-20190926-C00106" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="305" height="985" alt="Figure US20190292130A1-20190926-C00106" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/61/52/b25a9c9178453a/US20190292130A1-20190926-C00106.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00106" attachment-type="cdx" file="US20190292130A1-20190926-C00106.CDX"> </attachment>
          <attachment idref="CHEM-US-00106" attachment-type="mol" file="US20190292130A1-20190926-C00106.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00107" num="00107">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/11/ee/ca/cffe432141ad2c/US20190292130A1-20190926-C00107.png"><img id="EMI-C00107" he="20.24mm" wi="31.75mm" file="US20190292130A1-20190926-C00107.TIF" alt="Figure US20190292130A1-20190926-C00107" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="127" height="81" alt="Figure US20190292130A1-20190926-C00107" class="patent-full-image" src="https://patentimages.storage.googleapis.com/11/ee/ca/cffe432141ad2c/US20190292130A1-20190926-C00107.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00107" attachment-type="cdx" file="US20190292130A1-20190926-C00107.CDX"> </attachment>
          <attachment idref="CHEM-US-00107" attachment-type="mol" file="US20190292130A1-20190926-C00107.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0341" num="0000" class="description-line">
      <tables id="TABLE-US-00003" num="00003">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2"> <figure-callout id="2" label="SCHEME" filenames="US20190292130A1-20190926-D00018.png,US20190292130A1-20190926-D00021.png" state="{{state}}">SCHEME</figure-callout> 2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">General Scheme</td>
                <td class="description-td">Method</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00108" num="00108">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/15/44/64/1fe422620048ff/US20190292130A1-20190926-C00108.png"><img id="EMI-C00108" he="16.68mm" wi="60.37mm" file="US20190292130A1-20190926-C00108.TIF" alt="Figure US20190292130A1-20190926-C00108" img-content="table" img-format="tif" orientation="portrait" inline="no" width="241" height="67" alt="Figure US20190292130A1-20190926-C00108" class="patent-full-image" src="https://patentimages.storage.googleapis.com/15/44/64/1fe422620048ff/US20190292130A1-20190926-C00108.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00108" attachment-type="cdx" file="US20190292130A1-20190926-C00108.CDX"> </attachment>
                      <attachment idref="CHEM-US-00108" attachment-type="mol" file="US20190292130A1-20190926-C00108.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">C</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00109" num="00109">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/68/c0/85/37c9f617842472/US20190292130A1-20190926-C00109.png"><img id="EMI-C00109" he="25.23mm" wi="48.60mm" file="US20190292130A1-20190926-C00109.TIF" alt="Figure US20190292130A1-20190926-C00109" img-content="table" img-format="tif" orientation="portrait" inline="no" width="194" height="101" alt="Figure US20190292130A1-20190926-C00109" class="patent-full-image" src="https://patentimages.storage.googleapis.com/68/c0/85/37c9f617842472/US20190292130A1-20190926-C00109.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00109" attachment-type="cdx" file="US20190292130A1-20190926-C00109.CDX"> </attachment>
                      <attachment idref="CHEM-US-00109" attachment-type="mol" file="US20190292130A1-20190926-C00109.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00110" num="00110">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/2e/a3/1f593ab9530750/US20190292130A1-20190926-C00110.png"><img id="EMI-C00110" he="5.25mm" wi="26.42mm" file="US20190292130A1-20190926-C00110.TIF" alt="Figure US20190292130A1-20190926-C00110" img-content="table" img-format="tif" orientation="portrait" inline="no" width="106" height="21" alt="Figure US20190292130A1-20190926-C00110" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/2e/a3/1f593ab9530750/US20190292130A1-20190926-C00110.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00110" attachment-type="cdx" file="US20190292130A1-20190926-C00110.CDX"> </attachment>
                      <attachment idref="CHEM-US-00110" attachment-type="mol" file="US20190292130A1-20190926-C00110.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">A&amp;B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00111" num="00111">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fd/cb/b4/bcbd540cfcb2d0/US20190292130A1-20190926-C00111.png"><img id="EMI-C00111" he="13.12mm" wi="42.93mm" file="US20190292130A1-20190926-C00111.TIF" alt="Figure US20190292130A1-20190926-C00111" img-content="table" img-format="tif" orientation="portrait" inline="no" width="172" height="52" alt="Figure US20190292130A1-20190926-C00111" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fd/cb/b4/bcbd540cfcb2d0/US20190292130A1-20190926-C00111.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00111" attachment-type="cdx" file="US20190292130A1-20190926-C00111.CDX"> </attachment>
                      <attachment idref="CHEM-US-00111" attachment-type="mol" file="US20190292130A1-20190926-C00111.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00112" num="00112">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bb/f2/a6/d872614fdd08a1/US20190292130A1-20190926-C00112.png"><img id="EMI-C00112" he="16.17mm" wi="33.53mm" file="US20190292130A1-20190926-C00112.TIF" alt="Figure US20190292130A1-20190926-C00112" img-content="table" img-format="tif" orientation="portrait" inline="no" width="134" height="65" alt="Figure US20190292130A1-20190926-C00112" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bb/f2/a6/d872614fdd08a1/US20190292130A1-20190926-C00112.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00112" attachment-type="cdx" file="US20190292130A1-20190926-C00112.CDX"> </attachment>
                      <attachment idref="CHEM-US-00112" attachment-type="mol" file="US20190292130A1-20190926-C00112.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00113" num="00113">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/57/8a/7a/48580e18792f22/US20190292130A1-20190926-C00113.png"><img id="EMI-C00113" he="10.58mm" wi="49.11mm" file="US20190292130A1-20190926-C00113.TIF" alt="Figure US20190292130A1-20190926-C00113" img-content="table" img-format="tif" orientation="portrait" inline="no" width="196" height="42" alt="Figure US20190292130A1-20190926-C00113" class="patent-full-image" src="https://patentimages.storage.googleapis.com/57/8a/7a/48580e18792f22/US20190292130A1-20190926-C00113.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00113" attachment-type="cdx" file="US20190292130A1-20190926-C00113.CDX"> </attachment>
                      <attachment idref="CHEM-US-00113" attachment-type="mol" file="US20190292130A1-20190926-C00113.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00114" num="00114">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/79/86/ac/d56e9d3cc8d84e/US20190292130A1-20190926-C00114.png"><img id="EMI-C00114" he="17.53mm" wi="50.38mm" file="US20190292130A1-20190926-C00114.TIF" alt="Figure US20190292130A1-20190926-C00114" img-content="table" img-format="tif" orientation="portrait" inline="no" width="202" height="70" alt="Figure US20190292130A1-20190926-C00114" class="patent-full-image" src="https://patentimages.storage.googleapis.com/79/86/ac/d56e9d3cc8d84e/US20190292130A1-20190926-C00114.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00114" attachment-type="cdx" file="US20190292130A1-20190926-C00114.CDX"> </attachment>
                      <attachment idref="CHEM-US-00114" attachment-type="mol" file="US20190292130A1-20190926-C00114.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00115" num="00115">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b3/70/67/490eab555c76ea/US20190292130A1-20190926-C00115.png"><img id="EMI-C00115" he="11.18mm" wi="41.49mm" file="US20190292130A1-20190926-C00115.TIF" alt="Figure US20190292130A1-20190926-C00115" img-content="table" img-format="tif" orientation="portrait" inline="no" width="166" height="45" alt="Figure US20190292130A1-20190926-C00115" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b3/70/67/490eab555c76ea/US20190292130A1-20190926-C00115.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00115" attachment-type="cdx" file="US20190292130A1-20190926-C00115.CDX"> </attachment>
                      <attachment idref="CHEM-US-00115" attachment-type="mol" file="US20190292130A1-20190926-C00115.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00116" num="00116">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/49/5e/9cfef8587a9c45/US20190292130A1-20190926-C00116.png"><img id="EMI-C00116" he="14.90mm" wi="37.17mm" file="US20190292130A1-20190926-C00116.TIF" alt="Figure US20190292130A1-20190926-C00116" img-content="table" img-format="tif" orientation="portrait" inline="no" width="149" height="60" alt="Figure US20190292130A1-20190926-C00116" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/49/5e/9cfef8587a9c45/US20190292130A1-20190926-C00116.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00116" attachment-type="cdx" file="US20190292130A1-20190926-C00116.CDX"> </attachment>
                      <attachment idref="CHEM-US-00116" attachment-type="mol" file="US20190292130A1-20190926-C00116.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">A&amp;B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00117" num="00117">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ae/d6/70/a47190a024b5b8/US20190292130A1-20190926-C00117.png"><img id="EMI-C00117" he="14.90mm" wi="51.31mm" file="US20190292130A1-20190926-C00117.TIF" alt="Figure US20190292130A1-20190926-C00117" img-content="table" img-format="tif" orientation="portrait" inline="no" width="205" height="60" alt="Figure US20190292130A1-20190926-C00117" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ae/d6/70/a47190a024b5b8/US20190292130A1-20190926-C00117.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00117" attachment-type="cdx" file="US20190292130A1-20190926-C00117.CDX"> </attachment>
                      <attachment idref="CHEM-US-00117" attachment-type="mol" file="US20190292130A1-20190926-C00117.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00118" num="00118">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/43/67/cf/7e389c69b0ac73/US20190292130A1-20190926-C00118.png"><img id="EMI-C00118" he="13.04mm" wi="37.08mm" file="US20190292130A1-20190926-C00118.TIF" alt="Figure US20190292130A1-20190926-C00118" img-content="table" img-format="tif" orientation="portrait" inline="no" width="148" height="52" alt="Figure US20190292130A1-20190926-C00118" class="patent-full-image" src="https://patentimages.storage.googleapis.com/43/67/cf/7e389c69b0ac73/US20190292130A1-20190926-C00118.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00118" attachment-type="cdx" file="US20190292130A1-20190926-C00118.CDX"> </attachment>
                      <attachment idref="CHEM-US-00118" attachment-type="mol" file="US20190292130A1-20190926-C00118.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00119" num="00119">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4c/f4/fc/e6041b394512d0/US20190292130A1-20190926-C00119.png"><img id="EMI-C00119" he="14.22mm" wi="41.74mm" file="US20190292130A1-20190926-C00119.TIF" alt="Figure US20190292130A1-20190926-C00119" img-content="table" img-format="tif" orientation="portrait" inline="no" width="167" height="57" alt="Figure US20190292130A1-20190926-C00119" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4c/f4/fc/e6041b394512d0/US20190292130A1-20190926-C00119.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00119" attachment-type="cdx" file="US20190292130A1-20190926-C00119.CDX"> </attachment>
                      <attachment idref="CHEM-US-00119" attachment-type="mol" file="US20190292130A1-20190926-C00119.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">A&amp;D</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00120" num="00120">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a1/87/82/9392a7f7744354/US20190292130A1-20190926-C00120.png"><img id="EMI-C00120" he="11.43mm" wi="42.33mm" file="US20190292130A1-20190926-C00120.TIF" alt="Figure US20190292130A1-20190926-C00120" img-content="table" img-format="tif" orientation="portrait" inline="no" width="169" height="46" alt="Figure US20190292130A1-20190926-C00120" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a1/87/82/9392a7f7744354/US20190292130A1-20190926-C00120.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00120" attachment-type="cdx" file="US20190292130A1-20190926-C00120.CDX"> </attachment>
                      <attachment idref="CHEM-US-00120" attachment-type="mol" file="US20190292130A1-20190926-C00120.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00121" num="00121">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ce/1e/e1/95b656495849c7/US20190292130A1-20190926-C00121.png"><img id="EMI-C00121" he="11.35mm" wi="58.00mm" file="US20190292130A1-20190926-C00121.TIF" alt="Figure US20190292130A1-20190926-C00121" img-content="table" img-format="tif" orientation="portrait" inline="no" width="232" height="45" alt="Figure US20190292130A1-20190926-C00121" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ce/1e/e1/95b656495849c7/US20190292130A1-20190926-C00121.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00121" attachment-type="cdx" file="US20190292130A1-20190926-C00121.CDX"> </attachment>
                      <attachment idref="CHEM-US-00121" attachment-type="mol" file="US20190292130A1-20190926-C00121.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00122" num="00122">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/15/49/38/ffc25a684f9874/US20190292130A1-20190926-C00122.png"><img id="EMI-C00122" he="25.57mm" wi="57.49mm" file="US20190292130A1-20190926-C00122.TIF" alt="Figure US20190292130A1-20190926-C00122" img-content="table" img-format="tif" orientation="portrait" inline="no" width="230" height="102" alt="Figure US20190292130A1-20190926-C00122" class="patent-full-image" src="https://patentimages.storage.googleapis.com/15/49/38/ffc25a684f9874/US20190292130A1-20190926-C00122.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00122" attachment-type="cdx" file="US20190292130A1-20190926-C00122.CDX"> </attachment>
                      <attachment idref="CHEM-US-00122" attachment-type="mol" file="US20190292130A1-20190926-C00122.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00123" num="00123">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/18/4f/59/14b208f4e958aa/US20190292130A1-20190926-C00123.png"><img id="EMI-C00123" he="25.57mm" wi="61.72mm" file="US20190292130A1-20190926-C00123.TIF" alt="Figure US20190292130A1-20190926-C00123" img-content="table" img-format="tif" orientation="portrait" inline="no" width="247" height="102" alt="Figure US20190292130A1-20190926-C00123" class="patent-full-image" src="https://patentimages.storage.googleapis.com/18/4f/59/14b208f4e958aa/US20190292130A1-20190926-C00123.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00123" attachment-type="cdx" file="US20190292130A1-20190926-C00123.CDX"> </attachment>
                      <attachment idref="CHEM-US-00123" attachment-type="mol" file="US20190292130A1-20190926-C00123.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00001" class="description-td" colspan="2">z = 0, 2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00002" class="description-td" colspan="2">z<sub>1</sub>, x = 2-10</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00003" class="description-td" colspan="2">n = 0,6</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00004" class="description-td" colspan="2">R = alkyl, alkenyl, alkynyl</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00005" class="description-td" colspan="2">R,R = alkyl</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00006" class="description-td" colspan="2">P = amine protecting group</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00007" class="description-td" colspan="2">LG-leaving group</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0342" num="0000" class="description-line">
      <tables id="TABLE-US-00004" num="00004">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2"> <figure-callout id="3" label="SCHEME" filenames="US20190292130A1-20190926-D00011.png,US20190292130A1-20190926-D00017.png" state="{{state}}">SCHEME</figure-callout> 3</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">General Scheme</td>
                <td class="description-td">Method</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00124" num="00124">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/17/7e/2b/be6bd1a46e533e/US20190292130A1-20190926-C00124.png"><img id="EMI-C00124" he="14.05mm" wi="103.12mm" file="US20190292130A1-20190926-C00124.TIF" alt="Figure US20190292130A1-20190926-C00124" img-content="table" img-format="tif" orientation="portrait" inline="no" width="412" height="56" alt="Figure US20190292130A1-20190926-C00124" class="patent-full-image" src="https://patentimages.storage.googleapis.com/17/7e/2b/be6bd1a46e533e/US20190292130A1-20190926-C00124.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00124" attachment-type="cdx" file="US20190292130A1-20190926-C00124.CDX"> </attachment>
                      <attachment idref="CHEM-US-00124" attachment-type="mol" file="US20190292130A1-20190926-C00124.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00125" num="00125">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9a/e3/e9/d473a4ba3ee390/US20190292130A1-20190926-C00125.png"><img id="EMI-C00125" he="19.22mm" wi="46.74mm" file="US20190292130A1-20190926-C00125.TIF" alt="Figure US20190292130A1-20190926-C00125" img-content="table" img-format="tif" orientation="portrait" inline="no" width="187" height="77" alt="Figure US20190292130A1-20190926-C00125" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9a/e3/e9/d473a4ba3ee390/US20190292130A1-20190926-C00125.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00125" attachment-type="cdx" file="US20190292130A1-20190926-C00125.CDX"> </attachment>
                      <attachment idref="CHEM-US-00125" attachment-type="mol" file="US20190292130A1-20190926-C00125.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00126" num="00126">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8f/7f/a0/382e690f3fdf1f/US20190292130A1-20190926-C00126.png"><img id="EMI-C00126" he="18.80mm" wi="85.60mm" file="US20190292130A1-20190926-C00126.TIF" alt="Figure US20190292130A1-20190926-C00126" img-content="table" img-format="tif" orientation="portrait" inline="no" width="342" height="75" alt="Figure US20190292130A1-20190926-C00126" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8f/7f/a0/382e690f3fdf1f/US20190292130A1-20190926-C00126.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00126" attachment-type="cdx" file="US20190292130A1-20190926-C00126.CDX"> </attachment>
                      <attachment idref="CHEM-US-00126" attachment-type="mol" file="US20190292130A1-20190926-C00126.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00127" num="00127">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4a/08/17/630e0a270e00e0/US20190292130A1-20190926-C00127.png"><img id="EMI-C00127" he="17.10mm" wi="73.91mm" file="US20190292130A1-20190926-C00127.TIF" alt="Figure US20190292130A1-20190926-C00127" img-content="table" img-format="tif" orientation="portrait" inline="no" width="296" height="68" alt="Figure US20190292130A1-20190926-C00127" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4a/08/17/630e0a270e00e0/US20190292130A1-20190926-C00127.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00127" attachment-type="cdx" file="US20190292130A1-20190926-C00127.CDX"> </attachment>
                      <attachment idref="CHEM-US-00127" attachment-type="mol" file="US20190292130A1-20190926-C00127.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00128" num="00128">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a6/78/24/48734ed5386afd/US20190292130A1-20190926-C00128.png"><img id="EMI-C00128" he="15.83mm" wi="81.79mm" file="US20190292130A1-20190926-C00128.TIF" alt="Figure US20190292130A1-20190926-C00128" img-content="table" img-format="tif" orientation="portrait" inline="no" width="327" height="63" alt="Figure US20190292130A1-20190926-C00128" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a6/78/24/48734ed5386afd/US20190292130A1-20190926-C00128.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00128" attachment-type="cdx" file="US20190292130A1-20190926-C00128.CDX"> </attachment>
                      <attachment idref="CHEM-US-00128" attachment-type="mol" file="US20190292130A1-20190926-C00128.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00129" num="00129">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/c8/38/2976d007a5b39c/US20190292130A1-20190926-C00129.png"><img id="EMI-C00129" he="36.32mm" wi="143.59mm" file="US20190292130A1-20190926-C00129.TIF" alt="Figure US20190292130A1-20190926-C00129" img-content="table" img-format="tif" orientation="portrait" inline="no" width="574" height="145" alt="Figure US20190292130A1-20190926-C00129" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/c8/38/2976d007a5b39c/US20190292130A1-20190926-C00129.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00129" attachment-type="cdx" file="US20190292130A1-20190926-C00129.CDX"> </attachment>
                      <attachment idref="CHEM-US-00129" attachment-type="mol" file="US20190292130A1-20190926-C00129.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B         B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00130" num="00130">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/01/98/c4/1cd503cf1a2239/US20190292130A1-20190926-C00130.png"><img id="EMI-C00130" he="13.55mm" wi="86.28mm" file="US20190292130A1-20190926-C00130.TIF" alt="Figure US20190292130A1-20190926-C00130" img-content="table" img-format="tif" orientation="portrait" inline="no" width="345" height="54" alt="Figure US20190292130A1-20190926-C00130" class="patent-full-image" src="https://patentimages.storage.googleapis.com/01/98/c4/1cd503cf1a2239/US20190292130A1-20190926-C00130.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00130" attachment-type="cdx" file="US20190292130A1-20190926-C00130.CDX"> </attachment>
                      <attachment idref="CHEM-US-00130" attachment-type="mol" file="US20190292130A1-20190926-C00130.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">D</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00131" num="00131">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ef/d0/a1/a000d2340ef573/US20190292130A1-20190926-C00131.png"><img id="EMI-C00131" he="64.60mm" wi="104.90mm" file="US20190292130A1-20190926-C00131.TIF" alt="Figure US20190292130A1-20190926-C00131" img-content="table" img-format="tif" orientation="portrait" inline="no" width="420" height="258" alt="Figure US20190292130A1-20190926-C00131" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ef/d0/a1/a000d2340ef573/US20190292130A1-20190926-C00131.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00131" attachment-type="cdx" file="US20190292130A1-20190926-C00131.CDX"> </attachment>
                      <attachment idref="CHEM-US-00131" attachment-type="mol" file="US20190292130A1-20190926-C00131.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00008" class="description-td" colspan="2">z = 0, 2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00009" class="description-td" colspan="2">x, z<sub>1 </sub>= 2-10</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00010" class="description-td" colspan="2">R = alkyl, alkenyl, alkynyl</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00011" class="description-td" colspan="2">P = protecting group</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00012" class="description-td" colspan="2">LG = leaving group</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0300]"> </para-num> <div id="p-0343" num="0300" class="description-line">The foregoing examples of the related art and limitations related therewith are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those of skill in the art upon a reading of the specification and a study of the figures.</div>
    </li> <li> <para-num num="[0301]"> </para-num> <div id="p-0344" num="0301" class="description-line">All references cited herein are hereby incorporated by references in their entirety herein.</div>
    </li> <heading id="h-0019">Example 1: Materials and Methods</heading>
    <heading id="h-0020">Materials</heading>
    <li> <para-num num="[0302]"> </para-num> <div id="p-0345" num="0302" class="description-line">Lipids: All lipids used for LNPs production (Cholesterol, DSPC and DSPE PEG-Mal) were purchased from Avanti Polar lipids (USA).
<br/>
Monoclonal antibodies: anti-CD45 AF647, Annexin-647 was purchased from BioLegend. Propodeum Iodide was purchased from Sigma-Aldrich.
<br/>
siRNA molecules were designed and screened by Alnylam Pharmaceuticals (USA).
<br/>
Chemically modified siRNAs sequences:
</div>
    </li> <li> <div id="p-0346" num="0000" class="description-line"> <tables id="TABLE-US-00005" num="00005"> <patent-tables frame="none" colsep="0" rowsep="0" tabstyle="monospace"> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">CD45siRNA:</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">(SEQIDNO:1)</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">Sensestrand:</td> <td class="description-td">cuGGcuGAAuuucAGAGcAdTsdT</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td"> </td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">(SEQIDNO:2)</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">Anti-Sensestrand:</td> <td class="description-td">UGCUCUGAAAUUcAGCcAGdTsdT</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td"> </td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">NC5siRNA(siNC5orctlsiRNA):</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">Sensestrand:</td> <td class="description-td">CAUAUUGCGCGUAUAGUCGCGUUAG</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">Anti-Sensestrand:</td> <td class="description-td">UGGUAUAACGCGCAUAUCAGCGCAAUC</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td"> </td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">LucsiRNA(siLuc):</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">(SEQIDNO:3)</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">Sensestrand:</td> <td class="description-td">cuuAcGcuGAGuAcuucGAdTsdT</td> </tr> <tr class="description-tr"> <td class="description-td"> </td> <td class="description-td"> </td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">(SEQIDNO:4)</td> </tr>  </tbody></table> <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%"> <tbody><tr class="description-tr"> <td class="description-td"> </td> <td class="description-td">Anti-Sensestrand:</td> <td class="description-td">UCGAAGuACUcAGCGuAAGdTsdT</td> </tr>  </tbody></table> </patent-tables> </tables> <br/>
Alexa-647-labeled siRNA possessed the same sequence as siLuc. 2-OMe modified nucleotides are in lower case, and phosphorothioate linkages are represented by s.
</div>
    </li> <li> <div id="p-0347" num="0000" class="description-line">
      <tables id="TABLE-US-00006" num="00006">
        <patent-tables frame="none" colsep="0" rowsep="0" tabstyle="monospace">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> <figure-callout id="1" label="PLK" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">PLK</figure-callout>1siRNA(PLK1)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Sensestrand</td>
                <td class="description-td">GCUUAAUGACGAGUUCUUUACUUCT</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Anti-Sensestrand:</td>
                <td class="description-td">GACGAAUUACUGCUCAAGAAAUGAAGA</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0021">Cell Lines:</heading>
    <li> <para-num num="[0303]"> </para-num> <div id="p-0348" num="0303" class="description-line">SupT1, HEK 293, NAR and OVCAR-8 cells were purchased from the American Type Culture Collection (ATCC) and cultured as recommended.
<br/>
Preparation of Lipid-Based Nanoparticles (LNPs) Entrapping siRNAs
</div>
    </li> <li> <para-num num="[0304]"> </para-num> <div id="p-0349" num="0304" class="description-line">LNPs were prepared by using microfluidic micro mixture (Precision NanoSystems, Vancouver, BC, Canada) as described by Cohen et. al. One volume of lipid mixtures (cationic lipid, DSPC, Chol, DMG-PEG and DSPE-PEG Mal at 50:10:38:1.5:0.5 mole ratio, 9.64 nM total lipid concentration) in ethanol and three volumes of siRNA (1:16 w/w siRNA to lipid) containing acetate buffer solutions were injected through the micro mixer at a combined flow rate of 2 mL/minute (0.5 mL/min for ethanol and 1.5 mL/min for aqueous buffer). For labeled LNPs, 10% of Alexa-647 labeled siRNA were incorporated. For Cy5 labeled particles, 10% Cy5 labeled non-targeted siRNA was used. The resultant mixture was dialyzed against PBS (pH 7.4) for 16 h to remove ethanol.</div>
    </li> <heading id="h-0022">Size, -Potential and Ultrastructure Analysis of a CD38-LNPs-siRNA</heading>
    <li> <para-num num="[0305]"> </para-num> <div id="p-0350" num="0305" class="description-line">LNPs size distribution and  potential were determined by dynamic light scattering using a Malvern nano ZS -sizer (Malvern instruments, UK). For size measurements, LNPs were diluted 1:20 in PBS. All utilized samples showed a polydispersity index (PDI) lower than 0.2. For  potential measurements, LNPs were diluted 1:200 in DDW. In some cases, as indicated, size and zeta potential measurements were performed in water.</div>
    </li> <heading id="h-0023">Quantitative Real-Time PCR</heading>
    <li> <para-num num="[0306]"> </para-num> <div id="p-0351" num="0306" class="description-line">The mRNA levels of pololike kinase 1 (PLK1 gene) in cells was quantified by real-time PCR, forty eight or Seventy-two hours post-transfection. Total RNA was isolated using the E-Z RNA purification kit (Biological industries, Beit Haemek, Israel), and 1 g of RNA from each sample was reverse transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif.), Quantification of cDNA (5 ng total) was performed on the step one Sequence Detection System (Applied Biosystems, Foster City, Calif.) using syber green (Applied Biosystems). GAPDH was chosen as a housekeeping gene.</div>
    </li> <li> <div id="p-0352" num="0000" class="description-line">For real time PCR the following primers were chosen:</div>
    </li> <li> <div id="p-0353" num="0000" class="description-line">
      <tables id="TABLE-US-00007" num="00007">
        <patent-tables frame="none" colsep="0" rowsep="0" tabstyle="monospace">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PrimersforPLK1:</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">forward-ACCAGCACGTCGTAGGATTC</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">reverse-CAAGCACAATTTGCCGTAGG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">PrimersforGAPDH:</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">forward-TCAGGGTTTCACATTTGGCA</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">reverse-GAGCATGGATCGGAAAACCA</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0024">In Vitro Gene Silencing</heading>
    <li> <para-num num="[0307]"> </para-num> <div id="p-0354" num="0307" class="description-line">Supt1 or NAR or OVCAR cells were placed in tissue culture 12-wells plates at a density of 110<sup>5 </sup>cells with 1 mL of full medium. LNPs containing different siRNAs (siPLK1 or siCD45 or siLUC) were added to the wells and the concentration was mentioned in figures. Cells were isolated at different time intervals mentioned in the figures and analyzed by either flow cytometry (for siCD45 knockdown), or qPCR for analysis of PLK1 silencing. Apoptosis assay using PI/Annexin was analyzed by flow cytometry in case of siPLK1 induced cell death.</div>
    </li> <heading id="h-0025">Cell Cycle Studies:</heading>
    <li> <para-num num="[0308]"> </para-num> <div id="p-0355" num="0308" class="description-line">The transfected cells were washed with ice-cold PBS, and fixed with 70% ethanol for 1 h. Then, the cells were washed twice with cold PBS and incubated for 10 min at 37 C. in 250 L PBS with 10 g/mL propidium iodide (PI), 2.5 g/mL DNase-free RNase A (Sigma, USA) and 0.01% Triton-X. PI fluorescence was assessed by flow cytometry. Analyzes by FlowJo were performed on at least 9000 cells per samples after gating out debris and cell duplets based on the FL2-Area/FL2-Width channels. Cell cycle distributions were obtained via the application of the Dean-Jett-Fox model on gated cells with RMS scores ranging between 1.5 and 2.5.</div>
    </li> <heading id="h-0026">Example 2: Synthesis of Lipids</heading>
    <heading id="h-0027">General Preparation Methods (Exemplary Embodiments of Schemes 1-3).</heading>
    <li> <para-num num="[0309]"> </para-num> <div id="p-0356" num="0309" class="description-line"> </div>
    </li> <li> <div id="p-0357" num="0000" class="description-line">
      <tables id="TABLE-US-00008" num="00008">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2"> <figure-callout id="4" label="SCHEME" filenames="US20190292130A1-20190926-D00018.png,US20190292130A1-20190926-D00019.png" state="{{state}}">SCHEME</figure-callout> 4</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">General Scheme</td>
                <td class="description-td">Method</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00132" num="00132">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/b0/30/c9d68b62d1e011/US20190292130A1-20190926-C00132.png"><img id="EMI-C00132" he="16.51mm" wi="51.05mm" file="US20190292130A1-20190926-C00132.TIF" alt="Figure US20190292130A1-20190926-C00132" img-content="table" img-format="tif" orientation="portrait" inline="no" width="204" height="66" alt="Figure US20190292130A1-20190926-C00132" class="patent-full-image" src="https://patentimages.storage.googleapis.com/66/b0/30/c9d68b62d1e011/US20190292130A1-20190926-C00132.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00132" attachment-type="cdx" file="US20190292130A1-20190926-C00132.CDX"> </attachment>
                      <attachment idref="CHEM-US-00132" attachment-type="mol" file="US20190292130A1-20190926-C00132.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">A</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00133" num="00133">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/cc/3a/35d0466e111824/US20190292130A1-20190926-C00133.png"><img id="EMI-C00133" he="24.38mm" wi="49.02mm" file="US20190292130A1-20190926-C00133.TIF" alt="Figure US20190292130A1-20190926-C00133" img-content="table" img-format="tif" orientation="portrait" inline="no" width="196" height="98" alt="Figure US20190292130A1-20190926-C00133" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/cc/3a/35d0466e111824/US20190292130A1-20190926-C00133.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00133" attachment-type="cdx" file="US20190292130A1-20190926-C00133.CDX"> </attachment>
                      <attachment idref="CHEM-US-00133" attachment-type="mol" file="US20190292130A1-20190926-C00133.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00134" num="00134">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7d/1a/78/1521c302a615b8/US20190292130A1-20190926-C00134.png"><img id="EMI-C00134" he="24.38mm" wi="32.34mm" file="US20190292130A1-20190926-C00134.TIF" alt="Figure US20190292130A1-20190926-C00134" img-content="table" img-format="tif" orientation="portrait" inline="no" width="129" height="98" alt="Figure US20190292130A1-20190926-C00134" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7d/1a/78/1521c302a615b8/US20190292130A1-20190926-C00134.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00134" attachment-type="cdx" file="US20190292130A1-20190926-C00134.CDX"> </attachment>
                      <attachment idref="CHEM-US-00134" attachment-type="mol" file="US20190292130A1-20190926-C00134.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00135" num="00135">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/14/71/92/5e022def082401/US20190292130A1-20190926-C00135.png"><img id="EMI-C00135" he="24.38mm" wi="80.60mm" file="US20190292130A1-20190926-C00135.TIF" alt="Figure US20190292130A1-20190926-C00135" img-content="table" img-format="tif" orientation="portrait" inline="no" width="322" height="98" alt="Figure US20190292130A1-20190926-C00135" class="patent-full-image" src="https://patentimages.storage.googleapis.com/14/71/92/5e022def082401/US20190292130A1-20190926-C00135.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00135" attachment-type="cdx" file="US20190292130A1-20190926-C00135.CDX"> </attachment>
                      <attachment idref="CHEM-US-00135" attachment-type="mol" file="US20190292130A1-20190926-C00135.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00136" num="00136">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/a2/86/6e4a902a978611/US20190292130A1-20190926-C00136.png"><img id="EMI-C00136" he="24.38mm" wi="83.82mm" file="US20190292130A1-20190926-C00136.TIF" alt="Figure US20190292130A1-20190926-C00136" img-content="table" img-format="tif" orientation="portrait" inline="no" width="335" height="98" alt="Figure US20190292130A1-20190926-C00136" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/a2/86/6e4a902a978611/US20190292130A1-20190926-C00136.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00136" attachment-type="cdx" file="US20190292130A1-20190926-C00136.CDX"> </attachment>
                      <attachment idref="CHEM-US-00136" attachment-type="mol" file="US20190292130A1-20190926-C00136.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">C</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00137" num="00137">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/47/55/27/e5a253e381e47b/US20190292130A1-20190926-C00137.png"><img id="EMI-C00137" he="18.71mm" wi="86.44mm" file="US20190292130A1-20190926-C00137.TIF" alt="Figure US20190292130A1-20190926-C00137" img-content="table" img-format="tif" orientation="portrait" inline="no" width="346" height="75" alt="Figure US20190292130A1-20190926-C00137" class="patent-full-image" src="https://patentimages.storage.googleapis.com/47/55/27/e5a253e381e47b/US20190292130A1-20190926-C00137.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00137" attachment-type="cdx" file="US20190292130A1-20190926-C00137.CDX"> </attachment>
                      <attachment idref="CHEM-US-00137" attachment-type="mol" file="US20190292130A1-20190926-C00137.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">D</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00138" num="00138">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/40/f7/082a469156c081/US20190292130A1-20190926-C00138.png"><img id="EMI-C00138" he="19.47mm" wi="69.43mm" file="US20190292130A1-20190926-C00138.TIF" alt="Figure US20190292130A1-20190926-C00138" img-content="table" img-format="tif" orientation="portrait" inline="no" width="278" height="78" alt="Figure US20190292130A1-20190926-C00138" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/40/f7/082a469156c081/US20190292130A1-20190926-C00138.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00138" attachment-type="cdx" file="US20190292130A1-20190926-C00138.CDX"> </attachment>
                      <attachment idref="CHEM-US-00138" attachment-type="mol" file="US20190292130A1-20190926-C00138.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00139" num="00139">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f9/d6/dc/07b14e7fcbd4bb/US20190292130A1-20190926-C00139.png"><img id="EMI-C00139" he="27.60mm" wi="59.61mm" file="US20190292130A1-20190926-C00139.TIF" alt="Figure US20190292130A1-20190926-C00139" img-content="table" img-format="tif" orientation="portrait" inline="no" width="238" height="110" alt="Figure US20190292130A1-20190926-C00139" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f9/d6/dc/07b14e7fcbd4bb/US20190292130A1-20190926-C00139.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00139" attachment-type="cdx" file="US20190292130A1-20190926-C00139.CDX"> </attachment>
                      <attachment idref="CHEM-US-00139" attachment-type="mol" file="US20190292130A1-20190926-C00139.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00013" class="description-td" colspan="2">z = 0, 2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00014" class="description-td" colspan="2">z<sub>1 </sub>= 2-10</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00015" class="description-td" colspan="2">R = alkyl, alkenyl, alkynyl</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0358" num="0000" class="description-line">
      <tables id="TABLE-US-00009" num="00009">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2"> <figure-callout id="5" label="SCHEME" filenames="US20190292130A1-20190926-D00014.png,US20190292130A1-20190926-D00019.png" state="{{state}}">SCHEME</figure-callout> 5</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">General Scheme</td>
                <td class="description-td">Method</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00140" num="00140">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6d/a1/cb/b3aadc2ba407cf/US20190292130A1-20190926-C00140.png"><img id="EMI-C00140" he="14.56mm" wi="62.40mm" file="US20190292130A1-20190926-C00140.TIF" alt="Figure US20190292130A1-20190926-C00140" img-content="table" img-format="tif" orientation="portrait" inline="no" width="250" height="58" alt="Figure US20190292130A1-20190926-C00140" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6d/a1/cb/b3aadc2ba407cf/US20190292130A1-20190926-C00140.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00140" attachment-type="cdx" file="US20190292130A1-20190926-C00140.CDX"> </attachment>
                      <attachment idref="CHEM-US-00140" attachment-type="mol" file="US20190292130A1-20190926-C00140.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">C</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00141" num="00141">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9b/e1/f3/f41bcff380756e/US20190292130A1-20190926-C00141.png"><img id="EMI-C00141" he="22.86mm" wi="51.56mm" file="US20190292130A1-20190926-C00141.TIF" alt="Figure US20190292130A1-20190926-C00141" img-content="table" img-format="tif" orientation="portrait" inline="no" width="206" height="91" alt="Figure US20190292130A1-20190926-C00141" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9b/e1/f3/f41bcff380756e/US20190292130A1-20190926-C00141.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00141" attachment-type="cdx" file="US20190292130A1-20190926-C00141.CDX"> </attachment>
                      <attachment idref="CHEM-US-00141" attachment-type="mol" file="US20190292130A1-20190926-C00141.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00142" num="00142">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/30/7e/37/f399525d2525b8/US20190292130A1-20190926-C00142.png"><img id="EMI-C00142" he="17.70mm" wi="73.32mm" file="US20190292130A1-20190926-C00142.TIF" alt="Figure US20190292130A1-20190926-C00142" img-content="table" img-format="tif" orientation="portrait" inline="no" width="293" height="71" alt="Figure US20190292130A1-20190926-C00142" class="patent-full-image" src="https://patentimages.storage.googleapis.com/30/7e/37/f399525d2525b8/US20190292130A1-20190926-C00142.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00142" attachment-type="cdx" file="US20190292130A1-20190926-C00142.CDX"> </attachment>
                      <attachment idref="CHEM-US-00142" attachment-type="mol" file="US20190292130A1-20190926-C00142.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">A&amp;B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00143" num="00143">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/89/d9/fe/71f6d2e53aa17b/US20190292130A1-20190926-C00143.png"><img id="EMI-C00143" he="15.24mm" wi="34.97mm" file="US20190292130A1-20190926-C00143.TIF" alt="Figure US20190292130A1-20190926-C00143" img-content="table" img-format="tif" orientation="portrait" inline="no" width="140" height="61" alt="Figure US20190292130A1-20190926-C00143" class="patent-full-image" src="https://patentimages.storage.googleapis.com/89/d9/fe/71f6d2e53aa17b/US20190292130A1-20190926-C00143.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00143" attachment-type="cdx" file="US20190292130A1-20190926-C00143.CDX"> </attachment>
                      <attachment idref="CHEM-US-00143" attachment-type="mol" file="US20190292130A1-20190926-C00143.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00144" num="00144">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/fe/af/4145368d5a075e/US20190292130A1-20190926-C00144.png"><img id="EMI-C00144" he="12.11mm" wi="50.88mm" file="US20190292130A1-20190926-C00144.TIF" alt="Figure US20190292130A1-20190926-C00144" img-content="table" img-format="tif" orientation="portrait" inline="no" width="204" height="48" alt="Figure US20190292130A1-20190926-C00144" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/fe/af/4145368d5a075e/US20190292130A1-20190926-C00144.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00144" attachment-type="cdx" file="US20190292130A1-20190926-C00144.CDX"> </attachment>
                      <attachment idref="CHEM-US-00144" attachment-type="mol" file="US20190292130A1-20190926-C00144.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00145" num="00145">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/50/a2/38/20688cd38095f0/US20190292130A1-20190926-C00145.png"><img id="EMI-C00145" he="17.27mm" wi="52.83mm" file="US20190292130A1-20190926-C00145.TIF" alt="Figure US20190292130A1-20190926-C00145" img-content="table" img-format="tif" orientation="portrait" inline="no" width="211" height="69" alt="Figure US20190292130A1-20190926-C00145" class="patent-full-image" src="https://patentimages.storage.googleapis.com/50/a2/38/20688cd38095f0/US20190292130A1-20190926-C00145.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00145" attachment-type="cdx" file="US20190292130A1-20190926-C00145.CDX"> </attachment>
                      <attachment idref="CHEM-US-00145" attachment-type="mol" file="US20190292130A1-20190926-C00145.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00146" num="00146">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/11/6c/59/c72cb374440f49/US20190292130A1-20190926-C00146.png"><img id="EMI-C00146" he="12.19mm" wi="43.86mm" file="US20190292130A1-20190926-C00146.TIF" alt="Figure US20190292130A1-20190926-C00146" img-content="table" img-format="tif" orientation="portrait" inline="no" width="175" height="49" alt="Figure US20190292130A1-20190926-C00146" class="patent-full-image" src="https://patentimages.storage.googleapis.com/11/6c/59/c72cb374440f49/US20190292130A1-20190926-C00146.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00146" attachment-type="cdx" file="US20190292130A1-20190926-C00146.CDX"> </attachment>
                      <attachment idref="CHEM-US-00146" attachment-type="mol" file="US20190292130A1-20190926-C00146.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00147" num="00147">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/82/78/e0/9bb014453f514d/US20190292130A1-20190926-C00147.png"><img id="EMI-C00147" he="15.16mm" wi="37.59mm" file="US20190292130A1-20190926-C00147.TIF" alt="Figure US20190292130A1-20190926-C00147" img-content="table" img-format="tif" orientation="portrait" inline="no" width="150" height="61" alt="Figure US20190292130A1-20190926-C00147" class="patent-full-image" src="https://patentimages.storage.googleapis.com/82/78/e0/9bb014453f514d/US20190292130A1-20190926-C00147.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00147" attachment-type="cdx" file="US20190292130A1-20190926-C00147.CDX"> </attachment>
                      <attachment idref="CHEM-US-00147" attachment-type="mol" file="US20190292130A1-20190926-C00147.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">A&amp;B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00148" num="00148">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/6c/85/3be978d6600806/US20190292130A1-20190926-C00148.png"><img id="EMI-C00148" he="12.70mm" wi="49.28mm" file="US20190292130A1-20190926-C00148.TIF" alt="Figure US20190292130A1-20190926-C00148" img-content="table" img-format="tif" orientation="portrait" inline="no" width="197" height="51" alt="Figure US20190292130A1-20190926-C00148" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/6c/85/3be978d6600806/US20190292130A1-20190926-C00148.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00148" attachment-type="cdx" file="US20190292130A1-20190926-C00148.CDX"> </attachment>
                      <attachment idref="CHEM-US-00148" attachment-type="mol" file="US20190292130A1-20190926-C00148.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00149" num="00149">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/f6/19/41e141d0cdaa0f/US20190292130A1-20190926-C00149.png"><img id="EMI-C00149" he="12.95mm" wi="35.14mm" file="US20190292130A1-20190926-C00149.TIF" alt="Figure US20190292130A1-20190926-C00149" img-content="table" img-format="tif" orientation="portrait" inline="no" width="141" height="52" alt="Figure US20190292130A1-20190926-C00149" class="patent-full-image" src="https://patentimages.storage.googleapis.com/39/f6/19/41e141d0cdaa0f/US20190292130A1-20190926-C00149.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00149" attachment-type="cdx" file="US20190292130A1-20190926-C00149.CDX"> </attachment>
                      <attachment idref="CHEM-US-00149" attachment-type="mol" file="US20190292130A1-20190926-C00149.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00150" num="00150">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/49/58/bf5369e900f815/US20190292130A1-20190926-C00150.png"><img id="EMI-C00150" he="13.29mm" wi="87.04mm" file="US20190292130A1-20190926-C00150.TIF" alt="Figure US20190292130A1-20190926-C00150" img-content="table" img-format="tif" orientation="portrait" inline="no" width="348" height="53" alt="Figure US20190292130A1-20190926-C00150" class="patent-full-image" src="https://patentimages.storage.googleapis.com/66/49/58/bf5369e900f815/US20190292130A1-20190926-C00150.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00150" attachment-type="cdx" file="US20190292130A1-20190926-C00150.CDX"> </attachment>
                      <attachment idref="CHEM-US-00150" attachment-type="mol" file="US20190292130A1-20190926-C00150.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">A&amp;D</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00151" num="00151">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1f/1a/9c/73de8c89e17401/US20190292130A1-20190926-C00151.png"><img id="EMI-C00151" he="11.01mm" wi="57.57mm" file="US20190292130A1-20190926-C00151.TIF" alt="Figure US20190292130A1-20190926-C00151" img-content="table" img-format="tif" orientation="portrait" inline="no" width="230" height="44" alt="Figure US20190292130A1-20190926-C00151" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1f/1a/9c/73de8c89e17401/US20190292130A1-20190926-C00151.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00151" attachment-type="cdx" file="US20190292130A1-20190926-C00151.CDX"> </attachment>
                      <attachment idref="CHEM-US-00151" attachment-type="mol" file="US20190292130A1-20190926-C00151.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00152" num="00152">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/73/fe/3a/5a730da52622d8/US20190292130A1-20190926-C00152.png"><img id="EMI-C00152" he="24.38mm" wi="57.66mm" file="US20190292130A1-20190926-C00152.TIF" alt="Figure US20190292130A1-20190926-C00152" img-content="table" img-format="tif" orientation="portrait" inline="no" width="231" height="98" alt="Figure US20190292130A1-20190926-C00152" class="patent-full-image" src="https://patentimages.storage.googleapis.com/73/fe/3a/5a730da52622d8/US20190292130A1-20190926-C00152.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00152" attachment-type="cdx" file="US20190292130A1-20190926-C00152.CDX"> </attachment>
                      <attachment idref="CHEM-US-00152" attachment-type="mol" file="US20190292130A1-20190926-C00152.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00153" num="00153">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9c/d3/48/c2026e3831178a/US20190292130A1-20190926-C00153.png"><img id="EMI-C00153" he="24.38mm" wi="59.61mm" file="US20190292130A1-20190926-C00153.TIF" alt="Figure US20190292130A1-20190926-C00153" img-content="table" img-format="tif" orientation="portrait" inline="no" width="238" height="98" alt="Figure US20190292130A1-20190926-C00153" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9c/d3/48/c2026e3831178a/US20190292130A1-20190926-C00153.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00153" attachment-type="cdx" file="US20190292130A1-20190926-C00153.CDX"> </attachment>
                      <attachment idref="CHEM-US-00153" attachment-type="mol" file="US20190292130A1-20190926-C00153.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00016" class="description-td" colspan="2">z = 0,2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00017" class="description-td" colspan="2">z<sub>1</sub>, x = 2-10</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00018" class="description-td" colspan="2">R = alkyl, alkenyl, alkynyl</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0359" num="0000" class="description-line">
      <tables id="TABLE-US-00010" num="00010">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2"> <figure-callout id="6" label="SCHEME" filenames="US20190292130A1-20190926-D00018.png" state="{{state}}">SCHEME</figure-callout> 6</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">General Scheme</td>
                <td class="description-td">Method</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00154" num="00154">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/77/61/50/64e31836a76a11/US20190292130A1-20190926-C00154.png"><img id="EMI-C00154" he="12.87mm" wi="48.51mm" file="US20190292130A1-20190926-C00154.TIF" alt="Figure US20190292130A1-20190926-C00154" img-content="table" img-format="tif" orientation="portrait" inline="no" width="194" height="51" alt="Figure US20190292130A1-20190926-C00154" class="patent-full-image" src="https://patentimages.storage.googleapis.com/77/61/50/64e31836a76a11/US20190292130A1-20190926-C00154.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00154" attachment-type="cdx" file="US20190292130A1-20190926-C00154.CDX"> </attachment>
                      <attachment idref="CHEM-US-00154" attachment-type="mol" file="US20190292130A1-20190926-C00154.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00155" num="00155">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4e/55/6d/5f6c273855ad4a/US20190292130A1-20190926-C00155.png"><img id="EMI-C00155" he="11.35mm" wi="54.10mm" file="US20190292130A1-20190926-C00155.TIF" alt="Figure US20190292130A1-20190926-C00155" img-content="table" img-format="tif" orientation="portrait" inline="no" width="216" height="45" alt="Figure US20190292130A1-20190926-C00155" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4e/55/6d/5f6c273855ad4a/US20190292130A1-20190926-C00155.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00155" attachment-type="cdx" file="US20190292130A1-20190926-C00155.CDX"> </attachment>
                      <attachment idref="CHEM-US-00155" attachment-type="mol" file="US20190292130A1-20190926-C00155.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00156" num="00156">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ab/fd/bb/fb21615cbc3b7f/US20190292130A1-20190926-C00156.png"><img id="EMI-C00156" he="18.46mm" wi="48.18mm" file="US20190292130A1-20190926-C00156.TIF" alt="Figure US20190292130A1-20190926-C00156" img-content="table" img-format="tif" orientation="portrait" inline="no" width="193" height="74" alt="Figure US20190292130A1-20190926-C00156" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ab/fd/bb/fb21615cbc3b7f/US20190292130A1-20190926-C00156.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00156" attachment-type="cdx" file="US20190292130A1-20190926-C00156.CDX"> </attachment>
                      <attachment idref="CHEM-US-00156" attachment-type="mol" file="US20190292130A1-20190926-C00156.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00157" num="00157">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/32/ff/159c5261843883/US20190292130A1-20190926-C00157.png"><img id="EMI-C00157" he="17.78mm" wi="48.34mm" file="US20190292130A1-20190926-C00157.TIF" alt="Figure US20190292130A1-20190926-C00157" img-content="table" img-format="tif" orientation="portrait" inline="no" width="193" height="71" alt="Figure US20190292130A1-20190926-C00157" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/32/ff/159c5261843883/US20190292130A1-20190926-C00157.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00157" attachment-type="cdx" file="US20190292130A1-20190926-C00157.CDX"> </attachment>
                      <attachment idref="CHEM-US-00157" attachment-type="mol" file="US20190292130A1-20190926-C00157.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00158" num="00158">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/46/62/9b/fb71f5046b025f/US20190292130A1-20190926-C00158.png"><img id="EMI-C00158" he="17.78mm" wi="30.31mm" file="US20190292130A1-20190926-C00158.TIF" alt="Figure US20190292130A1-20190926-C00158" img-content="table" img-format="tif" orientation="portrait" inline="no" width="121" height="71" alt="Figure US20190292130A1-20190926-C00158" class="patent-full-image" src="https://patentimages.storage.googleapis.com/46/62/9b/fb71f5046b025f/US20190292130A1-20190926-C00158.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00158" attachment-type="cdx" file="US20190292130A1-20190926-C00158.CDX"> </attachment>
                      <attachment idref="CHEM-US-00158" attachment-type="mol" file="US20190292130A1-20190926-C00158.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00159" num="00159">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/74/08/7c/fe4fc04986f8d6/US20190292130A1-20190926-C00159.png"><img id="EMI-C00159" he="14.05mm" wi="38.18mm" file="US20190292130A1-20190926-C00159.TIF" alt="Figure US20190292130A1-20190926-C00159" img-content="table" img-format="tif" orientation="portrait" inline="no" width="153" height="56" alt="Figure US20190292130A1-20190926-C00159" class="patent-full-image" src="https://patentimages.storage.googleapis.com/74/08/7c/fe4fc04986f8d6/US20190292130A1-20190926-C00159.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00159" attachment-type="cdx" file="US20190292130A1-20190926-C00159.CDX"> </attachment>
                      <attachment idref="CHEM-US-00159" attachment-type="mol" file="US20190292130A1-20190926-C00159.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00160" num="00160">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/26/ab/aa/5715af5a0c19f9/US20190292130A1-20190926-C00160.png"><img id="EMI-C00160" he="7.54mm" wi="75.10mm" file="US20190292130A1-20190926-C00160.TIF" alt="Figure US20190292130A1-20190926-C00160" img-content="table" img-format="tif" orientation="portrait" inline="no" width="300" height="30" alt="Figure US20190292130A1-20190926-C00160" class="patent-full-image" src="https://patentimages.storage.googleapis.com/26/ab/aa/5715af5a0c19f9/US20190292130A1-20190926-C00160.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00160" attachment-type="cdx" file="US20190292130A1-20190926-C00160.CDX"> </attachment>
                      <attachment idref="CHEM-US-00160" attachment-type="mol" file="US20190292130A1-20190926-C00160.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00161" num="00161">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/33/7f/ab/e11af39f39db06/US20190292130A1-20190926-C00161.png"><img id="EMI-C00161" he="14.14mm" wi="39.88mm" file="US20190292130A1-20190926-C00161.TIF" alt="Figure US20190292130A1-20190926-C00161" img-content="table" img-format="tif" orientation="portrait" inline="no" width="160" height="57" alt="Figure US20190292130A1-20190926-C00161" class="patent-full-image" src="https://patentimages.storage.googleapis.com/33/7f/ab/e11af39f39db06/US20190292130A1-20190926-C00161.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00161" attachment-type="cdx" file="US20190292130A1-20190926-C00161.CDX"> </attachment>
                      <attachment idref="CHEM-US-00161" attachment-type="mol" file="US20190292130A1-20190926-C00161.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00162" num="00162">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d3/a0/1d/9f735b3ee817c6/US20190292130A1-20190926-C00162.png"><img id="EMI-C00162" he="9.40mm" wi="31.50mm" file="US20190292130A1-20190926-C00162.TIF" alt="Figure US20190292130A1-20190926-C00162" img-content="table" img-format="tif" orientation="portrait" inline="no" width="126" height="38" alt="Figure US20190292130A1-20190926-C00162" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d3/a0/1d/9f735b3ee817c6/US20190292130A1-20190926-C00162.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00162" attachment-type="cdx" file="US20190292130A1-20190926-C00162.CDX"> </attachment>
                      <attachment idref="CHEM-US-00162" attachment-type="mol" file="US20190292130A1-20190926-C00162.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00163" num="00163">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/53/db/0d/fb50bb18cd87d5/US20190292130A1-20190926-C00163.png"><img id="EMI-C00163" he="7.62mm" wi="57.57mm" file="US20190292130A1-20190926-C00163.TIF" alt="Figure US20190292130A1-20190926-C00163" img-content="table" img-format="tif" orientation="portrait" inline="no" width="230" height="30" alt="Figure US20190292130A1-20190926-C00163" class="patent-full-image" src="https://patentimages.storage.googleapis.com/53/db/0d/fb50bb18cd87d5/US20190292130A1-20190926-C00163.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00163" attachment-type="cdx" file="US20190292130A1-20190926-C00163.CDX"> </attachment>
                      <attachment idref="CHEM-US-00163" attachment-type="mol" file="US20190292130A1-20190926-C00163.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00164" num="00164">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/32/b6/92/b0e71a5b854253/US20190292130A1-20190926-C00164.png"><img id="EMI-C00164" he="12.95mm" wi="35.14mm" file="US20190292130A1-20190926-C00164.TIF" alt="Figure US20190292130A1-20190926-C00164" img-content="table" img-format="tif" orientation="portrait" inline="no" width="141" height="52" alt="Figure US20190292130A1-20190926-C00164" class="patent-full-image" src="https://patentimages.storage.googleapis.com/32/b6/92/b0e71a5b854253/US20190292130A1-20190926-C00164.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00164" attachment-type="cdx" file="US20190292130A1-20190926-C00164.CDX"> </attachment>
                      <attachment idref="CHEM-US-00164" attachment-type="mol" file="US20190292130A1-20190926-C00164.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00165" num="00165">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/dd/95/dd783c874921f2/US20190292130A1-20190926-C00165.png"><img id="EMI-C00165" he="13.29mm" wi="87.04mm" file="US20190292130A1-20190926-C00165.TIF" alt="Figure US20190292130A1-20190926-C00165" img-content="table" img-format="tif" orientation="portrait" inline="no" width="348" height="53" alt="Figure US20190292130A1-20190926-C00165" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/dd/95/dd783c874921f2/US20190292130A1-20190926-C00165.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00165" attachment-type="cdx" file="US20190292130A1-20190926-C00165.CDX"> </attachment>
                      <attachment idref="CHEM-US-00165" attachment-type="mol" file="US20190292130A1-20190926-C00165.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td">B&amp;D</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00166" num="00166">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/92/71/b5/c04c3534dad423/US20190292130A1-20190926-C00166.png"><img id="EMI-C00166" he="11.01mm" wi="52.66mm" file="US20190292130A1-20190926-C00166.TIF" alt="Figure US20190292130A1-20190926-C00166" img-content="table" img-format="tif" orientation="portrait" inline="no" width="211" height="44" alt="Figure US20190292130A1-20190926-C00166" class="patent-full-image" src="https://patentimages.storage.googleapis.com/92/71/b5/c04c3534dad423/US20190292130A1-20190926-C00166.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00166" attachment-type="cdx" file="US20190292130A1-20190926-C00166.CDX"> </attachment>
                      <attachment idref="CHEM-US-00166" attachment-type="mol" file="US20190292130A1-20190926-C00166.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00167" num="00167">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/55/2c/a2/f30ecaa40c62b5/US20190292130A1-20190926-C00167.png"><img id="EMI-C00167" he="24.38mm" wi="68.50mm" file="US20190292130A1-20190926-C00167.TIF" alt="Figure US20190292130A1-20190926-C00167" img-content="table" img-format="tif" orientation="portrait" inline="no" width="274" height="98" alt="Figure US20190292130A1-20190926-C00167" class="patent-full-image" src="https://patentimages.storage.googleapis.com/55/2c/a2/f30ecaa40c62b5/US20190292130A1-20190926-C00167.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00167" attachment-type="cdx" file="US20190292130A1-20190926-C00167.CDX"> </attachment>
                      <attachment idref="CHEM-US-00167" attachment-type="mol" file="US20190292130A1-20190926-C00167.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">
                  <chemistry id="CHEM-US-00168" num="00168">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4a/30/3e/dd69cfd6f0a85b/US20190292130A1-20190926-C00168.png"><img id="EMI-C00168" he="24.38mm" wi="59.61mm" file="US20190292130A1-20190926-C00168.TIF" alt="Figure US20190292130A1-20190926-C00168" img-content="table" img-format="tif" orientation="portrait" inline="no" width="238" height="98" alt="Figure US20190292130A1-20190926-C00168" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4a/30/3e/dd69cfd6f0a85b/US20190292130A1-20190926-C00168.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00168" attachment-type="cdx" file="US20190292130A1-20190926-C00168.CDX"> </attachment>
                      <attachment idref="CHEM-US-00168" attachment-type="mol" file="US20190292130A1-20190926-C00168.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00019" class="description-td" colspan="2">z = 0, 2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00020" class="description-td" colspan="2">zl, x = 2-10</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="left" id="FOO-00021" class="description-td" colspan="2">R, R<sup>2, </sup>R<sup>3 </sup>= alkyl, alkenyl, alkynyl</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0028">Method A:</heading>
    <li> <para-num num="[0310]"> </para-num> <div id="p-0360" num="0310" class="description-line">Compound (i) or the amine functional compound as defined above is conjugated to fatty acids via standard EDC/NHC coupling method yielded the compound (ii). Further reduction with Lithium aluminum hydride (LAH) followed by silica gel column chromatography purification give desired final compound (iii).</div>
    </li> <heading id="h-0029">Method B:</heading>
    <li> <para-num num="[0311]"> </para-num> <div id="p-0361" num="0311" class="description-line">Compound (i) and/or the amine functional compound and alkyl/alkenyl fatty chain corresponding aldehyde stirred for 2 hr at RT under argon, followed by reduction with NaCNBH<sub>4 </sub>or Sodium triacetoxy borohydride and silica gel column chromatography purification yields desired final compound.</div>
    </li> <heading id="h-0030">Method C:</heading>
    <li> <para-num num="[0312]"> </para-num> <div id="p-0362" num="0312" class="description-line">Compound (i) or the amine functional compound as defined above, is heated with corresponding alkyl/alkenyl bromide (any other as defined above) for overnight followed by column chromatography purification yields desired final compound (ii).</div>
    </li> <heading id="h-0031">Method D:</heading>
    <li> <para-num num="[0313]"> </para-num> <div id="p-0363" num="0313" class="description-line">Di-hydroxyl compound reacted with fatty acid chloride in presence of tri ethyl amine give the compound (ii). The compound (ii) is further oxidized with pyridinium chlorochromate (PCC) followed by reacted with amine functional compound and silica gel column chromatography purification yields desired compound (iv).</div>
    </li> <heading id="h-0032">Synthesis of Lipid 1 (Method A)</heading>
    <li> <para-num num="[0314]"> </para-num> <div id="p-0364" num="0314" class="description-line">
      <chemistry id="CHEM-US-00169" num="00169">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8c/41/68/406e74ac36a86a/US20190292130A1-20190926-C00169.png"><img id="EMI-C00169" he="92.96mm" wi="131.74mm" file="US20190292130A1-20190926-C00169.TIF" alt="Figure US20190292130A1-20190926-C00169" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="527" height="372" alt="Figure US20190292130A1-20190926-C00169" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8c/41/68/406e74ac36a86a/US20190292130A1-20190926-C00169.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00169" attachment-type="cdx" file="US20190292130A1-20190926-C00169.CDX"> </attachment>
          <attachment idref="CHEM-US-00169" attachment-type="mol" file="US20190292130A1-20190926-C00169.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0315]"> </para-num> <div id="p-0365" num="0315" class="description-line">Linoleic acid (0.88 mg, 3.14 mmol) and EDCI (0.9 mg, 4.71 mmol) were taken in a 100 mL flask and dissolved in dry DCM followed by addition of dimethylaminoethyl hydrazine hydrochloride (0.2 mg, 1.25 mmol) and tri ethylamine (0.1 ml). The reaction mixture was stirred for 24 hr, washed with water and brine solution. The crude compound was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(4:96)) to yield 0.8 g of pure compound (9Z,12Z)N-(2-(dimethylamino)ethyl)-N-((9Z,12Z)-octadeca-9,12-dienoyl)octadeca-9,12-dienehydrazide.</div>
    </li> <li> <para-num num="[0316]"> </para-num> <div id="p-0366" num="0316" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.22-5.45 (8H, m); 3.7-3.8 (1H, t); 3.2-3.3 (1H, m); 2.8 (4H, t), 2.6 (2H, t), 2.3 (6H, s); 2.2 (4H, m); 2.0 (8H, q); 1.2-1.4 (32H, m), 0.9 (6H, t).</div>
    </li> <li> <para-num num="[0317]"> </para-num> <div id="p-0367" num="0317" class="description-line">ESI-MS: 628.6 (M+1)</div>
    </li> <li> <para-num num="[0318]"> </para-num> <div id="p-0368" num="0318" class="description-line">The above compound (0.8 mg, 1.27 mmol) was taken in a 50 mL round bottomed (RB) flask and dissolved in 5 mL of dry THF, followed by addition of 1N LAH in THF solution (6 mL, 6.36 mmol) and the reaction mixture was refluxed for 24 hr. The reaction was quenched with saturated ammonium chloride at 0 C. followed by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(2:98)) purification to yield 0.3 g of pure compound 2-(1,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)-N,N-dimethylethan-1-amine as pale yellow liquid.</div>
    </li> <li> <para-num num="[0319]"> </para-num> <div id="p-0369" num="0319" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  NMR: 5.22-5.45 (8H, m); 3.2 (2H, t); 3.1 (2H, t); 2.8 (4H, t), 2.5 (2H, m); 2.4 (6H, s); 2.3 (1H, m); 2.0 (12H, q); 1.5 (4H, m); 1.2-1.4 (32H, m), 0.9 (6H, t).</div>
    </li> <li> <para-num num="[0320]"> </para-num> <div id="p-0370" num="0320" class="description-line">ESI-MS: 600.6 (M+1)</div>
    </li> <heading id="h-0033">Synthesis of <figure-callout id="10" label="Lipids" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">Lipids</figure-callout> 10 &amp; 12</heading>
    <li> <para-num num="[0321]"> </para-num> <div id="p-0371" num="0321" class="description-line">
      <chemistry id="CHEM-US-00170" num="00170">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b9/49/cb/97d4d8d2827ef5/US20190292130A1-20190926-C00170.png"><img id="EMI-C00170" he="175.34mm" wi="123.70mm" file="US20190292130A1-20190926-C00170.TIF" alt="Figure US20190292130A1-20190926-C00170" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="495" height="701" alt="Figure US20190292130A1-20190926-C00170" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b9/49/cb/97d4d8d2827ef5/US20190292130A1-20190926-C00170.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00170" attachment-type="cdx" file="US20190292130A1-20190926-C00170.CDX"> </attachment>
          <attachment idref="CHEM-US-00170" attachment-type="mol" file="US20190292130A1-20190926-C00170.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0322]"> </para-num> <div id="p-0372" num="0322" class="description-line">Linoleic alcohol (1.7 g, 6.3 mmol) was dissolved in dry DCM under argon and molecular sieves were added to the reaction mixture. PCC (2 g, 9.5 mmol) was added by fractions to the reaction mixture over a period of 10 min. The reaction mixture was stirred for 1 hr and filtered through silica pad to remove PCC followed by evaporating the solvent to yield 1.5 g of crude linoleic aldehyde. The crude aldehyde (1.5 g, 5.6 mmol) and Boc-hydrazide (0.6 g, 4.5 mmol) were dissolved in dry DCM under argon atmosphere then Sodium triacetoxy borohydride (4.7 g, 22.6 mmol) was added to the reaction mixture and stirred for 24 hr at room temperature. The reaction was quenched with sodium hydroxide solution and extract with DCM (350 mL) followed by washing with water and brine solution. The solvent was evaporated and the residue was purified by silica column chromatography (EtOAc:Hexane (5:95) yielded 1.3 g of pure compound N, N-dilinoleyl-boc hydrazide.</div>
    </li> <li> <para-num num="[0323]"> </para-num> <div id="p-0373" num="0323" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.22-5.45 (8H, m); 2.8 (4H, t), 2.6 (3H, bs), 2.0-2.1 (8H, q); 1.5-1.8 (6H, m); 1.4-1.5 (12H, s), 1.2-1.4 (32H, m), 0.9 (6H, t)</div>
    </li> <li> <para-num num="[0324]"> </para-num> <div id="p-0374" num="0324" class="description-line">ESI-MS: 629.6 (M+1)<sup>+</sup> </div>
    </li> <li> <para-num num="[0325]"> </para-num> <div id="p-0375" num="0325" class="description-line">N, N-dilinoleyl-boc hydrazide (1.3 g, 2.07 mmol) was dissolved in dry DCM under argon atmosphere. The reaction mixture was cooled to 0 C. and trifluoroacetic acid (TFA) (2 mL) was added drop wise and stirred for 3 hr. Upon completion of reaction by TLC analysis, the reaction mixture was washed with sodium bicarbonate followed by brine solution. The solvent was evaporated and the crude reaction mixture (0.4 g, 0.76 mmol), N, N-dimethyl aminobutyric acid (0.19 g, 1.3 mmol) and EDCI (0.43 g, 2.26 mmol) were dissolved in dry DCM under argon atmosphere. Triethylamine was added and the reaction stirred for 24 hr. The reaction mixture was washed with water followed by sodium bicarbonate and brine solution. The solvent was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(2:98) to yield 0.3 g of <figure-callout id="10" label="pure lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">pure lipid</figure-callout> 10 as colorless liquid.</div>
    </li> <li> <para-num num="[0326]"> </para-num> <div id="p-0376" num="0326" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.22-5.45 (8H, m); 2.8 (4H, t), 2.6 (3H, m), 2.3-2.5 (4H, m); 2.2 (6H, s); 2.0 (8H, q); 1.6-1.8 (8H, m); 1.2-1.5 (36H, m), 0.9 (6H, t)</div>
    </li> <li> <para-num num="[0327]"> </para-num> <div id="p-0377" num="0327" class="description-line">ESI-MS: 642.6 (M+1)<sup>+</sup> </div>
    </li> <li> <para-num num="[0328]"> </para-num> <div id="p-0378" num="0328" class="description-line">The <figure-callout id="2" label="compound" filenames="US20190292130A1-20190926-D00018.png,US20190292130A1-20190926-D00021.png" state="{{state}}">compound</figure-callout> 2 was dissolved in dry THF and 1M LAH in THF solution was added to the reaction mixture and refluxed for 12 h. The reaction was quenched with ammonium chloride solution followed by solvent evaporation and silica gel column chromatography purification yielded pure lipid 12.</div>
    </li> <li> <para-num num="[0329]"> </para-num> <div id="p-0379" num="0329" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  NMR: 5.22-5.45 (8H, m); 2.8 (4H, t), 2.6 (2H, m), 2.4-2.5 (6H, m); 2.2 (6H, s); 2.0 (8H, q); 1.6-1.8 (8H, m); 1.2-1.5 (36H, m), 0.9 (6H, t)</div>
    </li> <li> <para-num num="[0330]"> </para-num> <div id="p-0380" num="0330" class="description-line">ESI-MS: 629.1 (M+1)<sup>+</sup> </div>
    </li> <heading id="h-0034">Synthesis of Lipid 11</heading>
    <li> <para-num num="[0331]"> </para-num> <div id="p-0381" num="0331" class="description-line">
      <chemistry id="CHEM-US-00171" num="00171">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d3/b0/39/37790327160fc0/US20190292130A1-20190926-C00171.png"><img id="EMI-C00171" he="93.73mm" wi="133.52mm" file="US20190292130A1-20190926-C00171.TIF" alt="Figure US20190292130A1-20190926-C00171" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="534" height="375" alt="Figure US20190292130A1-20190926-C00171" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d3/b0/39/37790327160fc0/US20190292130A1-20190926-C00171.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00171" attachment-type="cdx" file="US20190292130A1-20190926-C00171.CDX"> </attachment>
          <attachment idref="CHEM-US-00171" attachment-type="mol" file="US20190292130A1-20190926-C00171.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0332]"> </para-num> <div id="p-0382" num="0332" class="description-line">N,N-dilinoleyl hydrazine (300 mg, 0.56 mmol), N<sub></sub>,N<sub></sub> dimethyl-N<sub> </sub>boc L-lysine (180 mg, 1.13 mmol) and EDCI (320 mg, 1.68 mmol) were taken in 50 mL RB flask and dissolved in 10 mL dry DCM under argon. The reaction mixture was stirred for 24 h, and then the reaction mixture was washed with water followed by sodium bicarbonate and brine solution. The crude product was purified by silica gel column chromatography (MeOH:CHCl<sub>3</sub>; 3:97) to yield 200 mg of pure compound.</div>
    </li> <li> <para-num num="[0333]"> </para-num> <div id="p-0383" num="0333" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.22-5.45 (8H, m); 3.8-4.0 (1H, m); 2.8 (4H, t), 2.6-2.7 (4H, t), 2.4 (2H, m); 2.2 (6H, s), 2.0 (8H, m), 1.5-1.8 (6H, m); 1.4 (9H, s), 1.2-1.4 (34H, m), 0.9 (6H, t).</div>
    </li> <li> <para-num num="[0334]"> </para-num> <div id="p-0384" num="0334" class="description-line">ESI-MS: 785.6 (M+1)<sup>+</sup> </div>
    </li> <li> <para-num num="[0335]"> </para-num> <div id="p-0385" num="0335" class="description-line">The above compound (200 mg, 0.25 mmol) was taken in 50 mL RB flask and dissolved in 4 mL dry DCM under argon atmosphere. Trifluoroacetic acid (2 mL) was added drop-wise at 0 C. The reaction mixture was stirred for 3 hr. The solvent was washed with sodium bicarbnonate solution followed by brine. The reaction mixture was purified by silica gel column chromatography using chloroform and methanol solvent system (95:5) to yield 120 mg of pure compound 11 (2-amino-6-(dimethylamino)-N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hexanehydrazide) as semi solid.</div>
    </li> <li> <para-num num="[0336]"> </para-num> <div id="p-0386" num="0336" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.22-5.45 (8H, m); 3.4 (1H, m), 2.8 (4H, t), 2.7 (4H, t), 2.5 (2H, t), 2.4 (6H, s), 2.0 (m), 1.6 (2H, m), 1.4-1.5 (6H, m), 1.2-1.4 (34H, m), 0.9 (6H, t)</div>
    </li> <li> <para-num num="[0337]"> </para-num> <div id="p-0387" num="0337" class="description-line">ESI-MS: 686.6 (M+1)<sup>+</sup> </div>
    </li> <heading id="h-0035">Synthesis of Lipid 14</heading>
    <li> <para-num num="[0338]"> </para-num> <div id="p-0388" num="0338" class="description-line">
      <chemistry id="CHEM-US-00172" num="00172">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a3/23/c3/4270e2d57b9153/US20190292130A1-20190926-C00172.png"><img id="EMI-C00172" he="68.50mm" wi="123.70mm" file="US20190292130A1-20190926-C00172.TIF" alt="Figure US20190292130A1-20190926-C00172" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="495" height="274" alt="Figure US20190292130A1-20190926-C00172" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a3/23/c3/4270e2d57b9153/US20190292130A1-20190926-C00172.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00172" attachment-type="cdx" file="US20190292130A1-20190926-C00172.CDX"> </attachment>
          <attachment idref="CHEM-US-00172" attachment-type="mol" file="US20190292130A1-20190926-C00172.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0339]"> </para-num> <div id="p-0389" num="0339" class="description-line">Linoleyl aldehyde (2.64 g, 10.0 mmol, 2 equiv.) and hydroxylamine hydrochloride (0.34 g, 5.0 mmol, 1.0 equiv.) were dissolved in dry DCM under argon atmosphere then trimethylamine (0.7 ml, 5.0 mmol, 1.0 equiv.) was added. After dissolving the compounds, sodium triacetoxyborohydride (3.1 g, 15.0 mmol, 3 equiv.) was added to the reaction mixture and stirred for 24 hr at room temperature. The reaction was quenched with sodium hydroxide solution followed by washing with water and brine solution. The solvent was evaporated and the residue was purified by silica column chromatography (EtOAc:Hexane (5:95) to yield 1.5 g (55%) of pure white color compound N,N-dilinoleyl-hydroxylamine.</div>
    </li> <li> <para-num num="[0340]"> </para-num> <div id="p-0390" num="0340" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.27-5.39 (8H, m); 2.77 (4H, t, J=6.84 Hz), 2.57-2.68 (4H, m), 2.05 (8H, q, J=6.80, 6.87 Hz); 1.50-1.65 (4H, m); 1.22-1.42 (32H, m), 0.89 (6H, t, J=6.86 Hz).</div>
    </li> <li> <para-num num="[0341]"> </para-num> <div id="p-0391" num="0341" class="description-line">ESI-MS: 530 [M+1]<sup>+</sup> </div>
    </li> <li> <para-num num="[0342]"> </para-num> <div id="p-0392" num="0342" class="description-line">N,N-dilinoleyl-hydroxylamine (0.48 g, 0.90 mmol, 1 equiv.) N, N-dimethyl aminobutyric acid hydrochloride (0.30 g, 1.8 mmol, 2 equiv.), EDCI (0.34 g, 1.8 mmol, 2 equiv.) and DMAP (0.01 g, 0.09 mmol, 0.1 equiv.) were dissolved in dry DCM under argon atmosphere. Then trimethylamine (0.25 ml, 1.8 mmol, 2 equiv.) was added and the reaction was stirred for 24 hr. The reaction mixture was washed with water, followed by sodium bicarbonate and brine solution. The solvent was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl3 (3:97) to yield 0.6 g (85%) of pure lipid 14 as colorless liquid.</div>
    </li> <li> <para-num num="[0343]"> </para-num> <div id="p-0393" num="0343" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.22-5.45 (8H, m); 2.71-2.87 (8H, m), 2.24-2.36 (4H, m); 2.21 (6H, s); 1.93-2.12 (8H, m); 1.74-1.81 (2H, m); 1.42-1.58 (4H, m); 1.6-1.8 (8H, m); 1.20-1.40 (32H, m), 0.89 (6H, t, J=6.90 Hz).</div>
    </li> <li> <para-num num="[0344]"> </para-num> <div id="p-0394" num="0344" class="description-line">Mass: 643.1 [M]<sup>+</sup>; 644.1 [M+1]<sup>+</sup> </div>
    </li> <heading id="h-0036">Synthesis of <figure-callout id="15" label="Lipid" filenames="US20190292130A1-20190926-D00009.png,US20190292130A1-20190926-D00020.png" state="{{state}}">Lipid</figure-callout> 15</heading>
    <li> <para-num num="[0345]"> </para-num> <div id="p-0395" num="0345" class="description-line">
      <chemistry id="CHEM-US-00173" num="00173">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/14/85/a79e1969bb0a55/US20190292130A1-20190926-C00173.png"><img id="EMI-C00173" he="38.69mm" wi="113.96mm" file="US20190292130A1-20190926-C00173.TIF" alt="Figure US20190292130A1-20190926-C00173" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="456" height="155" alt="Figure US20190292130A1-20190926-C00173" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/14/85/a79e1969bb0a55/US20190292130A1-20190926-C00173.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00173" attachment-type="cdx" file="US20190292130A1-20190926-C00173.CDX"> </attachment>
          <attachment idref="CHEM-US-00173" attachment-type="mol" file="US20190292130A1-20190926-C00173.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0346]"> </para-num> <div id="p-0396" num="0346" class="description-line">Linoleyl aldehyde (1.7 g, 6.06 mmol, 2 equiv.), N,N-dimethylaminoethyl hydrazine hydrochloride (0.53 g, 3.03 mmol, 1 equiv.) and trimethylamine (0.84 ml, 6.06 mmol, 2 equiv.) were dissolved in dry DCM under argon atmosphere, then sodium tri acetoxyborohydride (1.91 g, 9.09 mmol, 3 equiv.) was added and the reaction mixture was stirred for 24 hr at room temperature. The reaction was quenched with sodium hydroxide solution followed by washing with water and brine solution. The solvent was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(3:97) yielded 1.08 g (60%) of <figure-callout id="15" label="pure lipid" filenames="US20190292130A1-20190926-D00009.png,US20190292130A1-20190926-D00020.png" state="{{state}}">pure lipid</figure-callout> 15 as colorless liquid.</div>
    </li> <li> <para-num num="[0347]"> </para-num> <div id="p-0397" num="0347" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  6.77 (1H, t, J=5.55 Hz), 5.34-5.48 (8H, m); 3.13 (2H, m), 3.00-3.05 (2H, m), 2.77 (4H, t, J=6.44 Hz), 2.41-2.48 (4H, m), 2.22-2.34 (2H, m), 2.28 (s, 6H); 1.46-1.51 (4H, m); 1.32-1.40 (32H, m), 0.89 (6H, t, J=6.90 Hz).</div>
    </li> <li> <para-num num="[0348]"> </para-num> <div id="p-0398" num="0348" class="description-line">ESI-MS: 599 ([M]<sup>+</sup>), 600 ([M+1]<sup>+</sup>).</div>
    </li> <heading id="h-0037">Synthesis of Lipid 22</heading>
    <li> <para-num num="[0349]"> </para-num> <div id="p-0399" num="0349" class="description-line">
      <chemistry id="CHEM-US-00174" num="00174">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/74/0e/4b/5a05e5edcc7ea2/US20190292130A1-20190926-C00174.png"><img id="EMI-C00174" he="54.27mm" wi="128.19mm" file="US20190292130A1-20190926-C00174.TIF" alt="Figure US20190292130A1-20190926-C00174" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="513" height="217" alt="Figure US20190292130A1-20190926-C00174" class="patent-full-image" src="https://patentimages.storage.googleapis.com/74/0e/4b/5a05e5edcc7ea2/US20190292130A1-20190926-C00174.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00174" attachment-type="cdx" file="US20190292130A1-20190926-C00174.CDX"> </attachment>
          <attachment idref="CHEM-US-00174" attachment-type="mol" file="US20190292130A1-20190926-C00174.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0350]"> </para-num> <div id="p-0400" num="0350" class="description-line">N,N-dilinoleyl-hydroxylamine (0.20 g, 0.37 mmol, 1 equiv.) N-methyl piperazine propanoic acid (0.12 g, 0.74 mmol, 2 equiv.), EDCI (0.13 g, 0.74 mmol, 2 equiv.) and DMAP (5 mg, 0.03 mmol, 0.1 equiv.) were dissolved in dry DCM under argon atmosphere. Then trimethylamine (0.1 ml, 0.74 mmol, 2 equiv.) was added and the reaction was stirred for 24 hr. The reaction mixture was washed with water, followed by sodium bicarbonate and brine solution. The solvent was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(5:95) to yield 0.21 g (76%) of pure lipid as colorless liquid.</div>
    </li> <li> <para-num num="[0351]"> </para-num> <div id="p-0401" num="0351" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.21-5.45 (8H, m); 2.75-2.87 (8H, m), 2.70 (2H, t, J=7.28 Hz); 2.47 (2H, t, J=7.25 Hz); 2.27 (3H, s); 1.98-2.10 (8H, m); 1.44-1.57 (4H, m); 1.15-1.40 (32H, m), 0.88 (6H, t, J=6.81 Hz).</div>
    </li> <li> <para-num num="[0352]"> </para-num> <div id="p-0402" num="0352" class="description-line">Mass: 684.8 [M+1]<sup>+</sup> </div>
    </li> <heading id="h-0038">Synthesis of <figure-callout id="38" label="Lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">Lipid</figure-callout> 38</heading>
    <li> <para-num num="[0353]"> </para-num> <div id="p-0403" num="0353" class="description-line">
      <chemistry id="CHEM-US-00175" num="00175">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9e/b2/02/03d187ec2daa74/US20190292130A1-20190926-C00175.png"><img id="EMI-C00175" he="70.19mm" wi="131.83mm" file="US20190292130A1-20190926-C00175.TIF" alt="Figure US20190292130A1-20190926-C00175" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="527" height="281" alt="Figure US20190292130A1-20190926-C00175" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9e/b2/02/03d187ec2daa74/US20190292130A1-20190926-C00175.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00175" attachment-type="cdx" file="US20190292130A1-20190926-C00175.CDX"> </attachment>
          <attachment idref="CHEM-US-00175" attachment-type="mol" file="US20190292130A1-20190926-C00175.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0354]"> </para-num> <div id="p-0404" num="0354" class="description-line">Linoleyl aldehyde (2.64 g, 10.0 mmol, 2 equiv.) and ethanolamine (0.30 g, 5.0 mmol, 1 equiv.) were dissolved in dry DCM under argon atmosphere, then sodium tri acetoxyborohydride (3.1 g, 15.0 mmol, 3 equiv.) was added, and the reaction mixture was stirred for 24 hr at room temperature. The reaction was quenched with sodium hydroxide solution followed by washing with water and brine solution. The solvent was evaporated and the residue was purified by column chromatography (MeOH:CHCl<sub>3 </sub>(2:98) to yield 2.3 g (85%) of pure yellowish color compound N,N-dilinoleyl-aminoethanol.</div>
    </li> <li> <para-num num="[0355]"> </para-num> <div id="p-0405" num="0355" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.35-5.46 (8H, m); 3.52 (2H, t, J=5.38 Hz); 2.77 (4H, t, J=6.37 Hz), 2.57 (2H, t, J=5.38 Hz), 2.43-2.49 (4H, m), 2.05 (8H, q, J=6.73, 6.75 Hz), 1.43-1.48 (4H, m), 1.32-1.38 (32H, m), 0.89 (6H, t, J=6.85 Hz)</div>
    </li> <li> <para-num num="[0356]"> </para-num> <div id="p-0406" num="0356" class="description-line">ESI-MS: 558 [M+1]<sup>+</sup> </div>
    </li> <li> <para-num num="[0357]"> </para-num> <div id="p-0407" num="0357" class="description-line">N, N-dilinoleyl-aminoethanol (0.55 g, 1.0 mmol, 1 equiv.), N,N-dimethyl aminobutyric acid (0.33 g, 2.0 mmol, 2 equiv.), EDCI (0.38 g, 2.0 mmol, 2 equiv.) and DMAP (0.01 g, 0.01 mmol, 0.1 equiv.) were dissolved in dry DCM under argon atmosphere. Trimethylamine (0.28 ml, 2.00 mmol, 2 equiv.) was added and the reaction mixture was stirred for 24 hr. The reaction mixture was washed with water, followed by sodium bicarbonate and brine solution. The solvent was evaporated and the residue was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(3:97) to yield 0.46 g (70%) of <figure-callout id="38" label="pure lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">pure lipid</figure-callout> 38 as colorless liquid.</div>
    </li> <li> <para-num num="[0358]"> </para-num> <div id="p-0408" num="0358" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.27-5.45 (8H, m); 4.12 (2H, t, J=6.33 Hz); 2.77 (4H, t, J=6.37 Hz); 2.67 (2H, t, J=6.34 Hz); 2.38-2.49 (4H, m), 2.19-2.38 (4H, m); 2.21 (6H, s); 2.05 (8H, q, J=6.82, 6.84 Hz); 1.70-1.85 (4H, m); 1.20-1.50 (36H, m), 0.9 (6H, t, J=6.85 Hz).</div>
    </li> <li> <para-num num="[0359]"> </para-num> <div id="p-0409" num="0359" class="description-line">ESI-MS: 671 ([M]<sup>+</sup>), 672 ([M+1]<sup>+</sup>).</div>
    </li> <heading id="h-0039">Synthesis of <figure-callout id="54" label="Lipids" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">Lipids</figure-callout> 54 and 57</heading>
    <li> <para-num num="[0360]"> </para-num> <div id="p-0410" num="0360" class="description-line">
      <chemistry id="CHEM-US-00176" num="00176">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a9/bb/05/e6e471a06abf30/US20190292130A1-20190926-C00176.png"><img id="EMI-C00176" he="164.08mm" wi="157.99mm" file="US20190292130A1-20190926-C00176.TIF" alt="Figure US20190292130A1-20190926-C00176" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="632" height="656" alt="Figure US20190292130A1-20190926-C00176" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a9/bb/05/e6e471a06abf30/US20190292130A1-20190926-C00176.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00176" attachment-type="cdx" file="US20190292130A1-20190926-C00176.CDX"> </attachment>
          <attachment idref="CHEM-US-00176" attachment-type="mol" file="US20190292130A1-20190926-C00176.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0040">7-oxoheptyl decanoate</heading>
    <li> <para-num num="[0361]"> </para-num> <div id="p-0411" num="0361" class="description-line">
      <chemistry id="CHEM-US-00177" num="00177">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ee/3a/5f/a9f6ce00fe3d4b/US20190292130A1-20190926-C00177.png"><img id="EMI-C00177" he="16.34mm" wi="75.35mm" file="US20190292130A1-20190926-C00177.TIF" alt="Figure US20190292130A1-20190926-C00177" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="65" alt="Figure US20190292130A1-20190926-C00177" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ee/3a/5f/a9f6ce00fe3d4b/US20190292130A1-20190926-C00177.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00177" attachment-type="cdx" file="US20190292130A1-20190926-C00177.CDX"> </attachment>
          <attachment idref="CHEM-US-00177" attachment-type="mol" file="US20190292130A1-20190926-C00177.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0362]"> </para-num> <div id="p-0412" num="0362" class="description-line">1,7-heptanediol (5 g, 37 mmol) was taken in a 100 mL flask and dissolved in dry DCM followed by portion-wise slow addition of PCC (8.9 g, 41.6 mmol) for 15 min. Then, the reaction mixture was stirred at room temperature for 2 h. The crude reaction mixture was filtered through a silica gel pad and washed with DCM (250 mL). The organic solvent was dried over with Na<sub>2</sub>SO<sub>4 </sub>and the solvent was removed under reduced pressure. The obtained crude hydroxyl aldehyde was used directly without any further purification.</div>
    </li> <li> <para-num num="[0363]"> </para-num> <div id="p-0413" num="0363" class="description-line">The crude hydroxy aldehyde (1.3 g, 10.0 mmol), decanoic acid (2.0 g, 12.0 mmol) and EDC (2.8 g, 15.0 mmol) were taken in a 100 mL flask and dissolved in dry DCM and addition of DMAP (cat.) at 0 C. The reaction mixture was stirred for 24 hr at RT. The reaction mixture was then washed with water followed by brine solution and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The crude mixture was purified by silica column chromatography (EtOAc:Hexane (05:95) to give colorless oil with 90% (2.4 g) yield.</div>
    </li> <li> <para-num num="[0364]"> </para-num> <div id="p-0414" num="0364" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  9.76 (1H, t, J=1.91 Hz); 4.05 (2H, t, J=6.76 Hz), 2.43 (2H, dt, J=7.48, 5.70 Hz); 2.28 (2H, t, J=7.68 Hz); 1.78-1.52 (8H, m); 1.44-1.33 (4H, m); 1.32-1.20 (12H, m), 0.87 (3H, t, J=6.62 Hz).</div>
    </li> <li> <para-num num="[0365]"> </para-num> <div id="p-0415" num="0365" class="description-line">Mass: 285.8 [M+1]<sup>+</sup>, 283.8 [M1]<sup>+</sup> </div>
    </li> <heading id="h-0041">(2-(2-(dimethylamino)ethyl)hydrazine-1,1-diyl)bis(heptane-7,1-diyl) bis(decanoate) (Lipid 57)</heading>
    <li> <para-num num="[0366]"> </para-num> <div id="p-0416" num="0366" class="description-line">
      <chemistry id="CHEM-US-00178" num="00178">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0a/e9/6f/be0d7b115be635/US20190292130A1-20190926-C00178.png"><img id="EMI-C00178" he="40.39mm" wi="106.34mm" file="US20190292130A1-20190926-C00178.TIF" alt="Figure US20190292130A1-20190926-C00178" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="425" height="162" alt="Figure US20190292130A1-20190926-C00178" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0a/e9/6f/be0d7b115be635/US20190292130A1-20190926-C00178.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00178" attachment-type="cdx" file="US20190292130A1-20190926-C00178.CDX"> </attachment>
          <attachment idref="CHEM-US-00178" attachment-type="mol" file="US20190292130A1-20190926-C00178.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0367]"> </para-num> <div id="p-0417" num="0367" class="description-line">7-oxoheptyl decanoate (0.6 g, 2.2 mmol) and dimethylaminoethyl hydrazine hydrochloride (0.18 g, 1.0 mmol) were dissolved in dry DCM followed by addition of trimethylamine (0.1 ml). Sodium triacetoxyborohydride (0.6 g, 3.0 mmol) was added to the reaction mixture and stirred for 24 hr at room temperature. The reaction mixture was washed with NaHCO<sub>3 </sub>solution followed by brine solution and dried over sodium sulphate. The crude mixture was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(5:95) to yield 73% (0.51 g) pure (2-(2-(dimethylamino)ethyl)hydrazine-1,1-diyl)bis(heptane-7,1-diyl) bis(decanoate) as pale yellow liquid.</div>
    </li> <li> <para-num num="[0368]"> </para-num> <div id="p-0418" num="0368" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  9.28 (1H, t, J=5.55 Hz); 4.01 (1H, t, J=6.60 Hz), 3.70 (2H, t, J=7.70 Hz), 3.30-3.20 (3H, m), 2.54 (3H, t, J=7.55 Hz), 2.33-2.21 (6H, m), 2.20 (s, 6H); 1.80-1.70 (4H, m); 1.37-1.17 (24H, m), 0.83 (6H, t, J=6.90 Hz).</div>
    </li> <li> <para-num num="[0369]"> </para-num> <div id="p-0419" num="0369" class="description-line">ESI-MS: 640 ([M+1]<sup>+</sup>).</div>
    </li> <heading id="h-0042">((2-hydroxyethyl)azanediyl)bis(heptane-7,1-diyl) bis(decanoate)</heading>
    <li> <para-num num="[0370]"> </para-num> <div id="p-0420" num="0370" class="description-line">
      <chemistry id="CHEM-US-00179" num="00179">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0f/c1/20/ba0877ddc605fe/US20190292130A1-20190926-C00179.png"><img id="EMI-C00179" he="40.39mm" wi="98.47mm" file="US20190292130A1-20190926-C00179.TIF" alt="Figure US20190292130A1-20190926-C00179" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="394" height="162" alt="Figure US20190292130A1-20190926-C00179" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0f/c1/20/ba0877ddc605fe/US20190292130A1-20190926-C00179.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00179" attachment-type="cdx" file="US20190292130A1-20190926-C00179.CDX"> </attachment>
          <attachment idref="CHEM-US-00179" attachment-type="mol" file="US20190292130A1-20190926-C00179.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0371]"> </para-num> <div id="p-0421" num="0371" class="description-line">7-oxoheptyl decanoate (1.0 g, 3.7 mmol) and ethanolamine (0.11 g, 1.85 mmol) were dissolved in dry DCM followed by addition of sodium tri acetoxyborohydride (1.1 g, 5.5 mmol), and the reaction mixture was stirred for 24 hr at room temperature. The reaction mixture was washed with sodium bicarbonate solution followed by brine solution and dried over sodium sulphate. The crude mixture was was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(2:97) to yield 85% (0.91 g) of pure ((2-hydroxyethyl)azanediyl)bis(heptane-7,1-diyl) bis(decanoate) as pale liquid.</div>
    </li> <li> <para-num num="[0372]"> </para-num> <div id="p-0422" num="0372" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  4.05 (4H, t, J=6.98 Hz); 3.60 (2H, t, J=5.31 Hz); 2.66 (2H, t, J=5.31 Hz); 2.54 (4H, t, J=7.58 Hz); 2.28 (4H, t, J=7.58 Hz); 1.68-1.54 (8H, m); 1.53-1.41 (4H, m); 1.20-1.40 (32H, m), 0.89 (6H, t, J=6.80 Hz).</div>
    </li> <li> <para-num num="[0373]"> </para-num> <div id="p-0423" num="0373" class="description-line">ESI-MS: 598 ([M+1]<sup>+</sup>).</div>
    </li> <heading id="h-0043">((2-((4-(dimethylamino)butanoyl)oxy)ethyl)azanediyl)bis(heptane-7,1-diyl) bis(decanoate) (Lipid 54)</heading>
    <li> <para-num num="[0374]"> </para-num> <div id="p-0424" num="0374" class="description-line">
      <chemistry id="CHEM-US-00180" num="00180">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4f/48/7e/ab2c31d49a87b3/US20190292130A1-20190926-C00180.png"><img id="EMI-C00180" he="40.39mm" wi="125.14mm" file="US20190292130A1-20190926-C00180.TIF" alt="Figure US20190292130A1-20190926-C00180" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="501" height="162" alt="Figure US20190292130A1-20190926-C00180" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4f/48/7e/ab2c31d49a87b3/US20190292130A1-20190926-C00180.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00180" attachment-type="cdx" file="US20190292130A1-20190926-C00180.CDX"> </attachment>
          <attachment idref="CHEM-US-00180" attachment-type="mol" file="US20190292130A1-20190926-C00180.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0375]"> </para-num> <div id="p-0425" num="0375" class="description-line">((2-hydroxyethyl)azanediyl)bis(heptane-7,1-diyl) bis(decanoate) (0.4 g, 0.7 mmol) and 4-(dimethylamino)butanoic acid (0.17 g, 1.0 mmol) was taken in 100 mL flask and dissolved in dry DCM. Than EDCI (0.27 g, 1.4 mmol) was added to the reaction mixture followed by DMAP (cat.) and stirred it for overnight. The reaction mixture was washed with water followed by brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>. The crude mixture was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(2:98) to yield 75% (0.37 g) pure ((2-((4-(dimethylamino)butanoyl) oxy)ethyl)azanediyl)bis(heptane-7,1-diyl) bis(decanoate) as pale liquid.</div>
    </li> <li> <para-num num="[0376]"> </para-num> <div id="p-0426" num="0376" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  4.11 (2H, t, J=6.51 Hz); 4.04 (4H, t, J=6.78 Hz); 2.66 (2H, t, J=6.51 Hz); 2.43 (4H, t, J=7.73 Hz); 2.33 (2H, t, J=7.58 Hz); 2.28 (4H, t, J=7.58 Hz); 2.21 (6H, s); 1.68-1.54 (6H, m); 1.67-1.52 (8H, m); 1.46-1.36 (4H, m); 1.20-1.40 (32H, m), 0.87 (6H, t, J=6.80 Hz).</div>
    </li> <li> <para-num num="[0377]"> </para-num> <div id="p-0427" num="0377" class="description-line">ESI-MS: 711 ([M+1]<sup>+</sup>).</div>
    </li> <heading id="h-0044">Synthesis of Lipid 24</heading>
    <li> <para-num num="[0378]"> </para-num> <div id="p-0428" num="0378" class="description-line">
      <chemistry id="CHEM-US-00181" num="00181">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cf/65/19/212c063de2930f/US20190292130A1-20190926-C00181.png"><img id="EMI-C00181" he="104.90mm" wi="158.58mm" file="US20190292130A1-20190926-C00181.TIF" alt="Figure US20190292130A1-20190926-C00181" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="634" height="420" alt="Figure US20190292130A1-20190926-C00181" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cf/65/19/212c063de2930f/US20190292130A1-20190926-C00181.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00181" attachment-type="cdx" file="US20190292130A1-20190926-C00181.CDX"> </attachment>
          <attachment idref="CHEM-US-00181" attachment-type="mol" file="US20190292130A1-20190926-C00181.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0045">2-hexyldecanoic acid</heading>
    <li> <para-num num="[0379]"> </para-num> <div id="p-0429" num="0379" class="description-line">
      <chemistry id="CHEM-US-00182" num="00182">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ef/ee/60/6ef097bb365e1a/US20190292130A1-20190926-C00182.png"><img id="EMI-C00182" he="33.10mm" wi="50.29mm" file="US20190292130A1-20190926-C00182.TIF" alt="Figure US20190292130A1-20190926-C00182" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="201" height="132" alt="Figure US20190292130A1-20190926-C00182" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ef/ee/60/6ef097bb365e1a/US20190292130A1-20190926-C00182.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00182" attachment-type="cdx" file="US20190292130A1-20190926-C00182.CDX"> </attachment>
          <attachment idref="CHEM-US-00182" attachment-type="mol" file="US20190292130A1-20190926-C00182.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0380]"> </para-num> <div id="p-0430" num="0380" class="description-line">The freshly prepared LDA (9.0 mL, 2M in THF, 18.0 mmol) in THF (30 mL) was slowly added to a solution of decanoic acid (2.6 g, 15.3 mmol) and NaH (60 w/w % mineral oil suspension, 690 mg, 18.0 mmol) in THF (19 mL) at 0 C. and stirred for 30 min at room temperature. After addition of n-C<sub>6</sub>H<sub>13</sub>I (2.6 mL, 18.0 mmol), the reaction mixture was stirred for 6 h at 45 C. then quenched with 1N HCl at room temperature. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4 </sub>and concentrated under reduced pressure. The residue was purified by flash silica column chromatography (EtOAc:Hex (10:90) to give (3.7 g, 65%) as a colorless liquid.</div>
    </li> <li> <para-num num="[0381]"> </para-num> <div id="p-0431" num="0381" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  2.38-2.28 (1H, m); 1.69-1.53 (2H, m); 1.50-1.40 (2H, m); 1.36-1.20 (20H, m); 0.87 (6H, t, J=6.87 Hz).</div>
    </li> <li> <para-num num="[0382]"> </para-num> <div id="p-0432" num="0382" class="description-line">Mass: 255 [M1]<sup>+</sup> </div>
    </li> <heading id="h-0046"> <figure-callout id="6" label="Dimethyl" filenames="US20190292130A1-20190926-D00018.png" state="{{state}}"> <figure-callout id="6" label="Dimethyl" filenames="US20190292130A1-20190926-D00018.png" state="{{state}}">Dimethyl</figure-callout> </figure-callout> 6,6-(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(6-oxohexanoate)</heading>
    <li> <para-num num="[0383]"> </para-num> <div id="p-0433" num="0383" class="description-line">
      <chemistry id="CHEM-US-00183" num="00183">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/82/9e/41/430eaad3af0c67/US20190292130A1-20190926-C00183.png"><img id="EMI-C00183" he="29.97mm" wi="54.02mm" file="US20190292130A1-20190926-C00183.TIF" alt="Figure US20190292130A1-20190926-C00183" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="216" height="120" alt="Figure US20190292130A1-20190926-C00183" class="patent-full-image" src="https://patentimages.storage.googleapis.com/82/9e/41/430eaad3af0c67/US20190292130A1-20190926-C00183.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00183" attachment-type="cdx" file="US20190292130A1-20190926-C00183.CDX"> </attachment>
          <attachment idref="CHEM-US-00183" attachment-type="mol" file="US20190292130A1-20190926-C00183.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0384]"> </para-num> <div id="p-0434" num="0384" class="description-line">Methyl adipate (1.6 g, 10.0 mmol), dimethylaminoethyl hydrazine (0.88 g, 5. 0 mmol) and EDC (2.8 g, 15.0 mmol) were dissolved in dry DCM followed by addition of triethyl amine. The reaction mixture was stirred for overnight. The reaction mixture was washed with water followed by brine solution and dried over sodium sulphate. The crude mixture was purified by column chromatography (MeOH:CHCl<sub>3 </sub>(5:95) to give pale yellow liquid.</div>
    </li> <li> <para-num num="[0385]"> </para-num> <div id="p-0435" num="0385" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  3.66 (3H, s); 3.64 (3H, s); 2.26-2.41 (6H, m); 2.15-2.26 (12H, s); 1.65-1.54 (4H, m); 1.65-1.55 (4H, m).</div>
    </li> <li> <para-num num="[0386]"> </para-num> <div id="p-0436" num="0386" class="description-line">Mass: 388 [M+1]<sup>+</sup> </div>
    </li> <heading id="h-0047">6,6-(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(hexan-1-ol)</heading>
    <li> <para-num num="[0387]"> </para-num> <div id="p-0437" num="0387" class="description-line">
      <chemistry id="CHEM-US-00184" num="00184">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/52/68/d948fe1b0ab180/US20190292130A1-20190926-C00184.png"><img id="EMI-C00184" he="13.04mm" wi="56.64mm" file="US20190292130A1-20190926-C00184.TIF" alt="Figure US20190292130A1-20190926-C00184" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="227" height="52" alt="Figure US20190292130A1-20190926-C00184" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/52/68/d948fe1b0ab180/US20190292130A1-20190926-C00184.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00184" attachment-type="cdx" file="US20190292130A1-20190926-C00184.CDX"> </attachment>
          <attachment idref="CHEM-US-00184" attachment-type="mol" file="US20190292130A1-20190926-C00184.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0388]"> </para-num> <div id="p-0438" num="0388" class="description-line">Dimethyl-6,6-(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(6-oxohexanoate) (0.77 g, 2.0 mmol) was dissolved in dry THF followed by addition of excess LAH (10.0 mL, 2M in THF, 20.0 mmol). The reaction mixture was refluxed for 24 hr, quenched by slow addition of H<sub>2</sub>O and filtered and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent removed by under reduced pressure purified by silica gel column chromatography to yield 90% (0.5 g) pure 6,6-(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(hexan-1-ol).</div>
    </li> <li> <para-num num="[0389]"> </para-num> <div id="p-0439" num="0389" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  3.62 (4H, t, J=6.70 Hz); 2.70 (2H, t, J=6.87 Hz); 2.65 (2H, t, J=7.10 Hz); 2.50-2.60 (4H, m,); 2.44 (2H, t, J=6.91 Hz); 2.29 (6H, s); 1.65-1.45 (6H, m); 1.44-1.25 (8H, m).</div>
    </li> <li> <para-num num="[0390]"> </para-num> <div id="p-0440" num="0390" class="description-line">ESI-MS: 304 ([M+1]<sup>+</sup>).</div>
    </li> <heading id="h-0048">(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate) (Lipid 24)</heading>
    <li> <para-num num="[0391]"> </para-num> <div id="p-0441" num="0391" class="description-line">
      <chemistry id="CHEM-US-00185" num="00185">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9c/1b/9d/0defa0dbceeda9/US20190292130A1-20190926-C00185.png"><img id="EMI-C00185" he="34.97mm" wi="75.35mm" file="US20190292130A1-20190926-C00185.TIF" alt="Figure US20190292130A1-20190926-C00185" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="140" alt="Figure US20190292130A1-20190926-C00185" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9c/1b/9d/0defa0dbceeda9/US20190292130A1-20190926-C00185.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00185" attachment-type="cdx" file="US20190292130A1-20190926-C00185.CDX"> </attachment>
          <attachment idref="CHEM-US-00185" attachment-type="mol" file="US20190292130A1-20190926-C00185.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0392]"> </para-num> <div id="p-0442" num="0392" class="description-line">6,6-(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(hexan-1-ol) (0.30 g, 1.0 mmol) and 2-hexyl-decanoic acid (0.50 g, 2.2 mmol, 2 equiv.) were taken in 50 mL flask and dissolved in dry DCM. Than EDC (0.27 g, 1.4 mmol) was added to the reaction mixture followed by DMAP (cat.), and the reaction was stirred for overnight. The reaction mixture was washed with water followed by brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>. The crude mixture was purified by silica gel column chromatography (MeOH:CHCl<sub>3 </sub>(5:95) to yield 65% (0.49 g) pure compound as pale liquid.</div>
    </li> <li> <para-num num="[0393]"> </para-num> <div id="p-0443" num="0393" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  3.72 (4H, t, J=5.65 Hz); 3.20-3.34 (4H, m); 2.31 (4H, t, J=6.71 Hz); 2.21 (6H, s); 1.71-1.85 (4H, m); 1.68-1.50 (6H, m); 1.50-1.36 (6H, m); 1.32-1.17 (50H, m), 0.84 (12H, t, J=6.91 Hz).</div>
    </li> <li> <para-num num="[0394]"> </para-num> <div id="p-0444" num="0394" class="description-line">ESI-MS: 780 ([M+1]<sup>+</sup>).</div>
    </li> <heading id="h-0049">Synthesis of Lipid 56</heading>
    <li> <para-num num="[0395]"> </para-num> <div id="p-0445" num="0395" class="description-line">
      <chemistry id="CHEM-US-00186" num="00186">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/40/3c/79/20cee866abede9/US20190292130A1-20190926-C00186.png"><img id="EMI-C00186" he="137.75mm" wi="158.33mm" file="US20190292130A1-20190926-C00186.TIF" alt="Figure US20190292130A1-20190926-C00186" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="633" height="551" alt="Figure US20190292130A1-20190926-C00186" class="patent-full-image" src="https://patentimages.storage.googleapis.com/40/3c/79/20cee866abede9/US20190292130A1-20190926-C00186.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00186" attachment-type="cdx" file="US20190292130A1-20190926-C00186.CDX"> </attachment>
          <attachment idref="CHEM-US-00186" attachment-type="mol" file="US20190292130A1-20190926-C00186.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0050">6-hydroxyhexanoic acid</heading>
    <li> <para-num num="[0396]"> </para-num> <div id="p-0446" num="0396" class="description-line">
      <chemistry id="CHEM-US-00187" num="00187">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e4/11/5e/2aa6b114d192cf/US20190292130A1-20190926-C00187.png"><img id="EMI-C00187" he="3.81mm" wi="38.27mm" file="US20190292130A1-20190926-C00187.TIF" alt="Figure US20190292130A1-20190926-C00187" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="153" height="15" alt="Figure US20190292130A1-20190926-C00187" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e4/11/5e/2aa6b114d192cf/US20190292130A1-20190926-C00187.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00187" attachment-type="cdx" file="US20190292130A1-20190926-C00187.CDX"> </attachment>
          <attachment idref="CHEM-US-00187" attachment-type="mol" file="US20190292130A1-20190926-C00187.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0397]"> </para-num> <div id="p-0447" num="0397" class="description-line">-caprolactone (2.2 g, 20.0 mmol) was dissolved in <figure-callout id="6" label="dioxane" filenames="US20190292130A1-20190926-D00018.png" state="{{state}}">dioxane</figure-callout> 6 mL, and 50 ml of a 3M NaOH solution was added. The mixture was stirred at room temperature overnight. The solution was washed with ethyl acetate to remove some organic impurities. The aqueous layer was acidified to pH 3-4 with concentrated HCl 37% and then extracted with ethyl acetate (250 mL). The organic layer was washed with saturated NaCl (250 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and filtered. The organic layer was concentrated in vacuo to yield&gt;90% (2.0 g) as colorless oil.</div>
    </li> <li> <para-num num="[0398]"> </para-num> <div id="p-0448" num="0398" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  3.62 (2H, t, J=6.30 Hz); 2.33 (2H, t, J=7.45 Hz); 1.63 (2H, pent); 1.55 (2H, q, J=7.45 Hz); 1.42-1.32 (2H, m).</div>
    </li> <heading id="h-0051">7-oxoheptanoic acid</heading>
    <li> <para-num num="[0399]"> </para-num> <div id="p-0449" num="0399" class="description-line">
      <chemistry id="CHEM-US-00188" num="00188">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ec/1f/bd/edb5b106048346/US20190292130A1-20190926-C00188.png"><img id="EMI-C00188" he="3.81mm" wi="39.96mm" file="US20190292130A1-20190926-C00188.TIF" alt="Figure US20190292130A1-20190926-C00188" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="160" height="15" alt="Figure US20190292130A1-20190926-C00188" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ec/1f/bd/edb5b106048346/US20190292130A1-20190926-C00188.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00188" attachment-type="cdx" file="US20190292130A1-20190926-C00188.CDX"> </attachment>
          <attachment idref="CHEM-US-00188" attachment-type="mol" file="US20190292130A1-20190926-C00188.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0400]"> </para-num> <div id="p-0450" num="0400" class="description-line">IBX (1.0 g, 3.5 mmol, 1.5 eq) was added to a solution of 6-hydroxyhexanoic acid (0.60 g, 4.5 mmol) in DMSO (10 mL). The mixture was stirred for 6 h and quenched by addition of water. The precipitate was removed by filtration. Extraction with ethyl acetate (250 ml), anhydrification with Na<sub>2</sub>SO<sub>4</sub>, and removal of the solvent in vacuo gave almost pure oxoacid yield 0.46 g (78%) as colorless oil.</div>
    </li> <li> <para-num num="[0401]"> </para-num> <div id="p-0451" num="0401" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  9.48 (1H, t, J=1.57 Hz); 2.33 (2H, t, J=7.45 Hz); 2.20 (2H, t, J=7.20 Hz); 2.10-1.95 (2H, m), 1.45-1.32 (2H, m).</div>
    </li> <heading id="h-0052">(Z)-non-2-en-1-yl 6-oxohexanoate</heading>
    <li> <para-num num="[0402]"> </para-num> <div id="p-0452" num="0402" class="description-line">
      <chemistry id="CHEM-US-00189" num="00189">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f7/17/0f/c2443e6ac2c258/US20190292130A1-20190926-C00189.png"><img id="EMI-C00189" he="15.16mm" wi="72.14mm" file="US20190292130A1-20190926-C00189.TIF" alt="Figure US20190292130A1-20190926-C00189" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="289" height="61" alt="Figure US20190292130A1-20190926-C00189" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f7/17/0f/c2443e6ac2c258/US20190292130A1-20190926-C00189.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00189" attachment-type="cdx" file="US20190292130A1-20190926-C00189.CDX"> </attachment>
          <attachment idref="CHEM-US-00189" attachment-type="mol" file="US20190292130A1-20190926-C00189.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0403]"> </para-num> <div id="p-0453" num="0403" class="description-line">7-oxoheptanoic acid (0.26 g, 2.0 mmol) and cis-2-nonen-1-ol (0.28 g, 2.0 mmol, 1 equiv.) taken in 50 mL flask and dissolved in dry DCM and EDCI (0.27 g, 1.4 mmol) was added to the reaction mixture followed by DMAP (cat) stirred for overnight. The reaction mixture was washed with water followed by brine solution and dried over sodium sulphite. The crude mixture was purified by silica gel column chromatography (EtOAc:Hexane (5:95) to yield 85% (0.44 g) pure compound as liquid.</div>
    </li> <li> <para-num num="[0404]"> </para-num> <div id="p-0454" num="0404" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  9.74 (1H, t, J=1.69 Hz), 5.68-5.58 (1H, m); 5.54-5.44 (1H, m); 4.60 (2H, d, J=7.20 Hz); 2.40-2.50 (2H, m); 2.38-2.28 (2H, m); 2.08 (2H, q, J=7.70, 6.90 Hz); 1.70-1.60 (4H, m); 1.40-1.20 (8H, m); 0.86 (6H, t, J=6.95 Hz).</div>
    </li> <li> <para-num num="[0405]"> </para-num> <div id="p-0455" num="0405" class="description-line">ESI-MS: 277 ([M+Na]<sup>+</sup>).</div>
    </li> <heading id="h-0053">Di((Z)-non-2-en-1-yl) 6,6-(2-(tert-butoxycarbonyl)hydrazine-1,1-diyl)dihexanoate</heading>
    <li> <para-num num="[0406]"> </para-num> <div id="p-0456" num="0406" class="description-line">
      <chemistry id="CHEM-US-00190" num="00190">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/04/45/da/aeb9debbaabd16/US20190292130A1-20190926-C00190.png"><img id="EMI-C00190" he="29.72mm" wi="75.01mm" file="US20190292130A1-20190926-C00190.TIF" alt="Figure US20190292130A1-20190926-C00190" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="119" alt="Figure US20190292130A1-20190926-C00190" class="patent-full-image" src="https://patentimages.storage.googleapis.com/04/45/da/aeb9debbaabd16/US20190292130A1-20190926-C00190.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00190" attachment-type="cdx" file="US20190292130A1-20190926-C00190.CDX"> </attachment>
          <attachment idref="CHEM-US-00190" attachment-type="mol" file="US20190292130A1-20190926-C00190.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0407]"> </para-num> <div id="p-0457" num="0407" class="description-line">(Z)-non-2-en-1-yl 6-oxohexanoate (0.25 g, 1.0 mmol, 2 equiv.) and Boc-hydrazine (0.06 g, 0.5 mmol, 1.0 equiv.) were dissolved in dry DCM under nitrogen atmosphere then sodium tri acetoxyborohydride (0.63 g, 3.0 mmol, 3.0 equiv) was added to the reaction mixture and stirred for 12 h at room temperature. The reaction was quenched with sodium bicarbonate solution and extracted with DCM followed by washing with water and brine solution. The solvent was evaporated and purified by column chromatography (EtOAc:Hexane (10:90) to yield 0.21 g (78%) of pure lipid as colorless liquid.</div>
    </li> <li> <para-num num="[0408]"> </para-num> <div id="p-0458" num="0408" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.60-5.50 (2H, m); 5.47-5.37 (2H, m); 5.25 (br s, 1H), 4.53 (2H, s), 4.51 (2H, s), 2.65-2.42 (4H, m), 2.21 (4H, t, J=7.50 Hz), 2.00 (4H, q, J=7.90, 7.11 Hz), 1.54 (4H, pent); 1.32-1.45 (15H, m), 1.30-1.09 (18H, m), 0.79 (6H, t, J=6.75 Hz).</div>
    </li> <li> <para-num num="[0409]"> </para-num> <div id="p-0459" num="0409" class="description-line">ESI-MS: 609 ([M+1]<sup>+</sup>), 553 ([M-t-Bu]<sup>+</sup>).</div>
    </li> <heading id="h-0054">Di((Z)-non-2-en-1-yl) 6,6-(hydrazine-1,1-diyl)dihexanoate</heading>
    <li> <para-num num="[0410]"> </para-num> <div id="p-0460" num="0410" class="description-line">
      <chemistry id="CHEM-US-00191" num="00191">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/68/f3/46/cf184021c1fb61/US20190292130A1-20190926-C00191.png"><img id="EMI-C00191" he="35.22mm" wi="75.01mm" file="US20190292130A1-20190926-C00191.TIF" alt="Figure US20190292130A1-20190926-C00191" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="141" alt="Figure US20190292130A1-20190926-C00191" class="patent-full-image" src="https://patentimages.storage.googleapis.com/68/f3/46/cf184021c1fb61/US20190292130A1-20190926-C00191.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00191" attachment-type="cdx" file="US20190292130A1-20190926-C00191.CDX"> </attachment>
          <attachment idref="CHEM-US-00191" attachment-type="mol" file="US20190292130A1-20190926-C00191.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0411]"> </para-num> <div id="p-0461" num="0411" class="description-line">The above Boc-protected-hydrazine compound (0.25 g, 0.41 mmol) was dissolved in TFA/DCM (2:8) 10 mL under nitrogen atmosphere for 2 h at room temperature. The reaction was quenched with sodium bicarbonate solution and extracted with DCM followed by washing with water and brine solution and drying over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated to yield, without further purification 0.20 g (99%) of pure hydrazine as pale yellow liquid.</div>
    </li> <li> <para-num num="[0412]"> </para-num> <div id="p-0462" num="0412" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.70-5.58 (2H, m); 5.56-5.42 (2H, m); 4.62 (2H, s), 4.60 (2H, s); 2.44 (4H, t, J=7.52 Hz); 2.31 (4H, t, J=7.52 Hz); 2.09 (4H, q, J=7.52, 7.15 Hz); 1.64 (4H, pent); 1.55 (4H, pent); 1.43-1.20 (18H, m); 0.87 (6H, t, J=7.15 Hz).</div>
    </li> <li> <para-num num="[0413]"> </para-num> <div id="p-0463" num="0413" class="description-line">ESI-MS: 509 ([M+1]<sup>+</sup>)</div>
    </li> <heading id="h-0055">Di((Z)-non-2-en-1-yl) 6,6-(2-(4-(dimethylamino)butanoyl)hydrazine-1,1-diyl)dihexanoate (Lipid 56)</heading>
    <li> <para-num num="[0414]"> </para-num> <div id="p-0464" num="0414" class="description-line">
      <chemistry id="CHEM-US-00192" num="00192">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/26/df/6d/e16b8d89a3df17/US20190292130A1-20190926-C00192.png"><img id="EMI-C00192" he="38.44mm" wi="107.70mm" file="US20190292130A1-20190926-C00192.TIF" alt="Figure US20190292130A1-20190926-C00192" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="431" height="154" alt="Figure US20190292130A1-20190926-C00192" class="patent-full-image" src="https://patentimages.storage.googleapis.com/26/df/6d/e16b8d89a3df17/US20190292130A1-20190926-C00192.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00192" attachment-type="cdx" file="US20190292130A1-20190926-C00192.CDX"> </attachment>
          <attachment idref="CHEM-US-00192" attachment-type="mol" file="US20190292130A1-20190926-C00192.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0415]"> </para-num> <div id="p-0465" num="0415" class="description-line">Di((Z)-non-2-en-1-yl) 6,6-(hydrazine-1,1-diyl)dihexanoate (0.20 g, 0.4 mmol, 1 equiv.), N,N-dimethyl aminobutyric acid hydrochloride (0.10 g, 0.6 mmol, 1.5 equiv.), EDC (0.15 g, 0.8 mmol, 2.0 equiv.) and DMAP (cat.) were dissolved in dry DCM under nitrogen atmosphere. Then trimethylamine (0.28 ml, 2.00 mmol, 2 equiv.) was added and the reaction was stirred for 12 h. To the reaction mixture was added sodium bicarbonate and the mixture was washed with water, followed by and brine solution and drying over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated and the reaction mixture was purified by silica column chromatography (MeOH:CHCl<sub>3 </sub>(5:95) to yield 85% (0.20 g) of pure lipid as pale yellow liquid.</div>
    </li> <li> <para-num num="[0416]"> </para-num> <div id="p-0466" num="0416" class="description-line"> <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  5.67-5.57 (4H, m); 5.57-5.44 (4H, m); 4.61 (4H, t, J=5.52 Hz); 2.66 (2H, t, J=8.16 Hz); 2.45 (2H, t, J=7.47 Hz); 2.40 (2H, t, J=7.75 Hz); 2.34-2.20 (4H, m); 2.28 (6H, s); 2.08 (4H, q, J=7.80 Hz); 2.00-1.90 (4H, m); 1.86-1.76 (2H, m); 1.70-1.55 (4H, m), 1.54-1.40 (4H, m), 1.38-1.20 (14H, m), 0.87 (6H, t, J=6.92 Hz).</div>
    </li> <li> <para-num num="[0417]"> </para-num> <div id="p-0467" num="0417" class="description-line">ESI-MS: 622 ([M+1]<sup>+</sup>).</div>
    </li> <heading id="h-0056">Example 3: Physico-Chemical Characterization</heading>
    <li> <para-num num="[0418]"> </para-num> <div id="p-0468" num="0418" class="description-line"> </div>
    </li> <li> <div id="p-0469" num="0000" class="description-line">
      <tables id="TABLE-US-00011" num="00011">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">LNP-siRNA</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">formulations</td>
                <td class="description-td">Size (d  nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">Zeta-potential (mV)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Dlin-MC3-DMA</td>
                <td class="description-td">44.5</td>
                <td class="description-td">0.18</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> <figure-callout id="1" label="Lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">Lipid</figure-callout> 1</td>
                <td class="description-td">45.1</td>
                <td class="description-td">0.14</td>
                <td class="description-td">18.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> <figure-callout id="2" label="Lipid" filenames="US20190292130A1-20190926-D00018.png,US20190292130A1-20190926-D00021.png" state="{{state}}">Lipid</figure-callout> 2</td>
                <td class="description-td">56.3</td>
                <td class="description-td">0.06</td>
                <td class="description-td">13.9</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> <figure-callout id="9" label="Lipid" filenames="US20190292130A1-20190926-D00007.png" state="{{state}}">Lipid</figure-callout> 9</td>
                <td class="description-td">75.1</td>
                <td class="description-td">0.04</td>
                <td class="description-td">13.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> <figure-callout id="10" label="Lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">Lipid</figure-callout> 10</td>
                <td class="description-td">50.5</td>
                <td class="description-td">0.08</td>
                <td class="description-td">18.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid 11</td>
                <td class="description-td">108.5</td>
                <td class="description-td">0.10</td>
                <td class="description-td">20.4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid 14</td>
                <td class="description-td">44.3</td>
                <td class="description-td">0.09</td>
                <td class="description-td">3.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> <figure-callout id="15" label="Lipid" filenames="US20190292130A1-20190926-D00009.png,US20190292130A1-20190926-D00020.png" state="{{state}}">Lipid</figure-callout> 15</td>
                <td class="description-td">52.5</td>
                <td class="description-td">0.11</td>
                <td class="description-td">10.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid 33</td>
                <td class="description-td">46.0</td>
                <td class="description-td">0.15</td>
                <td class="description-td">10.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid 21</td>
                <td class="description-td">67.7</td>
                <td class="description-td">0.16</td>
                <td class="description-td">2.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> <figure-callout id="38" label="Lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">Lipid</figure-callout> 38</td>
                <td class="description-td">59.0</td>
                <td class="description-td">0.08</td>
                <td class="description-td">6.7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid 55</td>
                <td class="description-td">97.0</td>
                <td class="description-td">0.17</td>
                <td class="description-td">1.28</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> <figure-callout id="54" label="Lipid" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">Lipid</figure-callout> 54</td>
                <td class="description-td">138.6</td>
                <td class="description-td">0.06</td>
                <td class="description-td">1.82</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0057">Example 4: Biological Results</heading>
    <li> <para-num num="[0419]"> </para-num> <div id="p-0470" num="0419" class="description-line">In vitro gene silencing was performed as described in Example 1.</div>
    </li> <li> <para-num num="[0420]"> </para-num> <div id="p-0471" num="0420" class="description-line"> <figref idrefs="DRAWINGS">FIG. 1</figref> depicts in vitro gene silencing effect lipid 1: Human T cells SupT1 were treated with lipid nanoparticle (LNP) comprising of <figure-callout id="1" label="cationic lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">cationic lipid</figure-callout> 1 encapsulated siCD45 for 48 hrs (A) or 72 hrs (B) at different siRNA doses (0.4 M, 0.2 M, 0.1 M). The results demonstrate the efficiency of the <figure-callout id="1" label="lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">lipid</figure-callout> 1 to down-regulate CD45 gene in hard to transfect T cells.</div>
    </li> <li> <para-num num="[0421]"> </para-num> <div id="p-0472" num="0421" class="description-line">Drug resistant human ovarian carcinoma cells (NAR) were treated with either LNP-siPLK-1 or LNP-<figure-callout id="1" label="siLuc nanoparticles Lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">siLuc nanoparticles Lipid</figure-callout> 1 LNPs (A); Lipid 10&amp;11 LNPs (B) for 72 hrs and PLK-1 expression was measured by qPCR as described in Example 1. As shown in <figref idrefs="DRAWINGS">FIG. 2A</figref>, Lipid1 containing LNPs downregulating the proto-oncogene PLK1 efficiently, this can induce the apoptosis in cancer cells. At higher doses of cntr LUC-siRNA, LNPs with <figure-callout id="1" label="lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">lipid</figure-callout> 1 did not affect plk1 expression. Further as shown in <figref idrefs="DRAWINGS">FIG. 2B</figref>, lipid 10&amp;11 containing LNPs-siPLK1 also down regulating plk1 gene efficiently at different doses whereas siLUC LNPs has no effect on plk1 expression.</div>
    </li> <heading id="h-0058">In Vitro Gene Silencing Effect of <figure-callout id="1" label="Lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">Lipid</figure-callout> 1 in NAR Cells:</heading>
    <li> <para-num num="[0422]"> </para-num> <div id="p-0473" num="0422" class="description-line">Human ovarian cancer cells (NAR cells) were treated with lipid1/siPLK1 nanoparticles for 48 hr at different siRNA concentrations (0.2 M and 0.1 M). Apoptotic cells were analyzed by FACS using PI/Annexin. As shown in <figref idrefs="DRAWINGS">FIG. 3</figref>, siPLK1-LNPs with lipid1 inducing apoptosis in cancer cell due to downregulation of proto-oncogene plk1. Percentage of early apoptotic cells was higher in cells treated with siPLK1-LNPs at 0.2 uM dose of siPLK1. There was no effect on cell cycle in cells treated with siLUC-LNPs indicating the efficient delivery of siPLK1 to NAR cells.</div>
    </li> <heading id="h-0059">In Vitro Gene Silencing Effect of <figure-callout id="10" label="Lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">Lipid</figure-callout> 10 and 11 in NAR Cells:</heading>
    <li> <para-num num="[0423]"> </para-num> <div id="p-0474" num="0423" class="description-line">Human ovarian cancer cells (NAR cells) were treated with either lipid10 or lipid 11/siPLK1 nanoparticles for 48 hr at different siRNA concentrations (0.1 M and 0.05 M). siLUC-LNPs used as a negative control. Apoptotic cells were analyzed by FACS using PI/Annexin. As shown in <figref idrefs="DRAWINGS">FIG. 4</figref>, siPLK1-LNPs composed of either lipid10 or lipid 11 efficiently downregulating PLK1 gene followed by inducing apoptosis in NAR cells.</div>
    </li> <li> <para-num num="[0424]"> </para-num> <div id="p-0475" num="0424" class="description-line">Human ovarian carcinoma cells (OVCAR 8) were treated with <figure-callout id="1" label="lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">lipid</figure-callout> 1 containing LNPs with either siPLK1 or siLUC for 72 hr and PLK-1 expression was measured by qPCR. As shown in <figref idrefs="DRAWINGS">FIG. 5</figref>, <figure-callout id="1" label="lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">lipid</figure-callout> 1 containing siPLK1-LNPs efficiently downregulating PLK1 gene compared to dlin-mc3-dma containing LNPs.</div>
    </li> <li> <para-num num="[0425]"> </para-num> <div id="p-0476" num="0425" class="description-line">Spheroids of drug resistant human ovarian carcinoma cells (NAR) were treated with LNPs composed of lipid1 and with either siPLK-1 or siLuc s for 72 hr and PLK-1 expression was measured by qPCR. Spheroids are 3D cultures of tumor cells mimicking in vivo tumors. As shown in <figref idrefs="DRAWINGS">FIG. 6</figref>, lipid1 containing siPLK1-LNPs significantly downregulating PLK1 gene compared to siLUC-LNPs indicating the efficiency of lipid1 to deliver siRNA in to NAR spheroids.</div>
    </li> <li> <para-num num="[0426]"> </para-num> <div id="p-0477" num="0426" class="description-line">Human colon carcinoma cells (HCT116) were incubated with LNPs with ctl siRNA (see methods) for 72 hrs. The cell viability was measured by XTT assay. Toxicity of LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or lipid 55 is compared with gold standard LNPs composed of Dlin-MC3-DMA. As shown in <figref idrefs="DRAWINGS">FIG. 7</figref>, LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or lipid 55 are less toxic than LNPs composed of Dlin-MC3-DMA in a dose dependent manner.</div>
    </li> <heading id="h-0060">In Vitro Gene Silencing Effects of Lipids 38&amp;55.</heading>
    <li> <para-num num="[0427]"> </para-num> <div id="p-0478" num="0427" class="description-line">Human multiple myeloma suspension cells (U266) were incubated with LNPs containing siPLK1 at different concentrations for 48 hrs. PLK1 expression was measured by qPCR. PLK1-mRNA levels were normalized to LNPs-ctl siRNA treated cells. As shown in <figref idrefs="DRAWINGS">FIG. 8</figref>, PLK1 gene was efficiently down regulate in cells treated with siPLK1-LNPs composed of either lipid38 or lipid 55 and comparable to Dlin-MC3-DMA LNPs.</div>
    </li> <heading id="h-0061">Effect of PLK1 Downregulation on Multiple Myeloma Cell Survival:</heading>
    <li> <para-num num="[0428]"> </para-num> <div id="p-0479" num="0428" class="description-line">Human multiple myeloma suspension cells (U266) were incubated with siPLK1-LNPs or siCtl-LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or 55 at different concentrations for 48 hrs. Cell viability affected by PLK1 down regulation was measured by XTT assay. As shown in <figref idrefs="DRAWINGS">FIG. 9</figref>, siPLK1-LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or lipid 55 has more effect on cell viability compared to Dlin-MC3-DMA LNPs due to efficient downregulation of PLK1 gene, whereas siCtl-LNPs has no effect on the cell viability indicating the safe use of new lipids.</div>
    </li> <heading id="h-0062">Effect of PLK1 Silencing on B-Cell Lymphoma Viability:</heading>
    <li> <para-num num="[0429]"> </para-num> <div id="p-0480" num="0429" class="description-line">Human B-cell lymphoma suspension cells (RPMI-8226) were incubated with siPLK1-LNPs or siCtl-LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or 55 at different concentrations for 48 hrs. Cell viability affected by PLK1 down regulation was measured by XTT assay. As shown in <figref idrefs="DRAWINGS">FIG. 10</figref>, siPLK1-LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or lipid 55 exhibiting a dose dependent effect on B-cell lymphoma cancer cell viability due to efficient downregulation of PLK1 gene, whereas siCtl-LNPs has no effect on the cell viability.</div>
    </li> <heading id="h-0063">Effect of PLK1 Silencing on Cell Viability:</heading>
    <li> <para-num num="[0430]"> </para-num> <div id="p-0481" num="0430" class="description-line">Human multiple myeloma suspension cells (MM1) were incubated with siPLK1-LNPs or siCtl-LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or 55 at different concentrations for 48 hrs. Cell viability affected by PLK1 down regulation was measured by XTT assay. As shown in <figref idrefs="DRAWINGS">FIG. 11</figref>, siPLK1-LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or lipid 55 exhibiting a dose dependent effect on multiple myeloma cancer cell viability due to PLK1 downregulation, whereas siCtl-LNPs has no effect on the cell viability.</div>
    </li> <li> <div id="p-0482" num="0000" class="description-line">In Vitro Expression of pDNA:</div>
    </li> <li> <para-num num="[0431]"> </para-num> <div id="p-0483" num="0431" class="description-line">Human colon carcinoma cells (HCT 116) were incubated with LNPs-LUC pDNA at different concentrations for 48 hrs. Luciferase expression was measured by luminometer. Lipofectamine 2000 (Lipo 2000) was used as positive control. LNPs were composed of <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 and different amounts of co-lipid DOPE, along with other co-lipids such as Chol, PEG-DMG. As shown in <figref idrefs="DRAWINGS">FIG. 12</figref>, LNPs-pDNA composed of <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 efficiently delivering pDNA to the nucleus. The amount of luciferase expression was similar to <figure-callout id="2000" label="positive control lipo" filenames="US20190292130A1-20190926-D00014.png" state="{{state}}">positive control lipo</figure-callout> 2000.</div>
    </li> <li> <para-num num="[0432]"> </para-num> <div id="p-0484" num="0432" class="description-line">In vitro expression of pDNA in HEK 293 cells: HEK cells were treated with LNPs composed of either lipid1 or <figure-callout id="10" label="lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">lipid</figure-callout> 10 encapsulated with mKATE-pDNA at the concentration of 0.6 nM pDNA. After 72 hr, mKATE expression was analyzed by flow cytometry. As shown in <figref idrefs="DRAWINGS">FIG. 13</figref>, LNPs composed of either lipid1 or <figure-callout id="10" label="lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">lipid</figure-callout> 10 efficiently delivering the pDNA to the nucleus and mKATE expression was observed, whereas Dlin-MC3-DMA LNPs did not show any effect on mKATE expression.</div>
    </li> <li> <para-num num="[0433]"> </para-num> <div id="p-0485" num="0433" class="description-line">Dose dependent expression of pDNA in HEK 293 cells: HEK cells were treated with LNPs composed of either lipid1 or <figure-callout id="10" label="lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">lipid</figure-callout> 10 encapsulated with mKATE-pDNA at different amount pDNA. After 72 hr, mKATE expression was analyzed by flow cytometry. As shown in <figref idrefs="DRAWINGS">FIG. 14A</figref>, LNPs-pDNA composed of <figure-callout id="1" label="lipid" filenames="US20190292130A1-20190926-D00003.png,US20190292130A1-20190926-D00007.png" state="{{state}}">lipid</figure-callout> 1 did not show any dose dependent expression, but as shown in <figref idrefs="DRAWINGS">FIG. 14B</figref>, <figure-callout id="10" label="lipid" filenames="US20190292130A1-20190926-D00000.png,US20190292130A1-20190926-D00001.png" state="{{state}}">lipid</figure-callout> 10 containing LNPs exhibiting a dose dependent expression of mKATE.</div>
    </li> <li> <div id="p-0486" num="0000" class="description-line">In Vitro Delivery of mRNA:</div>
    </li> <li> <para-num num="[0434]"> </para-num> <div id="p-0487" num="0434" class="description-line">Hard to transfect murine macrophage cells (RAW 264.7) were treated with LNPs composed of either Lipid38 or <figure-callout id="54" label="Lipid" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">Lipid</figure-callout> 54 and formulated with luciferase mRNA at different amounts of mRNA. After 18 hrs luciferase expression was measured by luminometer. As shown in <figref idrefs="DRAWINGS">FIG. 15</figref>, luciferase expression was observed in cells treated with lipid 38-LNPs efficiently compared to lipid 54-LNPs, further a dose dependent expression was observed in <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 containing LNPs.</div>
    </li> <li> <div id="p-0488" num="0000" class="description-line">In Vivo Delivery of mRNA to Muscle Cells:</div>
    </li> <li> <para-num num="[0435]"> </para-num> <div id="p-0489" num="0435" class="description-line">LNPs composed of either <figure-callout id="54" label="lipid" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">lipid</figure-callout> 54 or <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 formulated with luciferase mRNA were administered intramuscularly in to C57BL6/j mice at 1 mg/kg body weight. Luciferase expression was measured by bioluminescence imaging system Biospace: (a) after 8 hrs of i.m. administration; and (b) after 24 hrs. As shown in <figref idrefs="DRAWINGS">FIG. 16</figref>, significant amounts of luciferase were observed after 8 hrs of administration for both LNPs composed of either <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 or <figure-callout id="54" label="lipid" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">lipid</figure-callout> 54. The expression was still high 24 hrs after the administration of LNPs indicating the efficiency of these lipids in delivering mRNA in vivo.</div>
    </li> <li> <div id="p-0490" num="0000" class="description-line">In Vivo Delivery of mRNA to Liver:</div>
    </li> <li> <para-num num="[0436]"> </para-num> <div id="p-0491" num="0436" class="description-line">LNPs composed of either <figure-callout id="54" label="lipid" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">lipid</figure-callout> 54 or <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 formulated with luciferase mRNA were administered intravenously into C57BL6/j mice at 1 mg/kg body weight. After 8 hrs, luciferase expression was measured by bioluminescence imaging system Biospace. As shown in <figref idrefs="DRAWINGS">FIG. 17</figref>, mice treated with LNPs composed of <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 and mRNA showing significant amount of luciferase in mouse liver compared to LNPs composed of <figure-callout id="54" label="lipid" filenames="US20190292130A1-20190926-D00017.png,US20190292130A1-20190926-D00018.png" state="{{state}}">lipid</figure-callout> 54.</div>
    </li> <li> <div id="p-0492" num="0000" class="description-line">In Vivo Delivery of mRNA to Liver:</div>
    </li> <li> <para-num num="[0437]"> </para-num> <div id="p-0493" num="0437" class="description-line">LNPs composed of <figure-callout id="38" label="lipid" filenames="US20190292130A1-20190926-D00010.png,US20190292130A1-20190926-D00014.png" state="{{state}}">lipid</figure-callout> 38 formulated with luciferase mRNA were administered intravenously into C57BL6/j mice at 1 mg/kg body weight. After 8 hrs and 24 hrs of administration, luciferase expression was measured by bioluminescence imaging system Biospace. As shown in <figref idrefs="DRAWINGS">FIG. 18</figref>, significant amount of luciferase expression was observed in liver. Moreover the luciferase expression was high after 8 hrs compared to after 24 hrs.</div>
    </li> <li> <para-num num="[0438]"> </para-num> <div id="p-0494" num="0438" class="description-line"> <figref idrefs="DRAWINGS">FIG. 19</figref>: demonstrates that there is no liver toxicity in Non-human primate compared with MC3. Cynomolgus monkeys (n=2 per group, males) received a single I.v. administration (1 ml/kg) of (0.5 mg/kg) of MC3 particles with siNC5 and lipid 38-based particles with siNC5 (0.5 mg/Kg). At 1 and 24 h post administration serum was collected at and analyzed for ALT, AST (by Roch Cobra Auto analyzer). Each data point is an average of 2 animalsSEM.</div>
    </li> <li> <para-num num="[0439]"> </para-num> <div id="p-0495" num="0439" class="description-line">While the present invention has been particularly described, persons skilled in the art will appreciate that many variations and modifications can be made. Therefore, the invention is not to be construed as restricted to the particularly described embodiments, and the scope and concept of the invention will be more readily understood by reference to the claims, which follow.</div>
    
  </li> </ul>
  </div>
  </section>

  <section itemprop="claims" itemscope>
    <h2>Claims (<span itemprop="count">25</span>)</h2>
    
    <div itemprop="content" html><div mxw-id="PCLM202105674" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-01-61" num="01-61" class="claim">
      <div class="claim-text"> <b>1</b>-<b>61</b>. (canceled)</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00062" num="00062" class="claim">
      <div class="claim-text"> <b>62</b>. A cationic lipid comprising a functional group represented by the structure:
<div class="claim-text"> <br/>W-(T=O)<sub>m</sub>X(CH<sub>2</sub>)<sub>z</sub>Y
</div> <div class="claim-text">wherein
<div class="claim-text">X and Y are each independently O, N or NH, wherein X and Y cannot both be O;</div>
<div class="claim-text">W is a bond, O, NH or S;</div>
<div class="claim-text">T is C or S;</div>
<div class="claim-text">m is 0 or 1; and</div>
<div class="claim-text">z is 0 or 2;</div>
</div> <div class="claim-text">wherein said functional group is linked to at least one saturated or unsaturated fatty acid residue.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00063" num="00063" class="claim">
      <div class="claim-text"> <b>63</b>. The cationic lipid according to <claim-ref idref="CLM-00062">claim 62</claim-ref>, which is represented by the structure of formula (I):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00193" num="00193">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/6d/56/116700c4b5ff87/US20190292130A1-20190926-C00193.png"><img id="EMI-C00193" he="23.62mm" wi="69.93mm" file="US20190292130A1-20190926-C00193.TIF" alt="Figure US20190292130A1-20190926-C00193" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="94" alt="Figure US20190292130A1-20190926-C00193" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7a/6d/56/116700c4b5ff87/US20190292130A1-20190926-C00193.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00193" attachment-type="cdx" file="US20190292130A1-20190926-C00193.CDX"> </attachment>
            <attachment idref="CHEM-US-00193" attachment-type="mol" file="US20190292130A1-20190926-C00193.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">Y is O or NH;</div>
<div class="claim-text">T is C or S;</div>
<div class="claim-text">W is a bond, O, NH or S;</div>
<div class="claim-text">R<sup>1 </sup>is selected from the group consisting of:
<div class="claim-text">(a) NR<sup>4</sup>R<sup>5 </sup>wherein R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</div>
<div class="claim-text">(b) the side chain of a natural or unnatural amino acid; and</div>
<div class="claim-text">(c) a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from the group consisting of O, N and S; ---</div>
</div>
<div class="claim-text">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
<div class="claim-text">(a) C10-C22 alkyl;</div>
<div class="claim-text">(b) C10-C22 alkenyl;</div>
<div class="claim-text">(c) C10-C22 alkynyl;</div>
<div class="claim-text">(d) C4-C10 alkylene-ZC4-C22 alkyl; and</div>
<div class="claim-text">(e) C4-C10 alkylene-ZC4-C22 alkenyl;</div>
</div>
<div class="claim-text">Z is OC(O), C(O)O or O;</div>
<div class="claim-text">n is 0, 1, 2, 3, 4, 5 or 6;</div>
<div class="claim-text">m is 0 or 1;</div>
<div class="claim-text">p is 0 or 1; and</div>
<div class="claim-text">z is 0 or 2;</div>
</div>
        <div class="claim-text">including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</div>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00064" num="00064" class="claim">
      <div class="claim-text"> <b>64</b>. The cationic lipid according to <claim-ref idref="CLM-00063">claim 63</claim-ref>,
<div class="claim-text">wherein m is 0 and p is 0; or</div> <div class="claim-text">wherein m is 1 and p is 0; or</div> <div class="claim-text">wherein T is C; or</div> <div class="claim-text">wherein W is a bond; or</div> <div class="claim-text">wherein R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00065" num="00065" class="claim">
      <div class="claim-text"> <b>65</b>. The cationic lipid according to <claim-ref idref="CLM-00063">claim 63</claim-ref>, wherein p is 0, W is a bond and T is C, and the compound is represented by the structure of formula (Ia):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00194" num="00194">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b5/cf/9e/7bd93146b7c308/US20190292130A1-20190926-C00194.png"><img id="EMI-C00194" he="23.62mm" wi="69.93mm" file="US20190292130A1-20190926-C00194.TIF" alt="Figure US20190292130A1-20190926-C00194" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="94" alt="Figure US20190292130A1-20190926-C00194" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b5/cf/9e/7bd93146b7c308/US20190292130A1-20190926-C00194.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00194" attachment-type="cdx" file="US20190292130A1-20190926-C00194.CDX"> </attachment>
            <attachment idref="CHEM-US-00194" attachment-type="mol" file="US20190292130A1-20190926-C00194.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00066" num="00066" class="claim">
      <div class="claim-text"> <b>66</b>. The cationic lipid according to <claim-ref idref="CLM-00065">claim 65</claim-ref>, wherein R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (Ia-1):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00195" num="00195">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/53/f2/ca/380dd44c26a681/US20190292130A1-20190926-C00195.png"><img id="EMI-C00195" he="23.62mm" wi="69.93mm" file="US20190292130A1-20190926-C00195.TIF" alt="Figure US20190292130A1-20190926-C00195" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="94" alt="Figure US20190292130A1-20190926-C00195" class="patent-full-image" src="https://patentimages.storage.googleapis.com/53/f2/ca/380dd44c26a681/US20190292130A1-20190926-C00195.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00195" attachment-type="cdx" file="US20190292130A1-20190926-C00195.CDX"> </attachment>
            <attachment idref="CHEM-US-00195" attachment-type="mol" file="US20190292130A1-20190926-C00195.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
<div class="claim-text">(a) C10-C22 alkyl;</div>
<div class="claim-text">(b) C10-C22 alkenyl;</div>
<div class="claim-text">(c) C10-C22 alkynyl;</div>
<div class="claim-text">(d) C4-C10 alkylene-ZC4-C22 alkyl; and</div>
<div class="claim-text">(e) C4-C10 alkylene-ZC4-C22 alkenyl;</div>
</div>
<div class="claim-text">R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</div>
<div class="claim-text">Y is O or NH;</div>
<div class="claim-text">m is 0 or 1;</div>
<div class="claim-text">n is 0, 1, 2, 3, 4, 5 or 6; and</div>
<div class="claim-text">Z is OC(O), C(O)O or O.</div>
</div>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00067" num="00067" class="claim">
      <div class="claim-text"> <b>67</b>. The cationic lipid according to <claim-ref idref="CLM-00062">claim 62</claim-ref>, which is represented by the structure of formula (II):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00196" num="00196">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/f2/e7/e983783c2f842f/US20190292130A1-20190926-C00196.png"><img id="EMI-C00196" he="24.13mm" wi="69.93mm" file="US20190292130A1-20190926-C00196.TIF" alt="Figure US20190292130A1-20190926-C00196" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="97" alt="Figure US20190292130A1-20190926-C00196" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/f2/e7/e983783c2f842f/US20190292130A1-20190926-C00196.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00196" attachment-type="cdx" file="US20190292130A1-20190926-C00196.CDX"> </attachment>
            <attachment idref="CHEM-US-00196" attachment-type="mol" file="US20190292130A1-20190926-C00196.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">A is</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00197" num="00197">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5c/75/3c/a8c689e2df7165/US20190292130A1-20190926-C00197.png"><img id="EMI-C00197" he="12.45mm" wi="46.14mm" file="US20190292130A1-20190926-C00197.TIF" alt="Figure US20190292130A1-20190926-C00197" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="185" height="50" alt="Figure US20190292130A1-20190926-C00197" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5c/75/3c/a8c689e2df7165/US20190292130A1-20190926-C00197.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00197" attachment-type="cdx" file="US20190292130A1-20190926-C00197.CDX"> </attachment>
            <attachment idref="CHEM-US-00197" attachment-type="mol" file="US20190292130A1-20190926-C00197.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">
          <div class="claim-text">X is O or NH;</div>
          <div class="claim-text">Y is O or NH;</div>
          <div class="claim-text">provided that when A is</div>
        </div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00198" num="00198">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3d/8a/de/26fa0a52834f0b/US20190292130A1-20190926-C00198.png"><img id="EMI-C00198" he="12.45mm" wi="22.27mm" file="US20190292130A1-20190926-C00198.TIF" alt="Figure US20190292130A1-20190926-C00198" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="89" height="50" alt="Figure US20190292130A1-20190926-C00198" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3d/8a/de/26fa0a52834f0b/US20190292130A1-20190926-C00198.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00198" attachment-type="cdx" file="US20190292130A1-20190926-C00198.CDX"> </attachment>
            <attachment idref="CHEM-US-00198" attachment-type="mol" file="US20190292130A1-20190926-C00198.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">
          <div class="claim-text">X and Y cannot both be O;</div>
          <div class="claim-text">T is C or S;</div>
          <div class="claim-text">W is a bond, O, NH or S;</div>
          <div class="claim-text">R<sup>1 </sup>is selected from the group consisting of:
<div class="claim-text">(a) NR<sup>4</sup>R<sup>5 </sup>wherein R<sup>4 </sup>and R<sup>5 </sup>are each independently a C<sub>1</sub>-C<sub>4 </sub>alkyl; or R<sup>4 </sup>and R<sup>5 </sup>together with the nitrogen to which they are attached form a 5 or 6 membered heterocyclic or heteroaromatic ring, optionally containing one or more additional heteroatoms selected from the group consisting of O, N and S; or NR<sup>4</sup>R<sup>5 </sup>represent a guanidine group (NHC(NH)NH<sub>2</sub>);</div>
<div class="claim-text">(b) the side chain of a natural or unnatural amino acid; and</div>
<div class="claim-text">(c) a 5 or 6 membered heterocyclic or heteroaromatic ring containing one or more heteroatoms selected from the group consisting of O, N and S;</div>
</div>
          <div class="claim-text">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
<div class="claim-text">(a) C10-C22 alkyl;</div>
<div class="claim-text">(b) C10-C22 alkenyl;</div>
<div class="claim-text">(c) C10-C22 alkynyl;</div>
<div class="claim-text">(d) C4-C10 alkylene-ZC4-C22 alkyl; and</div>
<div class="claim-text">(e) C4-C10 alkylene-ZC4-C22 alkenyl;</div>
</div>
          <div class="claim-text">Z is OC(O), C(O)O or O;</div>
          <div class="claim-text">n is 0, 1, 2, 3, 4, 5 or 6;</div>
          <div class="claim-text">m is 0 or 1;</div>
          <div class="claim-text">p is 0 or 1; and</div>
          <div class="claim-text">z is 0 or 2;</div>
        </div>
        <div class="claim-text">including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</div>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00068" num="00068" class="claim">
      <div class="claim-text"> <b>68</b>. The cationic lipid according to <claim-ref idref="CLM-00067">claim 67</claim-ref>, which is represented by the structure of formula (IIa):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00199" num="00199">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0c/42/bb/b0bf53b18432e0/US20190292130A1-20190926-C00199.png"><img id="EMI-C00199" he="24.13mm" wi="69.93mm" file="US20190292130A1-20190926-C00199.TIF" alt="Figure US20190292130A1-20190926-C00199" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="97" alt="Figure US20190292130A1-20190926-C00199" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0c/42/bb/b0bf53b18432e0/US20190292130A1-20190926-C00199.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00199" attachment-type="cdx" file="US20190292130A1-20190926-C00199.CDX"> </attachment>
            <attachment idref="CHEM-US-00199" attachment-type="mol" file="US20190292130A1-20190926-C00199.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00069" num="00069" class="claim">
      <div class="claim-text"> <b>69</b>. The cationic lipid according to <claim-ref idref="CLM-00068">claim 68</claim-ref>, wherein p is 0, W is a bond and T is C, and the compound is represented by the structure of formula (IIa-1):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00200" num="00200">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ad/02/ec/138046caf498ef/US20190292130A1-20190926-C00200.png"><img id="EMI-C00200" he="20.07mm" wi="69.93mm" file="US20190292130A1-20190926-C00200.TIF" alt="Figure US20190292130A1-20190926-C00200" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="80" alt="Figure US20190292130A1-20190926-C00200" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ad/02/ec/138046caf498ef/US20190292130A1-20190926-C00200.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00200" attachment-type="cdx" file="US20190292130A1-20190926-C00200.CDX"> </attachment>
            <attachment idref="CHEM-US-00200" attachment-type="mol" file="US20190292130A1-20190926-C00200.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00070" num="00070" class="claim">
      <div class="claim-text"> <b>70</b>. The cationic lipid according to <claim-ref idref="CLM-00069">claim 69</claim-ref>, wherein R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (IIa-2):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00201" num="00201">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e4/91/d3/65a2c7e70f35f8/US20190292130A1-20190926-C00201.png"><img id="EMI-C00201" he="20.07mm" wi="69.93mm" file="US20190292130A1-20190926-C00201.TIF" alt="Figure US20190292130A1-20190926-C00201" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="80" alt="Figure US20190292130A1-20190926-C00201" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e4/91/d3/65a2c7e70f35f8/US20190292130A1-20190926-C00201.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00201" attachment-type="cdx" file="US20190292130A1-20190926-C00201.CDX"> </attachment>
            <attachment idref="CHEM-US-00201" attachment-type="mol" file="US20190292130A1-20190926-C00201.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00071" num="00071" class="claim">
      <div class="claim-text"> <b>71</b>. The cationic lipid according to <claim-ref idref="CLM-00068">claim 68</claim-ref>, wherein p is 1, m is 1, W is a bond and T is C, and the compound is represented by the structure of formula (IIa-3):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00202" num="00202">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8f/b9/27/f26813b0b10703/US20190292130A1-20190926-C00202.png"><img id="EMI-C00202" he="19.39mm" wi="69.93mm" file="US20190292130A1-20190926-C00202.TIF" alt="Figure US20190292130A1-20190926-C00202" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="78" alt="Figure US20190292130A1-20190926-C00202" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8f/b9/27/f26813b0b10703/US20190292130A1-20190926-C00202.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00202" attachment-type="cdx" file="US20190292130A1-20190926-C00202.CDX"> </attachment>
            <attachment idref="CHEM-US-00202" attachment-type="mol" file="US20190292130A1-20190926-C00202.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein R<sup>1 </sup>is the side chain of a natural or unnatural amino acid.</div>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00072" num="00072" class="claim">
      <div class="claim-text"> <b>72</b>. The cationic lipid according to <claim-ref idref="CLM-00068">claim 68</claim-ref>, wherein p is 0, R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, W is a bond, m is 0 and X is O, and the compound is represented by the structure of formula (IIa-4):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00203" num="00203">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7d/7d/98/a24790c7f45925/US20190292130A1-20190926-C00203.png"><img id="EMI-C00203" he="14.82mm" wi="69.93mm" file="US20190292130A1-20190926-C00203.TIF" alt="Figure US20190292130A1-20190926-C00203" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="59" alt="Figure US20190292130A1-20190926-C00203" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7d/7d/98/a24790c7f45925/US20190292130A1-20190926-C00203.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00203" attachment-type="cdx" file="US20190292130A1-20190926-C00203.CDX"> </attachment>
            <attachment idref="CHEM-US-00203" attachment-type="mol" file="US20190292130A1-20190926-C00203.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00073" num="00073" class="claim">
      <div class="claim-text"> <b>73</b>. The cationic lipid according to <claim-ref idref="CLM-00067">claim 67</claim-ref>, which is represented by the structure of formula (IIb):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00204" num="00204">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/17/a8/e1/a531bf780f4631/US20190292130A1-20190926-C00204.png"><img id="EMI-C00204" he="24.13mm" wi="69.93mm" file="US20190292130A1-20190926-C00204.TIF" alt="Figure US20190292130A1-20190926-C00204" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="97" alt="Figure US20190292130A1-20190926-C00204" class="patent-full-image" src="https://patentimages.storage.googleapis.com/17/a8/e1/a531bf780f4631/US20190292130A1-20190926-C00204.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00204" attachment-type="cdx" file="US20190292130A1-20190926-C00204.CDX"> </attachment>
            <attachment idref="CHEM-US-00204" attachment-type="mol" file="US20190292130A1-20190926-C00204.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00074" num="00074" class="claim">
      <div class="claim-text"> <b>74</b>. The cationic lipid according to <claim-ref idref="CLM-00073">claim 73</claim-ref>, wherein p is 0, W is a bond, T is C, and R<sup>1 </sup>is NR<sup>4</sup>R<sup>5</sup>, and the compound is represented by the structure of formula (IIb-1):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00205" num="00205">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/cb/3b/f24d0b4fc20fec/US20190292130A1-20190926-C00205.png"><img id="EMI-C00205" he="20.15mm" wi="69.93mm" file="US20190292130A1-20190926-C00205.TIF" alt="Figure US20190292130A1-20190926-C00205" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="81" alt="Figure US20190292130A1-20190926-C00205" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/cb/3b/f24d0b4fc20fec/US20190292130A1-20190926-C00205.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00205" attachment-type="cdx" file="US20190292130A1-20190926-C00205.CDX"> </attachment>
            <attachment idref="CHEM-US-00205" attachment-type="mol" file="US20190292130A1-20190926-C00205.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00075" num="00075" class="claim">
      <div class="claim-text"> <b>75</b>. The cationic lipid according to <claim-ref idref="CLM-00062">claim 62</claim-ref>, which is selected from the group consisting of:
<div class="claim-text">2-(1,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)-N,N-dimethylethan-1-amine;</div> <div class="claim-text">4-(1,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)-N,N-dimethylbutan-1-amine;</div> <div class="claim-text">1-(4-(1,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)butyl)pyrrolidine;</div> <div class="claim-text">N,N-dimethyl-4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)amino)butan-1-amine;</div> <div class="claim-text">4-(dimethylamino)-N((Z)-octadec-9-en-1-yl)-N-((9Z,12Z)-octadeca-9,12-dien-1-yl)butanehydrazide;</div> <div class="claim-text">4-((di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)oxy)-N,N-dimethylbutan-1-amine;</div> <div class="claim-text">1-(4-(2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)butyl)pyrrolidine;</div> <div class="claim-text">4-((((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl)amino)oxy)-N,N-dimethylbutan-1-amine;</div> <div class="claim-text">2-((di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)oxy)-N,N-dimethyl-2-oxoethan-1-amine;</div> <div class="claim-text">4-(dimethylamino)-N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl)butanehydrazide;</div> <div class="claim-text">(S)-2-amino-6-(dimethylamino)-N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hexanehydrazide;</div> <div class="claim-text">4-(2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)-N,N-dimethylbutan-1-amine;</div> <div class="claim-text">1-((S)-4-amino-5-(2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)-5-oxopentyl)guanidine;</div> <div class="claim-text">4-((di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)oxy)-N,N-dimethyl-4-oxobutan-1-amine;</div> <div class="claim-text">2-(2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)-N,N-dimethylethan-1-amine;</div> <div class="claim-text">4-(dimethylamino)-N-((9Z,12Z)-octadeca-9,12-dien-1-yl)-N-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)butanamide;</div> <div class="claim-text">N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl)-4-(pyrrolidin-1-yl)butanehydrazide;</div> <div class="claim-text">(S)-2-amino-3-(1H-imidazol-4-yl)-N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl)propanehydrazide;</div> <div class="claim-text">N,N-dimethyl-2-(2-((Z)-octadec-9-en-1-yl)-1-((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)ethan-1-amine;</div> <div class="claim-text">N,N-dimethyl-2-(1-((9Z,12Z)-octadeca-9,12-dien-1-yl)-2-octadecylhydrazinyl)ethan-1-amine;</div> <div class="claim-text">4-(4-methylpiperazin-1-yl)-N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl)butanehydrazide;</div> <div class="claim-text">O-(4-(4-methylpiperazin-1-yl)butanoyl)-N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydroxylamine;</div> <div class="claim-text">(2-(4-(dimethylamino)butanoyl)hydrazine-1,1-diyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate);</div> <div class="claim-text">(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate);</div> <div class="claim-text">(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(nonane-9,1-diyl) bis(2-hexyl decanoate);</div> <div class="claim-text">di(tridecan-7-yl) 10,10-(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(decanoate);</div> <div class="claim-text">(2-(4-(dimethylamino)butyl)hydrazine-1,1-diyl)bis(hexane-6,1-diyl) bis(2-hexyl decanoate);</div> <div class="claim-text">(2-(4-(dimethylamino)butyl)hydrazine-1,1-diyl)bis(nonane-9,1-diyl) bis(2-hexyl decanoate);</div> <div class="claim-text">((4-(dimethylamino)butoxy)azanediyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate);</div> <div class="claim-text">((4-(dimethylamino)butoxy)azanediyl)bis(nonane-9,1-diyl) bis(2-hexyldecanoate);</div> <div class="claim-text">4-(2-(2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)ethyl)-1H-imidazole;</div> <div class="claim-text">1-(2-(2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)hydrazinyl)ethyl)guanidine;</div> <div class="claim-text">O-(2-(1H-imidazol-4-yl)acetyl)-N,N-di((9Z,12Z)-octadeca-9,12-dien-1-yl) hydroxylamine;</div> <div class="claim-text">1-(2-((di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)oxy)-2-oxoethyl)guanidine;</div> <div class="claim-text">2-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethyl 2-(1H-imidazol-4-yl)acetate;</div> <div class="claim-text">2-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethyl carbamimidoylglycinate;</div> <div class="claim-text">2-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethyl dimethylglycinate;</div> <div class="claim-text">2-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethyl 4-(dimethylamino)butanoate;</div> <div class="claim-text">2-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethyl L-histidinate;</div> <div class="claim-text">(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(octane-8,1-diyl) (4Z,4Z)-bis(2-hexyldec-4-enoate);</div> <div class="claim-text">(1-(2-(dimethylamino)ethyl)hydrazine-1,2-diyl)bis(octane-8,1-diyl) (3Z,3Z)-bis(non-3-enoate);</div> <div class="claim-text">di((Z)-non-3-en-1-yl) 8,8-(2-(2-(dimethylamino)ethyl)hydrazine-1,1-diyl)dioctanoate;</div> <div class="claim-text">di((Z)-pentadec-9-en-7-yl) 8,8-(2-(2-(dimethylamino)ethyl)hydrazine-1,1-diyl) dioctanoate;</div> <div class="claim-text">di((Z)-pentadec-9-en-7-yl) 8,8-(((4-(dimethylamino)butanoyl)oxy)azanediyl)dioctanoate;</div> <div class="claim-text">di((Z)-non-3-en-1-yl) 8,8-(((4-(dimethylamino)butanoyl)oxy)azanediyl)dioctanoate;</div> <div class="claim-text">di((Z)-pentadec-9-en-7-yl) 8,8-(2-(((2-(dimethylamino)ethyl)thio)carbonyl)hydrazine-1,1-diyl)dioctanoate;</div> <div class="claim-text">di(tridecan-7-yl) 8,8-(2-(((2-(dimethylamino)ethyl)thio)carbonyl)hydrazine-1,1-diyl) dioctanoate;</div> <div class="claim-text">8-((((2-(dimethylamino)ethyl)thio)carbonyl)((8-(((Z)-non-3-enoyl)oxy)octyl)oxy) amino) octyl (Z)-non-3-enoate;</div> <div class="claim-text">di((Z)-pentadec-9-en-7-yl) 8,8-((2-((dimethylglycyl)oxy)ethyl)azanediyl)dioctanoate;</div> <div class="claim-text">di((Z)-non-3-en-1-yl) 8,8-((2-((4-(dimethylamino)butanoyl)oxy) ethyl)azanediyl) dioctanoate;</div> <div class="claim-text">di((Z)-non-3-en-1-yl) 8,8-((2-((carbamimidoylglycyl)oxy)ethyl)azanediyl)dioctanoate;</div> <div class="claim-text">di(tridecan-7-yl) 8,8-((2-((4-(dimethylamino)butanoyl)oxy)ethyl)azanediyl)dioctanoate;</div> <div class="claim-text">((2-((4-(dimethylamino)butanoyl)oxy)ethyl)azanediyl)bis(octane-8,1-diyl) (3Z,3Z)-bis(non-3-enoate);</div> <div class="claim-text">((2-((4-(dimethylamino)butanoyl)oxy)ethyl)azanediyl)bis(heptane-7,1-diyl) bis(decanoate);</div> <div class="claim-text">2-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethyl 4-(4-methylpiperazin-1-yl)butanoate;</div> <div class="claim-text">di((Z)-non-3-en-1-yl) 6,6-(2-(4-(dimethylamino)butanoyl)hydrazine-1,1-diyl)dihexanoate;</div> <div class="claim-text">(2-(2-(dimethylamino)ethyl)hydrazine-1,1-diyl)bis(heptane-7,1-diyl) bis(decanoate);</div> <div class="claim-text">(9Z,12Z)N-(2-(4-(dimethylamino)butoxy)ethyl)-N-((9Z,12Z)-octadeca-9,12-dien-1-yl)octadeca-9,12-dien-1-amine;</div> <div class="claim-text">4-(dimethylamino)-N,N-bis(6-(((Z)-non-3-en-1-yl)oxy)hexyl)butanehydrazide;</div> <div class="claim-text">2-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethyl 4-(pyrrolidin-1-yl)butanoate;</div> <div class="claim-text">N-(2-(4-(dimethylamino)butoxy)ethyl)-6-(((Z)-non-3-en-1-yl)oxy)-N-(6-(((Z)-non-3-en-1-yl)oxy)hexyl)hexan-1-amine;</div> <div class="claim-text">((2-(4-(dimethylamino)butoxy)ethyl)azanediyl)bis(heptane-7,1-diyl) bis(decanoate); and</div> <div class="claim-text">di((Z)-non-3-en-1-yl) 6,6-((2-(4-(dimethylamino)butoxy)ethyl)azanediyl)dihexanoate.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00076" num="00076" class="claim">
      <div class="claim-text"> <b>76</b>. The cationic lipid according to <claim-ref idref="CLM-00062">claim 62</claim-ref>, which is represented by the structure of formula (III):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00206" num="00206">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/de/f0/83/0786829bd3a8b4/US20190292130A1-20190926-C00206.png"><img id="EMI-C00206" he="19.30mm" wi="69.93mm" file="US20190292130A1-20190926-C00206.TIF" alt="Figure US20190292130A1-20190926-C00206" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="77" alt="Figure US20190292130A1-20190926-C00206" class="patent-full-image" src="https://patentimages.storage.googleapis.com/de/f0/83/0786829bd3a8b4/US20190292130A1-20190926-C00206.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00206" attachment-type="cdx" file="US20190292130A1-20190926-C00206.CDX"> </attachment>
            <attachment idref="CHEM-US-00206" attachment-type="mol" file="US20190292130A1-20190926-C00206.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">X and Y are each independently O, N or NH;</div>
<div class="claim-text">each of R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is independently absent or a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl; and</div>
<div class="claim-text">n is 1 to 30;</div>
</div>
        <div class="claim-text">including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</div>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00077" num="00077" class="claim">
      <div class="claim-text"> <b>77</b>. The cationic lipid according to <claim-ref idref="CLM-00076">claim 76</claim-ref>, which is selected from the group consisting of:</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00207" num="00207">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f9/b8/98/01f2fcee2b1268/US20190292130A1-20190926-C00207.png"><img id="EMI-C00207" he="115.32mm" wi="60.79mm" file="US20190292130A1-20190926-C00207.TIF" alt="Figure US20190292130A1-20190926-C00207" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="243" height="461" alt="Figure US20190292130A1-20190926-C00207" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f9/b8/98/01f2fcee2b1268/US20190292130A1-20190926-C00207.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00207" attachment-type="cdx" file="US20190292130A1-20190926-C00207.CDX"> </attachment>
            <attachment idref="CHEM-US-00207" attachment-type="mol" file="US20190292130A1-20190926-C00207.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00078" num="00078" class="claim">
      <div class="claim-text"> <b>78</b>. The cationic lipid according to <claim-ref idref="CLM-00062">claim 62</claim-ref>, which is represented by the structure of formula (IIIA):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00208" num="00208">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8a/71/f8/d8d6c0b97260f8/US20190292130A1-20190926-C00208.png"><img id="EMI-C00208" he="19.30mm" wi="69.93mm" file="US20190292130A1-20190926-C00208.TIF" alt="Figure US20190292130A1-20190926-C00208" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="77" alt="Figure US20190292130A1-20190926-C00208" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8a/71/f8/d8d6c0b97260f8/US20190292130A1-20190926-C00208.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00208" attachment-type="cdx" file="US20190292130A1-20190926-C00208.CDX"> </attachment>
            <attachment idref="CHEM-US-00208" attachment-type="mol" file="US20190292130A1-20190926-C00208.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">X and Y are each independently O, N or NH, wherein X and Y cannot both be O;</div>
<div class="claim-text">each of R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is independently absent or a C<sub>10</sub>-C<sub>22 </sub>alkyl, a C<sub>10</sub>-C<sub>22 </sub>alkenyl or a C<sub>10</sub>-C<sub>22 </sub>alkynyl;</div>
<div class="claim-text">n is an integer between 1 and 30; and</div>
<div class="claim-text">x is 0 or 2;</div>
</div>
        <div class="claim-text">including salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, and mixtures thereof.</div>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00079" num="00079" class="claim">
      <div class="claim-text"> <b>79</b>. A composition comprising a cationic lipid according to <claim-ref idref="CLM-00062">claim 62</claim-ref>, optionally further comprising at least one additional neutral or PEG-modified lipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00080" num="00080" class="claim">
      <div class="claim-text"> <b>80</b>. A method of gene silencing, comprising the step of contacting a cell with a composition according to <claim-ref idref="CLM-00079">claim 79</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00081" num="00081" class="claim">
      <div class="claim-text"> <b>81</b>. A method of treating a leukocyte associated condition, the method comprising the step of administering to a subject in need thereof a composition according <claim-ref idref="CLM-00079">claim 79</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00082" num="00082" class="claim">
      <div class="claim-text"> <b>82</b>. A composition according to <claim-ref idref="CLM-00079">claim 79</claim-ref>, further comprising a nucleic acid selected from the group consisting of small interfering RNA (siRNA), antisense oligo nucleotides, micro RNA (miRNA), ribozymes, pDNA, CRISPR mRNA, gRNA and immune stimulating nucleic acids.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00083" num="00083" class="claim">
      <div class="claim-text"> <b>83</b>. A composition according to <claim-ref idref="CLM-00079">claim 79</claim-ref>, further comprising messenger RNA (mRNA).</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00084" num="00084" class="claim">
      <div class="claim-text"> <b>84</b>. A method of expressing a protein encoded by mRNA, comprising the step of administering a composition according to <claim-ref idref="CLM-00083">claim 83</claim-ref>.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00085" num="00085" class="claim">
      <div class="claim-text"> <b>85</b>. An intermediate compound represented by the structure of formula (IIa-5):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00209" num="00209">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0b/cf/ae/f5e94c2c849e25/US20190292130A1-20190926-C00209.png"><img id="EMI-C00209" he="13.21mm" wi="69.93mm" file="US20190292130A1-20190926-C00209.TIF" alt="Figure US20190292130A1-20190926-C00209" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="53" alt="Figure US20190292130A1-20190926-C00209" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0b/cf/ae/f5e94c2c849e25/US20190292130A1-20190926-C00209.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00209" attachment-type="cdx" file="US20190292130A1-20190926-C00209.CDX"> </attachment>
            <attachment idref="CHEM-US-00209" attachment-type="mol" file="US20190292130A1-20190926-C00209.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein</div>
        <div class="claim-text">R<sup>2 </sup>and R<sup>3 </sup>are selected from the group consisting of:
<div class="claim-text">(a) C<sub>10</sub>-C<sub>22 </sub>alkyl;</div>
<div class="claim-text">(b) C<sub>10</sub>-C<sub>22 </sub>alkenyl;</div>
<div class="claim-text">(c) C<sub>10</sub>-C<sub>22 </sub>alkynyl;</div>
<div class="claim-text">(d) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkyl; and</div>
<div class="claim-text">(e) C<sub>4</sub>-C<sub>10 </sub>alkylene-ZC<sub>4</sub>-C<sub>22 </sub>alkenyl; and</div>
</div>
        <div class="claim-text">z is 0 or 2.</div>
      </div>
    </div>
  </div> </div>
  </div>
  </section>

  <section itemprop="application" itemscope>

    <section itemprop="metadata" itemscope>
      <span itemprop="applicationNumber">US16/347,995</span>
      <span itemprop="priorityDate">2016-11-08</span>
      <span itemprop="filingDate">2017-11-07</span>
      <span itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </span>
      <span itemprop="ifiStatus">Active</span>
      <span itemprop="ifiExpiration">2039-11-18</span>
      <a href="/patent/US11851389B2/en">
        <span itemprop="representativePublication">US11851389B2</span>
        (<span itemprop="primaryLanguage">en</span>)
      </a>
    </section>

    <h2>Priority Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/347,995</span>
            
            <a href="/patent/US11851389B2/en">
              <span itemprop="representativePublication">US11851389B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2017-11-07</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Applications Claiming Priority (4)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201662418844P</span>
            
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2016-11-08</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201762507829P</span>
            
          </td>
          <td itemprop="priorityDate">2017-05-18</td>
          <td itemprop="filingDate">2017-05-18</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/IL2017/051212</span>
            <a href="/patent/WO2018087753A1/en">
              <span itemprop="representativePublication">WO2018087753A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2017-11-07</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/347,995</span>
            <a href="/patent/US11851389B2/en">
              <span itemprop="representativePublication">US11851389B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2017-11-07</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Related Parent Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="parentApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/IL2017/051212</span>
            <span itemprop="relationType">A-371-Of-International</span>
            <a href="/patent/WO2018087753A1/en">
              <span itemprop="representativePublication">WO2018087753A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2017-11-07</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Related Child Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="childApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US18/489,240</span>
            <span itemprop="relationType">Continuation</span>
            <a href="/patent/US20240246898A1/en">
              <span itemprop="representativePublication">US20240246898A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2023-10-18</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Publications (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Publication Number</th>
          <th>Publication Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">US20190292130A1</span>
            
            <span itemprop="thisPatent">true</span>
            <a href="/patent/US20190292130A1/en">
              US20190292130A1
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-09-26</td>
        </tr>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">US11851389B2</span>
            
            <a href="/patent/US11851389B2/en">
              US11851389B2
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-12-26</td>
        </tr>
      </tbody>
    </table>

  </section>

  <section itemprop="family" itemscope>
    <h1>Family</h1>
    <h2>ID=62109569</h2>

    <h2>Family Applications (3)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/347,995</span>
            <span itemprop="ifiStatus">Active</span>
            <span itemprop="ifiExpiration">2039-11-18</span>
            <a href="/patent/US11851389B2/en">
              <span itemprop="representativePublication">US11851389B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2017-11-07</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US18/489,240</span>
            <span itemprop="ifiStatus">Pending</span>
            
            <a href="/patent/US20240246898A1/en">
              <span itemprop="representativePublication">US20240246898A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2023-10-18</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US18/921,310</span>
            <span itemprop="ifiStatus">Pending</span>
            
            <a href="/patent/US20250162978A1/en">
              <span itemprop="representativePublication">US20250162978A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2024-10-21</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
     </td>
        </tr>
      </tbody>
    </table>

    

    <h2>Family Applications After (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US18/489,240</span>
            <span itemprop="ifiStatus">Pending</span>
            
            <a href="/patent/US20240246898A1/en">
                <span itemprop="representativePublication">US20240246898A1</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2023-10-18</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
       </td>
        </tr>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US18/921,310</span>
            <span itemprop="ifiStatus">Pending</span>
            
            <a href="/patent/US20250162978A1/en">
                <span itemprop="representativePublication">US20250162978A1</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="filingDate">2024-10-21</td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
     </td>
        </tr>
      </tbody>
    </table>

    <h2>Country Status (11)</h2>
    <table>
      <thead>
        <tr>
          <th>Country</th>
          <th>Link</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">US</span>
            (<span itemprop="num">3</span>)
            <meta itemprop="thisCountry" content="true">
          </td>
          <td>
            <a href="/patent/US11851389B2/en">
              <span itemprop="representativePublication">US11851389B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">EP</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/EP3538515B1/en">
              <span itemprop="representativePublication">EP3538515B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">JP</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/JP7075669B2/en">
              <span itemprop="representativePublication">JP7075669B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CN</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CN110167922B/en">
              <span itemprop="representativePublication">CN110167922B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">AU</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/AU2017356699B2/en">
              <span itemprop="representativePublication">AU2017356699B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CA</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CA3039137A1/en">
              <span itemprop="representativePublication">CA3039137A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">DK</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/DK3538515T3/en">
              <span itemprop="representativePublication">DK3538515T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">ES</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/ES2928358T3/en">
              <span itemprop="representativePublication">ES2928358T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">MX</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/MX2019005287A/en">
              <span itemprop="representativePublication">MX2019005287A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">PT</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/PT3538515T/en">
              <span itemprop="representativePublication">PT3538515T</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">WO</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/WO2018087753A1/en">
              <span itemprop="representativePublication">WO2018087753A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
      </tbody>
    </table>

    <h2>Cited By (5)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11472766B2/en">
              <span itemprop="publicationNumber">US11472766B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-04-09</td>
          <td itemprop="publicationDate">2022-10-18</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
          <td itemprop="title">Lipid nanoparticle composition 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11510977B2/en">
              <span itemprop="publicationNumber">US11510977B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-04-09</td>
          <td itemprop="publicationDate">2022-11-29</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
          <td itemprop="title">Nucleic acid vaccines for coronavirus 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/CN116354836A/en">
              <span itemprop="publicationNumber">CN116354836A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-03-25</td>
          <td itemprop="publicationDate">2023-06-30</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Cationic lipid compound, preparation method and application thereof, and mRNA delivery system
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11865190B2/en">
              <span itemprop="publicationNumber">US11865190B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-10-09</td>
          <td itemprop="publicationDate">2024-01-09</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025160118A1/en">
              <span itemprop="publicationNumber">WO2025160118A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2024-01-22</td>
          <td itemprop="publicationDate">2025-07-31</td>
          <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
          <td itemprop="title">Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Families Citing this family (50)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12491261B2/en">
              <span itemprop="publicationNumber">US12491261B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-10-26</td>
          <td itemprop="publicationDate">2025-12-09</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN112262122B/en">
              <span itemprop="publicationNumber">CN112262122B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-06-08</td>
          <td itemprop="publicationDate">2023-10-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Compounds or salts thereof and lipid particles
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2021003726A/en">
              <span itemprop="publicationNumber">MX2021003726A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-10-01</td>
          <td itemprop="publicationDate">2021-05-13</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna particles comprising polysarcosine. 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3117924A1/en">
              <span itemprop="publicationNumber">CA3117924A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-11-13</td>
          <td itemprop="publicationDate">2020-05-22</td>
          <td><span itemprop="assigneeOriginal">Oncorus, Inc.</span></td>
          <td itemprop="title">Encapsulated polynucleotides and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/BR112021010853A2/en">
              <span itemprop="publicationNumber">BR112021010853A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-12-05</td>
          <td itemprop="publicationDate">2021-08-31</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span></td>
          <td itemprop="title">
        MODIFIED AMINE LIPIDS
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7241869B2/en">
              <span itemprop="publicationNumber">JP7241869B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-06-07</td>
          <td itemprop="publicationDate">2023-03-17</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Lipid composition
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/PL4328309T3/en">
              <span itemprop="publicationNumber">PL4328309T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-11-15</td>
          <td itemprop="publicationDate">2025-11-17</td>
          <td><span itemprop="assigneeOriginal">Fujifilm Corporation</span></td>
          <td itemprop="title">Lipid composition 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20230241223A1/en">
              <span itemprop="publicationNumber">US20230241223A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-03-25</td>
          <td itemprop="publicationDate">2023-08-03</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna particles comprising polysarcosine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4153560A4/en">
              <span itemprop="publicationNumber">EP4153560A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-05-19</td>
          <td itemprop="publicationDate">2024-04-24</td>
          <td><span itemprop="assigneeOriginal">Ramot at Tel-Aviv University Ltd.</span></td>
          <td itemprop="title">Lipid particles for nucleic acid delivery and clinical applications of same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7798855B2/en">
              <span itemprop="publicationNumber">JP7798855B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-07-16</td>
          <td itemprop="publicationDate">2026-01-14</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Cationic lipids for use in lipid nanoparticles - Patent Application 20070122999
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN116457027A/en">
              <span itemprop="publicationNumber">CN116457027A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-09-23</td>
          <td itemprop="publicationDate">2023-07-18</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Piperazine-based cationic lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CZ2020529A3/en">
              <span itemprop="publicationNumber">CZ2020529A3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-09-23</td>
          <td itemprop="publicationDate">2022-03-30</td>
          <td><span itemprop="assigneeOriginal">stav organick chemie a biochemie AV R, v. v. i.</span></td>
          <td itemprop="title">
        Lipidoids for nucleic acid transfection and their use
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN113185421B/en">
              <span itemprop="publicationNumber">CN113185421B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-11-27</td>
          <td itemprop="publicationDate">2022-01-25</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid compounds and compositions thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2022168085A1/en">
              <span itemprop="publicationNumber">WO2022168085A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-02-02</td>
          <td itemprop="publicationDate">2022-08-11</td>
          <td><span itemprop="assigneeOriginal">Ramot At Tel-Aviv University Ltd.</span></td>
          <td itemprop="title">Lipids suitable for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115197080A/en">
              <span itemprop="publicationNumber">CN115197080A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-04-08</td>
          <td itemprop="publicationDate">2022-10-18</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240197633A1/en">
              <span itemprop="publicationNumber">US20240197633A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-04-08</td>
          <td itemprop="publicationDate">2024-06-20</td>
          <td><span itemprop="assigneeOriginal">Xiamen Sinopeg Biotech Co., Ltd.</span></td>
          <td itemprop="title">Pegylated lipid, liposome modified by the lipid, pharmaceutical composition containing the liposome, formulation and application thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4320093A1/en">
              <span itemprop="publicationNumber">EP4320093A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-04-09</td>
          <td itemprop="publicationDate">2024-02-14</td>
          <td><span itemprop="assigneeOriginal">Pfizer Inc.</span></td>
          <td itemprop="title">Methods for producing of lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL307874A/en">
              <span itemprop="publicationNumber">IL307874A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-04-22</td>
          <td itemprop="publicationDate">2023-12-01</td>
          <td><span itemprop="assigneeOriginal">Univ Texas</span></td>
          <td itemprop="title">All-in-one dendrimer-based lipid nanoparticles enable precise hdr-mediated gene editing in vivo 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20230162973A/en">
              <span itemprop="publicationNumber">KR20230162973A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-05-28</td>
          <td itemprop="publicationDate">2023-11-29</td>
          <td><span itemprop="assigneeOriginal">   </span></td>
          <td itemprop="title">
        Lipid compounds and their applications in nucleic acid delivery
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN120289775A/en">
              <span itemprop="publicationNumber">CN120289775A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-07-23</td>
          <td itemprop="publicationDate">2025-07-11</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        A polyglycol-modified lipid compound and its preparation method and application
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115010681A/en">
              <span itemprop="publicationNumber">CN115010681A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-09-07</td>
          <td itemprop="publicationDate">2022-09-06</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Cationic liposome molecule and preparation and application thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023061460A1/en">
              <span itemprop="publicationNumber">WO2023061460A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-10-15</td>
          <td itemprop="publicationDate">2023-04-20</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Nitrogen-containing cationic lipid and application thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN113999128B/en">
              <span itemprop="publicationNumber">CN113999128B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-11-25</td>
          <td itemprop="publicationDate">2024-05-10</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid compound, lipid carrier based on lipid compound, nucleic acid lipid nanoparticle composition and pharmaceutical preparation 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114213346B/en">
              <span itemprop="publicationNumber">CN114213346B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-02-22</td>
          <td itemprop="publicationDate">2022-05-20</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">
        A kind of bivalent ionizable lipid compound, composition and application thereof
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114213347B/en">
              <span itemprop="publicationNumber">CN114213347B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-02-22</td>
          <td itemprop="publicationDate">2022-05-20</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">Bivalent ionizable lipid compound, composition and application thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN118804743A/en">
              <span itemprop="publicationNumber">CN118804743A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-03-04</td>
          <td itemprop="publicationDate">2024-10-18</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">
        Targeted delivery systems and methods
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114874146B/en">
              <span itemprop="publicationNumber">CN114874146B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-03-25</td>
          <td itemprop="publicationDate">2023-09-12</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">Histidine lipid, histidine lipid nanoparticle, and preparation method and application thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023232148A1/en">
              <span itemprop="publicationNumber">WO2023232148A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-06-02</td>
          <td itemprop="publicationDate">2023-12-07</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Amino acid-based cationic lipid containing unsaturated bonds 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115557851B/en">
              <span itemprop="publicationNumber">CN115557851B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-06-27</td>
          <td itemprop="publicationDate">2023-04-18</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Amino lipid, synthetic method, particle and application thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024051825A1/en">
              <span itemprop="publicationNumber">WO2024051825A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-09-09</td>
          <td itemprop="publicationDate">2024-03-14</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Carbon nucleus cationic lipid 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2023413766A1/en">
              <span itemprop="publicationNumber">AU2023413766A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-23</td>
          <td itemprop="publicationDate">2025-05-29</td>
          <td><span itemprop="assigneeOriginal">Biontech Delivery Technologies Gmbh</span></td>
          <td itemprop="title">Composition 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024160829A1/en">
              <span itemprop="publicationNumber">WO2024160829A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-01-31</td>
          <td itemprop="publicationDate">2024-08-08</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN116143707B/en">
              <span itemprop="publicationNumber">CN116143707B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-02-24</td>
          <td itemprop="publicationDate">2024-04-19</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        A kind of base ionizable lipid and its preparation method and application
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN117384055B/en">
              <span itemprop="publicationNumber">CN117384055B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-04-27</td>
          <td itemprop="publicationDate">2024-11-19</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">Ionizable lipids for delivery of therapeutic agents and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024249954A1/en">
              <span itemprop="publicationNumber">WO2024249954A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-31</td>
          <td itemprop="publicationDate">2024-12-05</td>
          <td><span itemprop="assigneeOriginal">Capstan Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulations and compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024257088A1/en">
              <span itemprop="publicationNumber">WO2024257088A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-06-13</td>
          <td itemprop="publicationDate">2024-12-19</td>
          <td><span itemprop="assigneeOriginal">Ramot At Tel-Aviv University Ltd.</span></td>
          <td itemprop="title">Biodegradable carbamate lipids with increased stability 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025027019A1/en">
              <span itemprop="publicationNumber">WO2025027019A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-07-31</td>
          <td itemprop="publicationDate">2025-02-06</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Method of determining nucleic acid concentration in aqueous solution or dispersion 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025064850A1/en">
              <span itemprop="publicationNumber">WO2025064850A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-22</td>
          <td itemprop="publicationDate">2025-03-27</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna constructs with n-terminal degrons to enhance an immune response 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025093665A1/en">
              <span itemprop="publicationNumber">WO2025093665A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-10-31</td>
          <td itemprop="publicationDate">2025-05-08</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Particles, compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025106754A1/en">
              <span itemprop="publicationNumber">WO2025106754A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-15</td>
          <td itemprop="publicationDate">2025-05-22</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Coronavirus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102024133412A1/en">
              <span itemprop="publicationNumber">DE102024133412A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-15</td>
          <td itemprop="publicationDate">2025-05-15</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">
        SARS-COV-2 IMMUNOGENIC COMPOSITIONS
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025133105A1/en">
              <span itemprop="publicationNumber">WO2025133105A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-21</td>
          <td itemprop="publicationDate">2025-06-26</td>
          <td><span itemprop="assigneeOriginal">Biontech Delivery Technologies Gmbh</span></td>
          <td itemprop="title">Compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20250106223A/en">
              <span itemprop="publicationNumber">KR20250106223A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-12-29</td>
          <td itemprop="publicationDate">2025-07-09</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">Nanoparticle composition for drug delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025149492A1/en">
              <span itemprop="publicationNumber">WO2025149492A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-08</td>
          <td itemprop="publicationDate">2025-07-17</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna encoding an immune inhibitory il-1 family member 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025176732A1/en">
              <span itemprop="publicationNumber">WO2025176732A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-02-20</td>
          <td itemprop="publicationDate">2025-08-28</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025215636A1/en">
              <span itemprop="publicationNumber">WO2025215636A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-04-08</td>
          <td itemprop="publicationDate">2025-10-16</td>
          <td><span itemprop="assigneeOriginal">Yeda Research And Development Co. Ltd.</span></td>
          <td itemprop="title">Anti-defense system polypeptides and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025228979A1/en">
              <span itemprop="publicationNumber">WO2025228979A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-04-30</td>
          <td itemprop="publicationDate">2025-11-06</td>
          <td><span itemprop="assigneeOriginal">Neovac Ltd.</span></td>
          <td itemprop="title">Lipids nanoparticle formulations suitable for lung targeting 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025261607A1/en">
              <span itemprop="publicationNumber">WO2025261607A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-06-21</td>
          <td itemprop="publicationDate">2025-12-26</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Particles, compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2026003582A2/en">
              <span itemprop="publicationNumber">WO2026003582A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-06-27</td>
          <td itemprop="publicationDate">2026-01-02</td>
          <td><span itemprop="assigneeOriginal">Axelyf ehf.</span></td>
          <td itemprop="title">Lipids and lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2026009227A1/en">
              <span itemprop="publicationNumber">WO2026009227A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-07-04</td>
          <td itemprop="publicationDate">2026-01-08</td>
          <td><span itemprop="assigneeOriginal">Yeda Research And Development Co. Ltd.</span></td>
          <td itemprop="title">Compositions for downregulating zeb2 in macrophages and uses thereof 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Citations (1)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US3703554A/en">
              <span itemprop="publicationNumber">US3703554A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">1969-07-22</td>
          <td itemprop="publicationDate">1972-11-21</td>
          <td>
            <span itemprop="assigneeOriginal">Scm Corp</span>
          </td>
          <td itemprop="title">Terpenylamino ethers and thioethers 
     </td>
        </tr>
      </tbody>
    </table>

    <h2>Family Cites Families (13)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/NL58413C/en">
              <span itemprop="publicationNumber">NL58413C</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">1941-12-04</td>
          <td itemprop="publicationDate"></td>
          <td></td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/GB1367089A/en">
              <span itemprop="publicationNumber">GB1367089A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">1970-07-23</td>
          <td itemprop="publicationDate">1974-09-18</td>
          <td><span itemprop="assigneeOriginal">Marumo H</span></td>
          <td itemprop="title">Surface modifier for synthetic high polymers 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4034040A/en">
              <span itemprop="publicationNumber">US4034040A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">1971-05-24</td>
          <td itemprop="publicationDate">1977-07-05</td>
          <td><span itemprop="assigneeOriginal">Pfizer Inc.</span></td>
          <td itemprop="title">Xylene-diamines as antiviral agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP3544429B2/en">
              <span itemprop="publicationNumber">JP3544429B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">1996-04-25</td>
          <td itemprop="publicationDate">2004-07-21</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Reversible thermosensitive recording material
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1871889B1/en">
              <span itemprop="publicationNumber">EP1871889B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2005-04-21</td>
          <td itemprop="publicationDate">2012-10-17</td>
          <td><span itemprop="assigneeOriginal">National Research Development Corporation</span></td>
          <td itemprop="title">A process for producing modified reconstituted sendai viral envelope specific for drug and/or gene delivery to liver cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP5747282B2/en">
              <span itemprop="publicationNumber">JP5747282B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2008-11-10</td>
          <td itemprop="publicationDate">2015-07-15</td>
          <td><span itemprop="assigneeOriginal">    </span></td>
          <td itemprop="title">
        Novel lipids and compositions for delivering therapeutic agents
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2010315124B2/en">
              <span itemprop="publicationNumber">AU2010315124B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-11-04</td>
          <td itemprop="publicationDate">2016-12-01</td>
          <td><span itemprop="assigneeOriginal">Marina Biotech, Inc.</span></td>
          <td itemprop="title">Activity generating delivery molecules 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013016058A1/en">
              <span itemprop="publicationNumber">WO2013016058A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-07-22</td>
          <td itemprop="publicationDate">2013-01-31</td>
          <td><span itemprop="assigneeOriginal">Merck Sharp &amp; Dohme Corp.</span></td>
          <td itemprop="title">Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW201408625A/en">
              <span itemprop="publicationNumber">TW201408625A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2012-07-06</td>
          <td itemprop="publicationDate">2014-03-01</td>
          <td><span itemprop="assigneeOriginal">Kyowa Hakko Kirin Co Ltd</span></td>
          <td itemprop="title">Cationic lipid 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3766916T1/en">
              <span itemprop="publicationNumber">SI3766916T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2014-06-25</td>
          <td itemprop="publicationDate">2023-01-31</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc.</span></td>
          <td itemprop="title">Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2016021673A1/en">
              <span itemprop="publicationNumber">WO2016021673A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-08-06</td>
          <td itemprop="publicationDate">2016-02-11</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Method for predicting drug efficacy of pharmaceutical composition containing small rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2016176330A1/en">
              <span itemprop="publicationNumber">WO2016176330A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-04-27</td>
          <td itemprop="publicationDate">2016-11-03</td>
          <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
          <td itemprop="title">Nucleoside-modified rna for inducing an adaptive immune response 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3368507T1/en">
              <span itemprop="publicationNumber">SI3368507T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-28</td>
          <td itemprop="publicationDate">2023-04-28</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc.</span></td>
          <td itemprop="title">
        Novel lipids and lipid nanoparticle formulations for nucleic acid delivery
       
       </td>
        </tr>
      </tbody>
    </table>

    <ul>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2017</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">PT</span>
            <span itemprop="applicationNumber">PT178696209T</span>
            <a href="/patent/PT3538515T/en"><span itemprop="documentId">patent/PT3538515T/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">CA</span>
            <span itemprop="applicationNumber">CA3039137A</span>
            <a href="/patent/CA3039137A1/en"><span itemprop="documentId">patent/CA3039137A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">ES</span>
            <span itemprop="applicationNumber">ES17869620T</span>
            <a href="/patent/ES2928358T3/en"><span itemprop="documentId">patent/ES2928358T3/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">WO</span>
            <span itemprop="applicationNumber">PCT/IL2017/051212</span>
            <a href="/patent/WO2018087753A1/en"><span itemprop="documentId">patent/WO2018087753A1/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Ceased</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US16/347,995</span>
            <a href="/patent/US11851389B2/en"><span itemprop="documentId">patent/US11851389B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            <span itemprop="thisApp" content="true" bool></span>
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">AU</span>
            <span itemprop="applicationNumber">AU2017356699A</span>
            <a href="/patent/AU2017356699B2/en"><span itemprop="documentId">patent/AU2017356699B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">MX</span>
            <span itemprop="applicationNumber">MX2019005287A</span>
            <a href="/patent/MX2019005287A/en"><span itemprop="documentId">patent/MX2019005287A/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">DK</span>
            <span itemprop="applicationNumber">DK17869620.9T</span>
            <a href="/patent/DK3538515T3/en"><span itemprop="documentId">patent/DK3538515T3/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2019522244A</span>
            <a href="/patent/JP7075669B2/en"><span itemprop="documentId">patent/JP7075669B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">CN</span>
            <span itemprop="applicationNumber">CN201780082052.XA</span>
            <a href="/patent/CN110167922B/en"><span itemprop="documentId">patent/CN110167922B/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-11-07</span>
            <span itemprop="countryCode">EP</span>
            <span itemprop="applicationNumber">EP17869620.9A</span>
            <a href="/patent/EP3538515B1/en"><span itemprop="documentId">patent/EP3538515B1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2023</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2023-10-18</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US18/489,240</span>
            <a href="/patent/US20240246898A1/en"><span itemprop="documentId">patent/US20240246898A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2024</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2024-10-21</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US18/921,310</span>
            <a href="/patent/US20250162978A1/en"><span itemprop="documentId">patent/US20250162978A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
        </ul>
      </li>
    </ul>

    </section>

  <section>
    <h2>Patent Citations (1)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferences" itemscope repeat>
          <td>
            <a href="/patent/US3703554A/en">
              <span itemprop="publicationNumber">US3703554A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">1969-07-22</td>
          <td itemprop="publicationDate">1972-11-21</td>
          <td><span itemprop="assigneeOriginal">Scm Corp</span></td>
          <td itemprop="title">Terpenylamino ethers and thioethers 
     </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Non-Patent Citations (3)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="detailedNonPatentLiterature" itemscope repeat>
          <td>
            <span itemprop="title">Anonymous, database CAS Registry, compound 38456-03-0, retrieved from CAS using CAS SciFiner on 2/13/2023.</span>
            <span itemprop="examinerCited">*</span>
            
          </td>
        </tr>
        <tr itemprop="detailedNonPatentLiterature" itemscope repeat>
          <td>
            <span itemprop="title">BORDENCA, CAS SciFinder n abstract of US 3,703,554 (database CAPLUS AN: 1973:93638), 1973, 2 pages.</span>
            <span itemprop="examinerCited">*</span>
            
          </td>
        </tr>
        <tr itemprop="detailedNonPatentLiterature" itemscope repeat>
          <td>
            <span itemprop="title">RICE et al., Journal of the American Chemical Society (1953), 75, p. 1750.</span>
            <span itemprop="examinerCited">*</span>
            
          </td>
        </tr>
      </tbody>
    </table>
  </section>

  <h2>Cited By (6)</h2>
  <table>
    <caption>* Cited by examiner,  Cited by third party</caption>
    <thead>
      <tr>
        <th>Publication number</th>
        <th>Priority date</th>
        <th>Publication date</th>
        <th>Assignee</th>
        <th>Title</th>
      </tr>
    </thead>
    <tbody>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11865190B2/en">
            <span itemprop="publicationNumber">US11865190B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2018-10-09</td>
        <td itemprop="publicationDate">2024-01-09</td>
        <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
        <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11980673B2/en">
            <span itemprop="publicationNumber">US11980673B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2018-10-09</td>
        <td itemprop="publicationDate">2024-05-14</td>
        <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
        <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11472766B2/en">
            <span itemprop="publicationNumber">US11472766B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-04-09</td>
        <td itemprop="publicationDate">2022-10-18</td>
        <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
        <td itemprop="title">Lipid nanoparticle composition 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11510977B2/en">
            <span itemprop="publicationNumber">US11510977B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-04-09</td>
        <td itemprop="publicationDate">2022-11-29</td>
        <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
        <td itemprop="title">Nucleic acid vaccines for coronavirus 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN116354836A/en">
            <span itemprop="publicationNumber">CN116354836A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-03-25</td>
        <td itemprop="publicationDate">2023-06-30</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">
        Cationic lipid compound, preparation method and application thereof, and mRNA delivery system
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025160118A1/en">
            <span itemprop="publicationNumber">WO2025160118A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2024-01-22</td>
        <td itemprop="publicationDate">2025-07-31</td>
        <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
        <td itemprop="title">Compositions and methods for hematopoietic stem cell (hsc) targeted delivery of therapeutic agents 
       </td>
      </tr>
    </tbody>
  </table>

  <section>
    <h2>Also Published As</h2>
    <table>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Publication date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3039137A1/en">
              <span itemprop="publicationNumber">CA3039137A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-05-17</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2019005287A/en">
              <span itemprop="publicationNumber">MX2019005287A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-10-14</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2017356699A1/en">
              <span itemprop="publicationNumber">AU2017356699A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-04-18</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2928358T3/en">
              <span itemprop="publicationNumber">ES2928358T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-11-17</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US11851389B2/en">
              <span itemprop="publicationNumber">US11851389B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-12-26</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3538515A4/en">
              <span itemprop="publicationNumber">EP3538515A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-07-08</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7075669B2/en">
              <span itemprop="publicationNumber">JP7075669B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-05-26</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CN110167922A/en">
              <span itemprop="publicationNumber">CN110167922A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-08-23</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CN110167922B/en">
              <span itemprop="publicationNumber">CN110167922B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-09-19</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3538515B1/en">
              <span itemprop="publicationNumber">EP3538515B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-07-20</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2020512272A/en">
              <span itemprop="publicationNumber">JP2020512272A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-04-23</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240246898A1/en">
              <span itemprop="publicationNumber">US20240246898A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-07-25</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/PT3538515T/en">
              <span itemprop="publicationNumber">PT3538515T</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-09-30</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/DK3538515T3/en">
              <span itemprop="publicationNumber">DK3538515T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-10-17</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3538515A1/en">
              <span itemprop="publicationNumber">EP3538515A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-09-18</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2017356699B2/en">
              <span itemprop="publicationNumber">AU2017356699B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-11-11</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018087753A1/en">
              <span itemprop="publicationNumber">WO2018087753A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-05-17</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250162978A1/en">
              <span itemprop="publicationNumber">US20250162978A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2025-05-22</td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Similar Documents</h2>
    <table>
      <thead>
        <tr>
          <th>Publication</th>
          <th>Publication Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20250162978A1/en">
                <span itemprop="publicationNumber">US20250162978A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-05-22">2025-05-22</time>
            
            
          </td>
          <td itemprop="title">Cationic lipids for nucleic acid delivery and preparation thereof 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US11446394B2/en">
                <span itemprop="publicationNumber">US11446394B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2022-09-20">2022-09-20</time>
            
            
          </td>
          <td itemprop="title">Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/CN104922676B/en">
                <span itemprop="publicationNumber">CN104922676B</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2019-03-12">2019-03-12</time>
            
            
          </td>
          <td itemprop="title">Polyamine derivatives 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US8933047B2/en">
                <span itemprop="publicationNumber">US8933047B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2015-01-13">2015-01-13</time>
            
            
          </td>
          <td itemprop="title">Poly(acrylate) polymers for in vivo nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20240166593A1/en">
                <span itemprop="publicationNumber">US20240166593A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-05-23">2024-05-23</time>
            
            
          </td>
          <td itemprop="title">Lipids suitable for nucleic acid delivery 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/CN101842347B/en">
                <span itemprop="publicationNumber">CN101842347B</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2014-06-11">2014-06-11</time>
            
            
          </td>
          <td itemprop="title">A novel cationic lipid, a preparation method of the same and a delivery system comprising the same 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20230263742A1/en">
                <span itemprop="publicationNumber">US20230263742A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2023-08-24">2023-08-24</time>
            
            
          </td>
          <td itemprop="title">A lipid 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/KR100909786B1/en">
                <span itemprop="publicationNumber">KR100909786B1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2009-07-29">2009-07-29</time>
            
            
          </td>
          <td itemprop="title">
        Novel cationic lipids modified with oligopeptides, preparation methods thereof, and carriers comprising the same
       
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2024121167A1/en">
                <span itemprop="publicationNumber">WO2024121167A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-06-13">2024-06-13</time>
            
            
          </td>
          <td itemprop="title">Compounds and compositions for delivery of agents to cells 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/JP6774965B2/en">
                <span itemprop="publicationNumber">JP6774965B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2020-10-28">2020-10-28</time>
            
            
          </td>
          <td itemprop="title">
        Compounds as cationic lipids
       
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/KR20240159310A/en">
                <span itemprop="publicationNumber">KR20240159310A</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-11-05">2024-11-05</time>
            
            
          </td>
          <td itemprop="title">Lipid nanoparticle compositions using novel ionizable lipids 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/CN121241051A/en">
                <span itemprop="publicationNumber">CN121241051A</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-12-30">2025-12-30</time>
            
            
          </td>
          <td itemprop="title">
        A cationic lipid containing nitrogen-containing heterocyclic compounds and glycine
       
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/AU2024302998A1/en">
                <span itemprop="publicationNumber">AU2024302998A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2026-01-22">2026-01-22</time>
            
            
          </td>
          <td itemprop="title">Biodegradable carbamate lipids with increased stability 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2024257088A1/en">
                <span itemprop="publicationNumber">WO2024257088A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-12-19">2024-12-19</time>
            
            
          </td>
          <td itemprop="title">Biodegradable carbamate lipids with increased stability 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/EP2838544A1/en">
                <span itemprop="publicationNumber">EP2838544A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2015-02-25">2015-02-25</time>
            
            
          </td>
          <td itemprop="title">Poly(acrylate) polymers for in vivo nucleic acid delivery 
       </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Legal Events</h2>
    <table>
      <thead>
        <tr>
          <th>Date</th>
          <th>Code</th>
          <th>Title</th>
          <th>Description</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2019-05-07">2019-05-07</time></td>
          <td itemprop="code">AS</td>
          <td itemprop="title">Assignment</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Owner name</strong>:
              <span itemprop="value">RAMOT AT TEL-AVIV UNIVERSITY LTD., ISRAEL</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PEER, DAN;RAMISHETTI, SRINIVAS;REEL/FRAME:049101/0531</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Effective date</strong>:
              <span itemprop="value">20190325</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2019-05-07">2019-05-07</time></td>
          <td itemprop="code">FEPP</td>
          <td itemprop="title">Fee payment procedure</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2019-06-20">2019-06-20</time></td>
          <td itemprop="code">FEPP</td>
          <td itemprop="title">Fee payment procedure</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-11-09">2021-11-09</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NON FINAL ACTION MAILED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-12-16">2021-12-16</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-01-26">2022-01-26</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NON FINAL ACTION MAILED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-04-11">2022-04-11</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-06-10">2022-06-10</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">FINAL REJECTION MAILED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-08-31">2022-08-31</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">DOCKETED NEW CASE - READY FOR EXAMINATION</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-09-19">2022-09-19</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NON FINAL ACTION MAILED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-12-30">2022-12-30</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2023-05-10">2023-05-10</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">DOCKETED NEW CASE - READY FOR EXAMINATION</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2023-08-08">2023-08-08</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2023-10-19">2023-10-19</time></td>
          <td itemprop="code">FEPP</td>
          <td itemprop="title">Fee payment procedure</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2023-10-23">2023-10-23</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2023-12-06">2023-12-06</time></td>
          <td itemprop="code">STCF</td>
          <td itemprop="title">Information on status: patent grant</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PATENTED CASE</span>
            </p>
          </td>
        </tr>
      </tbody>
    </table>
  </section>

</article>

    </search-app>
    
    <script></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  </body>
</html>
